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Abstract 
 
The physicochemical properties of leads are of vital importance to obtain drugs 
with the desired therapeutic effect. In central nervous system (CNS) drug 
discovery, the properties of CNS-leads are even more restricted due to the fact 
that the resulting drugs must cross the blood-brain barrier (BBB). This thesis is 
focused on the development of computational and synthetic approaches that 
can assist the identification of molecular scaffolds that, after decoration, can 
yield high-quality lead-like molecules for CNS drug discovery. 
 
Chapter 1 describes the drug discovery process and its productivity decline. It 
discusses the importance of physicochemical properties in the early stages, 
particularly for CNS-drugs. It describes the current computational 
methodologies and synthetic approaches used to obtain high-quality lead-like 
molecules. 
 
Chapter 2 features the development and validation of a novel computational 
tool to assist the identification of scaffolds likely to yield high-quality lead-like 
molecules for CNS drug discovery. Successively, it describes the 
exemplification of this tool using a Lead-Oriented Synthesis (LOS) approach.  
 
Chapter 3 details the elaboration of a novel LOS approach for the synthesis of 
diverse scaffolds able to yield lead-like molecules with the desired properties for 
CNS. This approach involves the preparation of highly functionalised cyclisation 
precursors. Subsequently, different cyclisation reactions are investigated and 
optimised to yield a library of different scaffolds. The previously developed 
computational tool is used to assess the value of the scaffolds for CNS. 
 
Chapter 4 shows the decoration of some of the prior scaffolds to produce 
diverse derived molecules, which are used for ligand discovery against the 
CNS-target BACE1 (β-site amyloid precursor protein cleaving enzyme 1). 
 
Chapter 5 describes the methods and materials for the preparation of the 
computational tool, for the synthesis of all the scaffolds and derived compounds 
and for the assessment of the biological activity. 
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Chapter 1: Importance of Molecular Properties in CNS Drug 
Discovery 
 
1.1. Introduction 
Despite the recent improvements in the fields of life science and technology, the 
pharmaceutical industry has experienced a decrease in its R&D productivity.1–7 
Most of the drug candidates fail during the last stages of the drug discovery 
process, when a large amount of time and cost has already been spent.8 One of 
the reasons is that drug candidates have poor ADMET (absorption, distribution, 
metabolism, excretion and toxicity) properties.8,9 Consequently, improving the 
quality of leads in the early stages of the drug discovery process can help to 
increase the later clinical success.8,10 Different in silico methodologies have 
been developed to control the physicochemical properties during the lead 
optimisation stage.9,11,12  
 
However, there is a low success in the development of drugs for diseases of the 
central nervous system (CNS).13,14 This low success is due to the presence of 
the blood-brain barrier (BBB), which limits the penetration of drugs to the CNS. 
CNS-drugs must have special physicochemical properties to be able to cross 
this barrier. As a result, the identification of CNS-leads is difficult. In silico MPO 
(multi-parameter optimisation) systems15,16 and synthetic methodologies like 
lead-oriented synthesis (LOS)17 are approaches that can help in the 
development of a variety of molecular scaffolds with suitable properties. These 
scaffolds could be decorated to yield high-quality CNS-leads that would yield 
CNS-drugs more likely to cross the BBB.  
 
1.2. The Drug Discovery Process 
The drug discovery process starts when there is an unmet medical need or 
when the current treatment for a disease could be improved. The main objective 
of pharmaceutical companies is to discover suitable new drugs, which are 
effective and safe. The drug discovery process is very complex and it can be 
divided into different stages (Figure 1).11,18 In the initial stages, research is done 
to identify a “druggable” biological target, whose modulation can give a 
therapeutic response to the unmet disease.19–21 The biological targets include 
enzymes, receptors, ion channels and nucleic acids.22,23 Once the target is 
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identified, it is validated to prove that its modulation can give the desired 
response.19–21 Subsequently, research for small molecules that are able to 
modulate its activity starts.  
 
 
 
Figure 1: Stages of the drug discovery process. Adapted from references.11,18  
 
Small bioactive molecules are usually identified via high throughput screening 
(HTS).24,25 In this approach, large libraries of compounds are tested against the 
biological target to identify if some of them can bind to it and modulate its 
activity. As a result, molecules that are able to bind weakly to the desired target 
can be identified. These molecules are initially called hits,26 which can be 
developed to generate leads.26 Leads are molecules that display activity and 
selectivity in a particular pharmacological or biochemically relevant screen and 
form the basis for identifying new drug candidates.23 For this reason, when a 
lead is generated, different studies in silico and in vitro are performed to 
optimise its potency and safety profile.23,27 During the lead optimisation stage, 
the chemical structure of the lead is modified. When a lead is modified and its 
profile is improved, the new molecule can become a drug candidate, also 
known as a new molecular entity (NME) (Figure 2).8,11 
 
 
 
Figure 2: The lead optimisation process. A lead is modified and tested to improve its potency 
and safety. If the potency and safety increases, it can become a drug candidate. If its profile is 
not optimised, the lead is modified again until there is improvement. 
 
Once a drug candidate is identified, the preclinical development starts. During 
this stage, the drug candidate is tested in vivo to check its efficacy and its safety 
profile in animal models. If the drug candidate is successful, it is submitted to 
clinical trials to study the effect in humans. Clinical trials are divided into three 
phases (Phase I, Phase II and Phase III) and they are the longest and the most 
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expensive stages of the drug discovery process.8 If the drug candidate is 
successful in all of these phases, it is approved and it is brought to the market. 
As a result, the process finishes with the launch of a final effective and safe 
product to the market. 
 
1.3. The Productivity Decline in Pharmaceutical R&D 
In the last few decades, many successful drugs have succeeded through all the 
stages of the drug discovery process and they have been released to the 
market.1 The success was especially high during the year 1996, when 56 drugs 
were approved by the Food and Drug Administration (FDA) in the US.1 Some of 
these drugs became blockbuster drugs, giving high sales to pharmaceutical 
companies. In addition, techniques in molecular biology, computational drug 
design, HTS and combinatorial chemistry have also improved, allowing 
widespread identification of targets and screening of compounds.2,6,28 However, 
despite all these advances and the high investment in research and 
development, there has not been the corresponding increase in the number of 
approved drugs in the last few decades by the FDA (Figure 3).1,2,5–8,10,23,28–31 
 
 
 
Figure 3: Total number of drugs approved per year by the FDA since 1950.6,30 
 
There has not been a very high increase in the number of approved drugs per 
year in the last few decades in part due to a decline in the R&D productivity of 
pharmaceutical companies.1,10,32 This fact can be explained by the patent cliff 
and by the low success in the drug discovery process.1,8 A high investment in 
time and costs is necessary to undertake every one of the drug discovery 
stages.33 The drug discovery process usually takes between 12–15 years and it 
can cost more than $1 billion.18 During the years 2009–2014, many patents of 
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current blockbuster drugs expired.1,8 This fact has decreased the number of 
sales (around $100 billion) due to the increase of generic drugs, which now 
represent around 70% of total prescriptions in the US.1,3,8 Consequently, 
pharmaceutical companies are less likely to develop new drugs. In addition, at 
the end of every stage of the drug discovery process, many efficacy and safety 
requirements need to be satisfied for every molecule in order to proceed to the 
next stage. Recently, these safety requirements have become stricter, 
decreasing the success rate.3 Furthermore, more complicated “druggable” 
targets are currently being investigated. To be able to increase R&D 
productivity, companies should increase their efficiency (drugs brought to the 
market per billion dollars of R&D spending).6 As a result, they would increase 
their success and they would be able to counteract their current loss of sales. 
However, due to the recent high investments and high fails, R&D efficiency has 
decreased during the last decades (Figure 4).1–3,5,6,8 
 
 
 
Figure 4: Decreasing in the R&D efficiency of pharmaceutical companies during the last 
decades. R&D efficiency as drugs brought to the market per billion dollars of R&D spending 
(inflation-adjusted). Adapted from a reference.6 
 
Increasing R&D efficiency in the drug discovery process is a difficult challenge.2 
The process normally starts with thousands of promising compounds, but 
normally most of them are unsuccessful. Occasionally only one arrives to the 
market as a new drug (Figure 5). In addition, every stage has different costs 
and duration. The first stages of the drug discovery program (target 
identification, lead generation and lead optimisation) are the ones with lowest 
cost and with the shortest time. However, for every successful drug into the 
market, preclinical costs comprises approximately 32% of the total costs and 
clinical costs approximately 63%.8,10 In addition, they are the longest stages. 
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Most drug candidates fail during clinical trials (66% of compounds fail in Phase 
II),8 when a high amount of time and cost has already been spent. 
 
 
 
Figure 5: Overview of the time, cost and success of developing a new drug. Adapted from 
references.18,23 
 
Failure in the last stages should be reduced.10 Drug candidates can fail during 
clinical trials due to different reasons such as lack of efficacy, lack of 
improvement and poor/unexpected ADMET profile.6,8,23,34–36 The lack of 
efficacy/improvement can be due to the fact that the wrong target was selected 
or its biological role in the disease is poorly understood. This can lead to 
failures at the last stages of the clinical trials (Phases II and III).8,35 A poor 
ADMET profile can make that candidates that are active against the target 
cannot reach it or they give toxicity. As a result, they are not successful. It has 
been observed that an improvement in the ADMET profile leads to an increased 
clinical success in the early stages of the clinical trials (Phase I).8,35  
 
The ADMET properties of the drug candidates that arrive to the clinical phases 
are related with the ADMET properties of their previous leads. Few alterations 
can usually be made to the structural core of the molecule during the lead 
optimisation process.37 Therefore, more effective research should be done 
during the early stages,4,33 especially during lead generation4,23 because this 
stage is much cheaper and shorter.37 A better lead generation with an improved 
ADMET profile removes molecules likely to fail later in the early stages of 
clinical trials, saving more costs and more time.4,23 In the past, attention was not 
paid to the ADMET profile because the main objective was to increase the 
potency and selectivity of leads,29 as achieving nanomolar activity was the main 
goal. Consequently, many candidates passed the first stages but they failed 
during clinical trials.23 Therefore, libraries of better leads with a controlled 
ADMET profile should be used before the lead optimisation process. Leads with 
undesired ADMET profile should be identified and removed from the library.6,8,38 
Consequently, the lead optimisation would yield drug candidates with the 
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desired ADMET profile and they would be less likely to fail in the clinical 
stages.8 As a result, this selection of better leads could increase R&D 
efficiency.10,28 Accordingly, R&D productivity could also increase and the 
number of drugs launched to the market would be higher. 
 
1.4. Physicochemical Properties of Drugs 
A successful drug must have a balance of biological and physicochemical 
properties.15 The ADMET profile is directly related to the physicochemical 
properties of the molecule. To be able to achieve therapeutic concentrations at 
the site of action, drugs must pass through biological membranes. To be able to 
pass through these membranes drugs must have determined physicochemical 
properties. If they do not satisfy these properties, they cannot reach the site of 
action with enough concentration to produce the desired effect.  
 
Experimental pharmacokinetic and pharmacodynamic studies are performed 
during the early stages of the drug discovery process to identify molecules with 
the desired ADMET profile and to discard the others.28,34,38 These studies can 
involve different evaluations such as the determination of bioavailability (% of 
drug dose in blood plasma), the fraction of drug in blood plasma bound to 
proteins, the volume of distribution of the drug in the organism, the rate of 
clearance (elimination) of the drug from the blood plasma, the metabolic 
stability of the drug, the toxicity (off-target effects) and the minimum effective 
dose. However, when large libraries of compounds need to be tested, these 
experimental studies can take a long time and they can have high costs. 
Therefore, in silico ADMET studies have also been implemented.9,34 They are 
much faster, cheaper and they can be applied to large libraries of compounds. 
These studies have an accuracy of 60–90% with respect to the experimental 
studies.34 Therefore, they are used as a filter to discard compounds likely to fail 
in the future in vitro/in vivo studies. As a result, fewer compounds need to be 
synthesised and tested experimentally.34 There are different in silico models 
available.34 All of them are based on the physicochemical properties of the 
molecules. They calculate the value of each property for a selected molecule 
and they predict its ADMET profile. These methods allow control of the 
physicochemical properties during the early stages of a drug discovery 
program, when a large library of compounds is being investigated. 
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A molecule is defined by several physicochemical properties. The main ones 
are molecular weight (MW), clogP, clogD, net charge, number of atoms that can 
produce hydrogen bonds and polar surface area (PSA). MW refers to the size 
of the molecule and it is quantified as the sum of the masses of all its atoms (in 
daltons) or as the number of its heavy atoms.39 clogP is a property that defines 
the lipohilicity of the molecule.39,40 It is the calculated logarithm of the coefficient 
of partition between octanol:water of the neutral molecule. Lipophilic molecules 
will have high values of clogP. clogD is a property related to clogP, the 
difference is that clogD is the calculated logarithm of the coefficient of partition 
octanol:water of the molecule at a specific pH. It also takes an account the net 
charge of the molecule, which is a property that is influenced by the pKa. The 
number of atoms that can make hydrogen bonds is related with the polarity of 
the molecule and its ability to be solvated by water. It can be described by the 
number of hydrogen bond donors (HBD) and the number of hydrogen bond 
acceptors (HBA). Another property related with the polarity of the molecule is 
the PSA, which is defined as the surface area occupied by the nitrogen and 
oxygen atoms and by the polar hydrogen atoms bound to them.39,41 
Nevertheless, it has been said that clogP and clogD (lipophilicity) are the most 
important properties.41 The reason is because lipophilicity influences drug 
potency and the ADMET profile.39,40 Normally, a drug needs a balanced 
lipophilicity, if the lipophilicity is too high or too low the molecule will have a poor 
ADMET profile.40 
 
1.4.1. Physicochemical Properties in the Design of Oral Drugs 
The physicochemical properties have to be carefully controlled in the design of 
new drugs. They are particularly important in the case of oral drugs. Oral drugs 
have to be absorbed into the bloodstream from the gastrointestinal tract. 
Therefore, they must have a balance between lipophilicity and hydrophilicity. 
There are some rules that can be used as guidelines for the design of oral 
drugs. Lipinski’s guidelines, also called rule-of-five, state the preferred 
properties for absorption of oral drugs.42–44 These guidelines state that a 
molecule should have a MW below or equal to 500, the clogP should be below 
or equal to 5, the maximum number of HBD should be 5 and the maximum 
number of HBA should be 10. Only one violation of these rules is allowed. 
Recently, more properties have been added.42,43 These are PSA, which should 
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not be greater than 140 Å2; the number of rotatable bonds (RB), which should 
not be greater than 10;41 the clogD7.4, which should not be greater than 3; the 
net charge, which should range from -2 to +2; and the molar refractivity, which 
should be between 40–130. In a first instance, most oral drugs satisfy these 
rules. However, there are some exceptions for drugs that are absorbed to the 
bloodstream through active transport. For this reason, these guidelines only 
apply for oral drugs absorbed by simple passive diffusion.  
 
In the past, the majority of oral drug candidates that showed desirable ADMET 
profile, satisfied most of the previous requirements.42 Therefore, the properties 
of new oral drugs should be controlled during the lead generation and 
optimisation stages. During the lead optimisation stage, there is generally an 
increase in complexity, lipophilicity and molecular size (Figure 6).17,29,45,46 
Consequently, the library of compounds for screening should have determined 
physicochemical properties. Therefore, if a lead is identified, it can be optimised 
to a final candidate that will satisfy Lipinski’s guidelines. In this manner, an 
increased rate of success can be expected after the lead optimisation process.  
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Figure 6: Increase of the lipophilicity and the size of the molecules during the lead optimisation 
stage. Panel A: Diagram showing the difference in lipophilicity and size of leads and drugs. 
Adapted from a reference.17 Panel B: Example of some leads (left) and corresponding drugs 
(right).46 Compound 1 is also known as sulfathiazole, which is optimised to 2 (BMS-182874). 
Compound 3 is also known as chlorotiazide, which is optimised to 4 (furosemide). 
 
Due to the increase in MW and clogP during the lead optimisation, leads should 
have more restricted molecular properties than their derived oral drugs.46,47 
There are guidelines that suggest the preferred properties for leads.17,48 They 
suggest that the MW should be between 200–350 and the clogP should be 
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between -1 and 3. In addition, some other recomendations have been included, 
suggesting that leads should have fewer sp2 carbons.17,48 Consequently, they 
should not have more than 3 aromatic rings.17,48  
 
In silico approaches have been widely used to control the physicochemical 
properties of leads during the lead generation stage.11,12 These approaches can 
help to identify leads with the desired efficacy and ADMET properties.49 The 
final ADMET profile of a molecule depends on the combination of all its 
physiochemical properties. The different physicochemical properties have to be 
optimised at the same time. Therefore, in silico multi-parameter optimisation 
(MPO) methodologies are used.15,16,36,50,51 The first models of these 
methodologies were usually pass/fail filters.15,16 Only molecules that satisfy the 
specified rules will be accepted. However, it was observed that these models 
could be too strict. Consequently, a lead compound that has a property 
narrowly outside the desired range is rejected. However it could still be a good 
lead for the design of oral drugs if the other properties are optimal. 
Consequently, models involving desirability functions are now used.15,16,51 
These models assign a total desirability score for each molecule depending on 
all its physicochemical properties. The score is an indicator of the lead-likeness 
of the molecule. This approach employs a single value that defines all 
properties. Consequently, it allows more flexibility, a better balance of the 
properties and avoids a straight cut off for compounds with some properties out 
of the optimal range.  
 
1.4.2. Physicochemical Properties in the Design of CNS-Drugs 
More than one billion people are affected by central nervous system (CNS) 
disorders worldwide.52 It is predicted that CNS disorders like Alzheimer’s 
disease, Parkinson’s disease, stroke and brain cancers will be the major cause 
of health expenses by 2040.14,41 Currently, there is a low clinical success (8%) 
in the CNS drug discovery area compared with other therapeutic areas (Figure 
7).13,14  
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Figure 7: Percentage of clinical success of the drug discovery process in different therapeutic 
areas. Adapted from a reference.13 
 
This low clinical success is due to the fact that the causes of CNS diseases are 
poorly understood.53 It is difficult to study drug candidates for CNS disorders 
due to lack of predictable animal disease models.8,13,28 Consequently, there are 
high fail rates in clinical trials due to lack of efficacy.13 In addition to the 
gastrointestinal membrane, which separates the gastrointestinal tract from the 
bloodstream, there is also another biological membrane that separates the 
bloodstream from the CNS. This membrane is called the blood-brain barrier 
(BBB) (Figure 8). 
 
 
Figure 8: Diagram of the blood-brain barrier. Adapted from a reference.54 
 
The BBB is formed by endothelial cells that have very tight junctions (areas of 
two cells whose membranes join together creating an impermeable barrier to 
fluids) compared to the endothelial cells that separate the bloodstream from 
others parts of the body. These tight junctions allow the passage of nutrients 
and hormones but they protect the CNS from the passage of many other 
molecules through paracellular diffusion. In addition, these cells do not have 
many fenestrations (small pores in the cellular membrane) and they do not 
undergo pinocytosis (invagination of small particles through the cellular 
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membrane) frequently.55 Consequently, most of molecules must pass through 
transcellular passive diffusion through cells, which are rich in enzymes that 
metabolise them.55 In addition, the lipid bilayer of the cells of the BBB has an 
heterogeneous organisation of phospholipids with highly limited mobility and 
charged head moieties that interact with water molecules in the interface.55 This 
makes the process of passive diffusion difficult due to the fact that molecules 
must displace the water bound to the membrane and separate the tightly 
bounded phospholipids. Finally, another feature of the BBB is the presence of a 
transmembrane protein called P-glycoprotein (P-gp) in the endothelial cells.56 P-
gp makes an active efflux of small molecules, which have entered the 
cytoplasm of the cells of the BBB, back to the bloodstream. Due to these 
features, the BBB is more selective than the gastrointestinal membrane. The 
BBB is an effective membrane that protects the CNS from xenobiotics. 
Therefore, the BBB is very selective to the passage of most drugs (98% of 
drugs do not cross this membrane).14 This makes the discovery of drugs with 
CNS exposure difficult. 
 
To be able to treat CNS disorders, CNS-drugs must cross the BBB. Therefore, 
they must have different physicochemical properties to non CNS-drugs. It has 
been observed that like for gastrointestinal absorption; molecular weight, 
lipophilicity and hydrogen bonding are also very important for brain 
penetration.55 However, due to the characteristics of the BBB, these properties 
are more restricted than for gastrointestinal absorption. Consequently, CNS-
drugs must have more restricted physicochemical properties than non CNS-
drugs.28,41 CNS-drugs should be polar enough to be able to dissolve in the 
extracellular fluid and displace the waters bound to the phospholipids of the 
BBB; small and rigid enough to be able to afford the entropic cost of desolvation 
and membrane disruption; and have a balance of lipophilicity to cross the 
cellular membrane of the BBB. It has been suggested that CNS-drugs should 
have lower molecular weight, less HBD and HBA, less charge, smaller PSA and 
more limited flexibility than non CNS-drugs.14,41,55 For this reason, the Lipinski’s 
rule-of-five cannot be applied for the design of CNS-drugs. The differences 
between the physicochemical properties of CNS-drugs and non CNS-drugs 
have been studied. As a result, radar charts,14 classification trees14,57 and 
different physicochemical properties for CNS-drugs have been proposed to be 
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able to discriminate between CNS drug-like molecules and non CNS drug-like 
molecules (Figure 9).  
 
 
From the values in Figure 9, it could be suggested that generally CNS-drugs 
should have a MW not greater than 450, a clogP and a clogD7.4 not more than 
5, the number of HBD should not be greater than 3, the number of HBA should 
not be greater than 7, the PSA should be <90 Å2, the number of RB should be 
not greater than 8 and the pKa should be lower than 10.5. However, other 
publications14,45,60 suggest that the clogP - (number of N + O atoms) should be 
greater than 0, the number of linear chains (unbranched chains outside rings) 
should be less than 7, the sum of O and N atoms should be between 1–7 and 
the volume of the molecule should be between 460–1250 Å3. In addition, it has 
been suggested that some substructures can negatively affect brain 
penetration.62 Substructures identified as undesired for brain penetration are 
A 
 
B 
 Value / Range 
Ref. Pfizer58 Cephalon14 Neuromed    Technologies55 Amgen
59 Pfizer60 
Gedeon Richter and 
Argenta Discovery60,61 
AstraZeneca39,60 
MW 305.3 140–450 <450 <500 <400 <450 310 
clogP 2.8 -0.66–6.1 <5 2–5 <5 1–3 2.5 
PSA (Å2) 44.8 <76 <60–70 <90 NR <60–70 NR 
HBD 1 <3 <3 <3 <3 NR 1.5 
pKa 8.4 6–10.5 7.5–10.5 NR NR NR NR 
clogD7.4 1.7 -0.55–5.5 NR 2–5 NR NR NR 
RB NR ≤8 <8 NR NR NR 4.7 
HBA NR NR <7 NR <7 <6 2.1 
Figure 9: Guidelines for the physicochemical properties of CNS-drugs. Panel A: Classification 
tree to differentiate between CNS drug-like molecules and non CNS drug-like molecules.14 
Arrows in green mean that the property is satisfied. Arrows in red mean that the property is not 
satisfied. Panel B: Opinions on the desired physicochemical properties of CNS-drugs. NR (no 
referred). 
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sulfonamides, sulfones, tetrazoles, amine N-oxides and carboxylic acids.62 
Therefore, these substructures should be avoided in the design of CNS-drugs. 
However, there are some substructures that are preferred in CNS-drugs 
because they can help to cross the BBB and they can avoid P-gp transport.60,63 
A library of desired substructures with an occurrence in CNS-drugs higher than 
5% has been reported.14 Some of these substructures contain one tertiary 
nitrogen with a positive charge or/and one aromatic group. It has been 
observed that tertiary basic amines give resistance to P-gp transport.60 
Therefore, many CNS-drugs are basic molecules.41,60 The rule-of-four guideline 
suggests the properties that CNS-drugs should have to avoid interaction with 
the P-gp.41 This guideline states that molecules should have MW lower than 
400, number of N + O atoms lower than 4 and the most basic pKa should be 
lower than 8. In addition, it has also been suggested that to avoid P-gp 
recognition PSA should be lower than 60 Å2.41 However, P-gp recognition is not 
the only problem of CNS-drugs. Because CNS-drugs can sometimes be more 
lipophilic (clogP >3), they can present high levels of protein binding in blood 
plasma (which will decrease brain penetration) and can give toxic effects easily 
by interaction with other hydrophobic targets.55 Highly lipophilic drugs often 
produce liver toxicity due to interaction with the cytochrome P450 and 
cardiovascular toxicity due to inhibition of the hERG channel.28,39,55,58 As a 
result, CNS-drugs must have a delicate balance of properties to be able to 
cross the BBB, to avoid high levels of protein binding in blood plasma, to avoid 
the P-gp efflux and to avoid off-target effects. 
 
Therefore, in silico techniques have also been developed to help in the design 
of CNS-drugs.56,59,64,65 There are different softwares available that predict the 
likelihood of a molecule entering the CNS.14,64,65 These softwares calculate the 
physicochemical properties of the molecules and study how desirable they are 
for CNS penetration. In addition, they also predict the permeability for the BBB 
through the determination of the logBBB (logarithm of the brain-blood partition 
coefficient),64–66 logPS (permeability surface-area product)65 and the affinity for 
the P-gp.56 Recently, in silico MPO methodologies have also been applied to 
the selection of CNS-drugs.67–71 One example is the CNS MPO scoring system 
developed by Pfizer.67 In this method, six physicochemical properties (MW, 
clogP, clogD7.4, pKa, PSA and HBD) are calculated and scored by desirability 
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functions to identify CNS drug-like molecules. These functions can be a 
monotonic decreasing function or a hump function (Figure 10).67 Monotonic 
decreasing function is used for MW, clogP, clogD7.4, pKa and HBD. Hump 
function is used for PSA. A score between 0.00 and 1.00 is assigned to every 
value of the property depending on the CNS desirability (from 0.00 if the value 
of the property is completely undesired for brain penetration to 1.00 if it is 
completely desired). 
 
  
       Monotonic decreasing function         Hump function 
 
Figure 10: General examples of desirability functions used in the CNS MPO scoring system.67 
 
All six properties are balanced equally. As a sum of each score of every one of 
the six properties, a final score (CNS MPO score) between 0.00 and 6.00 is 
obtained for each molecule.67 Better CNS drug-like and safety profiles are 
achieved for molecules that have this score close to six. Therefore, molecules 
with CNS MPO score equal or higher than 4.00 are identified as molecules with 
desired CNS drug-like and safety properties. They should have high 
permeability through the BBB and poor P-gp binding. The CNS MPO score has 
already shown utility for a CNS-target where the scores obtained correlated with 
the experimental results.72 
 
These in silico approaches used to identify molecules with CNS-drug like 
properties could be used to identify molecules with CNS-lead like properties. 
Consequently, CNS-lead like molecules could be identified before the lead 
optimisation process. This could allow achieving the right ADMET profile for 
CNS-drugs candidates. As in the case of oral drugs, better CNS lead-like 
molecules would improve the success of CNS-drug candidates in clinical trials. 
However, CNS lead-like molecules should have even more restricted properties 
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than CNS-drugs. CNS-leads should have lower MW and lower lipophilicity. 
Consequently, after lead optimisation these leads could become CNS-drugs 
with the desired properties. Unlike the leads for the design of oral drugs, there is 
not any accepted rule (or guideline) to define the physicochemical properties of 
CNS-leads yet. Therefore, the design of CNS lead-like molecules is not easy. It 
is necessary to have access to molecules with different physicochemical 
properties to be able to identify CNS-leads with the in silico techniques.  
 
1.5. Diversity- and Lead-Oriented Synthesis 
Chemical space is the region defined by physicochemical properties that 
contains all the small organic molecules that could theoretically exist.73,74 The 
chemical space defined by molecules with MW lower than 500 is very large. It 
could contain from 1023 to 1060 organic compounds that could be of interest for 
drug discovery (Figure 11).73,75,76  
 
 
 
Figure 11: Explored chemical space. Adapted from a reference.77 
 
Drugs are placed in a region of chemical space called drug-like chemical space. 
Only a small portion of the total drug-like chemical space is known, and it has 
allowed the discovery of different drugs. Drug-like chemical space overlaps with 
biological space, which is the part of the chemical space where biologically 
active molecules are found.74 It has been proposed that more biologically-
relevant chemical space should be explored to be able to increase productivity 
in drug discovery.77 Currently, there is a limited diversity in the explored drug-
like chemical space.78–81 Most drugs have similar molecular frameworks and are 
sp2-rich. Consequently, compounds with new molecular frameworks and more 
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sp3-rich character could be of interest.82,83 For this reason, the chemical space 
occupied by the current small molecules is not necessarily valid for the 
discovery of new drugs.77 New “druggable” chemical space should be explored. 
Consequently, lead optimisation can still occur outside the drug-like chemical 
space known so far.84 Therefore, synthesis of new lead-like molecules is 
necessary to further investigate new drug-like chemical space.77 The use of 
libraries of molecular scaffolds for the search of NMEs has increased.74 
Molecular scaffolds are small synthetically accessible core structures that can 
be derivatised (decorated), using well-known reactions, to create libraries of 
molecules. Different definitions have been described.78 Molecular scaffolds able 
to yield molecules that reside in new lead-like chemical space are of vital 
importance.74,85  
 
To access molecules in new chemical space, new synthetic approaches are 
required. Diversity-oriented synthesis (DOS) is a methodology that allows the 
synthesis of different molecular scaffolds.86 Traditionally, combinatorial 
chemistry was used for the preparation of HTS libraries.87 However, it yields 
molecules with similar structures. Conversely, DOS yields molecules with very 
different structures,86,88 which allows a better exploration of chemical space 
(Figure 12). 
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Figure 12: Chemical space explored by combinatorial chemistry and by diversity-oriented 
synthesis. Adapted from a reference.88 
 
DOS allows chemical space to be explored.89 It allows access to complex 
scaffolds with high diversity in physicochemical properties and tri-dimensional 
shape using complex reactions with common and simple starting 
materials.86,88,90 There are two key strategies to achieve this molecular 
diversity.91 These approaches are the branching pathway (reagent-based 
17 
 
approach) and the folding pathway (substrate-based approach).88,90–92 In the 
branching pathway, common starting materials are transformed to different 
scaffolds using different reagents and reactions. In the folding pathway, 
different starting materials react under common reaction conditions to yield 
different scaffolds (Scheme 1). 
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Scheme 1: Two key approaches used in DOS. Panel A: Example of branching pathway. The 
starting material 5 can give up to 12 different scaffolds.93–95 Panel B: Example of folding 
pathway.94,96–98 Method: A: NH3, NaBH4, 250 mol% Ti(OEt)4, EtOH, then AcOH; B: 
NH2OH•HCl, NaOAc, MeCN, then toluene, µW, 140 °C; C: 1 mol% Rh2(OAc)4, benzene, 50 °C. 
 
The branching pathway and the folding pathway represent the pair stage 
(cyclisation stage) of an approach called the build/couple/pair 
(build/connect/cyclisation) strategy.86,99 The build stage consists in the 
synthesis of the starting materials, containing different sets of functionalities 
suitable for the next two steps. In the couple (connect) stage, the starting 
materials are coupled together to achieve highly functionalized molecules. 
Finally, diversity is generated in the pair (cyclisation) stage.99 In this stage 
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different intramolecular reactions are performed through the functional groups 
to yield the final scaffolds (Scheme 2).86  
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Scheme 2: Example of the build/couple/pair (build/connect/cyclisation) strategy used in DOS for 
the synthesis of diverse scaffolds.91,100 When more connective points (coloured blobs) present 
in the cyclisation precursor, more diversity can be obtained. Method: A: 10 mol% modified 
cinchona alkaloid catalyst,100 –20 °C or –40 °C, THF; B: Grubbs 1st generation 10 mol%, 
ethylene, µW, 150 W, 60 °C, DCM; C: PhNCO, Et3N, toluene, rt; D: Zn, AcOH/THF, rt, then 
Na2CO3 (aq).    
 
A high structural diversity of sp3-rich molecular scaffolds with different 
physicochemical properties has been obtained from DOS.101–103 Therefore, this 
strategy can be very useful to identify biologically active compounds.88,104,105 In 
addition, DOS can be focused to obtain molecules within the lead-like chemical 
space.94 It has been used to synthesise molecular scaffolds able to yield lead-
like compounds.106,107 There is a methodology called lead-oriented synthesis 
(LOS), which allows achieving structurally-diverse sp3-rich scaffolds able to 
yield different molecules within the lead-like chemical space.17 In LOS, synthetic 
approaches similar to the DOS (build/connect/cyclisation) strategies are used to 
achieve these molecular scaffolds (Scheme 3).  
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Scheme 3: Examples of the lead-oriented synthesis approach for the synthesis of different sp3-
rich scaffolds.48,108 These scaffolds could be decorated to yield different molecules with lead-like 
physicochemical properties. 
 
1.6. Molecular Scaffolds for the Design of Lead-like Molecules 
Molecular scaffolds can be used to achieve high-quality lead-like molecules for 
drug discovery programs.48,94 Different molecular scaffolds have been 
synthesised so far, using LOS methodologies (Figure 13).94,108–117 
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Figure 13: Examples of scaffolds obtained using LOS methodologies. In silico calculations have 
predicted that these scaffolds are likely to yield molecules with desirable lead-like 
physicochemical properties for the development of oral drugs.48,94,116–118 
 
In silico calculations demonstrated that these scaffolds can be decorated with 
medicinal chemistry capping groups to achieve molecules with desirable lead-
like physicochemical properties for the development of oral drugs.48,94,117 
Therefore, these derived molecules would have the desired properties and they 
could be tested in HTS to identify active molecules for a determined target. As a 
result, if an active molecule is found, it would be less likely to fail in the following 
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stages due to an undesired ADMET profile. Consequently, high-quality leads 
could be obtained from these molecular scaffolds. Due to the popularity of this 
approach, an open access tool called LLAMA (lead-likeness and molecular 
analysis) has been recently developed.119 Using this tool, one can rapidly know 
if a scaffold is likely to be decorated to yield many lead-like molecules. 
 
1.6.1. CNS Relevant Molecular Scaffolds 
Due to the different physicochemical properties of CNS-drugs, they occupy a 
more restricted region than other drugs in the chemical space. The chemical 
space of CNS-drugs has already been studied.28,58 Through the use of LOS, 
different scaffolds could be synthesised as precursors of lead-like molecules to 
identify CNS-drugs. This methodology has already been applied in CNS drug 
discovery. Few scaffolds stated to yield lead-like molecules with CNS molecular 
properties have been synthesised so far using LOS methodologies (Scheme 
4).106  
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Scheme 4: Example of a LOS approach to obtain azetidine-based scaffolds. These scaffolds 
have been designed to yield lead-like molecules with CNS molecular properties.106 
 
In silico approaches, like the Pfizer’s CNS MPO scoring system, showed that 
most of the physicochemical properties of the derived compounds from these 
scaffolds were in the desired range for brain penetration.106 In addition, 
subsequent in vitro assays also demonstrated good permeability. 
Consequently, these scaffolds were decorated to produce a derived library of 
lead-like molecules. As a result, this derived library could be used as screening 
library against CNS-targets. However, the CNS MPO scoring system has been 
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developed to identify CNS-drugs, not CNS-leads. Consequently, if a lead-like 
compound derived from the previous scaffolds is optimised to a drug-like 
compound, it could lose brain penetration. For this reason, new MPO scoring 
systems focused on CNS-leads would be of interest to be able to keep good 
brain penetration even when the leads are optimised to drug-like compounds. 
 
1.7. Conclusions 
High-quality leads are required to be able to increase the current R&D 
productivity of pharmaceutical companies. In silico MPO methodologies and 
synthetic methodologies based on LOS have been developed to obtain 
molecular scaffolds that are likely to yield lead-like molecules with the desired 
properties to become oral drugs. However, in the case of CNS-drugs this 
process is more difficult due to the existence of the BBB. Identifying molecular 
scaffolds for the development of high-quality leads for CNS drug discovery is a 
new challenge. Therefore, new in silico MPO methodologies and new LOS 
approaches are of interest to identify scaffolds able to yield molecules with CNS 
lead-like molecular properties.  
 
1.8. Project Outline 
The main goal of this project is to facilitate the identification of high-quality leads 
for drug discovery programs in the CNS area. To achieve this goal, this project 
will combine computational and synthetic methodologies. Through these two 
methodologies, molecular scaffolds able to yield molecules with CNS lead-like 
physicochemical properties are going to be identified. This project has five 
objectives:  
 
1) Develop and validate a computational tool that allows the identification of 
novel scaffolds for exploitation in CNS drug discovery (Chapter 2, Sections 
2.1–2.2). This computational protocol must identify novel scaffolds able to yield 
molecules with CNS lead-like molecular properties (Figure 14).  
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Figure 14: General idea of the computational protocol. 
 
To be able to achieve this objective, this computational methodology is going to 
use a new MPO scoring system called CNS Lead MPO system. This scoring 
system is a modification of the CNS MPO scoring system developed by Pfizer.67 
The difference is that the CNS Lead MPO system gives scores with more CNS 
lead-like character instead of CNS drug-like character. 
 
2) Exemplify the value of the computational tool using a set of molecular 
scaffolds that could be scored and easily synthesised using a known LOS 
approach. Consequently, these scaffolds could be decorated to experimentally 
test the permeability of the resulting lead-like molecules. As a result, the 
predictability of the computational tool could be validated experimentally 
(Chapter 2, Section 2.3).   
 
3) Develop a new LOS approach (build/connect/cyclisation approach) for the 
synthesis of novel scaffolds (Chapter 3, Sections 3.1–3.3). For this reason, 
connective reactions involving highly functionalised building blocks are going to 
be selected. These connective reactions need to yield cyclisation precursors 
that can undertake different cyclisation reactions to yield different scaffolds 
(Scheme 5). 
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+
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Scheme 5: General idea of connective reactions to yield cyclisation precursors, which can 
cyclise to afford different scaffolds. The coloured blobs correspond to different functional 
groups. 
 
4) Prioritise key cyclisation reactions from the developed LOS approach and 
exemplify the synthetic methodology through the synthesis of the novel 
scaffolds (Chapter 3, Section 3.3). Use the computational tool to demonstrate 
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the value of the scaffolds prepared for CNS drug discovery (Chapter 3, Section 
3.4). 
 
5) Realise the biological relevance of the prepared scaffolds. Consequently, 
some of the scaffolds are going to be decorated using a medicinal chemistry 
capping group to produce a library of derived molecules (Chapter 4, Section 
4.2). Subsequently, the biological activity of these derived molecules is going to 
be assessed against the CNS-target BACE 1 to allow ligand discovery (Chapter 
4, Section 4.3). 
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Chapter 2: Development of a Computational Tool to Assess 
Scaffolds for CNS Drug Discovery 
 
2.1. Development of the Computational Tool 
The design of new in silico MPO methodologies to identify molecular scaffolds 
for exploitation in CNS drug discovery is of interest. Consequently, it was 
decided to develop a computational tool to allow different scaffolds to be 
prioritised on the basis to yield lead-like molecules to support CNS drug 
discovery. The design of the computational tool would involve different steps 
(Figure 15). 
 
 
Figure 15: Overview of the in silico protocol for the identification of scaffolds for exploitation in 
CNS drug discovery. 
 
The computational protocol would start when a virtual library of molecular 
scaffolds is loaded into it. Subsequently, each scaffold would be decorated with 
different virtual medicinal chemistry capping groups. The resulting library of 
derived compounds would be then filtered to remove compounds with 
toxicophores and undesired substructures for brain penetration. Once 
molecules with undesired substructures have been removed, the 
physicochemical properties of the derived compounds that passed the filter 
would be calculated. Successively, each derived compound would be scored 
depending on its physicochemical properties. Subsequently, the mean score for 
each scaffold would be calculated from the scores of all of its derived 
compounds. This score would reflect the likelihood of the scaffold to give lead-
like compounds for CNS drug discovery. In addition, the novelty of each 
scaffold would also be assessed. Finally, this protocol would give three results 
for each scaffold. These results would be the mean score of its derived virtual 
compounds, the number of derived virtual compounds generated and the 
novelty.  
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To be able to generate every step of this computational protocol, two different 
sofwares will be used. These two softwares are Accelrys Pipeline Pilot and 
ChemAxon (see Section 5.1). These softwares are available under an 
academic licence and they are used to create, modify or analyse chemical 
databases. 
 
2.1.1. Enumeration of Virtual Libraries 
The scaffolds of interest need to be scored depending on their ability to yield 
lead-like molecules for CNS drug discovery. For this reason, the first step of the 
computational tool to be developed was the enumeration of virtual libraries. In 
this stage, each scaffold is decorated with a selected library of virtual medicinal 
chemistry capping groups (see Appendix). It was decided to decorate the 
scaffolds one or two times, depending on the points of decoration. The scaffolds 
were not decorated more than two times to avoid a high increase in MW. Well-
known decoration reactions were used to create the library of derived 
compounds (Figure 16).  
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A 
Type of decoration reaction Functionality in the scaffold Functionality in the reagent 
Amidation Acid chlorides Amines 
Amidation Amines Carboxylic acid 
Amidation Carboxylic acids Amines 
Sulfonylation Sulfonyl chlorides Amines 
Sulfonylation Amines Sulfonyl chlorides 
O-alkylation/arylation Alcohols, carboxylic acids Halides 
N-alkylation/arylation Amines, amides, sulfonamides Halides 
C-alkylation/arylation Halides Boronic acids 
Reductive amination Amines Ketones, aldehydes 
Reductive amination Ketones, aldehydes Amines 
Urea formation Amines Isocyanates 
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Figure 16: Generation of virtual libraries from scaffolds. Panel A: Reactions used for the 
decoration of the virtual scaffolds. Panel B: Example of derived compounds from 
scaffolds.112,120 
 
The medicinal chemistry capping groups were chosen depending on their 
commercial availability, their presence in drug molecules and their 
physicochemical properties. Capping groups with a specific range of MW and 
clogP were selected (see Appendix). Consequently, the different types of 
capping groups should all, on average, induce a similar change of properties to 
the scaffolds. 
 
2.1.2. Filtering of the Virtual Libraries 
The library of derived compounds created can contain compounds with 
toxicophores and undesired substructures for brain penetration. These 
compounds should not be included because they are not attractive molecules 
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for CNS. Consequently, a filter to remove these compounds was implemented 
before the scoring (Figure 17). Derived compounds that pass the filter go to the 
next step of the computational protocol. However, derived compounds that do 
not pass the filter are removed and they do not go to the next step.  
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A derived 
compound  
does not pass 
the filter if: 
It has a number of amides + sulfonamides + sulfamides + carbamates + 
ureas higher than one. 
or 
It has a number of basic amines higher than one. 
or 
It has carboxylic acids, esters, ketones, aldehydes, alkyl halides, 
electrophilic aryl halides, epoxides, aziridines, furans, pyrroles, thiophenes, 
aminothiazoles, indoles, anilines, silicon groups, thioethers or acetals. 
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Figure 17: Filtering of derived compounds. Panel A: Filtering rules for derived compounds. 
Panel B: Example of derived compounds that pass the filter and example of derived 
compounds that do not pass the filter.108,121,122 
 
It is important to indicate that due to the use of collections of capping groups 
with similar physicochemical properties, removing some derived molecules 
before scoring should not affect the final scaffold score. It should only affect the 
number of derived compounds that will be scored. As a result, this 
computational tool should penalise more the original scaffold rather than the 
capping groups used.  
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2.1.3. Calculation of Physicochemical Properties and Scoring 
The next step of the computational protocol is the calculation of the 
physicochemical properties of the filtered library of the derived compounds. It 
was decided to calculate the same six fundamental physicochemical properties 
(MW, clogP, clogD7.4, pKa, HBD and PSA) that Pfizer calculates in its CNS MPO 
scoring system.67 The reason is that these properties are usually used to 
address ADMET issues.67 Once these six physicochemical properties have 
been calculated, the scoring system is applied. The scoring system used is a 
modification of the Pfizer’s CNS MPO scoring system,67 which has been 
adapted for CNS-leads rather than CNS-drugs. Therefore, it was designated the 
name of CNS Lead MPO scoring system. 
 
The CNS Lead MPO scoring system scores using desirability functions focused 
on the desired physicochemical properties of CNS lead-like molecules. A model 
of a monotonic decreasing function and a model of a hump function were 
implemented to transform each physicochemical value in a score. A model of a 
monotonic decreasing function is used for MW, clogP, clogD7.4, pKa, HBD, and 
a model of a hump function is used for PSA (Figure 18). These models were 
adapted from Pfizer’s functions.67 Pfizer decided to use these functions of 
desirable, less desirable and undesirable ranges based on its medicinal 
chemistry experiences. However, in the CNS Lead MPO scoring system, the 
boundaries for optimal scores were reduced for MW, HBD and PSA to leave 
scope for subsequent lead optimisation. In addition, Pfizer’s CNS MPO scoring 
system scores from 0.00 (very undesirable property) to 1.00 (very desirable 
property). However, it was decided to score from 0.05 to 1.00 to give slightly 
higher score to undesired properties, making less strict the penalty. 
Consequently, properties with a value totally undesirable obtain a score of 0.05 
and properties with a value totally desirable obtain a score of 1.00. Accordingly, 
properties partially desirable/undesirable will obtain a score between 0.05 and 
1.00.  
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Figure 18: Desirability functions used in the scoring system. In black the developed CNS Lead 
MPO score. In grey the Pfizer’s CNS MPO score. 
 
As a result, six scores between 0.05 and 1.00 are obtained for each derived 
compound. Subsequently, these six scores are summed to achieve the final 
CNS Lead MPO score for each derived compound. This score ranges from 0.30 
to 6.00. The lowest score of 0.30 indicates a molecule with totally undesirable 
properties whereas the highest score of 6.00 shows the molecule has perfect 
properties. All other scores between 0.03 and 6.00 indicate that the compound 
will have a mixture of both desirable and undesirable properties. It was decided 
to give to all six properties the same weight, as Pfizer also did. The reason is 
that Pfizer observed that weighting all six properties equally gives the best 
predictions.67 Finally, the mean of all the CNS Lead MPO scores of all the 
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derived compounds that come from the same scaffold is calculated to obtain the 
mean CNS Lead MPO score per scaffold. The same scale from 0.30 to 6.00 is 
used to indicate the desirability of the parent scaffolds. Consequently, it was 
agreed that scaffolds with a mean CNS Lead MPO score close or >4.00 are 
going to be scaffolds with a good score and likely to yield molecules with lead-
like properties for CNS drug discovery.  
 
2.1.4. Novelty Assessment 
The value of the mean CNS Lead MPO score per scaffold is the main result. 
However, novel scaffolds are preferred. Therefore, a novelty assessment for the 
scaffolds was implemented in the protocol. This assessment is achieved 
comparing Murcko fragments from the scaffolds with Murcko fragments from a 
random 2% of the ZINC database (database of commercially available 
compounds).123,124 A Murcko fragment is generated when only the rings and the 
chains between the rings of a molecule (ring systems) are maintained. These 
Murcko fragments are compared without their α-atoms (only ring systems) and 
with their α-atoms (ring systems with the atoms attached directly to the rings) 
(Figure 19). The results are shown as the number of times (number of hits) that 
these two kinds of Murcko fragments have been found in the database. 
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Figure 19: Example of generation of Murcko fragments from two scaffolds and their hits 
(number of times found) in a random 2% of the ZINC database. It was observed that comparing 
2% or the entire database give the same results. Scaffold 53:106 Murcko fragment without and 
with α-atoms does not show any hit. Consequently the scaffold is novel. Scaffold 54:113 Murcko 
fragment without α-atoms shows 275 hits. However, when the α-atoms are considered, there is 
not any hit. As a result, the substitution pattern of the scaffold is novel. 
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2.1.5. Summary of Results 
Once the mean CNS Lead MPO score has been calculated and the novelty 
assessment has been performed, the computational tool gives the final results. 
The final results for each scaffold are the mean CNS Lead MPO score, the 
number of derived compounds generated and the novelty. Consequently, after 
using this computational tool, one could know how likely is a molecular scaffold 
to give lead-like molecules for CNS drug discovery programs (mean CNS Lead 
MPO score ~>4.00) and if the scaffold has a novel structure (number of hits 
without or with α-atoms = 0). 
 
2.2. Validation of the Computational Tool 
After developing the computational protocol, it was validated to know if each 
decision taken during the development (selection of capping groups, filtration 
rules, properties scored and scoring functions) was appropriate. For the 
validation, 29 different literature-related molecular scaffolds were scored (55–
83) (Figure 20). Literature-related scaffolds with two points of decoration, and 
with desirable and undesirable physicochemical properties to cross the BBB 
were selected. Consequently, they should give a library of derived compounds 
with both good and poor CNS Lead MPO scores. For example, scaffolds 64 and 
65 should give good mean CNS Lead MPO scores (>4.00) because they have 
already been reported as CNS relevant scaffolds.106 In contrast, scaffolds 77 
and 78 should give poor mean CNS Lead MPO scores (<4.00) due to the fact 
that they are scaffolds found in drugs that belong to the second generation of 
H1-antihistamines, which cross the BBB poorly.125 Finally, the Pfizer’s mean 
CNS MPO score was also calculated for each scaffold to be able to compare it 
to the mean CNS Lead MPO score. 
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Figure 20: Literature-related scaffolds selected for the validation of the computational protocol 
(references in Table 1). Scaffolds that should give a low mean CNS Lead MPO score and 
scaffolds that should give a high mean CNS Lead MPO score were selected. 
 
After applying the computational protocol, it was observed that the mean CNS 
Lead MPO score was always lower than the Pfizer’s mean CNS MPO score 
(Table 1). This is due to the fact that the CNS Lead MPO score penalises 
heavily for high MW, PSA and HBD. Some of these scaffolds have a good 
mean CNS Lead MPO score (>4.00) and others have a poor mean CNS Lead 
MPO score (<4.00). Consequently, some scaffolds are considered more likely 
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than others to yield lead-like molecules for CNS drug discovery. As expected, 
scaffolds 64 and 65 gave mean CNS Lead MPO scores closer or higher than 
4.00 and scaffolds 77 and 78 gave mean CNS Lead MPO scores much lower 
than 4.00. This shows that the selection of capping groups, the scoring 
functions and the equal weighting of the properties was appropriate. In addition, 
it can also be observed that some scaffolds like 61 and 62 score well but they 
give a smaller number of derived compounds than other scaffolds. The reason 
is that these scaffolds contain functionalities that will make most of the derived 
library fail during the filtration step. Consequently, these scaffolds would deliver 
a lower number of useful lead-like molecules than others and therefore they 
would be less interesting than other scaffolds with similar score but higher 
number of scored derived compounds. This shows that it was important to 
implement the filtration step. By scoring the derived compounds without the 
filtration step, it was observed that a very similar score was obtained for every 
scaffold. Consequently, the filtration step does not affect the final scaffold score, 
it only affects the number of useful derived compounds that could be prepared. 
This shows again that the selection of capping groups was appropriate because 
the derived compounds were penalised more by the original scaffold rather than 
by the capping groups. Finally, some of these scaffolds are novel due to the fact 
that they are not commercially available. 
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Scaffold 
number 
and ref. 
Mean 
Pfizer’s CNS 
MPO scoreb 
Mean 
CNS Lead 
MPO scorec 
Number of 
derived 
compounds 
    Noveltyd 
Hits without 
α-atoms 
Hits with 
α-atoms 
       55115 4.97 4.47 3038 0 0 
       56107 4.92 4.52 384 53 0 
       57120 4.37 3.96 1140 0 0 
       58106 5.09 4.59 3038 0 0 
       59126 5.84 4.86 696 0 0 
       60127 5.75 5.49 1522 1 1 
       61108 5.66 4.99 114 2924 585 
       62113 4.73 4.08 114 275 0 
       6348 4.69 4.22 3038 154 4 
       64106 4.13 3.89 795 0 0 
       65106 4.87 4.43 3038 0 0 
       66112 5.45 4.86 2204 1 0 
       67121 3.55 3.02 3038 104 0 
       68128 5.48 4.93 551 1850 1 
       69129 4.98 4.60 464 28392 3 
       70a 4.81 4.31 986 0 0 
       71130 4.34 3.69 3038 557 110 
       72122 3.87 2.83 551 27526 8608 
       73131 5.33 4.38 551 0 0 
       74132 3.94 3.48 360 7 0 
       75110 4.00 3.64 3038 0 0 
       76a 3.18 2.99 1140 0 0 
       77a 3.03 2.81 1140 17 0 
       78a 3.29 2.88 1140 0 0 
       79a 3.27 2.97 551 3 0 
       80133 3.42 2.70 285 1 0 
       81110 4.61 4.07 3038 0 0 
       82133 4.20 3.88 795 0 0 
       83107 2.76 2.52 848 0 0 
Table 1: Results obtained for the 29 literature-related scaffolds using the computational tool. 
aScaffolds derived from bioactive molecules (70 (sumanirole), 76 (rupatadine), 77 (mizolastine), 
78 (azelastine), 79 (olopatadine)). bMean of all the Pfizer’s CNS MPO scores of the derived 
compounds per scaffold. cMean of all the CNS Lead MPO scores of the derived compounds per 
scaffold. dBased on Murcko fragments against a random 2% of the ZINC database. 
 
To understand these scores, some scaffolds with good mean CNS Lead MPO 
scores and some scaffolds with poor mean CNS Lead MPO scores were 
selected and analysed (Figure 21). It was observed that some scaffolds like 60 
and 66 present good mean CNS Lead MPO scores because most of their 
derived compounds score values close to 6.00. This means that scaffolds 60 
and 66 are likely to yield lead-like molecules, which once optimised to drugs, 
will have the desired physicochemical properties to cross the BBB. However, 
scaffolds 67 and 77 present a poor mean CNS Lead MPO score. This poor 
score is due to the fact that most of their derived compounds only score 0.05 for 
MW, clogP and clogD7.4. These results mean that scaffolds 67 and 77 would be 
predicted to yield lead-like molecules, which once optimised to drugs, would 
have values for MW, clogP and clogD7.4 too high to be able to cross the BBB.  
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Figure 21: Panel A: Analysis of the mean CNS Lead MPO scores of the derived compounds 
for each literature-related scaffold. In green, examples of scaffolds with good scores (60 and 66) 
(score >4.00). In red, examples of scaffolds with poor scores (67 and 77) (score <4.00). Panels 
B, C, D, E: Distribution of the CNS Lead MPO scores of the derived compounds of the scaffolds 
60, 67, 66 and 77, respectively. 
 
To finish with the validation, some derived compounds from the scaffolds 55, 66 
and 71 were selected and their Pfizer’s CNS MPO scores were compared with 
their CNS Lead MPO scores (Table 2). It can be seen that all these derived 
compounds (84–87) have a high score using the Pfizer’s CNS MPO scoring 
system. Consequently, these four compounds would have the desired 
physicochemical properties to be drug-like molecules able to cross the BBB. 
36 
 
However, derived compounds 86 and 87 have a lower CNS Lead MPO score 
than derived compounds 84 and 85, due to higher MW and higher PSA. 
Consequently, if these compounds are used as lead-like molecules and 
undertake a lead optimisation process, they would increase their MW and PSA 
to yield drug-like molecules too large and too polar for brain penetration. Due to 
the fact that compounds 84 and 85 have a higher CNS Lead MPO score, there 
is more scope for lead optimisation and they could deliver drug-like molecules 
with the desired properties for brain penetration. For this reason, using the CNS 
Lead MPO score, one can distinguish that compounds 84 and 85 would be 
better lead-like molecules for CNS drug discovery than compounds 86 and 87.  
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Derived compound: 
Pfizer’s CNS MPO 
score: 5.21   6.00    5.57                  5.22 
CNS Lead MPO score: 5.21   6.00    3.86       3.36 
MW: 256   275    399                   391 
PSA (Å2): 23.5   47.5    83.8        88.0 
Table 2: Comparison of the Pfizer’s CNS MPO score and the CNS Lead MPO score of some 
derived compounds from scaffolds 55, 66 and 71. 
 
2.3. Exemplification of the Computational Tool 
After developing and validating the computational tool, it was used to assess a 
library of molecular scaffolds for CNS drug discovery. For this assessment, 
novel scaffolds that could be scored and quickly synthesised using a known 
LOS approach (build, connect and cyclise) were of interest. Consequently, 
these scaffolds could be decorated, and the resulting lead-like compounds 
could be experimentally assessed for permeability. As a result, it could be 
observed if the predictions of the computational tool are in accordance with the 
experimental results of permeability. 
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2.3.1. Identification of a Lead-Oriented Synthesis Approach Based on an 
Ir-catalysed Connective Reaction 
A LOS approach involving an Ir-catalysed connective reaction followed by a Pd-
catalysed cyclisation reaction was identified.116 Consequently, using these two 
reactions with an allylic carbonate building block, different amines and different 
electron deficient het(aryl) bromide groups, a library of pyrrolidine-derived 
scaffolds for CNS drug discovery could be prepared (Scheme 6).116,134,135 
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Scheme 6: Connective reaction involving iridium chemistry and subsequent cyclisation reaction 
involving palladium chemistry. Different pyrrolidine-derived scaffolds can be accessed by using 
different amines and different electron deficient (het)aryl bromide groups. Finally, the Boc group 
can be removed to allow one point of decoration. 
 
These two reactions were selected because their potential to yield different 
novel molecular scaffolds for the synthesis of lead-like molecules has already 
been investigated (Figure 22).116,135 Therefore, this connective reaction and the 
subsequent cyclisation reaction have already been optimised and their scopes 
are known. As a result, this would allow a quick access to a wide number of 
different potential scaffolds. These scaffolds could be scored with the 
computational tool, synthesised and decorated to yield lead-like molecules, 
which could be experimentally assessed for permeability. 
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Figure 22: Precedent showing the scope for the synthesis of pyrrolidine-derived scaffolds using 
different amines (in blue) and different aromatic groups (in red).116 First yields and ee/dr 
correspond to the Ir-catalysed asymmetric allylic substitution (amine, 4 mol% 91, 2 mol% 92, 
nBuNH2, DMSO, 55 °C), second yields and dr correspond to the Pd-catalysed aminoarylation 
reaction (ArBr, 5 mol% Pd(OAc)2, 10 mol% 93, Cs2CO3, 1,4-dioxane, 105 °C). 
 
2.3.2. Application of the Computational Tool 
The Ir-catalysed connective reaction and the Pd-catalysed cyclisation reaction 
were identified as a pathway for the preparation of different pyrrolidine-derived 
scaffolds. Consequently, a virtual library of 25 different scaffolds (94–118), 
which could be prepared using these reactions with different amines and 
different aromatic groups, was designed (Figure 23). The amine and aromatic 
substituents were selected depending on their structural diversity and 
availability/synthetic accessibility. However, the aromatic groups were required 
to have electron deficient bromide groups for the Pd-catalysed reaction to work. 
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Figure 23: Virtual library of 25 different pyrrolidine-derived scaffolds that could potentially be 
synthesised using the Ir- and Pd-catalysed reactions with different amines (in blue) and different 
aromatic groups (in red). 
 
Due to the synthetic accessibility of these 25 virtual scaffolds, they were scored 
with the computational protocol, using the secondary amine as the only point of 
decoration (Table 3). Consequently, it would be possible to identify which 
scaffolds are novel and more likely to yield molecules with CNS lead-like 
molecular properties. 
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Scaffold 
number 
Mean  
CNS Lead 
MPO scorea 
Number of 
derived  
compounds 
         Noveltyb 
Hits without 
α-atoms 
Hits with  
α-atoms 
94 5.03 53 0 0 
95 4.91 53 0 0 
96 4.67 53 0 0 
97 4.88 29 1 0 
98 4.27 53 0 0 
99 3.91 53 0 0 
100 5.12 29 0 0 
101 5.35 29 0 0 
102 4.64 53 0 0 
103 5.15 29 0 0 
104 4.52 29 0 0 
105 3.85 29 0 0 
106 4.27 53 0 0 
107 5.35 29 0 0 
108 4.45 53 0 0 
109 4.05 53 0 0 
110 5.18 29 0 0 
111 4.48 53 0 0 
112 5.05 29 0 0 
113 4.51 53 0 0 
114 4.90 53 0 0 
115 4.75 53 0 0 
116 5.05 29 0 0 
117 5.29 6 0 0 
118 4.21 53 0 0 
Table 3: Results obtained for the 25 virtual scaffolds using the computational protocol. Only the 
amines were used as point of decoration. aMean of all the CNS Lead MPO scores of the derived 
compounds per scaffold. bBased on Murcko fragments against a random 2% of the ZINC 
database.  
 
The results indicated that all of these scaffolds are novel (one of the scaffolds 
was found once without its α-atoms in the ZINC database; even here, it is novel 
when α-atoms are considered). In addition, most scaffolds have a score very 
close or higher than 4.00. Therefore, it suggests that most of them could yield 
lead-like molecules for CNS drug discovery. To understand these scores, some 
scaffolds with high mean CNS Lead MPO scores and some scaffolds with low 
mean CNS Lead MPO scores were selected and analysed (Figure 24). 
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Figure 24: Panel A: Analysis of the mean CNS Lead MPO scores of derived compounds for 
each of the 25 virtual scaffolds. In green, examples of scaffolds with good scores (101 and 114). 
In red, examples of scaffolds with lower scores (99 and 105). Panels B, C, D, E: Distribution of 
the CNS Lead MPO scores of the derived compounds of the scaffolds 101, 105, 99 and 114, 
respectively. 
 
It was observed that some scaffolds like 101 and 114 present a good mean 
score because all of their derived compounds score values close to 6.00. This 
means that scaffolds 101 and 114 are likely to yield molecules with the desired 
physicochemical properties to be CNS lead-like compounds. However, scaffolds 
99 and 105 present lower score. This lower score is because their derived 
library of compounds score only 0.05 for MW. These results mean that scaffolds 
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99 and 105 would yield molecules that could have values for MW too high to be 
CNS lead-like compounds. 
 
With the results obtained, the virtual scaffolds 95, 100, 101, 114 and 115 were 
selected for synthesis (Figure 25). They were selected because they are novel, 
they have a good mean CNS Lead MPO score (>4.00) and they are readily 
synthetically accessible. 
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Figure 25: Virtual pyrrolidine-derived scaffolds selected for synthesis. 
 
2.3.3. Preparation of Scaffolds 
The pyrrolidine-derived scaffolds 95, 100, 101, 114 and 115 were identified 
through the computational protocol as novel scaffolds likely to yield lead-like 
molecules for CNS drug discovery. Consequently, they were selected for the 
exemplification of the computational tool. 
 
2.3.3.1. Synthesis of Cyclisation Precursors 
2.3.3.1.1. Preparation of Building Blocks 
To be able to obtain the selected pyrrolidine-derived scaffolds, the synthesis of 
different cyclisation precursors is required. In addition, the synthesis of the 
cyclisation precursors requires the allylic carbonate building block 88. The 
synthesis of this building block is known116 and it was prepared in four steps 
(Scheme 7).  
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Scheme 7: Synthesis of the allylic carbonate building block 88. aLower yield compared to the 
other steps due to the formation of the isomer Z (detected by 1H-NMR spectroscopy of the 
crude product mixture). 
 
The synthesis started with the Boc protection of the nitrogen of the amino 
alcohol 119 using Boc2O to give the carbamate 120 with a quantitative yield. 
Successively, Parkih−Doering oxidation136 was applied to the carbamate 120 
followed by a Wittig reaction137 using carbethoxymethylene triphenylphos-
phorane to provide the α,β-unsaturated ester 121 in 62% yield. This ester was 
then reduced with DIBAL-H to give the allylic alcohol 122 in 96% yield. Finally, 
treatment of the allylic alcohol 122 with methyl chloroformate yielded the allylic 
carbonate building block 88 in 86% yield. The second step, which involved the 
Parkih−Doering reaction followed by the Wittig reaction, gave the lowest yield. 
The reason is that during this transformation, the undesired Z isomer of the 
ester 121 is also formed. Since the allylic carbonate 88 was necessary for the 
synthesis of five cyclisation precursors, it was prepared on a multi-gram scale. 
 
In addition to this building block, the synthesis of the cyclisation precursors also 
needs the chiral phosphoramidite ligand 91 and the Ir-catalyst 92 (Figure 26).116 
These compounds were prepared following literature procedures.134,138 The 
synthesis of the catalyst 92 is necessary because the dbcot ligand makes the 
catalyst more stable to oxygen.134 In addition, it increases the regioselectivity of 
the reaction for the desired product. 
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Figure 26: Structure of the ligand 91 and the Ir-catalyst 92. 
 
Once the allylic carbonate building block 88, the ligand 91 and the Ir-catalyst 92 
were available, the syntheses of the cyclisation precursors 89 started. The next 
step involved the Ir-catalysed asymmetric allylic substitution. 
 
2.3.3.1.2. Connective Reactions 
2.3.3.1.2.1. Ir-catalysed Asymmetric Allylic Substitution 
The Ir-catalysed connective reactions were performed combining the allylic 
carbonate 88 with different amines in the presence of 2 mol% of the catalyst 92, 
4 mol% of the chiral phosphoramidite ligand 91 and nBuNH2 in DMSO at 60 °C. 
The reactions were highly reproducible with the different amines, providing after 
18 h the cyclisation precursors 89a-e (Table 4). The different cyclisation 
precursors were obtained in similar yields from 58% to 63% and usually with a 
good ee from 83% to 86%, excluding the cyclisation precursor 89a, which was 
obtained in 67% ee (see below for methods for ee determination). In addition, 
the diastereselectivity for the synthesis of the alkene 89e was also high, with a 
crude dr 94:6. In some cases, an undesired regioisomer 123 was observed. 
This is due to the fact that this reaction is not completely selective for the 
formation of the cyclisation precursor, which has an alkene in the terminal 
position. This reaction can also yield small amounts of an undesirable 
regioisomer with the alkene in the internal position. This undesirable internal 
alkene 123 was obtained in higher amounts in the syntheses of the cyclisation 
precursors 89a-c (ratios terminal alkene:internal alkene (T:I) 85:15, 83:17 and 
71:29, respectively) than in the syntheses of the alkenes 89d-e (ratio T:I 
>95:<5). For the preparation of the alkenes 89a-c, a secondary amine was used 
as reagent. For the preparation of the alkenes 89d-e, primary amines were 
used instead. Consequently, the use of primary amines or secondary amines 
could affect the regioselectivity of this reaction. 
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4 mol% ligand 91
2 mol% catalyst 92
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BocHN O OMe
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BocHN N R
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Entry Amine Ligand Cyclisation precursor T:I a Yieldd ee 
1 
H
N
 
(S,S,aS)-91 BocHN N
89a  
85:15b 59% 67%e 
2 
HN
O
 
(R,R,aR)-91 BocHN N
89b
O
 
83:17b 63% 86%f 
3 HN
O  
(R,R,aR)-91 BocHN N
89c
O
 
71:29c 63% 83%e 
4 H2N
OH
 (S,S,aS)-91 BocHN NH
89d
OH
 
 
>95:<5b 
 
60% 85%g 
5 
H2N
OH
 
(S,S,aS)-91 BocHN N
H
OH
89e  
>95:<5b 58% –h 
Table 4: Ir-catalysed connective reaction of the allylic carbonate 88 with different amines to 
yield diverse cyclisation precursors. The absolute stereochemistry was determined by 
comparison to analogues.116 aRatio between the terminal:internal alkenes. bDetermined by 1H-
NMR spectroscopy (500 MHz) of the crude product mixture. cDetermined by 1H-NMR 
spectroscopy (300 MHz) of the crude product mixture. dYield of the purified cyclisation 
precursor. eDetermined by derivatisation to yield diastereomers (Scheme 8). fDetermined by 
chiral HPLC. gDetermined by derivatisation to yield benzoyl derivatives and chiral HPLC 
(Scheme 9). hThis reaction gave a pair of diastereomers due to the use of an enantiopure chiral 
amine. The crude dr of this reaction was 94:6 and it was determined by 1H-NMR spectroscopy 
(500 MHz) of the crude product mixture. The product 89e was isolated with dr >95:<5, which 
was determined by 1H-NMR spectroscopy (500 MHz) of the purified product.  
 
To be able to determine the ee of the Ir-catalysed reactions, the enantiomers of 
the cyclisation precursors 89a-d were prepared using the opposite chiral 
phosphoramidite ligand 91. Only the pair of enantiomers 89b were successfully 
separated by chiral HPLC to give an ee value of 86%. Consequently, other 
procedures were investigated for the determination of the ee of the other pair of 
enantiomers. The ee of the enantiomers 89a was determined by chiral 
derivatisation through two steps (Scheme 8, panel A). In the first step, each of 
the enantiomers of 89a was treated with TFA to remove the Boc group. 
Subsequently, the resulting amine salts 124 were individually treated with Et3N 
and the (S)-Mosher’s acid chloride ((S)-MTPA-Cl)139 to give 125 as a mixture of 
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two diastereomers. The same procedure was used to determine the ee of the 
enantiomers 89c (Scheme 8, panel B). Analysis of the crude product mixture of 
diastereomers by 1H-NMR spectroscopy (500 MHz) allowed the determination 
of the dr. From this result, the ee of the Ir-catalysed reaction for the cyclisation 
precursor 89a and 89c were determined, which were 67% and 83% 
respectively.  
 
A 
BocHN N TFA
DCM
(R)-89a
(S)-89a
H2N N
(R)-124, 96%a
(S)-124, >99%a
(S)-MTPA-Cl
N
H
N
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O
F3CEt3N
dr = 83.3:16.7b
OMePh
125
 
B 
TFA
DCM
(S)-89c
(R)-89c
(S)-126, 98%a
(R)-126, >99%a
(S)-MTPA-Cl
Et3N
BocHN N
O H2N N O
N
H
N
O
ODCM
F3C
OMePh
dr = 91.7:8.3b
127
 
 
Scheme 8: Derivatisation of the pair of enantiomers 89a (Panel A) and 89c (Panel B) to 
diastereomers using the (S)-Mosher’s acid chloride. aIsolated and characterised as TFA salts. 
bDetermined by 1H-NMR spectroscopy (500 MHz) of the crude product mixture. 
 
The pair of enantiomers 89d could not be separated by chiral HPLC either. 
However, these enantiomers were already known. Consequently, there is an 
established procedure to determine the ee.116 Following this procedure, each 
enantiomer of 89d was treated with TBDPSCl in the presence of Et3N and 
DMAP to give the silyl derivatives 128. Subsequently, these two enantiomers 
were independently treated with benzoyl chloride and Et3N to yield the benzoyl 
derivatives 129, which can be separated by chiral HPLC (Scheme 9). An ee of 
85% was determined for this Ir-catalysed reaction.  
 
BocHN N
H
OH
BocHN N
H
OTBDPS
TBDPSCl
Et3N, DMAP
DCM, 40 ºC
BocHN N
OTBDPS
Benzoyl chloride
Et3N
DCM
O
(R)-89d
(S)-89d
(R)-128, 78%
(S)-128, 62%
(R)-129 ,99%
(S)-129, 90%  
 
Scheme 9: Synthesis of the enantiomers 129, which can be separated by chiral HPLC. 
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Before moving to the Pd-catalysed cyclisation reaction, an extra transformation 
was required for the cyclisation precursors 89d-e (Scheme 10). The alkene 89d 
was reacted with CDI in the presence of DBU to provide the oxazolidinone 89f 
in 94% yield. The alkene 89e undertook four reactions in one pot. The first 
reaction was the protection of the hydroxyl group by TMS using trimethylsilyl 
chloride. Successively, the amine underwent a nucleophilic addition-elimination 
reaction with chloroacetyl chloride. After this reaction, the TMS protecting group 
was removed using acetic acid. Finally, the free hydroxyl group was treated with 
NaOH and Bu4N-HSO4 to undertake an intramolecular SN2 reaction to afford the 
morpholine derivative 89g in 49% yield. Once the alkenes 89f-g were obtained, 
they were used in the Pd-catalysed cyclisation reaction, conjointly with the 
cyclisation precursors 89a-c.  
 
BocHN N
H
89d
OH BocHN N
O
O
THF, 50 ºC
89f
CDI, DBU
94%
BocHN N
H
OH BocHN N
49%
O
O
1. TMSCl, Et3N, DCM
2. Chloroacetyl chloride,a Et3N
3. AcOH, H2O
4. NaOH, Bu4N-HSO4, H2O/DCM
89e 89g
 
 
Scheme 10: Extra transformation required for the cyclisation precursors 89d-e before 
undertaking the Pd-catalysed cyclisation reaction. aBromoacetyl bromide was firstly used 
instead of chloroacetyl chloride, but analysis of the crude product mixture by TLC (thin layer 
chromatography) did not show consumption of the starting material.  
 
2.3.3.2. Cyclisation Reactions 
2.3.3.2.1. Pd-catalysed Aminoarylation 
The Pd-catalysed cyclisation reactions were accomplished by combining the 
cyclisation precursors 89 with different het(aryl)bromide groups in the presence 
of 5 mol% of Pd(OAc)2, 10 mol% of the ligand 93 (DPE-Phos), and the base 
Cs2CO3 in 1,4-dioxane at 105 °C (Table 5). The reactions were highly 
reproducible with the different substrates, providing after 18 h of reaction the 
pyrrolidine-derived scaffolds 90j-n in yields ranging from 38% to 66% and crude 
dr varying from 83:17 to >95:<5. It was observed that the synthesis of the 
scaffolds 90j-l gave higher dr (crude dr >95:<5) than the synthesis of the 
scaffolds 90m-n (crude dr 83:17 and 89:11, respectively). Scaffolds 90j-l have a 
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basic aliphatic amine. Scaffolds 90m-n do not have a basic aliphatic amine. 
Consequently, this could affect the dr of the reaction. However, all the scaffolds 
were purified as single diastereomers. 
 
O
P P
PhPh PhPh
93
BocHN
Ar
BocN
N
N
ArBr
5 mol% Pd(OAc)2
10 mol% 93
Cs2CO3
1,4-Dioxane
105 ºC, 18 h
R1
R2
R1 R2
Cyclisation precursor Scaffold
89 90
 
 
Entry Cyclisation precursor Het(aryl)bromide Scaffold 
Crude 
dra 
Yield 
and drb 
1 BocHN N
89a  
N N
Br
 BocN
N
N
N
90j  
>95:<5 66% >95:<5 
2 BocHN N
89b
O
 
N N
Br
 BocN
N
N
N
O
90k  
>95:<5 61% >95:<5 
3 BocHN N
89c
O
 
N
Br
 BocN
N
N
O
90l  
>95:<5 38% >95:<5 
4 BocHN N O
O
89f  
N
Br
 BocN
N
O
N
O
90m  
83:17 42% >95:<5 
5 BocHN N
O
O
89g  
N
Br
 BocN
N
N
O
O
90n  
89:11 61% >95:<5 
Table 5: Pd-catalysed cyclisation reaction of the different cyclisation precursors with different 
het(aryl)bromide groups to yield the diverse pyrrolidine-derived scaffolds. The absolute 
stereochemistry was determined by comparison to analogues.116 aDetermined by 1H-NMR 
spectroscopy (500 MHz) of the crude product mixture. bYield and dr (1H-NMR, 500 MHz) of the 
purified scaffold.  
 
Once the pyrrolidine-derived scaffolds 90j-n were obtained, they were treated 
with TFA to yield the final deprotected scaffolds 95, 115, 114, 101 and 100 
(Scheme 11). All the Boc deprotections worked well with quantitative yields. 
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These scaffolds were prepared in enough amounts to allow the subsequent 
decorations. 
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Scheme 11: Boc deprotection of the pyrrolidine-derived scaffolds. All the scaffolds were 
isolated and characterised as TFA salts.   
 
2.3.4. Experimental Determination of Permeability (This section was 
performed by William Farnaby in collaboration with Takeda Cambridge) 
Once the five pyrrolidine-derived scaffolds 95, 100, 101, 114 and 115 were 
prepared, they were decorated at the free amine with different medicinal 
chemistry capping groups. This gave a library of sixteen lead-like compounds 
(130–145), whose chemical structure is not shown due to a confidentiality 
agreement with Takeda Cambridge. The aqueous solubility of these derived 
compounds was assessed using a kinetic solubility assay. This demonstrated 
that these compounds have high solubility, ranging from 79 µg/mL to 108 
µg/mL. 
 
Once the aqueous solubility was measured, the in vitro permeability of these 
lead-like compounds was assessed. In vitro assays to determine BBB 
permeability are expensive and time consuming.140 As a result, the in vitro 
permeability of these derived compounds for passive transport was evaluated 
using PAMPA (Parallel Artificial Membrane Permeability Assay).141 PAMPA 
does not correlate with BBB permeability, but it was used as an inexpensive 
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and quick filter for BBB permeability. If a compound is not permeable in a 
PAMPA, it is not going to be BBB penetrant. PAMPA demonstrated that 
fourteen out of the sixteen derived compounds were highly permeable (Papp 
(apparent permeability coefficient) >10–5 cm/s) (Table 6).72 Consequently, they 
could also be BBB penetrant. 
 
Lead-like compound CNS Lead MPO score Exp. logD7.4 Papp (10-6 cm/s) 
130 4.82 1.92 132.4 
131 5.13 1.27 70.8 
132 4.81 1.79 138.3 
133 4.60 1.05 34.4 
134 5.34 1.13 17.1 
135 5.37 1.89 116.8 
136 4.48 1.35 38.6 
137 5.49 1.41 55.5 
138 4.86 0.90 10.6 
139 5.00 1.03 6.0 
140 4.60 0.57 7.4 
141 5.24 1.90 71.3 
142 5.26 0.85 40.2 
143 4.73 2.17 186.3 
144 5.05 1.37 118.6 
145 5.00 2.02 125.5 
Table 6: CNS Lead MPO scores, experimental logD7.4 and Papp from the PAMPA of the sixteen 
lead-like compounds prepared from the previous pyrrolidine-derived scaffolds. 
 
In addition, a computational model that predicts brain penetration66 suggested 
that most of these lead-like compounds (fourteen out of sixteen) would have a 
logBBB >0.5. As a result, if these compounds were optimised to drug-like 
molecules, they should be likely to cross the BBB. 
 
2.4. Summary and Conclusions 
A computational tool for the identification of novel CNS molecular scaffolds was 
successfully developed. Subsequently, it was validated using a library of 
different literature-related scaffolds, which included CNS scaffolds and non-
CNS scaffolds. The validation showed that CNS scaffolds obtained higher CNS 
Lead MPO scores than non-CNS scaffolds. In addition, it showed that the CNS 
Lead MPO score could effectively identify more accurately CNS lead-like 
molecules than the Pfizer’s CNS MPO score. Successively, the value of the 
computational tool was exemplified using a library of pyrrolidine-based 
scaffolds. A virtual library of these scaffolds was scored. Consequently, five of 
these virtual scaffolds were selected for synthesis because they were novel, 
they obtained a good mean CNS Lead MPO score and they were readily 
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synthetically accessible. These five scaffolds were successfully synthesised 
using an Ir- and Pd-catalysed reactions, which were highly reproducible with the 
different substrates and usually gave high yields and high ee/dr. Subsequently, 
these scaffolds were decorated to obtain a library of lead-like compounds. 
These lead-like compounds were experimentally assessed and they showed 
high aqueous solubility and high permeability through a lipidic artificial 
membrane, indicating that these compounds could also be brain penetrant. 
Therefore, it can be suggested that the computational tool could correctly 
identify scaffolds that could be useful for CNS drug discovery programs.  
 
In conclusion, this computational tool could be very useful as a quick and 
inexpensive filter to improve the quality of lead-like molecules used in HTS 
libraries for CNS-targets. If a lead-like molecule from these improved screening 
libraries shows activity for a CNS-target, its potency could be improved to yield 
a CNS-drug that could cross the BBB. Consequently, less time, costs and 
efforts would be spent in unsuccessful lead-like compounds. This in silico tool 
could be another valuable predictor that could be added to the collection of 
predictors that are currently used in the early stages of CNS drug discovery. It 
could help to decrease the amount of experimental work and improve the 
clinical success in the later stages of CNS drug discovery programs, improving 
the current productivity. 
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Chapter 3: Development of a Modular Approach for the 
Synthesis of Scaffolds Relevant to CNS Drug Discovery 
 
3.1. Identification of a Lead-Oriented Synthesis Approach Based on a 
Mannich/Alkylation and a Pd-catalysed Connective Reactions 
The development of a new LOS approach is essential for the identification of 
novel scaffolds for CNS drug discovery. Consequently, connective reactions 
that yield highly functionalised cyclisation precursors were of interest. Ideally, 
the connective reaction should have easily accessible building blocks and 
provide a rapid route to cyclisation precursors. In addition, the cyclisation 
precursors should allow many alternative possible cyclisation reactions. They 
should be able to give scaffolds that can be decorated to yield compounds 
within the lead-like chemical space relevant to CNS drug discovery. 
 
As a result, a new attractive connective reaction to yield cyclisation precursors 
was identified (Scheme 12).142,143 This connective reaction starts with an allyl 
ester building block and involves a Mannich144/alkylation reaction followed by a 
palladium-catalysed decarboxylative allylic alkylation.145 The cyclisation 
precursor obtained could undertake different cyclisation reactions that could 
yield different novel, sp3-rich and structurally-diverse scaffolds. 
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Scheme 12: Mannich/alkylation reaction followed by a palladium-catalysed decarboxylative 
allylic alkylation as source of cyclisation precursors, which could yield novel, sp3-rich and 
structurally-diverse scaffolds. 
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It has been previously demonstrated that this connective reaction works with 
building blocks containing different ring sizes and different heteroatoms (Figure 
27).142,143 Consequently, it suggests how the scope for the synthesis of the 
cyclisation precursors might be extended. 
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Figure 27: Precedent that suggests how the scope for the synthesis of the cyclisation 
precursors might be extended. First yields correspond to the Mannich reaction (Cs2CO3, 153, 
DCM, rt) and to the alkylation reaction for the bottom-right compound (NaH, BnBr, THF, rt). 
Second yields and ee correspond to the palladium-catalysed asymmetric decarboxylative allylic 
alkylation (5 mol% Pd2(dba)3, 12.5 mol% PHOX ligand,142 toluene, rt). 
 
For this reason, this reaction would allow the use of different building blocks 
with different ring sizes and different heteroatoms. As a result, this could allow 
the synthesis of a wide number of different cyclisation precursors. 
Subsequently, these cyclisation precursors could undertake different cyclisation 
reactions to yield different potential novel scaffolds for CNS drug discovery.  
 
3.2. Synthesis of Cyclisation Precursors 
3.2.1. Preparation of Building Blocks 
To be able to study the value of the Mannich/alkylation reaction and the Pd-
catalysed decarboxylative allylic alkylation as a pathway to yield different novel, 
structurally-diverse and sp3-rich scaffolds; the synthesis of different cyclisation 
precursors was investigated. For this reason, the synthesis of different allyl 
esters building blocks 146 was firstly studied. The preparation of some of these 
building blocks is known in the literature.143,146 However, the procedure was not 
reproducible; or cyanoformate derivatives, which can give highly toxic by-
products, are used in the synthesis. Consequently, an alternative preparation of 
the allyl esters 146 was investigated.  
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During the investigation, it was shown that the synthesis of this type of 
compound was very irreproducible when using different carbonyl derivatives 
154. The use of specific electrophiles, bases and solvents was essential. 
Consequently, the carbonyl-derived starting materials 154 were usually treated 
under different optimised conditions (Table 7). Eventually, the different allyl 
ester building blocks 146 were successfully obtained. Compounds 146a-d were 
obtained in yields between 40%–47% and compound 146e in 29% yield (Table 
7, entries 1f, 2e, 3b, 4b and 5e). 
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O
Carbonyl derivative Building block
O
O
Method
O
N N O
O
156
O O
O
+
C-Acylated product O-Acylated product
154 146 155
 
 
Entry Carbonyl derivative Method
a Building block C-:O-Acylationd Yield
h 
    1 
a 
154a
BzN
O
O
 
A 
BzN
O
O O
O
146a  
32:68 6% 
b B –e 
c C <5:>95 –i 
d D 80:20 43% 
e E 75:25 –i 
f F >95:<5 41% 
    2 
a 
O
O
154b  
F 
O
O O
O
146bb  
>95:<5 27% 
b G >95:<5 5% 
c E >95:<5 36% 
d H >95:<5 8% 
e I >95:<5 45% 
    3 
a 
N
Cbz
O
154c  
I 
N
Cbz
OH
O
O
146cc  
>95:<5 20% 
b E >95:<5 40% 
    4 
a MeO
O
154d  
G MeO
O
O
O
146d  
–f 
b E >95:<5 47% 
     
    5 
a 
O
O
154e  
I 
146e
O
O O
O
 
–f 
b E –f 
c 
154f
O
O O
O
 
J –f 
d K –f 
e HO O
O
154g  
L –g 29% 
Table 7: Optimisation and synthesis of the allyl ester building blocks 146. aMethod: A: LiHMDS, 
allyl chloroformate, THF, –78 ºC; B: LiHMDS, diallyl carbonate, THF, –78 ºC; C: LDA, allyl 
chloroformate, THF:toluene, –78 ºC; D: LiHMDS, allyl chloroformate, toluene –78 ºC; E: 
LiHMDS, allyl chloroformate, toluene, 0 ºC to rt; F: LiHMDS, 156, toluene:THF, –78 ºC; G: NaH, 
diallyl carbonate, THF, rt; H: LiHMDS, 156, THF, –78 ºC; I: LiHMDS, 156, toluene, –78 ºC; J: 
Allyl alcohol, Zn(0), toluene, reflux; K: Allyl alcohol, DMAP, molecular sieves 3 Å, toluene, 
reflux; L: NaH, Et2O, rt, then allyl acrylate, DMSO, 0 ºC to rt. bObserved as a mixture of 24:76 
keto-enol tautomers (1H-NMR, CDCl3, 500 MHz). cOnly enol tautomer observed (1H-NMR, 
CDCl3, 400 MHz) dC-:O-Acylation ratio determined by 1H-NMR spectroscopy (300–500 MHz) of 
the crude product mixture. eNo reaction observed by TLC and 1H-NMR spectroscopy of the 
crude product mixture. fDecomposition observed by TLC and 1H-NMR spectroscopy of the crude 
product mixture. gNot applicable. hYield of the purified building block. iYield not determined.  
 
The preparation of the lactam-derived allyl ester 146a gave some problems 
because O-acylation was also possible when using allyl chloroformate. 
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Consequently, the use of the soft electrophile 156 was necessary (Table 7, 
entry 1).147 The synthesis of the ketone-derived allyl esters 146b-d needed non-
polar solvents to proceed148,149 and O-acylation was never observed (Table 7, 
entries 2–4). The preferred base for all of these previous reactions was always 
LiHMDS. The use of alternative bases such as LDA or NaH,150 or the use of 
different electrophiles such as diallyl carbonate resulted in a decreased yield 
(Table 7, entries 1b–c, 2b and 4a). Finally, the synthesis of the tetrahydrofuran-
derived allyl ester 146e was not successful using the optimised conditions used 
for the synthesis of the other allyl esters (Table 7, entries 5a–b). Consequently, 
a completely different pathway using the carbonyl derivative 154g and allyl 
acrylate as electrophile was used. This reaction involved a Michael addition and 
a subsequent intramolecular Dieckmann condensation.151 The use of other 
strategies such as the transesterification reaction did not work (Table 7, entries 
5c–d).152–154 
 
3.2.2. Connective Reactions 
3.2.2.1. Mannich/Alkylation Reaction 
Once the allyl ester building blocks 146 were obtained, they were taken into the 
next step, which involves the Mannich/alkylation connective reaction to form the 
quaternary centre. To perform the Mannich reactions, the allyl esters 146 were 
dissolved in DCM and treated with Cs2CO3 and the carbamate 153 at rt.155 
Consequently, the corresponding quaternary allyl esters 147a-e were obtained 
in yields ranging from 83% to >99% (Table 8, entries 1–4 and 5c). The reaction 
time for compounds 146a-d was of 18 h. However, the reaction time for the 
tetrahydrofuran derivative 146e was only of 3 h. The reason is that after 18 h, 
the desired product 147e was not observed. Instead, the product decomposed 
through a retro-Dieckmann reaction followed by a retro-Michael reaction156 to 
give the α,β-unsaturated ester 157 (Table 8, entry 5a and Scheme 13). 
Furthermore, the Mannich reaction did not work at 0 ºC (Table 8, entry 5b). 
 
After completing the Mannich reactions, the allyl ester building block 146c was 
also used as substrate for the alkylation reactions. Therefore, it was dissolved in 
acetone and combined with K2CO3 and two different aryl bromides.157 After 2 h 
at 70 ºC, these alkylations yielded the quaternary allyl esters 147f-g in 89% and 
49% yield, respectively (Table 8, entries 6–7). The yield of 147f was similar to 
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the yield of the previous Mannich rections. However, the yield of 147g was 
much lower. This lower yield could be related with the nucleophilicity and higher 
polarity of 3-(bromomethyl)pyridine. 
 
O
O
O
R
O O
O Conditions
Quaternary allyl esterBuilding block
Reagents
BocHN SO2Ph
153
146 147
 
 
Entry Building block Reagents & Conditions Quaternary allyl ester Yielda 
  1  BzN
O
O O
O
146a  
153, Cs2CO3, DCM, 18 h, rt BzN
O
O
O
O
NHBoc
147a  
83% 
  2  
O
O O
O
146b  
153, Cs2CO3, DCM, 18 h, rt 
O
O
O
O
NHBoc
147b  
85% 
  3  
N
Cbz
OH
O
O
146c  
153, Cs2CO3, DCM, 18 h, rt 
N
Cbz
O
O
O
NHBoc
147c  
84% 
  4  
MeO
O
O
O
146d  
153, Cs2CO3, DCM, 18 h, rt 
MeO
O
O
O
NHBoc
147d  
>99% 
  5 
a 
146e
O
O O
O
 
153, Cs2CO3, DCM, 18 h, rt 
147e
O
O O
O
NHBoc
 
–b 
b 153, Cs2CO3, DCM, 3 h, 0 ºC –c 
c 153, Cs2CO3, DCM, 3 h, rt 87% 
  6  
N
Cbz
OH
O
O
146c  
Benzyl bromide, K2CO3, 
acetone, 2 h, 70 ºC 
N
Cbz
O
O
O
147f  
89% 
  7  
N
Cbz
OH
O
O
146c  
3-(Bromomethyl)pyridine 
hydrobromide, K2CO3, 
acetone, 2 h, 70 ºC 
N
Cbz
O
O
O
147g
N
 
49% 
Table 8: Mannich/alkylation reactions of the different allyl ester building blocks 146 to form the 
quaternary allyl esters 147. aYield of the purified quaternary allyl ester. bNo product observed by 
1H-NMR spectroscopy (400 MHz) of the crude product mixture due to the formation of 
compound 157 (Scheme 13). cNo reaction observed by TLC of the crude product mixture.  
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Scheme 13: Proposed mechanism for the decomposition of the quaternary allyl ester 147e to 
give the α,β-unsaturated ester 157. This decomposition was observed in the Mannich reaction 
of 146e after 18 h of reaction at rt (Table 8, entry 5a). The hydroxide nucleophile that starts this 
reaction could come from residual water in the Cs2CO3. 
 
3.2.2.2. Pd-catalysed Decarboxylative Allylic Alkylation  
With the quaternary allyl esters 147 in hand, the Pd-catalysed decarboxylative 
allylic alkylation was the last step to the cyclisation precursors. To be able to 
perform this reaction with high enantioselectivity, a chiral PHOX ligand is 
required.142,143 However, this ligand is very expensive because it comes from an 
unnatural aminoacid. For this reason, it was decided to prepare the cyclisation 
precursors as racemates using PPh3 as ligand. Therefore, the different 
quaternary allyl esters 147 were treated with 5 mol% Pd(OAc)2 and 20 mol% 
PPh3 in THF at 70 °C for 1h.145 The reaction was highly reproducible with the 
different substrates and the corresponding cyclisation precursors 148 were 
obtained in yields ranging from 76% to 89% (Table 9, entries 1b and 2–7). 
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O
O
O
R O R
5 mol% Pd(OAc)2 
20 mol% PPh3
Conditions
Quaternary allyl ester Cyclisation precursor
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Entry Quaternary allyl ester Conditions Cyclisation precursor Yielda 
    1 
a 
BzN
O
O
O
O
NHBoc
147a  
Toluene, 40 ºC, 16 h 
BzN
O
O NHBoc
148h  
28%b 
b THF, 70 ºC, 1 h 80% 
2 
O
O
O
O
NHBoc
147b  
THF, 70 ºC, 1 h 
O
O NHBoc
148i  
76% 
3 
N
Cbz
O
O
O
NHBoc
147c  
THF, 70 ºC, 1 h 
N
Cbz
O NHBoc
148j  
87% 
4 
MeO
O
O
O
NHBoc
147d  
THF, 70 ºC, 1 h 
MeO
O
148k
NHBoc
 
81% 
5 
147e
O
O O
O
NHBoc
 
THF, 70 ºC, 1 h 
148l
O
O NHBoc
 
88% 
6 
N
Cbz
O
O
O
147f  
THF, 70 ºC, 1 h 
N
Cbz
O
148m  
89% 
7 
N
Cbz
O
O
O
147g
N
 
THF, 70 ºC, 1 h 
N
Cbz
O
148n
N
 
80% 
Table 9: Pd-catalysed decarboxylative allylic alkylation of the quaternary allyl esters 147 to 
yield the corresponding cyclisation precursors 148. aYield of the purified cyclisation precursor. 
bLower yield due to the formation of product 158 (Scheme 14). 
 
The polarity of the solvent and the temperature were important in this reaction. 
Consequently, the reaction of the quaternary allyl ester 147a in toluene at 
40°C142 gave the cyclisation precursor 148h in a lower yield because an 
undesired major product 158 was obtained (Table 9, entry 1a and Scheme 14). 
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O
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39%  
 
Scheme 14: Proposed mechanism for the formation of the undesired compound 158 obtained 
from the quaternary allyl ester 147a using the Pd-catalysed decarboxylative allylic alkylation in 
toluene at 40 °C (Table 9, Entry 1a). 
 
3.2.3. Summary and Conclusions 
The synthesis of the cyclisation precursors 148h-n was successfully 
accomplished after three steps. The most challenging step for the synthesis 
was the preparation of the allyl ester building blocks, which was very 
irreproducible when using different substrates and it gave lower yields. 
Consequently, different optimisations were required. However, the connective 
Mannich/alkylation step and the Pd-catalysed reaction were highly reproducible 
with all the substrates and high yields were obtained. For this reason, few 
optimisations were required. In addition, the Pd-catalysed reaction could be 
performed using a chiral PHOX ligand instead of PPh3, which would allow the 
synthesis of enantioenriched cyclisation precursors.142,143 
 
3.3. Investigation of the Scope of the Cyclisation Reactions and Synthesis 
of Scaffolds 
Once the synthesis of the cyclisation precursors was completed, the 
investigation of the scope of the cyclisation reactions started. The different 
cyclisation precursors previously prepared could undertake a different number 
of cyclisation reactions (Figure 28). The lactam-derived cyclisation precursor 
148h could undertake cyclisation reactions between the NHBoc and the 
terminal alkene. The ketone-derived cyclisation precursors 148i-j and 148l 
could undertake cyclisation reactions between the terminal alkene, the NHBoc, 
the ketone and the α-position of the ketone. The ketone-derivative 148k could 
undertake cyclisation reactions between the terminal alkene, the NHBoc and 
the ketone. Finally, the ketone-derived cyclisation precursors 148m-n could 
undertake cyclisation reactions between the ketone and the alkene.  
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Figure 28: Functional groups present in the cyclisation precursors that could allow different 
cyclisation reactions. 
 
These cyclisation precursors have closely related structures. Consequently, 
depending on the functional groups, each cyclisation precursor could undertake 
the same cyclisations under the same or similar reaction conditions. For this 
reason, it was decided to use the cyclisation precursor 148i to investigate and 
optimise the scope of the cyclisation reactions. Subsequently, the successful 
optimised cyclisations with 148i are going to be performed with the other 
cyclisation precursors. 
 
3.3.1. Cyclisation Reactions Between the Ketone and the Alkene 
It was decided to use the cyclisation precursor 148i to investigate and optimise 
the scope of the cyclisation reactions. Compound 148i could undertake 
cyclisation reactions between the terminal alkene, the NHBoc, the ketone and 
the α-position of the ketone. The first cyclisation reactions to be investigated 
were reactions involving the ketone and the terminal alkene.  
 
The first transformation studied was the hydroboration of the alkene to give a 
terminal alcohol. As a result, the terminal alcohol could react with the ketone to 
give a hemiacetal. Consequently, the cyclisation precursors 148i-n were treated 
with disiamylborane in THF followed by NaBO3 and H2O.158 The reaction was 
highly reproducible with the different substrates, giving the corresponding 
products 159 in yields from 58% to 83% (Table 10, entries 1d and 2–6). All the 
hemiacetals were obtained as single diastereomers. However, the relative 
configuration could not be determined. It was observed that the organoborane 
used in this reaction was crucial to get high yields of the desired hemiacetal. If 
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other organoborane reagents like 9-BBN, dicyclohexylborane or borane were 
used, the yield of the desired product was lower due to the fact that the cyclic 
ketone was reduced to the alcohol, giving a mixture of diastereoromeric diols 
160 (Table 10, entries 1a–c).159 This mixture of diols 160 was never observed 
when using disiamylborane. 
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O
HO
R
O R
Cyclisation precursor
1. Organoborane
2. NaBO3•4H2O
   THF/H2O, 0 ºC to rt
THF, 0 ºC
Hemiacetal
148 159
+
OH R
Diastereomeric diols
160
OH
 
 
Entry Cyclisation precursor Organoborane Hemiacetala Yieldg 
  1 
a 
O
O NHBoc
148i  
9-BBN 
O
O
HO
NHBoc
159ab  
35%h 
b BH3 –i 
c Dicyclohexylborane –j 
d Disiamylborane 76% 
  2  
N
Cbz
O NHBoc
148j  
Disiamylborane 
N
Cbz
O
HO
NHBoc
159bc  
58% 
  3  
MeO
O
148k
NHBoc
 
Disiamylborane 
MeO
O
159cd
NHBoc
OH  
61% 
  4  
148l
O
O NHBoc
 
Disiamylborane 
159de
O
O
HO
NHBoc
 
73% 
  5  
N
Cbz
O
148m  
Disiamylborane 
N
Cbz
O
HO
159ef  
83% 
  6  
N
Cbz
O
148n
N
 
Disiamylborane 
N
Cbz
O
HO
N
159ff  
70% 
Table 10: Optimisation and utilisation of the hydroboration reaction for the synthesis of the 
hemiacetals 159. aThe relative configuration of the hemiacetals could not be determined by 
NOESY (500 MHz). bObserved as a single diastereomer (CD3OD, 1H-NMR, 400 MHz). 
cObserved as a single diastereomer (CD3OD, 1H-NMR, 500 MHz). dObserved as the primary 
alcohol (CDCl3, 1H-NMR, 400 MHz; CDCl3, 13C-NMR, 100 MHz). eObserved as a 67:33 mixture 
of a hemicetal as a single diastereomer and primary alcohol (CDCl3, 1H-NMR, 400 MHz; CDCl3, 
13C-NMR, 100 MHz). fObserved >90% as a single hemiacetal (CD3OD, 1H-NMR, 500 MHz; 
CD3OD, 13C-NMR, 125 MHz). gYields of the purified hemiacetals. hLower yield due to the partial 
reduction of the cyclic ketone to give the diols 160, observed by LC-MS, TLC and 1H-NMR 
spectroscopy (400 MHz) of the crude product mixture. iDesired hemiacetal not observed by LC-
MS and TLC of the crude product mixture due to completely reduction of the cyclic ketone to the 
diols 160. jDecomposition observed by TLC and 1H-NMR spectroscopy of the crude product 
mixture. 
 
After optimising the hydroboration reaction and obtaining the different 
hemiacetals 159, the next step was their reduction to form the first scaffolds. In 
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this reduction, it was observed that the selection of the acid depended on the 
structure of the starting material. Consequently, the corresponding hemiacetals 
159 were dissolved in DCM, combined with Et3SiH and treated with different 
acids. It was shown that some of the products were very polar due to removal of 
the Boc group. Consequently, the Boc group was reintroduced. After 
reprotection (when required), these reactions gave the desired scaffolds 149 in 
yields ranging from 43% to 99% (Table 11, entries 1e, 2–3, 4c and 5–6). In 
addition, the diastereoselectivity of all of these reactions was always very high, 
obtaining the scaffolds with crude dr ≥91:≤9. The six-membered ring 
hemiacetals 159a-b and 159e-f were treated with TFA. However, the use of 
TFA did not work with the five-membered ring hemiacetal 159d (Table 11, 
entries 4a–b). This could be due to the fact that the rigidity of the five-
membered ring does not allow the formation of the intermediate oxocarbenium 
ion. Consequently, 159c-d were treated with the stronger Lewis-acid BF3 
instead of TFA.160,161 The use of BF3 in the six-membered rings gave lower 
yields due to decomposition (Table 11, entry 1a). Milder acids as FeCl3,162,163 
AcOH or other reducing agents like NaBH(OAc)3 only showed traces or no 
formation of product (Table 11, entries 1b–d).  
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Hemiacetal Scaffold
O
HO
R Method
159 149
 
 
Entry Hemiacetal Methoda Scaffold Crude dr Yield and dr 
  1 
a 
O
O
HO
NHBoc
159a  
A 
O
O
NHBoc
149a
H
 
>95:<5b 31%h, >95:<5i 
b B                     –c 
c C                     –d 
d D                     –e 
e E >95:<5b 99%, >95:<5j 
  2  
N
Cbz
O
HO
NHBoc
159b  
E 
N
Cbz
O
NHBoc
149b
H
 
>95:<5f 51%, >95:<5j 
  3  
MeO
O
159c
NHBoc
OH  
F 
MeO
149c
O
NHBoc
H
 
>95:<5g 65%, >95:<5j 
  4 
a 
159d
O
O
HO
NHBoc
 
E 
O
O
NHBoc
149d
H
 
                    –d 
b G                     –c 
c F >95:<5g 43%, >95:<5j 
  5  
N
Cbz
O
HO
159e  
H 
N
Cbz
O
149e
H
 
93:7f 63%, >95:<5j 
  6  
N
Cbz
O
HO
N
159f  
H 
N
Cbz
O N
149f
H
 
91:9f 88%, 91:9j 
Table 11: Optimisation and utilisation of the hemiacetal reduction to obtain different 
tetrahydropyran-derived scaffolds. aMethod: A: Et3SiH, BF3•Et2O, DCM, –78 °C to rt; B: Et3SiH, 
FeCl3, CH3NO2, rt; C: Et3SiH, AcOH, rt; D: NaBH(OAc)3, AcOH, rt; E: Et3SiH, TFA, DCM, rt, 
then Boc2O, Et3N, DCM, rt; F: Et3SiH, BF3•Et2O, DCM, –78 ºC to rt, then Boc2O, Et3N, DCM, rt; 
G: Et3SiH, TFA, DCM, 40 ºC, then Boc2O, Et3N, DCM, rt; H: Et3SiH, TFA, DCM, rt. bDetermined 
by 1H-NMR spectroscopy (400 MHz) of the crude product mixture. cDecomposition detected by 
TLC of the crude product mixture. dNo reaction detected by TLC of the crude product mixture. 
eTraces of product detected by LC-MS of the crude product mixture. fDetermined by 1H-NMR 
spectroscopy (500 MHz) of the crude product mixture. gDetermined by 1H-NMR spectroscopy 
(300 MHz) of the crude product mixture. hLower yield due to Boc removal and subsequent 
decomposition observed by TLC, LC-MS and 1H-NMR spectroscopy of the crude product 
mixture. iYield and dr (1H-NMR, 400 MHz) of purified scaffold. jYield and dr (1H-NMR, 500 MHz) 
of purified scaffold. 
 
Once these scaffolds 149 were obtained in good yields, it was decided to 
determine their relative configurations. 1H-NMR spectroscopy (400–500 MHz) 
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showed that all the protons in the tertiary carbon had a singlet or small doublet 
of J ≤4.0 Hz. Consequently, there should not be a vicinal proton in a trans 
position with respect to these protons because a much larger value of J would 
be expected. Therefore, these scaffolds should have a cis ring fusion. This was 
supported by NOESY (500 MHz), where different nOe enhancements were 
observed between the proton of the tertiary carbon, the protons next to the 
tertiary carbon and the protons in the adjacent chain (Figure 29, Panel A). If the 
scaffolds had a trans ring fusion, nOe enhancements between the proton of the 
tertiary carbon and the adjacent chain would not be observed. In addition, the 
cis ring fusion would be expected because when the intermediate six-
membered ring oxocarbenium ion is formed, only the observed product or a 
twisted boat, which is not stable, can be formed (Figure 29, Panel B).  
 
A 
O
H
OMe
H
N
Cbz
O
NHBoc
149b
H
H
H
H
H
CbzN
O
H
BocHN H
H
H
O
O
NHBoc
H
149d
H H
O
O
H
BocHN H
H
N
Cbz
O
H
H
149e
H
H
H
H
CbzN
O
H
H
H
H
N
Cbz
O
H
H
149f
H
H
H
CbzN
O
H
HB
H
N
N
MeO
OH
H
149c
BocHN H
H
O
O
NHBoc
149a
H
H
H
O
O
H
BocHN
H
8
8a
8
8a 8
8a
7a
8
8a
8
8a
8
8a
8
8a
8
8a
7a
9b
BocHN
H
H
9b
 
 
B 
R
O O
H
R
O
H
R
Attack from the bottom Attack from the top
Disfavoured Favoured
149Twist-boat
SiEt3
H
SiEt3
H
 
 
Figure 29: Determination of the relative configuration of  the scaffolds 149. Panel A: Key nOe 
enhancements of the NOESY (500 MHz). Panel B: Proposed rationale for the formation of the 
observed stereochemistry. 
67 
 
The scaffold 149a was the only one that crystallised. For this reason, it was 
analysed by X-ray crystallography. The X-ray structure also confirmed that 
scaffold 149a adopts a cis ring fusion (Figure 30). 
 
O
O
NHBoc
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Figure 30: X-ray structure of the scaffold 149a confirming the cis ring fusion. 
 
Before moving to the next cyclisation reaction, it was decided to investigate if 
the intermediate oxocarbenium ion (formed from the hemiacetals in the 
presence of an acid) could also be arylated. However, before doing this 
transformation, the hemiacetal needed to be converted to an acetal. This 
transformation was required to avoid the deprotonation of the hemiacetal by the 
reagents used in the arylation reaction. As a result, after treating the hemiacetal 
159a with catalytic amounts of TsOH in MeOH, compound 161 was purified in 
83% yield and dr >95:<5 (Table 12). Successively, the acetal 161 was 
combined with electron rich aromatic groups like anisole,164 with Grignard 
reagents like PhMgBr165 and with organocopper reagents made in situ from 
CuBr and PhMgBr.166 However, the arylation reaction was not successful (Table 
12). For this reason, the arylation of the hemiacetals was not continued. 
 
O
O
HO
NHBoc
MeOH
TsOH (cat.)
O
O
MeO
NHBoc
159a
83%
161a
dr >95:<5b
O
O
Ar
NH2
Reagents
Conditions
162
 
Entry Reagents & conditions Ar Yield 162 
1 BF3•Et2O, anisole 4-methoxyphenyl –d 
2 BF3•Et2O, DCM, –20 ºC, then PhMgBr, DCM, –20 ºC Ph –d 
3 Me2S•CuBr and PhMgBr, then Et2O•BF3, THFc Ph –e 
Table 12: Transformation of the hemiacetal 159a into the acetal 161 and attempts for its 
arylation. aThe relative configuration of 161 could not be resolved by NOESY. bDetermined by 
1H-NMR spectroscopy (400 MHz) of the purified product. cThe procedure followed uses Et2O as 
solvent. However, 161 was not soluble in Et2O and for this reason the solvent was changed to 
THF. dNo reaction observed by LC-MS of the crude product mixture. eDegradation observed by 
1H-NMR spectroscopy of the crude product mixture. 
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Due to the attempted arylation of the acetal 161 failing, a second cyclisation 
reaction between the ketone and the alkene was investigated. In this second 
transformation, the alkene of the cyclisation precursor 148 would be converted 
into an aldehyde to be able to perform a double reductive amination between 
the ketone and the resulting aldehyde. For this reason, compound 148i was 
treated with O3 gas followed by a reductive work-up with DMS. Consequently, 
compound 163 was obtained as a mixture of two hemiaminals in 75% yield 
(Table 13). The hemiaminal mixture 163 should interconvert with its aldehyde 
form. Consequently, a double reductive amination, involving the aldehyde and 
the ketone, could be possible starting from the hemiaminal mixture 163 and a 
primary amine. For this reason, the hemiaminal mixture 163 was treated with 
benzylamine in DCM followed by NaBH(OAc)3 and AcOH at rt. After purification, 
the corresponding amine 164 was isolated in 30% yield and dr 83:17 (Table 13, 
Entry 1). It was observed that this transformation was very particular. Changes 
in the temperature, solvent,167,168 reducing agent 169 or amine170–173 always gave 
lower yields and lower dr (Table 13, entries 2–8). Consequently, the reaction 
could not be improved. For this reason, it was decided not to try this cyclisation 
with the other cyclisation precursors. 
 
O
O NHBoc
O
O NBoc
OH
1. O3
DCM, –78 ºC
2. DMS, DCM, rt
148i
75%
163
Isolated with
dr 66:34a
O
RN
NHBoc
Method
164, R = Bn
165, R = CHPh2
166, R = H
H
Scaffold
 
 
Entry Methodb Time Yield scaffoldc drf 
1 A 18 h 30% of 164 83:17 
2 B 18 h 16% of 164 66:33 
3 C 72 h 19% of 164 53:47 
4 D 72 h Traces of product 164d 
5 E 18 h Only imine formationd 
6 F 24 h Traces of product 165d 
7 G 18 h –e 
8 H 24 h –e 
Table 13: Ozonolysis of the alkene 148i to give the hemiaminals 163 and optimisation of the 
following double reductive amination. aDetermined by 1H-NMR spectroscopy (400 MHz) of the 
purified hemiaminals. bMethod: A: BnNH2, AcOH, NaBH(OAc)3, DCM, rt; B: BnNH2, AcOH, 
NaBH(OAc)3, DCM, 0 °C to rt; C: BnNH2, AcOH, NaBH(OAc)3, THF, rt; D: BnNH2, NaCNBH3, 
THF, rt; E: BnNH2, AcOH, NaCNBH3, MeOH, –78 °C to rt; F: Ph2CHNH2, NaBH(OAc)3, AcOH, 
DCM, rt; G: Ph2CHNH2, NaCNBH3, AcOH, MeOH, –78 °C to rt; H: NH4OAc, NaBH3CN, AcOH, 
EtOH, rt. cYield of purified scaffold. dDetected by LC-MS of the crude product mixture. 
eDegredation detected by TLC of the crude product mixture. fDetermined by 1H-NMR 
spectroscopy (400 MHz) of the purified product. 
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The relative configuration of the major diastereomer of the amine-derived 
scaffold 164 was determined by 1H-NMR spectroscopy and NOESY. 1H-NMR 
spectroscopy (400 MHz) showed that proton 7a-H appears as an apparent 
singlet, suggesting that there is not a vicinal proton in trans respect 7a-H. 
NOESY (500 MHz) showed four nOe enhancements. Two between the protons 
of the methylcarbamate chain and the proton 7a-H, and two between the 
protons 7-H2 and 7a-H (Figure 31). For this reason, compound 164 should 
adopt a cis ring fusion. If 164 had a trans ring fusion, the nOe signals between 
7a-H and the methylcarbamate chain woud not be observed and nOe signals 
between 7a-H and the axial proton from the carbon at position six would be 
expected. 
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Figure 31: Multiplicity (1H-NMR, 400 MHz) and key nOe enhancements (NOESY, 500 MHz) to 
resolve the relative configuration of the major diastereomer of the amine 164. 
 
Due to the low success of the double reductive amination, more intramolecular 
reactions starting with the alkene and the ketone were investigated. The ketone 
could be reduced to a secondary alcohol. For this reason, the cyclisation 
precursors 148i-l were treated with DIBAL-H for 1 h.142 This gave the 
corresponding secondary alcohols 167 from 63% to 93% yield and with high 
diastereoselectivities (crude dr ≥86:≤14) (Table 14, entries 1a, 2c and 3–4). For 
most of the reductions, 2.20 eq of DIBAL-H was used. However, only 1.10 eq 
was used for the reduction of 148j. The reason is that DIBAL-H can cleave the 
Cbz group (Table 14, entry 2a). It was seen that DIBAL-H was essential to 
obtain these high dr. The use of other reducing agents always gave lower 
diastereoselectivity (Table 14, entries 1c-d and 2b). Therefore, it was suggested 
that DIBAL-H gave the best dr because it could coordinate to the NHBoc group.  
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O NHBoc OH NHBoc
Method
Cyclisation precursor Alcohol
148 167
 
 
Entry Cyclisation precursor Method
a Alcohol Crude dr Yield and dr 
   1 
a 
O
O NHBoc
148i  
A OH
O
NHBoc
167a  
86:14b     93%, 86:14e 
b B 86:14b –f 
c C 28:72b –f 
d D 56:44b –f 
   2 
a 
N
Cbz
O NHBoc
148j  
A 
OH
N
Cbz
NHBoc
167b  
                 –c 
b C    45:55d         –f 
c E   >95:<5d 78%, >95:<5g 
   3  
MeO
O
148k
NHBoc
 
A 
MeO
OH
167c
NHBoc
 
   90:10b 63%, >95:<5e 
   4  
148l
O
O NHBoc
 
A 
O
OH NHBoc
167d  
  >95:<5b 92%, >95:<5g 
Table 14: Optimisation and utilisation of the diastereoselective ketone reduction. aMethod: A: 
DIBAL-H 2.20 eq, DCM, –78 ºC; B: DIBAL-H 2.20 eq, DCM, –100 ºC; C: L-Selectride 2.20 eq, 
THF, –78 ºC; D: NaBH4 2.00 eq, MeOH, 0 ºC; E: DIBAL-H 1.10 eq, DCM, –100 ºC. bDetermined 
by 1H-NMR spectroscopy (400 MHz) of the crude product mixture. cCbz cleavage observed by 
TLC and 1H-NMR spectroscopy (500 MHz) of the crude product mixture. dDetermined by 1H-
NMR spectroscopy (500 MHz) of the crude product mixture. eYield and dr (1H-NMR, 400 MHz) 
of the purified alcohol. fNot purified. gYield and dr (1H-NMR, 500 MHz) of the purified alcohol. 
 
The relative configuration of the alcohols 167a-b was determined by analogy 
with the carbocyclic analogue,142 by 1H-NMR spectroscopy (400 MHz–500 
MHz) and NOESY (500 MHz). A high J value of 11.1 Hz and 9.7 Hz was 
observed for the proton 4-H in 167a-b, respectively. Consequently, proton 4-H 
must have a vicinal proton in a trans position. Different nOe interactions were 
observed between the proton 4-H and the protons in the methylcarbamate 
chain (Figure 32, Panel A). Consequently, the alcohol has a trans position 
compared with the methylcarbamate chain. If the relative configuration was cis, 
the nOe signal between 4-H and the methylcarbamate chain would not be 
detected or a smaller J value would be observed for 4-H because it would not 
have a vicinal proton in trans. In addition, DIBAL-H could coordinate to the 
NHBoc group. Therefore, it would deliver the hydride from the same face of the 
NHBoc chain, providing the expected stereochemistry (Figure 32, Panel B). The 
relative configuration of the five-membered ring alcohols 167c-d could not be 
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determined by NOESY and it was determined later using compounds 150c-d 
(Figure 34). 
 
A 
O OH
H
NHBoc
HB
O
167a
NHBoc
HB
4
4 CbzN
H
NHBoc
H
N
Cbz
167b
NHBoc
H
H 4
4
H
OH
OH
H
OH
H
167a: J4-H = 11.1 Hz and 4.8 Hz
167b: J4-H = 9.7 Hz and 4.4 Hz  
B 
X
BocHN
O
Al
H
X
H
OH
BocHN
X = O or NCbz
148i-j 167a-b
X
H
NHBoc
OH
 
 
Figure 32: Determination of the relative stereochemistry of compounds 167a-b. Panel A: Key 
nOe enhancements of the NOESY (500 MHz) and key J couplings (1H-NMR (400–500 MHz)). 
Panel B: Proposed rationale for the formation of the observed stereochemistry. 
 
Once the secondary alcohols were obtained, they were used for cyclisation 
reactions with the alkene. It has been stated that alcohols can be involved in 
intramolecular carboetherification reactions with alkenes.174 Consequently, it 
was decided to use compound 167a with the preferred conditions for this 
transformation to take place (Scheme 15). However, the reaction was not 
successful. This result could be due to the fact that the NHBoc could also react 
under these conditions.  
 
O
OH NHBoc
1-Bromo-3-methoxybenzene
1 mol% Pd2(dba)3
2 mol% 93
NaOtBu
THF, 65 ºC
O
O
OMe
167a
H
NHBoc
168a  
 
Scheme 15: Attempted carboetherification reaction of the alcohol 167a. aA complicated mixture 
was observed by TLC of the crude product mixture. 
 
Finally, it was decided to try an iodocyclisation reaction119 as another method to 
cyclise between the alcohol and the alkene. Therefore, the alcohol 167a was 
dissolved in acetonitrile and combined with I2 and NaHCO3. The reaction was 
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moderately diastereoselective and after purification, the scaffold 169 was 
obtained as a single diastereomer in 39% yield (Scheme 16). 
 
O
OH NHBoc
I2, NaHCO3
Acetonitrile, rt, 18 h
O
O
I
NHBoc
39%
Isolated with
dr >95:<5a
167a 169Crude dr 80:20
a
H
 
 
Scheme 16: Iodocyclisation reaction of the alcohol 167a to give the tetrahydrofuran-derived 
scaffold 169. aDetermined by 1H-NMR spectroscopy (500 MHz). 
 
Since compound 169 was isolated as a single diastereomer, the relative 
stereochemistry was investigated. 1H-NMR spectroscopy (500 MHz) showed a 
J value of 3.8 Hz for the proton 7a-H. Consequently, it should not have a vicinal 
proton in a trans position. NOESY (500 MHz) showed that compound 169 has 
two nOe signals between the proton 2-H from the tetrahydrofuran ring and the 
two protons from the methylcarbamate chain, and another nOe signal between 
2-H and 7a-H. Consequently, the new chiral centre formed in compound 169 
should adopt the same relative configuration than the other two chiral centres 
(Figure 33). If the relative configuration of the new chiral centre was the 
opposite, the previous nOe interactions could not be observed and nOe 
interactions would be observed between 2-H and 7-H2.  
 
O
O
I
H
H
NHBoc
O
H
O
BocHN H
I
S*2
H7a
169
S* S*
S*
2
7a
S*
S*
H
H
H
7
7
J7a-H = 3.8 Hz  
 
Figure 33: Key nOe enhancements observed by NOESY (500 MHz) for the resolution of the 
relative stereochemistry of compound 169.   
 
In conclusion, three successful cyclisation reactions were performed starting 
from the ketone and the alkene functionalities. One cyclisation reaction involved 
the formation of a hemiacetal. The other cyclisation reaction involved the 
formation of a hemiaminal. The last one involved an alcohol intermediate. The 
hemiacetal, the hemiaminal and the alcohol intermediates allowed the formation 
of cis fused-ring systems through an etherification reaction, a double reductive 
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amination and an iodocyclisation reaction, respectively. The cyclisation reaction 
involving the hemiacetals gave the best results. Consequently, it was 
successfully performed with the other cyclisation precursors. 
 
3.3.2. Cyclisation Reactions Between the Ketone and the NHBoc 
After investigating cyclisation reactions between the ketone and the alkene, 
cyclisation reactions between the ketone and the NHBoc were studied. The 
cyclisation precursors were previously reduced to the corresponding secondary 
alcohols in high yields and high dr. Consequently, these alcohols were used for 
the following cyclisation reactions. Treatment of the alcohols 167 with KOtBu 
gave the derived carbamates 150 in yields from 58% to 96% (Table 15, entries 
1b and 2–4). It was observed that the reaction time was different depending on 
the structure of the alcohol. Six-membered ring alcohols gave the 
corresponding carbamates in only 1 h. However, five-membered ring alcohols 
needed more than 1 h to give the corresponding carbamates. The reaction with 
the five-membered ring substrate could be slower because of the rigidity of the 
five-membered ring. In addition, during the optimisation it was shown that the 
use of other bases like NaH decreased the reaction time and the yield (Table 
15, entry 1a). Two explanations for this result could be that the potassium 
alkoxide intermediate has a harder character than the sodium alkoxide, and that 
KOtBu only deprotonates the alcohol, where NaH also deprotonates the NHBoc. 
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OH NHBoc
Base
THF, 0 ºC to rt
NHO
O
Alcohol Scaffold
H
167 150
 
 
Entry Alcohol Base Reaction time Scaffold Yielda 
      1 
a OH
O
NHBoc
167a  
NaH 18 h 
O
NHO
O
150a
H
 
22% 
b KOtBu 1 h 96% 
      2  
OH
N
Cbz
NHBoc
167b  
KOtBu 1 h 
N
Cbz
NHO
O
150b
H
 
63% 
      3  
MeO
OH
167c
NHBoc
 
KOtBu 18 h MeO
150c
NH
O
O
H
 
58% 
      4  
O
OH NHBoc
167d  
KOtBu 18 h 
O
NHO
O
150d
H
 
65% 
Table 15: Optimisation and utilisation of an intramolecular carbamate formation for the 
synthesis of carbamate-derived scaffolds. aYield of purified scaffold. 
 
The carbamates 150c-d were obtained as crystalline solids and they were 
analysed by X-ray crystallography to be able to corroborate the relative 
stereochemistry of the preceding alcohols 167c-d. The X-ray structures of 
150c-d demonstrated that they have a trans fused-ring system (Figure 34). 
Consequently, the relative stereochemistry of the five-membered ring 
secondary alcohols 167c-d is the same than the six-membered ring secondary 
alcohols 167a-b. 
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A 
MeO
150c
NH
O
O
H
 
 
B 
O
NHO
O
150d
H
 
 
 
Figure 34: Determination of the relative stereochemistry of the carbamates 150c-d. Panel A: X-
ray crystal structure of the carbamate-derived scaffold 150c confirming the trans relative 
configuration. Panel B: X-ray crystal structure of the carbamate-derived scaffold 150d 
confirming the trans relative configuration 
 
In conclusion, only one cyclisation reaction was achieved starting from the 
ketone and the NHBoc of the cyclisation precursors. This reaction involved an 
intermediate alcohol. However, the reaction worked very well. Therefore it was 
used with the different cyclisation precursors to obtain different trans fused-ring 
systems.  
 
3.3.3. Cyclisation Reactions Between the Alkene and the NHBoc 
Cyclisation reactions between the alkene and the NHBoc were the next ones to 
be investigated. The secondary alcohols 167 can be obtained in a good dr. For 
this reason, they were used as starting points for cyclisation reactions between 
the NHBoc and the alkene. As a result, it would allow access to diverse 
spirocyclic compounds. The use of compounds 148 was avoided because the 
reduction of their ketone in the subsequent spirocyclic products could give a 
poor dr.  
 
Therefore, the alcohol 167a was used as substrate in the ozonolysis reaction. 
Consequently, it was treated with O3 gas followed by DMS to give the 
intermediate aldehyde, which should give hemiaminals as a mixture of 
diastereomers. However, this reaction gave a complicated mixture of 
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compounds (Scheme 17). One explanation could be that the free alcohol of the 
aldehyde intermediate also reacts with the aldehyde to form hemiacetals. 
 
O
OH NHBoc 1. O3
DCM, –78 ºC
2. DMS, DCM, rt
167a
O
OH NBoc
OH
170  
 
Scheme 17: Ozonolysis of the alcohol 167a. As both the alcohol and the NHBoc could react 
with the aldehyde of the resulting product, a complicated mixture of compounds was observed 
by 1H-NMR spectroscopy of the crude product mixture. 
 
Consequently, it was decided to protect the secondary alcohols to avoid side-
reactions. Consequently, the secondary alcohols 167 were treated with Ac2O 
and pyridine142 (Table 16). The reaction worked very well and the 
corresponding esters 171 were obtained in ≥95% yield.  
 
OH NHBoc OAc NHBoc
Ac2O
pyridine, rt, 18 h
Alcohol Ester
167 171
 
 
Entry Alcohol Ester Yielda 
1 
OH
O
NHBoc
167a  
OAc
O
NHBoc
171a  
95% 
2 
OH
N
Cbz
NHBoc
167b  
OAc
N
Cbz
NHBoc
171b  
95% 
3 
MeO
OH
167c
NHBoc
 
MeO
OAc
171c
NHBoc
 
99% 
4 
O
OH NHBoc
167d  
O
OAc NHBoc
171d  
95% 
Table 16: Protection of the secondary alcohols with an acetyl group to form esters. aYield of 
purified ester. 
 
Once the esters 171 were obtained, they were used as substrates, conjointly 
with the cyclisation precursor 148h, in the ozonolysis reaction. Consequently, 
they were treated with O3 gas followed by the reductive work-up with DMS. This 
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yielded a mixture of diastereomeric hemiaminals. Successively, the 
hemiaminals were dissolved in AcOH and reduced with NaBH(OAc)3.175 The 
reaction was very reproducible with all the substrates and it gave the 
corresponding pyrrolidine-derived scaffolds 173 in yields ranging from 49% to 
76% (Table 17, entries 1b and 2–5). It was important to use a mild acid to form 
the cyclic N-acyliminium ion intermediate. Removal of the Boc group was 
observed if TFA was used as acid, making the deprotected product too polar 
and difficult to handle (Table 17, entry 1a). In addition, the use of TFA also 
produced decomposition of the resulting imine. 
 
NHBoc
1. O3, DCM, –78 ºC
2. DMS, DCM
–78 ºC to rt
NBoc
OH
NBoc
Method
X X X
Starting material Hemiaminal Scaffold
172 173
 
 
Entry Starting material Hemiaminal Yield & dra Methodc Scaffold Yield 
  1 
a 
OAc
O
NHBoc
171a  172a
O
OAc NBoc
OH
 
74%, 58:42 
A 
O
NBocOAc
173a  
–d 
b B 58%e 
  2  
OAc
N
Cbz
NHBoc
171b  
–b B 
N
Cbz
NBocOAc
173b  
61%f 
  3  
MeO
OAc
171c
NHBoc
 
–b B 
MeO
OAc
173c
NBoc
 
51%f 
  4  
O
OAc NHBoc
171d  
–b B 
173d
O
OAc
NBoc
 
76%f 
  5  BzN
O
O NHBoc
148h  
–b B BzN
O
NBocO
173e  
49%f 
Table 17: Optmisation and utilisation of the hemiaminal reduction to yield different pyrrolidine-
derived scaffolds. aYield and dr (1H-NMR, 500 MHz) of the purified hemiaminal. bHemiaminal 
not isolated. cMethod: A: TFA, DCM, rt, then NaBH(OAc)3, DCM, rt; B: NaBH(OAc)3, AcOH, rt. 
dRemoval of the Boc group and subsequent decomposition observed by TLC, LC-MS and 1H-
NMR spectroscopy of the crude product mixture. eYield of the purified scaffold after the two 
steps, the yield of the second step was 79%. fYield of the purified scaffold after the two steps. 
 
In addition to the reduction of the hemiaminals 172, their oxidations were also 
investigated to obtain lactam-derived scaffolds. Consequently, the preceding 
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hemiaminals 172 were dissolved in DCM and treated with PDC at rt.176 This 
reaction was also highly reproducible with the different substrates and it gave 
the desired lactam-derived scaffolds 174 from 37% to 76% yield (Table 18, 
entries 1c and 2–4). Nevertheless, these reactions with PDC were very slow 
and all needed one week to be completed. It was observed that this oxidation 
was very particular. The use of other oxidative conditions like the Parikh–
Doering oxidation136 and the use of TPAP/NMO177 only gave traces of product 
after one week (Table 18, entries 1a–b).  
 
NHBoc
1. O3, DCM, –78 ºC
2. DMS, DCM
–78 ºC to rt
NBoc
OH
NBoc
Method
Starting material Hemiaminal Scaffold
OAc OAc OAc
O
171 172 174
 
 
Entry Starting material Hemiaminal Methodb Scaffold Yield 
  1 
a OAc
O
NHBoc
171a  172a
O
OAc NBoc
OH
 
A 
O
NBocOAc
174a
O
 
–c 
b B –c 
c C 48%d 
  2  
OAc
N
Cbz
NHBoc
171b  
–a C 
N
Cbz
NBocOAc
O
174b  
60%e 
  3  
MeO
OAc
171c
NHBoc
 
–a C 
MeO
OAc
174c
NBoc
O
 
37%e 
  4  
O
OAc NHBoc
171d  
–a C 
O
OAc
NBoc
O
174d  
76%e 
Table 18: Optimisation and utilization of the hemiaminal oxidation to form different lactam-
derived scaffolds. aHemiaminal not isolated. bMethod: A: SO3•Pyr, DMSO, Et3N, DCM, 0 °C to 
rt, 1 week; B: TPAP, NMO, molecular sieves 4 Å, DCM, rt, 1 week; C: PDC, celite, DCM, rt, 1 
week. cTraces of product detected by LC-MS of the crude product mixture. dYield of the purified 
scaffold after the two steps, the yield of the second step was 65%. eYield of the purified scaffold 
after the two steps. 
 
Once the previous spirocyclic compounds were obtained, it was invesitgated if 
the N-acyliminium ion, formed from the hemiaminals under acidic conditions, 
could be arylated to obtain spirocycles with aromatic rings. As a result, it was 
decided to treat the hemiaminals 172a with MeOH and catalytic amounts of 
TsOH to achieve the aminals 175 in 77% yield and dr 77:23 (Scheme 18). Once 
the aminals 175 were obtained, their arylation using an organocopper reagent 
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(previously unsuccessful with the acetal 161) was attempted.166 Consequently, 
the aminals 175 were treated with DMS•CuBr, PhMgBr and BF3 in Et2O. This 
time the reaction worked, and the phenyl-derived scaffold 176 was isolated in 
88% yield with dr 57:43 (Scheme 18). The yield was high, but there was poor 
diastereoselectivity (crude dr 50:50). For this reason it was decided not to 
repeat this reaction with the other substrates. 
 
O
NBocOAc
OH
O
NBocOAc
OMe
MeOH
TsOH (cat.)
77%
172a 175
Isolated with
dr 77:23a
DMS•CuBr
PhMgBr, Et2O•BF3
Et2O, –78 ºC to 0 ºC
O
NHOAc
88%
Isolated with 
dr 57:43a
176Crude dr 50:50a
 
 
Scheme 18: Synthesis and arylation of the aminals 175 to form the scaffold 176. aDetermined 
by 1H-NMR spectroscopy (500 MHz). 
 
After completing the synthesis of the previous spirocycles, another pathway for 
the synthesis of more spirocyclic compounds was investigated. Disiamylborane 
previously showed good results for the hydroboration of terminal alkenes in the 
synthesis of the previous hemiacetal derivatives (Table 10). For this reason, the 
alkenes 171 and 148h were also treated with disiamylborane followed by 
NaBO3•4H2O. This reaction gave the terminal alcohols 177 in yields ranging 
from 41% to 86% (Table 19, entries 1b, 2–4 and 5a). The lower yield for the 
alcohol 177d was due to the fact that its acetyl group was partially removed. 
This undesired reaction was not observed with the other substrates when using 
disamylborane. However, the change of disiamylborane for 9-BBN completely 
hydrolysed the acetyl group of the product, or did not give the desired product 
when the substrate used contained a lactam (Table 19, entries 1a and 5b). 
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X NHBoc
Alkene
1. Organoborane
2. NaBO3•4H2O
   THF/H2O, 0 ºC to rt
THF, 0 ºC
Alcohol
X NHBoc
OH
177
 
 
Entry Alkene Organoborane Alcohol Yielda 
    1 
a 
OAc
O
NHBoc
171a  
9-BBN 
O
OAc NHBoc
OH
177a  
–b 
b Disiamylborane 73% 
    2  
OAc
N
Cbz
NHBoc
171b  
Disiamylborane 
N
Cbz
OAc NHBoc
OH
177b  
86% 
    3  
MeO
OAc
171c
NHBoc
 
Disiamylborane 
MeO
OAc
177c
NHBoc
OH  
83% 
    4  
O
OAc NHBoc
171d  
Disiamylborane 
O
OAc NHBoc
OH
177d  
41%c 
    5 
a 
BzN
O
O NHBoc
148h  
Disiamylborane 
HN
O
O NHBoc
OH
177e  
71% 
b 9-BBN –d 
Table 19: Hydroboration reaction to yield terminal alcohols. aYield of the purified alcohol. 
bDesired product not observed by 1H-NMR spectroscopy and LC-MS of the crude product 
mixture due to the fact that the acetyl group was completely removed. cA lower yield was 
obtained for this reaction due to the fact that it was observed by 1H-NMR spectroscopy and LC-
MS of the crude product mixture that the acetyl group was partially removed. dNo hydroboration 
reaction observed by TLC and 1H-NMR spectroscopy of the crude product mixture, only the 
cleavage of the benzoyl group by NaBO3•4H2O was observed. 
 
Once the alcohol derivatives 177 were obtained, their cyclisations were 
attempted to be able to form piperidine-derived scaffold. Consequently, the 
different primary alcohols were dissolved in DCM and treated with MsCl and 
Et3N to successfully form all the mesylated intermediates 178. Successively, 
they were treated with TFA to remove the Boc group. Once the Boc group was 
removed the resulting free amines should displace the mesylated alcohol to 
form the new piperidine ring.178 Due to the fact that a basic amine could be 
difficult to handle, the Boc group was always reintroduced once the cyclisation 
was completed. After reprotection, this cyclisation reaction gave different yields 
depending of the structure of the staring material. The reaction worked well for 
the six-membered rings 177a-b and 177e, giving the desired piperidine-derived 
81 
 
scaffolds in yields ranging from 40% to 57% (Table 20, entries 1b, 2 and 5). 
However, this reaction gave a lower yield of 13% and no product for the five-
membered rings 177c-d, respectively (Table 20, entries 3 and 4a–b). 
Consequently, the yield of this reaction could be affected by the rigidity of the 
ring in the starting material. In addition, other cyclisation conditions involving the 
use of NaH142 were not successful either with six- or five-membered rings 
(Table 20, entries 1a and 4c). 
 
Alcohol Scaffold
X NHBoc
OH
X
Boc
N
MsCl, Et3N
DCM, 0 ºC
X NHBoc
OMs
Method
177 178a 179
 
 
Entry Alcohol Methodb Scaffold Yieldc 
     1 
a 
O
OAc NHBoc
OH
177a  
A 
O
OAc
Boc
N
179a  
–d 
b B 57% 
       2 
N
Cbz
OAc NHBoc
OH
177b  
B 
N
Cbz
OAc
Boc
N
179b  
40% 
       3 
MeO
OAc
177c
NHBoc
OH  
B 
MeO
OAc
179c
NBoc
 
13% 
     4 
a 
O
OAc NHBoc
OH
177d  
B 
O
OAc BocN
179d  
–e 
b C –e 
c A –d 
       5 HN
O
O NHBoc
OH
177e  
B HN
O
O
Boc
N
179e  
57% 
Table 20: Optimisation and utilisation of an intramolecular SN2 cyclisation reaction to yield 
different piperidine-derived scaffolds. aThe mesylated alcohols 178 were always formed 
(observed by TLC and LC-MS of the crude product mixture after the first step). bMethod: A: 
NaH, THF, 65 ºC; B: TFA, DCM, rt, then Et3N, DCM, rt, then Boc2O, DCM, rt; C: TFA, (Bu)4NI, 
DCM, 40 ºC, then Et3N, DCM, rt, then Boc2O, DCM, rt. cYield of the purified scaffold. 
dDecomposition observed by TLC and 1H-NMR spectroscopy of the crude product mixture. eNo 
cyclisation observed by TLC and 1H-NMR spectroscopy of the crude product mixture. 
 
After the formation of the piperidine-derived scaffolds 179 was achieved, the 
synthesis of their oxidised versions was also attempted. For this reason, the 
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alcohol derivative 177a was treated with PDC in DCM. PDC should oxidise the 
alcohol 177a to the aldehyde, which would cyclise to form the hemiaminal 
intermediates 180. These hemiaminals would be oxidised again to form the 
scaffold 181. The use of PDC as oxidising agent worked well for the oxidation of 
the previous hemiaminals (Table 18). However, it did not work for the formation 
of compound 181 from 177a and only traces of product were observed after 4 
days of reaction (Scheme 19).  
 
O
OAc NHBoc
OH PDC, celite
O
OAc
Boc
N O
Tracesa
DCM, rt, 4 days
177a
181
PDC, celite
DCM, rt, 4 days
O
OAc
Boc
N OH
O
OAc NHBoc
O
180
 
 
Scheme 19: Failed attempt of a double oxidation reaction to form compound 181 from the 
alcohol 177a. aObserved by LC-MS of the crude product mixture. 
 
After obtaining the previous two-ring system spirocycles, the synthesis of more 
complex spirocyclic ring systems was investigated. However, due to the basic 
conditions of the following cyclisation reactions it was decided to change the 
acetyl protective group of compound 171a for a base-stable protecting group. 
Therefore, the protection of the alcohol 167a with a benzyl group was 
attempted. For this reason, the secondary alcohol 167a, BnBr and catalytic 
amounts of (Bu)4NI were dissolved in THF. Successively, NaH was added to 
the reaction mixture.179 This gave the benzylated product 182 in 86% yield 
(Table 21, entry 3). It was observed that the order of addition and the base used 
were important in this reaction. If NaH was added to the reaction mixture before 
BnBr, the yield decreased (Table 21, entry 1).179 If other bases like KOtBu were 
used, the reaction did not work well (Table 21, entry 2). The reason is that once 
the alcohol of 167a is deprotonated by KOtBu, it rapidly reacts with the NHBoc 
group to form the six-membered ring carbamate 150a previously synthesised 
(Table 15). 
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O
OH NHBoc
BnBr, Base
(Bu)4NI
O
OBn NHBoc
THF, 0 ºC
167a 182  
Entry Base Procedure Yielda 
1 NaH Addition of BnBr as the last reagent 52% 
2 KOtBu Addition of BnBr as the last reagent –b 
3 NaH Addition of NaH as the last reagent 86% 
Table 21: Optimisation of the benzyl protection of the alcohol 167a to form compound 182. 
aYield of purified product. bNot isolated, it was observed by 1H-NMR spectroscopy of the crude 
product mixture that most of the product is the carbamate 150a. 
 
With compound 182 in hand, it was used as substrate for a Pd-catalysed 
aminoarylation reaction,116 conjointly with the free alcohol 167a (to know if the 
reaction requires a protected alcohol) and the ketone 148i. The use of the 
cyclisation precursor 148i has been previously avoided for the synthesis of 
spirocycles because the reduction of the ketone in the resulting spirocyclic 
products could give a poor dr. Nevertheless, it was of interest to try the 
aminoarylation on the ketone 148i because the resulting spirocyclic product 
would have an additional chiral centre and consequently it could undertake a 
diastereoselective ketone reduction. Consequently, compounds 148i, 167a and 
182 were treated with 3-bromopyridine in the presence of 10 mol% of the ligand 
93, 5 mol% of Pd(OAc)2 and Cs2CO3 in 1,4-dioxane for 18 h at 105 ºC. As 
expected, the reaction did not work for the alcohol 167a due to the fact that the 
free alcohol could also react under this kind of conditions through a 
carboetherification reaction (Table 22, entry 2).174,180,181 However, the reaction 
worked for the ketone 148i and the protected alcohol 182, yielding the 
pyrrolidine-derived products 183 and 185 in 34% and 31% yield, respectively 
(Table 22, entries 1 and 3). Nevertheless, the reaction was not very 
diastereoselective, giving a crude dr 65:35 and 67:33, respectively. Only 
product 185 was purified as a single diastereomer. Consequently, the best 
substrate for the aminoarylation reaction was the protected alcohol 182. 
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3-Bromopyridine
5 mol% Pd(OAc)2
10 mol% 93
Cs2CO3
1,4-Dioxane
105 ºC, 18 h O
X NBoc
NO
X NHBoc
ScaffoldStarting material  
 
Entry Starting material Scaffold Crude dra Yield & drc 
1 
O
O NHBoc
148i  
O
O NBoc
N
183  
65:35 34%, 69:31 
2 
OH
O
NHBoc
167a  
O
NBocOH
N
184  
–b 
3 
O
OBn NHBoc
182  
O
OBn NBoc
N
185  
67:33 31%, >95:<5 
Table 22: Optimisation of the Pd-catalysed aminoarylation reaction to obtain pyrrolidine-derived 
scaffolds. aDetermined by 1H-NMR spectroscopy (500 MHz) of the crude product mixture. 
bComplicated mixture observed by TLC and 1H-NMR spectroscopy of the crude product mixture. 
cYield and dr (1H-NMR, 500 MHz) of the purified product. 
 
It was thought that changing the benzyl protecting group for a larger protecting 
group could improve the diastereoselectivity of the aminoarylation reaction. 
Consequently, a larger protecting group could give better selectivity for one 
diastereomer. Therefore, the TBDPS group was selected due to the fact that it 
has a larger size and because it has been used to protect similar alcohols.182 
However, the protection of the alcohol 167a with TBDPS did not work, even 
with the use of imidazole or DMAP. This result could be because the alcohol 
could be too hindered to react with TBDPS. Due to the fact that the 
aminoarylation reaction could not be improved, it was not attempted with other 
cyclisation precursors. 
 
Due to the fact that the pyrrolidine-derived scaffold 185 was isolated as a single 
diastereomer, the relative configuration of the new chiral centre was 
investigated by NOESY (500 MHz) analysis (Figure 35). One nOe interaction 
was observed between the proton 6-HA and the proton 3-H. Consequently, the 
new chiral centre at C-3 should have the opposite relative configuration respect 
the other chiral centres. If the relative configuration of the new chiral centre was 
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the same than the other chiral centres, this nOe signal would not be observed 
and nOe signals would be observed between the pyridinylmethyl chain and 6-
HA. 
O
OBn NBoc
H
N
O
NBoc
OBn
HA
H N
6
3 R*
185
S*
S*
6
3
R*S*
S*
HA
 
 
Figure 35: Key nOe enhancement of the NOESY (500 MHz) analysis for the determination of 
the relative stereochemistry of the scaffold 185. 
 
Due to the poor yield and dr of the aminoarylation reaction, the iodocyclisation 
reaction was investigated again as an alternative source of other complex 
spirocyclic compounds. It was assessed with the benzylated derivative 182 
because it gave the best result in the aminoarylation reaction. For this reason, 
compound 182 was dissolved in acetonitrile and combined with I2 and NaHCO3. 
After the reaction was completed, the expected product 186 was only obtained 
in 30% yield as a mixture of two inseparable diastereomers (dr 77:23) (Scheme 
20). This yield was low because two other products were also obtained in this 
reaction. One of these side-products is the iodo-derivative 169, which has been 
previously prepared (Scheme 16). The second side-product is the seven-
membered ring 187, which would be a new scaffold. Both of these two side-
products were isolated as single diastereomers, in 18% and 8% yield, 
respectively. Product 169 was obtained because iodide can remove the 
protecting Bn group, releasing a free alkoxide, which can react instead of the 
NH group. Product 187 was obtained due to the fact that the iodocyclisation 
reaction can also give a side-reaction where the Boc group reacts instead of the 
NH group. Since the reaction gave different products, the mixture was 
complicated and the crude dr could not be determined. Due to the low yield and 
dr of 186, this reaction was not tried with the other cyclisation precursors. 
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Scheme 20: Iodocyclisation reaction of the benzyl derivative 182 to form the expected product 
186 and two other unexpected products, the known scaffold 169 and the new scaffold 187. 
aDetermined by 1H-NMR spectroscopy (500 MHz) of the isolated product. 
 
Since the scaffold 187 was isolated as a single diastereomer, the relative 
stereochemistry was investigated by NOESY (500 MHz). One nOe signal was 
observed between 5-H and 11-H. Consequently, the new chiral centre formed in 
compound 187 should have the opposite relative configuration than the other 
two chiral centres (Figure 36). If the new chiral centre had the same relative 
configuration than the other chiral centres, this nOe interaction could not be 
observed and nOe interactions would be observed between 5-H and the 
iodomethyl chain. 
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Figure 36: Key nOe enhancement for the resolution of the relative stereochemistry of 
compound 187 by NOESY (500 MHz). 
 
In conclusion, different spirocyclic compounds were successfully prepared using 
cyclisation reactions between the alkene and the NHBoc. The ketone of 
compounds 148 can be reduced with a good dr to the corresponding alcohols. 
For this reason, the alcohols were usually used as starting points for cyclisation 
reactions between the NHBoc and the alkene. Protection of the alcohols was 
important before performing the cyclisation reactions. Some cyclisation 
reactions gave poor yields and/or poor dr. However, some others worked very 
well and they were used with the other cyclisation precursors. 
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3.3.4. Cyclisation Reactions Between the NHBoc and the α-position of the 
Ketone 
After investigating different cyclisation reactions between the main 
functionalities of the cyclisation precursors, a final cyclisation reaction was 
investigated. This cyclisation reaction could be an intramolecular Mannich 
reaction, involving the α-carbon of the ketone and the NHBoc. For this reason, it 
was decided to dissolve the cyclisation precursor 148i in MeOH and treat it with 
TFA and different aldehydes at 65 ºC. The reaction worked, giving the bridged 
bicyclic scaffolds 152 and 188 in 30% and 33% yield, respectively (Table 23, 
entries 1b and 2). In addition, compound 188 was obtained as a single 
diastereomer. Removal of the Boc group was necessary for this cyclisation to 
proceed. It was observed that when changing TFA for a milder acid as AcOH, 
there was no cyclisation (Table 23, entry 1a).  
 
O
O NHBoc
148i
Acid, aldehyde
O
H
NR O
MeOH, 65 ºC
Scaffold  
Entry   Acid Aldehyde Scaffold Crude dra Yield and drd 
   1 
a AcOH (CHO)n 
O
H
N
O
152  
–b 
b TFA (CHO)n –c 30%, –c 
   2 
 
TFA Benzaldehyde 
O
H
N
O
188  
>95:<5 33%, >95:<5 
Table 23: Optimisation of the intramolecular Mannich reaction to give bridged bicyclic scaffolds. 
aDetermined by 1H-NMR spectroscopy (500 MHz) of the crude product mixture. bNo cyclisation 
observed by TLC and 1H-NMR spectroscopy of the crude product mixture. cNot applicable. 
dYield and dr (1H-NMR, 500 MHz) of purified scaffold. 
 
The relative configuration of the scaffold 188 was confirmed by NOESY (500 
MHz). Protons from the aromatic ring showed nOe enhancements with the 
proton 4-HA. In addition, proton 6-H also showed two nOe signals; one with the 
proton 5-H and one with the proton 8-HB. These signals suggested that the 
phenyl ring should be situated in an equatorial position (Figure 37). If the phenyl 
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ring was situated in an axial position, these nOe interactions would not be 
observed and nOe interactions would be observed between the phenyl ring and 
the proton 8-HB, and between the protons 4-HA and 6-H. 
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Figure 37: Key nOe enhancements of the NOESY (500 MHz) analysis to resolve the relative 
configuration of compound 188. 
 
In conclusion, two other cyclisation reactions were performed from the 
cyclisation precursor 148i using an intramolecular Mannich reaction. This 
transformation afforded bridged bicyclic scaffolds. This result was interesting 
because these scaffolds have very different ring systems and tri-dimensional 
conformations compared to the scaffolds obtained from previous cyclisation 
reactions. However, these cyclisation reactions were not attempted with the 
other cyclisation precursors due to the challenging diastereoselective reduction 
of the resulting ketone. 
 
3.3.5. Summary of Results 
The cyclisation precursor 148i was used to investigate the scope of the different 
possible cyclisation reactions. As a result, thirteen different cyclisation reactions 
were accomplished with this cyclisation precursor as starting point and thirteen 
scaffolds were obtained (Figure 38). The scaffolds include fused-rings, 
spirocyclic rings and bridged bicyclic rings. Consequently, a high structural 
diversity of sp3-rich ring systems was achieved.  
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Figure 38: Summary of all the scaffolds obtained from cyclisation reactions of the cyclisation 
precursor 148i. 
 
Despite a large number of scaffolds being obtained from the cyclisation 
precursor 148i, not all the cyclisation reactions were successfully optimised to 
give good average yields (≥30%) and high diastereoselectivities (dr ≥80:≤20). 
For this reason, the cyclisation reactions that yielded these scaffolds in low 
average yields and low dr were not used for the synthesis of other scaffolds 
(Table 24). Consequently, scaffolds 164, 176, 185, 186 and 187 were not 
prioritised. In addition, compound 169 was also not prioritised because the main 
possible change of the iodine group would have been to form a primary amine, 
making the resulting compound too polar for CNS. However, if a less polar 
transformation was going to be used to displace the iodide, this compound 
could also be prioritised. Finally, scaffolds 152 and 188 were also not selected. 
The reason is that they have a bridgehead ketone, which would be difficult to 
reduce to a single diastereomer. However, these two scaffolds could also be 
prioritised if the ketone was removed using the Wolff-Kisher reaction.183 
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Entry Scaffold 
Number of steps from the 
cyclisation precursor 148i 
and average yield 
dr After 
purification 
Prioritised for the 
synthesis of other 
scaffolds 
1 
O
O
NHBoc
149a
H
 
Two steps, 75% >95:<5 ü 
2 
O
BnN
NHBoc
164
H
 
Two steps, 23% 83:17 û 
3 
O
O NH
O
150a
H
 
Two steps, 89% 86:14 ü 
4 
O
NBocOAc
173a  
Four steps, 52% >95:<5 ü 
5 
O
NBocOAc
O
174a  
Four steps, 42% >95:<5 ü 
6 
O
NHOAc
176  
Five steps, 44% 57:43 û 
7 
O
OAc
Boc
N
179a  
Four steps, 37% >95:<5 ü 
8 
OBn
O
NBoc
N
185  
Three steps, 25% >95:<5 û 
    9 
a 
OBn
O
Boc
N
I
186  
Three steps, 24% 77:23 û 
b 
O
OBn
O
H
N
O
I
187  
Three steps, 6% >95:<5 û 
10 
O
O
NHBoc
I
169
H
 
Two steps, 36% >95:<5 û 
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11 
152
O
H
N
O
 
One step, 30% >95:<5 û 
12 
188
O
H
N
O
 
One step, 33% >95:<5 û 
Table 24: Summary of the average yields and dr of all the scaffolds obtained from the 
cyclisation precursor 148i. Scaffolds prioritised depending on average yield, dr and functional 
groups. Scaffolds 186 and 187 (Entry 9) were obtained from the same reaction. 
 
As a result, the five cyclisation reactions that yielded the prioritised scaffolds 
were used with the other cyclisation precursors. The cyclisation reactions were 
highly reproducible with the different precursors, only in few instances the 
optimised cyclisation reaction had to be slightly modified. Consequently, 18 
additional scaffolds were obtained using the other six cyclisation precursors 
(Table 25).  
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Cyclisation precursor Additional scaffolds obtained using  the prioritised cyclisation reactions 
BzN
O
O
NHBoc
148h  
HN
O
Boc
NO
BzN
O
NBocO
179e173e  
O
N
Cbz
NHBoc
148j  
N
Cbz
O
NHBoc
N
Cbz
NBocOAc
N
Cbz
NBocOAc
O
N
Cbz
NHO
O
N
Cbz
Boc
NOAc
149b 150b 173b 174b 179b
H H
 
MeO
O
148k
NHBoc
 
MeO
149c
O
NHBoc
H
MeO
150c
NH
O
O
H
MeO
OAc
173c
NBoc
MeO
OAc
174c
NBoc
O
MeO
OAc
179c
NBoc
 
O
O NHBoc
148l  
NHO
O
O
O
NHBoc
O
NBoc
O
AcO NBoc
O
O
AcO
149d 150d 173d 174d
HH
 
O
N
Cbz
X
148m, X = CH
148n, X = N  
N
Cbz
O
149e
H
N
Cbz
O N
149f
H
 
Table 25: Additional scaffolds obtained from the cyclisation precursors 148h and 148j-n using 
the prioritised cyclisation reactions. 
 
Consequently, a total of 23 scaffolds were prepared from the seven cyclisation 
precursors using the prioritised cyclisation reactions. The reactions were very 
efficient, delivering the 23 scaffolds in 42 steps (steps counted as isolated and 
characterised compounds) from the seven cyclisation precursors. Due to the 
fact that these scaffolds can be prepared in good average yields and good dr, 
some of them were prepared on a larger scale to allow subsequent decoration 
to lead-like molecules. 
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3.4. Application of the Computational Tool 
After completing the synthesis of the 23 scaffolds using the prioritised 
cyclisation reactions, the value of these scaffolds for CNS drug discovery was 
assessed. Consequently, a virtual library of the unprotected/decorable versions 
of these scaffolds was prepared (Figure 39).  
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Figure 39: Virtual library of scaffolds assessed using the computational tool. Scaffolds with one 
point of decoration were decorated once. Scaffolds with two or more points of decoration were 
decorated twice. Primary amines served as two points of decoration. Terminal alkenes were 
converted into aldehydes, which were converted to alcohols before decoration or were 
decorated with a reductive amination reaction. As the deprotections, it is assumed that these 
transformations could be synthetically accessible. 
 
Successively, this virtual library of 23 scaffolds was decorated once or twice 
(depending of the points of decoration) and scored with the computational tool. 
It was observed that all the scaffolds were novel and most of them obtained a 
good mean CNS Lead MPO score ~>4.00 (Table 26). 
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Scaffold 
number 
Mean  
CNS Lead 
MPO scorea 
Number of 
derived 
compounds 
         Noveltyb 
Hits without  
α-atoms 
Hits with  
α-atoms 
189 4.54 1080 0 0 
190 4.75 2204 0 0 
191 4.91 2204 0 0 
192 5.30 696 0 0 
193 4.84 1798 0 0 
194 3.83 1798 0 0 
195 3.67 2204 0 0 
196 4.42 696 23 0 
197 4.14 7598 26 0 
198 4.15 6112 241 0 
199 4.62 2233 241 0 
200 4.18 2329 0 0 
201 4.07 6112 122 0 
202 5.30 696 0 0 
203 5.17 696 0 0 
204 4.65 1080 0 0 
205 4.94 1798 2 0 
206 5.01 2204 40 0 
207 5.40 696 40 0 
208 4.46 76 0 0 
209 5.05 76 0 0 
210 3.65 1080 0 0 
211 3.94 2204 23 0 
Table 26: Results obtained for the 23 virtual scaffolds using the computational protocol. aMean 
of all the CNS Lead MPO scores of the derived compounds per scaffold. bBased on Murcko 
fragments against a random 2% of the ZINC database. 
 
Once the results of the computational tool were obtained, the scores of some 
scaffolds were further analysed (Figure 40). It was observed that some 
scaffolds like 199 and 206 present a high score because all of their derived 
compounds have the desired physicochemical properties. Consequently, 
scaffolds 199 and 206 are likely to yield lead-like molecules, which once 
optimised, would have the desired physicochemical properties to cross the 
BBB. Scaffold 194 presents a lower score because its derived compounds 
usually have too high MW due to the presence of the aromatic ring. Finally, 
scaffold 201 also presents a lower score. This is due to the fact that its derived 
compounds usually have too high pKa. The reason is that this scaffold has two 
basic amines and one alcohol as points of decoration. All the scaffolds are not 
decorated more than twice. Consequently, some of the derived compounds of 
the scaffold 201 will always have a basic amine with a high pKa. However, due 
to the fact that the CNS Lead MPO score takes into account six different 
properties, scaffolds 194 and 201 do not score very low because the other 
properties have the desirable values. Consquently, they would also be likely to 
yield lead-like molecules for CNS drug discovery.  
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Figure 40: Panel A: Analysis of the mean CNS Lead MPO scores of the derived compounds 
for each of the 23 virtual scaffolds. In red, examples of scaffolds with lower scores (194 and 
201). In green, examples of scaffolds with higher scores (199 and 206). Panels B, C, D, E: 
Distribution of the CNS Lead MPO scores of the derived compounds of the scaffolds 194, 199, 
201 and 206, respectively. 
 
3.5. Conclusions 
In conclusion, a highly modular and efficient toolkit of cyclisation reactions was 
developed and used to prepare a library of 23 structurally-diverse and sp3-rich 
scaffolds. This library of scaffolds was subsequently assessed with the 
computational tool. It was observed that all the scaffolds were novel and they 
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had good mean CNS Lead MPO scores. Consequently, lead-like molecules 
derived from these scaffolds would allow to further study the CNS lead-like 
chemical space. The value of these scaffolds would be highlighted in the design 
of high-quality HTS libraries for CNS-targets. These scaffolds could be used as 
starting points for the synthesis of novel and high-quality lead-like molecules for 
CNS drug discovery programs. These lead-like molecules could be added to 
the current collection of compounds used for HTS in CNS drug discovery. If 
some of these molecules are active, their potency could be improved to deliver 
a drug-like molecule with the desired properties for crossing the BBB. This 
would improve the success in the later stages of the drug discovery 
programme. 
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Chapter 4: Realising the Biological Relevance of the Developed 
Scaffolds for CNS Drug Discovery 
 
4.1. Ligand Discovery Against BACE1 
β-Site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as β-
secretase 1, Asp2 or memapsin 2, is a transmembrane aspartic protease that 
belongs to the pepsin family.184,185 It is predominantly found in the neurons of 
the CNS.186 The inhibition of this protease has been of great interest for the 
treatment of Alzheimer’s disease.187 Alzheimer’s disease is a CNS disorder 
characterised by the loss of neurones due to the extracellular accumulation of 
an hydrophobic peptide called amyloid β.186 The formation of amyloid β is 
initiated by the proteolytic activity of BACE1. This enzyme cleaves a peptide 
called APP (amyloid precursor protein), which is subsequently cleaved by 
another secretase to form amyloid β (Figure 41).188  
 
 
 
Figure 41: Amyloid β formation initiated by BACE1 in Alzheimer’s disease. Adapted from a 
reference.188 
 
Consequently, inhibition of BACE1 has become of interest to stop the 
progression of the disease.189 Different inhibitors have been designed, which 
involve peptidomimetics, pseudo-peptidomimetics and non-peptidomimetics.190 
However, the problem of the peptidomimetics is that they do not have the 
desired properties to cross the BBB.190 Consequently, non-peptidomimetics 
inhibitors have attracted more attention due to the fact that they are smaller 
molecules. For this reason, they have better BBB penetration and lower P-gp 
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efflux.190 Different small molecule inhibitors have already been designed and 
reached clinical trials.190 However, some have recently been withdrawn after 
being successful in Phase I. One example is the drug candidate verubecestat, a 
BACE1 inhibitor developed by Merck. This candidate was removed in the last 
stages of clinical trials because it did not improve the cognitive function and 
showed side effects.189,191 For this reason, more studies are required to 
understand the physiological and pathological role of BACE1 and if its inhibition 
will significally improve cognitive funtions.  
 
To be able to continue studying BACE1 as target to treat Alzheimer’s disease, 
the screening of new small molecules is of interest.190 Recently, a fragment-
based HTS allowed the identification of an amidine-like hit 212 (Figure 42).192 It 
is known that amidine-like groups form interactions with the two catalytic 
aspartates in the active site of BACE1.192 
 
A B 
N N
O
O O
O
Asp32
Asp228
H
HH
 
N NH2
212  
 
Figure 42: Panel A: Binding mode of amidine-like groups in the active site of BACE1.192 Panel 
B: BACE1 hit identified by fragment-based HTS.192 
 
This initial hit was developed into the compound 213 (Figure 43, panel A).192 
Consequently, the fragment 212 was grown in opposite vectors to increase the 
number of interaction in the binding site. During this process, different 
intermediate compounds like 214 were prepared and tested against BACE1. 
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Figure 43: Panel A: Optimisation of the aminoquinoline fragment 212 to obtain the compound 
213. Panel B: Co-crystal structure of the intermediate 214 in the active site of BACE1 (PDB: 
3RU1).193 Compound 214 can adopt two binding conformations. Key interactions are shown in 
yellow dashes. 
 
It was observed by looking at the co-crystal structure of BACE1 with 214 that 
alternative optimisations could be possible if the cyclohexylmethyl ring of 214 
was changed for more interesting ring systems, due to the fact that the active 
site is quite large and the new ring system could fill it (Figure 43, panel B). For 
this reason, this cyclohexylmethyl ring could be changed for some of the 
scaffolds previously prepared using the Mannich/alkylation and palladium 
connective reactions. Using this approach, it could be possible to assess the 
biological value of the developed scaffolds for CNS drug discovery. 
 
4.2. Decoration of the Scaffolds 
The substructure of compound 214 without the cyclohexylmethyl group was 
identified as a potential medicinal chemistry capping group for BACE1. For this 
reason, it was decided to use this capping group to decorate some of the 
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scaffolds previously prepared (Scheme 21). Consequently, a library of derived 
compounds could be obtained. It was decided to use the amines of the 
scaffolds as point of decoration. Consequently, the substructure of 214 could be 
added to the amine through an amide bond. 
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Scheme 21: Overview of the selected approach for the design of different derived compounds 
from the substructure of compound 214 and different scaffolds. 
 
For this reason, 13 different virtual derived compounds were designed from the 
substructure of compound 214 coupled to different scaffolds (Figure 44). It was 
decided to generate eight derived compounds from the designed scaffolds and 
five from simpler commercially available scaffolds, including the already known 
compound 214. The designed scaffolds were selected on the basis of their 
suitability for the decoration, the CNS Lead MPO score of the corresponding 
derived molecule and their structural diversity. The commercially available 
scaffolds were selected as simpler substructures of the designed scaffolds. 
Consequently, it could be observed if the designed scaffolds have a higher 
value for the inhibition of BACE1 than the respective and simpler commercial 
scaffolds. Compound 214 was selected as a future reference compound. 
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Figure 44: Virtual derived compounds generated from coupling the BACE1 capping group with 
different scaffolds. Panel A: Derived molecules from the designed virtual scaffolds 190, 191, 
206, 211, 193, 205, 208 and 209; respectively. Panel B: Compound 214 and derived molecules 
from commercially available scaffolds.  
 
Successively, these derived molecules were scored with the computational tool 
(Table 27). It was observed that all of them have CNS Lead MPO ~>3.00. The 
reason the scores are below four is mainly due to the high MW of the 
decorating group. However, the MW of this capping group cannot be reduced 
because it would reduce the affinity for BACE1. For this reason, these scores 
were accepted as good. Consequently, if any of these derived compounds is 
active, it could be optimised to a compound that could be CNS-compliant. 
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Virtual derived compound CNS Lead MPO score 
214 3.71 
215 3.62 
216 3.74 
217 3.85 
218 3.05 
219 3.63 
220 3.74 
221 2.93 
222 3.45 
223 4.31 
224 5.32 
225 3.40 
226 4.20 
Table 27: CNS Lead MPO scores of the generated virtual derived compounds. 
 
Consequently, these 13 derived molecules were selected for synthesis. To be 
able to prepare these compounds, the synthesis of the capping group 227 is 
necessary. Compound 227 was prepared in three steps (Scheme 22).192 The 
first step involved the nucleophilic aromatic substitution of the commercially 
available chloro-derivative 228 with tBuNH2 to yield the amine derivative 229 in 
52% yield. Successively, a Wittig reaction was performed on 229 to give the 
alkene derivative 230 in a quantitative yield. Finally, the alkene 230 was 
dissolved in EtOH and treated with H2 gas in the presence of 10 mol% Pd/C. 
This yielded the capping group 227 in 97% yield. 
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H
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228 229
N NHtBu
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O
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N NHtBu
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EtO
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CH3CN, rt
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OEt
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Scheme 22: Synthesis of the capping group 227, necessary for the decoration of the scaffolds. 
 
Once the ester 227 was prepared, it was used for the decoration of the 
scaffolds. The decoration of the scaffolds to prepare the derived molecules 
involved two steps. The first step was the coupling reaction between each 
scaffold and the ester 227 using an aminolysis reaction.194 This step was 
always performed in one pot. Firstly, the scaffolds were fully deprotected (if 
required) and dissolved in toluene. Subsequently, they were combined with 
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1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) and Et3N (if required) and heated to 
75 °C. After purification, the corresponding intermediate amide-derived products 
231 were obtained in yields ranging from 20% to 98% (Table 28, where R = 
tBu). The second step involved the removal of the tBu group by treating the 
intermediates 231 with TFA at 75 °C.192 This yielded the final compounds 
(Table 28, where R = H). The yields of the deprotection were usually very high 
(≥83%), despite compounds 231d and 231j, which gave a yield of 32% and 
47%, respectively, due to decomposition. 
 
N NHtBu
R
O
R = Scaffold
Scaffold Method
N NH2
R
O
TFA
75 ºC
Step 1 Step 2
Derived compoundIntermediate
231
 
 
Entry Scaffold Methoda Intermediate, R = 
tBu 
Derived compound, R = H 
         Yieldb 
Step 1 
R = tBu 
Step 2 
R = H 
1 
 
O
OAc
Boc
N
179a  
A 
N
N
O
NHR
O
HO
 
231a,  
21% 
215, 
>99% 
2 
 
O
NBocOAc
173a  
A 
N
N
O
NHR O
HO
 
231b, 
60% 
216, 
93% 
3 
 
NBoc
O
AcO
173d  
A 
N
N
O
NHR
O
HO
 
231c, 
72% 
217, 
>99% 
4 
 
MeO
OAc
173c
NBoc
 
A 
N
N
O
NHR
HO
OMe
 
231d, 
75% 
218, 
32%c 
5 
 
O
O
NHBoc
149a
H
 
B 
N
N
H
O
NHR
O
HO  
231e, 
28% 
219, 
98% 
6 
O
NHBoc
O
149d
H
 
B 
N
N
H
O
NHR O
O
H
 
231f, 
31% 
220,  
>99% 
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7 
 
N
Cbz
O
149e
H
 
C 
N
N
O
NHR O
H  
231g, 
23% 
221, 
>99% 
8 
 
N
Cbz
O N
149f
H
 
C 
N
N
O
NHR O
H
N
 
231h, 
20% 
222, 
99% 
9 
 
 
NH2
232  
D 
N
N
H
O
NHR  
231i, 
98% 
214, 
83% 
10 
 
233
O
NH2
 
D 
N
N
H
O
NHR O  
231j, 
90% 
223, 
47%c 
11 
 
HN
O
234  
D 
N
N
O
NHR
O
 
231k, 
56% 
224, 
93% 
12 
 
H2N
Cl
235  
E 
N
O
NHR
N
 
231l, 
37% 
225, 
>99% 
13 
 
O
NH3
236
Cl
 
E 
N
N
H
O
NHR O  
231m, 
43% 
226, 
>99% 
Table 28: Decoration of the scaffolds to yield the final derived compounds where R = H. 
aMethod: A: NaOMe, MeOH, rt, then TFA, DCM, rt, then 227, TBD, Et3N, toluene, 75 °C; B: 
TFA, DCM, rt, then 227, TBD, Et3N, toluene, 75 °C; C: H2, Pd/C, MeOH, rt, then 227, TBD, 
toluene, 75 °C; D: 227, TBD, toluene, 75 °C; E: 227, TBD, Et3N, toluene, 75 °C. bYield of 
purified product. cLower yield due to decomposition (observed by TLC of the crude product 
mixture). 
 
4.3. Evaluation of the Biological Activity  
The biological activity of the library of 13 derived compounds was evaluated 
using a fluorescence-quenching assay.195 This assay exploited a peptide 
substrate containing in its termini a red-shifted fluorescent donor (λexcitation = 530 
nm, λemission = 595 nm) and a fluorescence quencher. The specific substrate 
used was important because of the intrinsic fluorescence of the compounds 
screened. Under light excitation, the quencher supresses the fluorescence of 
the fluorescent donor and low fluorescence is detected. However, BACE1-
catalysed cleavage of the peptide separates the donor and the quencher, 
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leading to an increase in fluorescence (Figure 45). Consequently, this assay 
enables potential BACE1 inhibitors to be screened.  
 
 
 
Figure 45: Principle of the flurorescence-quenching assay used to evaluate the biological 
activity of the 13 derived compounds. Under light excitation, the quencher supresses the 
fluorescence of the donor and low fluorescence is detected. However, after BACE1 cleaves the 
peptide and separates the quencher from the donor, an increase in fluorescence is observed. D, 
fluorescence donor (rhodamine derivative); Q, fluorescence quencher. Peptide sequence before 
cleavage, rhodamine-EVNLDAEFK-quencher; peptide sequence after cleavage, rhodamine-
EVNL + DAEFK-quencher.  
 
The fluorescence-quenching assay was firstly performed using the 13 derived 
compounds at 100 µM. Consequently, inhibitors could be first identified. After 
the assay, it was observed that none of the molecules derived from the 
commercially available scaffolds (223–226) was an inhibitor at 100 µM. 
However, reference compound 214 and three molecules derived from the 
designed scaffolds (218, 219 and 221) showed inhibition of BACE1 at 100 µM 
(Figure 46).  
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Figure 46: Determination of BACE1 inhibition of the 13 derived molecules using a red-shifted 
fluorescence-quenching assay. Normalised to negative and positive controls. Compounds were 
pre-incubated for 20 min with BACE1. Assay conditions were [BACE1] = 0.34 unit/mL; 
[Substrate] = 250 nM; [Compounds] = 100 µM; 0.50 mM sodium acetate buffer, pH 4.5, 25 °C. 
The above values were calculated from at three independent experiments. Some compounds 
showed enhanced BACE1 activity. This observation could be due to the aggregation of the 
compounds.  
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Some of the non-inhibitory compounds, in particular 217, 223 and 224, showed 
enhanced BACE1 activity at 100 µM (Figure 46). This observation could 
suggest that these compounds activate the enzyme. However, this could be 
due to the fact that these compounds could form aggregates at 100 µM. 
Consequently, the use of detergents could be investigated.  
 
Due to the fact that compounds 218, 219, 221 and 214 were inhibitors, their 
sigmoidal dose-response models were obtained using the same fluorescence-
quenching assay in concentrations between 0.67 mM and 1.00 µM (Figure 47). 
Consequently, the IC50 for each of these compounds could be determined. The 
IC50 of each compound was compared with the CNS Lead MPO score. It was 
observed that only compound 219 had similar potency and similar CNS Lead 
MPO score to the reference compound 214. The other two compounds had 
lower potency and lower score.  
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Figure 47: Panels A–D: Sigmoidal dose-response models, IC50 and CNS Lead MPO scores for 
the inhibitors 214 (reference), 218, 219 and 221, respectively. Dose-response models and IC50 
determined using a red-shifted fluorescence-quenching assay and normalised to negative and 
positive controls. Compounds were pre-incubated for 20 min with BACE1. Assay conditions 
were [BACE1] = 0.34 unit/mL; [Substrate] = 250 nM; [Compounds] from 0.67 mM to 1.00 µM; 
0.50 mM sodium acetate buffer, pH 4.5, 25 °C. The inhibition values were calculated from three 
independent experiments. Compound 214 is a compound known in the literature and it was 
used as reference compound. However, its IC50 was not reported before.192 
 
It was observed that some of the sigmoidal dose-response models do not start 
at zero % of inhibition and some start even below (Figure 47). This observation 
could be due to problems with the assay such as plate layout or edge effects, or 
because of aggregation of the compounds. For this reason, as mentioned 
previously, the addition of detergents could be investigated. In addition, the 
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slopes of the dose-response model curves are above one for all the 
compounds. This observation could be due to the fact that BACE1 can form 
dimers.196 Consequently, once the inhibitor has been bound to one monomer, it 
could modulate the binding of another molecule of inhibitor to the other 
monomer. 
 
4.4. Conclusions and Future Perspectives 
In conclusion, a library of 13 derived molecules was prepared from different 
scaffolds and successfully assessed for BACE1 ligand discovery. It was 
observed that none the molecules derived from commercially available 
scaffolds were inhibitors of BACE1 (despite the known reference compound 
214). However, three of the molecules derived from the designed scaffolds 
showed BACE1 inhibition. Consequently, the designed scaffolds could be more 
biologically relevant than the simpler commercially available scaffolds. 
 
It was expected that derived compounds containing structurally-related 
scaffolds would have similar biological activities against BACE1. However, the 
inhibitors 214, 218, 219 and 221 contain very structurally-diverse scaffolds, and 
the non-inhibitors 226, 217, 220 and 222 have very similar structures to the 
inhibitors, respectively. Consequently, it can be stated that there was not any 
structure-activity relationship observed. 
 
It was observed that compounds 218 and 221 were less potent than the 
reference compound 214. It has been previously reported that in these type of 
compounds, secondary amides can be more potent than tertiary amides due to 
an extra hydrogen bond donor interaction in the active site of BACE1 (Figure 
43, panel B).192 Consequently, the methylation of the amide on this class of 
compounds has previously shown a 70-fold lost in potency.192 However, the 
tertiary amides 218 and 221 do not show such a high decrease in potency 
compared to the reference compound 214. This could be because they might 
have different additional interactions in the active site of BACE1 with their 
aromatic rings. Therefore, compound 217, which is almost an analogue of 218 
without the aromatic ring, did not show inhibition at high concentrations (Figure 
46). In addition, compounds 218 and 221 also have lower CNS Lead MPO 
score than the control 214. Due to the lack in improved potency and lower CNS 
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Lead MPO score, compounds 218 and 221 would not be better starting points 
for optimisation than the reference 214. Nevertheless, other tertiary amides 
containing aromatic rings could be developed as another class of BACE1 
inhibitors (Figure 48). 
 
N
N
O
NH2
Ar
237  
Figure 48: General idea of tertiary amides that could be developed for BACE1 inhibition. 
 
However, compound 219 has similar potency and similar CNS Lead MPO score 
than the reported compound 214. Consequently, the highly lipophilic cyclohexyl 
ring of compound 214 could be changed for a more polar heterocyclic system, 
keeping the potency and the CNS-compliance. This would allow the active lead 
219 to be further developed to improve the potency as it was done with 
compound 214 (Figure 43, panel A). The comparison of the Pfizer’s CNS MPO 
scores of the possible optimisation products of 214 (213, 238 and 239) and 219 
(240, 241 and 242) shows that both can yield compounds that could have 
desirable properties for brain penetration (Pfizer’s CNS MPO scores ≥3.00) 
(Figure 49). However, the optimisation products from compound 219 could be 
more promising because they do not contain a highly lipophilic moiety.  
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Figure 49: Panel A: Structures of the BACE1 inhibitors 214 and 219 and their CNS Lead MPO 
scores. Panel B: Possible future optimisations of the lead molecules 214 and 219 to give 
optimised compounds, which could have higher potency and be CNS-compliant. Compound 
213 has been already reported (Figure 43, panel A). The idea for these optimisations has been 
obtained from a reference.192 
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Chapter 5: Methods & Materials 
 
5.1. Design of the Computational Tool 
Two different softwares were used to build the computational tool. These 
softwares were Accelrys Pipeline Pilot version 8.5 (Pipeline Pilot v8.5.0.200, 
Accelrys® Software Inc., 2011) and ChemAxon version 15.3.30.0. Pipeline Pilot 
was used to create a workflow to decorate each virtual scaffold in a derived 
library of compounds, to filter the derived library, to score the derived 
compounds using the CNS Lead MPO or Pfizer’s CNS MPO scoring systems, 
to calculate the mean CNS Lead MPO score per scaffold, and to assess the 
novelty of the scaffolds. ChemAxon was used to calculate the six 
physicochemical properties of the derived library of compounds. In addition, two 
other different softwares were used to analyse the data and to plot the results. 
These softwares were Dotmatics Vortex (Vortex v2013.12.25046) and OriginPro 
9.1.0.  
 
5.2. Synthesis and Decoration of the Scaffolds 
5.2.1. General Experimental 
Commercially available starting materials were obtained from Sigma−Aldrich, 
Acros, Fluorochem and Alfa Aesar. Ligands 91 and dbcot were synthesised 
according to literature procedures.138,197 All non-aqueous reactions were 
performed under nitrogen atmosphere unless otherwise stated. Water-sensitive 
reactions were performed in anhydrous solvents in oven-dried glassware cooled 
under nitrogen before use. Anhydrous dichloromethane, anhydrous 
tetrahydrofuran, anhydrous toluene, anhydrous diethyl ether, anhydrous 
ethanol, anhydrous methanol and anhydrous acetonitrile were obtained from a 
PureSolv MD5 Purification System. Anhydrous dimethyl sulfoxide and 
anhydrous 1,4-dioxane were obtained from SureSeal bottles from 
Sigma−Aldrich. All other solvents used were of chromatography or analytical 
grade. Petrol refers to petroleum spirit (b.p. 40–60 °C). An IKA RV 10 rotary 
evaporator was used to remove the solvents under reduced pressure. 
 
Thin layer chromatography was performed using aluminium backed silica 
(Merck silica gel 60 F254) plates obtained from Merck. Ultraviolet lamp (λmax = 
254 nm) and KMnO4 were used for visualization. Flash column chromatography 
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was performed using silica gel 60 (35–70 µm particles) supplied by Merck. 
Strong cation exchange solid phase extraction (SCX-SPE) was performed using 
pre-packed Discovery DSC-SCX cartridges supplied by Supleco. Optical 
rotation measurements were performed at the sodium D-line (589 nm) on a 
Schmidt and Haensch H532. They are given in 10-1 deg cm2g–1. Chiral HPLC 
was performed on an Agilent Infinity 1290 series HPLC system. Racemic 
standards were prepared by obtaining samples of both enantiomers and 
combining them in an approximated 50:50 ratio. Perkin-Elmer One FT-IR 
spectrometer was used to analyse the infrared spectra. Absorptions are 
reported in wavenumbers (cm–1). Melting points (m.p.) were determined using 
Stuart melting point apparatus SMP3. 
 
An Agilent 1200 series liquid chromatography system comprising a Bruker HCT 
Ultra ion trap mass spectrometer, a high vacuum degasser, a binary pump, a 
high performance autosampler and a micro well plate autosampler, an 
autosampler thermostat, a thermostated column compartment and a diode 
array detector was used for low-resolution mass spectrometry. The system 
used a Phenomenex Luna C18 50 x 2 mm 5 micron column with two solvent 
systems: MeCN/H2O + 0.1% formic acid or MeCN/H2O. A Bruker Daltonics 
micrOTOF spectrometer with electrospray (ES) ionisation source was used for 
high-resolution mass spectrometry (HRMS). X-ray measurements were carried 
out at 120 K on an Agilent SuperNova diffractometer equipped with an Atlas 
CCD detector and connected to an Oxford Cryostream low temperature device 
using mirror monochromated Cu Kα radiation (λ = 1.54184 Å) from a 
Microfocus X-ray source. The structure was solved by intrinsic phasing using 
SHELXT198 and refined by a full matrix least squares technique based on F2 
using SHELXL2014.199 
 
Proton (1H) and carbon (13C) NMR data was collected on a Bruker 300, 400 or 
500 MHz spectrometer. Data was collected at 300 K unless otherwise stated. 
Chemical shifts (δ) are given in parts per million (ppm) and they are referenced 
to the residual solvent peak. Coupling constants (J) are reported in Hertz (Hz) 
and splitting patterns are reported in an abbreviated manner: app. (apparent), s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad). 
Assignments were made using COSY, DEPT, HMQC and NOESY experiments. 
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5.2.2. Experimental for the Lead-Oriented Synthesis Approach Based on 
an Ir-catalysed Connective Reaction 
5.2.2.1. Preparation of Building Blocks 
tert-Butyl N-(3-hydroxypropyl)carbamate 
 
BocHN OH
120  
 
According to an existing procedure,134 the amine derivative 119 (10.3 g, 137 
mmol) was added dropwise to di-tert-butyl dicarbonate (29.8 g, 137 mmol) at 0 
°C.  The mixture was allowed to warm to room temperature and stirred for 21 h. 
Water (50 mL) and EtOAc (50 mL) were added and the aqueous layer was 
extracted with EtOAc (3 × 50 mL). The organic layers were combined, washed 
with brine (100 mL), dried (MgSO4), filtered and concentrated under reduced 
pressure to give the carbamate derivative 120134 (24.3 g, >99%) as a colourless 
oil, Rf 0.31 (30:70 petrol−EtOAc); νmax/cm-1 3339, 2975, 2932, 2874, 1681, 
1515, 1365, 1274, 1250, 1165; δH (500 MHz, CDCl3) 4.78 (1H, br. s, NH), 3.65 
(2H, t, J 5.7, 3-H2), 3.27 (2H, t, J 6.2, 1-H2), 2.70 (1H, br. s, OH), 1.66 (2H, app. 
p, J 5.9 2-H2), 1.44 (9H, s, tBu); m/z (ES) 198.0 (100%, MNa+). 
 
Ethyl (2E)-5-{[(tert-butoxy)carbonyl]amino}pent-2-enoate 
 
BocHN
121
OEt
O
 
 
According to an existing procedure,134 triethylamine (116 mL, 830 mmol), 
DMSO (108 mL, 1.52 mol) and SO3•Pyr (66.1 g, 415 mmol) were added to a 
solution of the carbamate 120 (24.3 g, 138 mmol) in DCM (300 mL) at 0 °C. The 
mixture was stirred for 10 min, warmed to room temperature and stirred for 1 h. 
Subsequently, the mixture was cooled to 0 °C and carbethoxymethylene 
triphenylphosphorane (72.3 g, 208 mmol) was added. The reaction mixture was 
stirred for 20 min, allowed to warm to room temperature, stirred overnight, 
cooled to 0 °C and acidified to pH 3 by addition of an aqueous solution of 3.0 M 
HCl (300 mL). The organic layer was separated and the aqueous layer was 
extracted with DCM (2 × 100 ml). The organic layers were combined and 
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washed with an aqueous solution of 1.0 M HCl (100 mL), with a saturated 
aqueous solution of NaHCO3 (100 ml) and with water (100 ml). The organic 
layer was dried (MgSO4), filtered and concentrated under reduced pressure to 
give a crude product, which was purified by flash column chromatography, 
eluting with 80:20 petrol−EtOAc to give the α,β-unsaturated ester 121134 (21.0 g, 
62%) as a yellow oil, Rf  0.57 (60:40 petrol−EtOAc); νmax/cm-1 3367, 2977, 2933, 
1691, 1654, 1516, 1365, 1267, 1248, 1165; δH (500 MHz, CDCl3) 6.89 (1H, dt, J 
15.7 and 7.1, 3-H), 5.87 (1H, dt, J 15.7 and 1.5, 2-H), 4.58 (1H, br. s, NH), 4.19 
(2H, q, J 7.1, ethyl 1-H2), 3.37-3.15 (2H, m, 5-H2), 2.40 (2H, app. q, J 6.6, 4-H2), 
1.43 (9H, s, tBu), 1.28 (3H, t, J 7.1, ethyl 2-H3); m/z (ES) 266.0 (100%, MNa+). 
 
tert-Butyl N-[(3E)-5-hydroxypent-3-en-1-yl]carbamate 
 
BocHN
122
OH
 
 
According to an existing procedure,134 diisobutylaluminium hydride (259 mL, 
259 mmol of a 1.0 M solution in hexane) was added dropwise to a solution of 
the ester 121 (21.0 g, 86.3 mmol) in DCM (200 mL) cooled to −78 °C. The 
reaction mixture was stirred at −78 °C for 2 h. Subsequently, it was quenched 
by addition of a saturated aqueous solution of NH4Cl (150 mL) dropwise, 
warmed to room temperature and stirred for 18 h. The solution was filtered 
through a celite pad and concentrated under reduced pressure to give a crude 
product. The crude product was dissolved in DCM (200 mL), washed with brine 
(200 mL), dried (MgSO4), filtered and concentrated under reduced pressure to 
give the alcohol 122134 (16.6 g, 96%) as a yellow oil, Rf 0.18 (60:40 petrol-
EtOAc); νmax/cm-1 3328, 2975, 2930, 2868, 1684, 1518, 1391, 1364, 1249, 
1165; δH (500 MHz, CDCl3) 5.71 (1H, dt, J 15.4 and 5.6, 4-H), 5.64 (1H, dt, J 
15.4 and 5.6, 3-H), 4.58 (1H, br. s, NH), 4.10 (2H, dd, J 5.4 and 1.1, 5-H2), 3.21-
3.14 (2H, m, 1-H2), 2.23 (2H, app. q, J 6.5, 2-H2), 1.66 (1H, br. s, OH) 1.43 (9H, 
s, tBu); m/z (ES) 224.3 (100%, MNa+). 
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2-({[(3E)-5-[(Methoxycarbonyl)oxy]pent-3-en-1-yl]carbamoyl}oxy)-2-methyl 
propane 
BocHN
88
O OMe
O
 
 
According to an existing procedure,134 pyridine (7.32 mL, 90.5 mmol) and 
methyl chloroformate (7.00 mL, 90.5 mmol) were added to a solution of the 
alcohol 122 (16.6 g, 82.3 mmol) in DCM (165 mL) cooled to 0 °C. The reaction 
mixture was allowed to warm to room temperature and stirred overnight. 
Afterwards, the reaction mixture was quenched with a saturated aqueous 
solution of NH4Cl (150 mL). The aqueous layer was separated and washed with 
DCM (2 × 100 mL). The organic layers were combined, washed with water (100 
mL), washed with brine (100 mL), dried (MgSO4), filtered and concentrated 
under reduced pressure to give a crude product. The crude product was purified 
by flash column chromatography, eluting with 80:20 petrol−EtOAc to give the 
allylic carbonate 88134 (18.4 g, 86%) as a colourless oil, Rf 0.36 (80:20 
petrol−EtOAc); νmax/cm-1 3366, 2975, 1746, 1692, 1513, 1442, 1365, 1249, 
1165; δH (500 MHz, CDCl3) 5.75 (1H, dt, J 15.4 and 6.5, 4-H), 5.65 (1H, dtt, J 
15.4, 6.5 and 1.1, 3-H), 4.57 (2H, dd, J 6.5 and 1.1, 5-H2), 4.55 (1H, br. s, NH), 
3.77 (3H, s, OMe 1-H3), 3.21-3.14 (2H, m, 1-H2), 2.24 (2H, app. q, J 6.7, 2-H2), 
1.43 (9H, s, tBu); m/z (ES) 282.0 (100%, MNa+). 
 
Chloro(dibenzo[a,e]cyclooctatetraene)iridium(I) dimer 
 
Ir
Cl
Cl
Ir
92  
 
According to an existing procedure,134 a solution of dbcot (0.35 g, 1.72 mmol) in 
DCM (10.0 mL) was added dropwise over 40 min to a solution of bis(1,5-
cyclooctadiene)diiridium(I)dichloride (0.59 g, 0.88 mmol) in DCM (10.0 mL). The 
reaction mixture was stirred for 20 min, cooled to 0 °C and filtered. The 
precipitate was washed with cold cyclohexane and dried under reduced 
pressure to give the Ir-catalyst 92200 (0.46 g, 61%) as a bright yellow solid, δH 
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(500 MHz, CDCl3) 6.99 (8H, dd, J 5.7 and 3.2, dbcot 1,4,7,10-H8), 6.85 (8H, dd, 
J 5.7 and 3.2, dbcot 2,3,8,9-H8), 5.33 (8H, s, dbcot 5,6,11,12-H8). 
 
5.2.2.2. Connective Reactions 
General Procedure A 
According to an existing procedure,116 nBuNH2 (0.04 eq) was added to a 
solution of the Ir-catalyst 92 (0.02 eq) and the chiral phosphoramidite 91 (0.04 
eq) in DMSO (concentration of 92 20.0 mM). The mixture was stirred and 
heated to 60 °C for 30 min (the mixture changes in colour from orange to 
yellow). A solution of the allylic carbonate 88 (1.00 eq) and the desired amine 
(1.30 eq) in DMSO (concentration of 88 2.00 M) was added and the resulting 
reaction mixture was stirred for 18 h at 60 °C. Afterwards, it was loaded into a 
SCX pad, eluting with MeOH and with a solution of saturated NH3 in MeOH. 
The fraction containing the saturated solution of NH3 in MeOH was collected 
and concentrated under reduced pressure to yield a crude material. 
 
General Procedure B 
The specified amount of TFA was added dropwise to a solution of the protected 
amine (1.00 eq) in DCM (0.10 M) under air atmosphere. The mixture was stirred 
at room temperature for 18 h. Subsequently, the solvent and TFA were 
removed under reduced pressure to give a TFA salt. 
 
General Procedure C 
According to an exissting procedure,139 (2S)-3,3,3-trifluoro-2-methoxy-2-
phenylpropanoyl chloride (1.90 eq) was added to a solution of triethylamine 
(5.00 eq) and the selected amine as TFA salt (1.00 eq) in DCM (concentration 
of the selected amine 55.0 mM) at 0 °C. The reaction mixture was stirred for 4 h 
at room temperature. Subsequently, DCM (53 mL for each 1.00 mmol of the 
amine) and water (18 mL for each 1.00 mmol of the amine) were added. The 
organic layer was separated and the aqueous layer was washed with DCM (3 × 
(53 mL for each 1.00 mmol of the amine)). The organic layers were combined, 
dried (MgSO4), filtered and concentrated under reduced pressure to give a 
mixture of two diastereomers. 
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General Procedure D 
According to an existing procedure,201 triethylamine (1.20 eq), DMAP (0.60 eq) 
and tert-butyl(chloro)diphenylsilane (1.20 eq) were added to a solution of the 
alkene derivative (1.00 eq) in DCM (51.2 mM). The reaction mixture was stirred 
for 18 h at 40 °C. Subsequently, the reaction was allowed to cool to room 
temperature and water (7 mL for each 1.00 mmol of the alkene) and ether (22 
mL for each 1.00 mmol of the alkene) were added. The organic phase was 
separated and washed with water (7 mL for each 1.00 mmol of the alkene) and 
brine (7 mL for each 1.00 mmol of the alkene). Afterwards, it was dried 
(MgSO4), filtered and concentrated under reduced pressure to give a crude 
material. 
 
General Procedure E 
According to an existing procedure,116 triethylamine (2.00 eq) and benzoyl 
chloride (1.30 eq) were added to a solution of the silyl derivative (1.00 eq) in 
DCM (0.10 M) at 0 °C. The reaction mixture was allowed to warm to room 
temperature and it was stirred for 18 h. Afterwards, it was quenched with a 
saturated aqueous solution of NH4Cl (16 mL for each 1.00 mmol of silyl). The 
organic phase was separated and the aqueous phase was extracted with DCM 
(3 × (16 mL for each 1.00 mmol of silyl)). The organic phases were combined, 
dried (MgSO4), filtered and concentrated under reduced pressure to give a 
crude material. 
 
tert-Butyl N-[(3R)-3-(pyrrolidin-1-yl)pent-4-en-1-yl]carbamate 
 
BocHN N
89a  
 
According to General Procedure A, the allylic carbonate 88 (2.50 g, 9.64 mmol), 
(S,S,aS)-91 (0.21 g, 0.39 mmol) and pyrrolidine (1.04 mL, 12.53 mmol) gave a 
crude material. The crude material (terminal:internal alkenes 85:15 by 1H-NMR) 
was purified by flash column chromatography, eluting with 92.4:6.8:0.8 
DCM−EtOH−NH4OH to give the alkene 89a (1.45 g, 59%, 67% ee) as a yellow 
oil, Rf 0.13 (92.4:6.8:0.8 DCM−EtOH−NH4OH); [αD26] −3.00 (c 1.00, CHCl3); 
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νmax/cm-1 3349, 2966, 2930, 2874, 2788, 1691, 1513, 1364, 1247, 1169; δH (500 
MHz, CDCl3) 5.75 (1H, ddd, J 16.7, 10.7 and 9.0, 4-H), 5.14 (1H, dd J 10.7 and 
1.7, 5-Hcis), 5.13 (1H, dd, J 16.7 and 1.7, 5-Htrans), 5.01 (1H br. NH), 3.25-3.15 
(1H, m, 1-HA), 3.15-3.07 (1H, m, 1-HB), 2.77 (1H, app. td, J 8.6 and 4.6, 3-H), 
2.61-2.49 (4H, m, pyrrolidinyl 2,5-H4), 1.91-1.81 (1H, m, 2-HA), 1.78-1.73 (4H, 
m, pyrrolidinyl 3,4-H4), 1.65 (1H, app. td, J 14.0 and 7.2, 2-HB), 1.43 (9H, s, 
tBu); δC (75 MHz, CDCl3) 156.1 (C=O), 138.7 (C-4), 117.3 (C-5), 79.1 (tBu C1), 
66.7 (C-3), 51.4 (pyrrolidinyl C2-2,5), 38.2 (C-1), 33.7 (C-2), 28.6 (tBu C3), 23.4 
(pyrrolidinyl C2-3,4); HRMS found MH+, 255.2075. C14H26N2O2 requires MH, 
255.2067. The absolute configuration was determined by comparison with 
analogues.116 
 
tert-Butyl N-[(3S)-3-(pyrrolidin-1-yl)pent-4-en-1-yl]carbamate 
\ 
BocHN N
89a  
 
According to General Procedure A, the allylic carbonate 88 (0.25 g, 0.96 mmol), 
(R,R,aR)-91 (20.0 mg, 38.0 µmol) and pyrrolidine (0.10 mL, 1.25 mmol) gave a 
crude material. The crude material (terminal:internal alkenes 85:15 by 1H-NMR) 
was purified by flash column chromatography, eluting with 92.4:6.8:0.8 
DCM−EtOH−NH4OH to give the alkene 89a (90.0 mg, 37%, 67% ee) as a 
yellow oil, [αD24] +1.25 (c 1.20, CHCl3); spectroscopically identical to the 
enantiomer previously prepared. The absolute configuration was determined by 
comparison with analogues.116 
 
(3R)-3-(Pyrrolidin-1-yl)pent-4-en-1-amine 
 
H2N N
124  
 
According to General Procedure B, TFA (0.50 mL, 6.53 mmol) and the 
protected amine 89a (15.0 mg, 58.0 µmol) gave the TFA salt of the amine 124 
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(21.8 mg, 96%) as an amorphous brown solid, Rf 0.34 (65.0:30.0:5.0 
DCM−EtOH−NH4OH); [αD23] +0.94 (c 0.73, MeOH); νmax/cm-1 3397, 2965, 1666, 
1426, 1175, 1124; δH (500 MHz, CD3OD) 5.86 (1H, ddd, J 17.0, 10.3 and 9.4, 4-
H), 5.66 (1H, dd, J 10.3 and 0.8, 5-Hcis), 5.64 (1H, dd, J 17.0 and 0.8, 5-Htrans), 
3.85 (1H, ddd, J 11.1, 9.4 and 3.5, 3-H), 3.72-3.62 (1H, m, pyrrolidinyl 2-HA), 
3.56-3.45 (1H, m, pyrrolidinyl 5-HA), 3.26-3.03 (2H, m, pyrrolidinyl 2-HB and 
pyrrolidinyl 5-HB), 2.94 (2H, app. t, J 8.0, 1-H2), 2.35-2.26 (1H, m, 2-HA), 2.16-
2.00 (5H, m, 2-HB and pyrrolidinyl 3,4-H4); δC (125 MHz, CD3OD) 162.9 (app. m, 
TFA C=O), 131.3 (C-4), 126.8 (C-5), 118.2 (app d, J 300.0, TFA CF3,), 66.6 (C-
3), 53.1 (pyrrolidinyl C2-2,5), 37.4 (C-1), 29.8 (C-2), 24.0 (pyrrolidinyl C2-3,4); 
HRMS found MH+, 155.1538. C9H18N2 requires MH, 155.1542.  
 
Determination of the ee: According to General Procedure C, the TFA salt of the 
amine 124 (19.0 mg, 49.7 µmol) gave a mixture of two diastereomers in a 
83.3:16.7 ratio. δH (500 MHz, C6D6) 4.87 (major) and 4.80 (minor). 
 
(3S)-3-(Pyrrolidin-1-yl)pent-4-en-1-amine 
 
H2N N
124  
 
According to General Procedure B, TFA (0.50 mL, 6.53 mmol) and the 
protected amine 89a (15.0 mg, 60.0 µmol) gave the TFA salt of the amine 124 
(22.5 mg, >99%) as an amorphous brown solid, [αD24] −0.06 (c 0.70, MeOH); 
spectroscopically identical to the enantiomer previously prepared.  
 
Determination of the ee: According to General Procedure C, the TFA salt of the 
amine 124 (22.5 mg, 59.0 µmol) gave a mixture of two diastereomers in a 
83.3:16.7 ratio. δH (500 MHz, C6D6) 4.89 (minor) and 4.83 (major). 
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tert-Butyl N-[(3S)-3-(morpholin-4-yl)pent-4-en-1-yl]carbamate 
 
BocHN N
89b
O
 
 
According to General Procedure A, the allylic carbonate 88 (2.72 g, 10.5 mmol), 
(R,R,aR)-91 (0.23 g, 0.42 mmol) and morpholine (1.20 mL, 13.7 mmol) gave a 
crude material. The crude material (terminal:internal alkenes 83:17 by 1H-NMR) 
was purified by flash column chromatography, eluting with EtOAc to give the 
alkene 89b (1.80 g, 63%, 86% ee) as a brown oil, Rf 0.28 (EtOAc); [αD23] +16.0 
(c 1.00, CHCl3); νmax/cm-1 3343, 2972, 2930, 2853, 2813, 1693, 1514, 1167, 
1114; δH (300 MHz, CDCl3) 5.69 (1H, ddd, J 17.1, 10.3 and 8.8, 4-H), 5.31 (1H, 
br. s, NH), 5.18 (1H, dd, J 10.3 and 1.5, 5-Hcis), 5.08 (1H, dd, J 17.1 and 1.5, 5-
Htrans), 3.71-3.61 (4H, m, morpholinyl 2,6-H4), 3.22 (1H, app. td, J 11.7 and 6.1, 
1-HA), 3.08 (1H, app. td, J 13.3 and 6.8, 1-HB), 2.82 (1H, app. q, J 6.9, 3-H), 
2.55 (2H, app. dt, J 11.2 and 4.7, morpholinyl 3-HA and morpholinyl 5-HA), 2.40 
(2H, app. dt, J 11.2 and 4.7, morpholinyl 3-HB and morpholinyl 5-HB), 1.89-1.70 
(1H, m, 2-HA), 1.66-1.50 (1H, m, 2-HB), 1.40 (9H, s, tBu); δC (75 MHz, CDCl3) 
156.0 (C=O), 136.2 (C-4), 118.3 (C-5), 78.9 (tBu C1), 67.4 (C-3), 67.3 
(morpholinyl C2-2,6), 50.0 (morpholinyl C2-3,5), 38.6 (C-1), 31.0 (C-2), 28.5 (tBu 
C3); HRMS found MH+, 271.2019. C14H26N2O3 requires MH, 271.2016; chiral 
HPLC: OD-H, 5.0:95.0 isopropyl alcohol–hexane over 60 min, 1.0 mL/min; t1 = 
8.81 min (minor), t2 = 9.56 min (major). The absolute configuration was 
determined by comparison with analogues.116 
 
tert-Butyl N-[(3R)-3-(morpholin-4-yl)pent-4-en-1-yl]carbamate 
 
BocHN N
89b
O
 
 
According to General Procedure A, the allylic carbonate 88 (0.25 g, 0.96 mmol), 
(S,S,aS)-91 (20.0 mg, 37.0 µmol) and morpholine (0.11 mL, 1.25 mmol) gave a 
crude material. The crude material (terminal:internal alkenes 83:17 by 1H-NMR) 
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was purified by flash column chromatography, eluting with EtOAc to give the 
alkene 89b (0.15 g, 57%, 86% ee) as a brown oil, [αD24] −14.0 (c 1.00, CHCl3); 
spectroscopically identical to the enantiomer previously prepared; chiral HPLC: 
OD-H, 5.0:95.0 isopropyl alcohol–hexane over 60 min, 1.0 mL/min; t1 = 8.79 
min (major), t2 = 9.65 min (minor). The absolute configuration was determined 
by comparison with analogues.116 
 
tert‐Butyl N‐[(3S)‐3‐{8‐oxa‐3‐azabicyclo[3.2.1]octan‐3‐yl}pent‐4‐en‐1‐yl] 
carbamate 
BocHN N
89c
O
 
 
According to General Procedure A, the allylic carbonate 88 (0.88 g, 3.40 mmol), 
(R,R,aR)-91 (73.4 mg, 136 µmol) and 8-oxa-3-azabicyclo[3.2.1]octane (0.50 g, 
4.42 mmol) gave a crude material. The crude material (terminal:internal alkenes 
71:29 by 1H-NMR) was purified by flash column chromatography, eluting with 
30:70 EtOAc−petrol to give the alkene 89c (0.63 g, 63%, 83% ee) as a yellow-
brown oil, Rf 0.28 (30:70 EtOAc−petrol); [αD23] +9.80 (c 1.00, CHCl3); νmax/cm-1 
3340, 2973, 2949, 2811, 1693, 1512, 1167; δH (500 MHz, CDCl3) 5.73 (1H, app. 
dt, J 18.0 and 9.5, 4-H), 5.64 (1H, br. s, NH), 5.17 (1H, dd, J 10.3 and 0.9, 5-
Hcis), 5.07 (1H, app. d, J 17.3, 5-Htrans), 4.28 (2H, app. br. s, bicyclooctanyl 1,5-
H2), 3.32-3.22 (1H, m, 1-HA), 3.16 (1H, app. td, J 12.9 and 6.9, 1-HB), 2.82 (1H, 
app. td, J 8.0 and 5.9, 3-H), 2.61 (1H, dd, J 10.9 and 0.9, bicyclooctanyl 2,4-HA), 
2.56 (1H, app. d, J 10.9, bicyclooctanyl 2,4-HB), 2.45 (1H, dd, J 10.9 and 0.4, 
bicyclooctanyl 2,4-HC), 2.40 (1H, dd, J 10.9 and 1.2, bicyclooctanyl 2,4-HD), 
2.00-1.90 (2H, m, bicyclooctanyl 6-HA and bicyclooctanyl 7-HA), 1.90-1.80 (2H, 
m, bicyclooctanyl 6-HB and bicyclooctanyl 7-HB), 1.75 (1H, app. td, J 14.4 and 
7.4, 2-HA), 1.60-1.54 (1H, m, 2-HB), 1.44 (9H, s, tBu); δC (75 MHz, CDCl3) 156.1 
(C=O), 136.2 (C-4), 117.8 (C-5), 78.9 (tBu C1), 74.8 (bicyclooctanyl C2-1,5), 
66.5 (C-3), 56.9 (bicyclooctanyl CA-2,4), 52.2 (bicyclooctanyl CB-2,4), 38.9 (C-
1), 30.2 (C-2), 28.5 (tBu C3), 27.0 (bicyclooctanyl C2-6,7); HRMS found MH+, 
297.2178. C16H28N2O3 requires MH, 297.2172. The absolute configuration was 
determined by comparison with analogues.116 
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tert‐Butyl N‐[(3R)‐3‐{8‐oxa‐3‐azabicyclo[3.2.1]octan‐3‐yl}pent‐4‐en‐1‐yl] 
carbamate 
BocHN N
89c
O
 
 
According to General Procedure A, the allylic carbonate 88 (0.25 g, 0.96 mmol), 
(S,S,aS)-91 (20.0 g, 37.0 µmol) and 8-oxa-3-azabicyclo[3.2.1]octane (0.14 g, 
1.25 mmol) gave a crude material. The crude material (terminal:internal alkenes 
71:29 by 1H-NMR) was purified by flash column chromatography, eluting with 
30:70 EtOAc−petrol to give the alkene 89c (0.19 g, 66%, 83% ee) as a yellow-
brown oil, [αD24] −8.30 (c 1.00, CHCl3); spectroscopically identical to the 
enantiomer previously prepared. The absolute configuration was determined by 
comparison with analogues.116 
 
(3S)‐3‐{8‐Oxa‐3‐azabicyclo[3.2.1]octan‐3‐yl}pent‐4‐en‐1‐amine 
 
H2N N O126  
 
According to General Procedure B, TFA (0.50 mL, 6.53 mmol) and the 
protected amine 89c (15.0 mg, 50.6 µmol) gave the TFA salt of the amine 126 
(21.0 mg, 98%) as an amorphous brown solid, Rf 0.13 (84.7:13.6:1.7 
DCM−EtOH−NH4OH); [αD23] −0.92 (c 0.52, MeOH); νmax/cm-1 3392, 2971, 1666, 
1426, 1176, 1124; δH (500 MHz, CD3OD) 5.85 (1H, app. dt, J 16.9 and 10.0, 4-
H), 5.71 (1H, dd, J 10.3 and 1.2, 5-Hcis), 5.62 (1H, dd, J 16.9 and 1.2, 5-Htrans), 
4.53 (2H, app. s, bicyclooctanyl 1,5-H2), 3.78 (1H, ddd, J 11.3, 9.6 and 3.3, 3-
H), 3.42 (1H, app. d, J 12.3, bicyclooctanyl 2,4-HA), 3.34 (1H, app. d, J 12.6, 
bicyclooctanyl 2,4-HB), 3.23 (1H, dd, J 12.4 and 2.9, bicyclooctanyl 2,4-HC), 
3.14 (1H, dd, J 12.4 and 2.9, bicyclooctanyl 2,4-HD), 2.95-2.83 (2H, m, 1-H2), 
2.45-2.28 (1H, m, 2-HA), 2.17-1.99 (5H, m, 2-HB and bicyclooctanyl 6,7-H4); δH 
(125 MHz, CD3OD) 163.2-161.6 (app m, TFA C=O,), 130.6 (C-4), 127.5 (C-5), 
118.0 (app d, J 293.5, TFA CF3), 116.8 (q, J 289.3, TFA CF3), 73.9 
(bicyclooctanyl C2-1,5), 69.6 (C-3), 56.4 (bicyclooctanyl CA-2,4), 55.0 
(bicyclooctanyl CB-2,4), 37.7 (C-1), 27.9 (C-2), 27.5 (bicyclooctanyl CA-6,7), 
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27.4 (bicyclooctanyl CB-6,7); HRMS found MH+, 197.1642. C11H20N2O requires 
MH, 197.1648.  
 
Determination of the ee: According to General Procedure C, the TFA salt of the 
amine 126 (23.1 mg, 54.5 µmol) gave a mixture of two diastereomers in a 
91.7:8.3 ratio. δH (500 MHz, C6D6) 7.73 (major) and 7.70 (minor). 
 
(3R)‐3‐{8‐Oxa‐3‐azabicyclo[3.2.1]octan‐3‐yl}pent‐4‐en‐1‐amine 
 
H2N N O126  
 
According to General Procedure B, TFA (0.50 mL, 6.53 mmol) and the 
protected amine 89c (15.0 mg, 50.6 µmol) gave the TFA salt of the amine 126 
(22.2 mg, >99%) as an amorphous brown solid, [αD23] +2.22 (c 0.81, MeOH); 
spectroscopically identical to the enantiomer previously prepared. 
 
Determination of the ee: According to General Procedure C, the TFA salt of the 
amine 126 (22.0 mg, 51.8 µmol) gave a mixture of two diastereomers in a 
91.7:8.3 ratio. δH (500 MHz, C6D6) 7.73 (minor) and 7.70 (major). 
 
tert-Butyl N-[(3R)-3-[(2-hydroxyethyl)amino]pent-4-en-1-yl]carbamate 
 
BocHN N
H
89d
OH
 
 
According to General Procedure A, the allylic carbonate 88 (3.00 g, 11.6 mmol), 
(S,S,aS)-91 (0.25 g, 0.46 mmol) and 2-aminoethan-1-ol (0.91 mL, 15.0 mmol) 
gave a crude material. The crude material (terminal:internal alkenes >95:<5 by 
1H-NMR) was purified by flash column chromatography, eluting with 
90.8:8.2:1.0 DCM−EtOH−NH4OH to give the alkene 89d (1.70 g, 60%, 85% ee) 
as an amorphous white solid, Rf 0.18 (90.8:8.2:1.0 DCM−EtOH−NH4OH); [αD26] 
−8.40 (c 1.00, CHCl3); νmax/cm-1 3368, 3267, 3071, 3014, 2975, 2933, 2840, 
1681, 1523, 1366, 1165, 1053; δH (500 MHz, CDCl3) 5.61 (1H, ddd, J 17.0, 10.0 
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and 8.1, 4-H), 5.14 (1H, dd, J 10.0 and 1.3, 5-Hcis), 5.12 (1H, dd, J 17.0 and 1.3, 
5-Htrans), 4.90 (1H, br. s, NH), 3.65 (1H, ddd, J 10.8, 7.1 and 3.6, hydroxyethyl 
2-HA), 3.59 (1H, ddd, J 10.8, 6.0 and 3.8, hydroxyethyl 2-HB), 3.38-3.23 (1H, m, 
1-HA), 3.15 (1H, m, 1-HB), 3.09 (1H, app. q, J 7.1, 3-H), 2.82 (1H, ddd, J 12.5, 
7.1 and 3.8, hydroxyethyl 1-HA), 2.65 (1H, ddd, J 12.5, 6.0 and 3.6, 
hydroxyethyl 1-HB), 2.01 (1H, br. s, OH), 1.64 (2H, app. ddt, J 16.0, 13.7 and 
6.9, 2-H2), 1.44 (9H, s, tBu); δC (75 MHz, CDCl3) 156.2 (C=O), 140.2 (C-4), 
116.5 (C-5), 79.2 (tBu C1), 60.8 (hydroxyethyl C-2), 59.3 (C-3), 48.7 
(hydroxyethyl C-1), 37.6 (C-1), 35.6 (C-2), 28.4 (tBu C3); HRMS found MH+, 
245.1862. C12H24N2O3 requires MH, 245.1859. The absolute configuration was 
determined by comparison with analogues.116 
 
tert-Butyl N-[(3S)-3-[(2-hydroxyethyl)amino]pent-4-en-1-yl]carbamate 
 
BocHN N
H
89d
OH
 
 
According to General Procedure A, the allylic carbonate 88 (0.25 g, 0.96 mmol), 
(R,R,aR)-91 (20.0 mg, 37.0 µmol) and 2-aminoethan-1-ol (75.6 µL, 1.25 mmol) 
gave a crude material. The crude material (terminal:internal alkenes >95:<5 by 
1H-NMR) was purified by flash column chromatography, eluting with 
90.8:8.2:1.0 DCM−EtOH−NH4OH to give the alkene 89d (90.0 mg, 38%, 85% 
ee) as an amorphous white solid, [αD24] +9.65 (c 0.64, CHCl3); spectroscopically 
identical to the enantiomer previously prepared. The absolute configuration was 
determined by comparison with analogues.116 
 
tert-Butyl N-[(3R)-3-({2-[(tert-butyldiphenylsilyl)oxy]ethyl}amino)pent-4-en-
1-yl]carbamate 
BocHN N
H
OTBDPS
128  
 
According to General Procedure D, the alkene 89d (0.11 g, 0.45 mmol) gave a 
crude material. The crude material was purified by flash column 
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chromatography, eluting with 30:70 EtOAc−petrol to give the silyl derivative 
128116 (0.17 g, 78%) as a yellow oil, Rf 0.19 (50:50 EtOAc−petrol); [αD23] −3.40 
(c 1.00, CHCl3); νmax/cm-1 3346, 3071, 2929, 2856, 1703, 1589, 1427, 1364, 
1248, 1169, 1109; δH (300 MHz, CDCl3) 7.71-7.63 (4H, m, phenyl 2,6-H4), 7.50-
7.30 (6H, m, phenyl 3,4,5-H6), 5.61 (1H, ddd, J 16.7, 9.8 and 7.9, 4-H), 5.12 
(1H, dd, J 9.8 and 1.0, 5-Hcis), 5.10 (1H, app. d, J 18.0, 5-Htrans), 4.73 (1H, br. s, 
NH), 3.87-3.63 (2H, m, ethyl 2-H2), 3.34-3.12 (2H, m, 1-H2), 3.07 (1H, app. q, J 
6.9, 3-H), 2.78 (1H, app. dt, J 11.6 and 5.3, ethyl 1-HA), 2.61 (1H, app. dt, J 
12.0 and 5.1, ethyl 1-HB), 1.63 (2H, app. q, J 6.7, 2-H2), 1.43 (9H, s, Boc tBu), 
1.06 (9H, s, TBDPS tBu); δC (75 MHz, CDCl3) 156.1 (C=O), 140.5 (C-4), 135.6 
(phenyl C4-2,6), 133.7 (phenyl C2-1), 129.8 (phenyl C2-4), 127.8 (phenyl C4-
3,5), 116.3 (C-5), 79.1 (Boc tBu C1), 63.4 (ethyl C-2), 60.1 (C-3), 48.9 (ethyl C-
1), 38.1 (C-1), 35.4 (C-2), 28.6 (Boc tBu C3), 27.0 (TBDPS tBu C3), 19.3 
(TBDPS tBu C1); HRMS found MH+, 483.3048. C28H42N2O3Si requires MH, 
483.3037. 
 
tert-Butyl N-[(3S)-3-({2-[(tert-butyldiphenylsilyl)oxy]ethyl}amino)pent-4-en-
1-yl]carbamate 
BocHN N
H
OTBDPS
128  
 
According to General Procedure D, the alkene 89d (90.4 mg, 0.37 mmol) gave 
a crude material. The crude material was purified by flash column 
chromatography, eluting with 30:70 EtOAc−petrol to give the silyl derivative 
128116 (0.11 g, 62%) as a yellow oil, [αD21] +4.10 (c 1.00, CHCl3); 
spectroscopically identical to the enantiomer previously prepared. 
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tert-Butyl N-[(3R)-3-(N-{2-[(tert-butyldiphenylsilyl)oxy]ethyl}-1-phenylforma 
mido)pent-4-en-1-yl]carbamate 
 
BocHN N
OTBDPS
O
129  
 
According to General Procedure E, the silyl derivative 128 (0.15 g, 0.31 mmol) 
gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 80:20 petrol−EtOAc to give the benzoyl derivative 
129116 (0.18 g, 99%) as a colourless oil, Rf 0.28 (75:25 petrol−EtOAc); [αD24] 
+19.6 (c 1.00, CHCl3); νmax/cm-1 3344, 3070, 2961, 2930, 2857, 1709, 1624, 
1507, 1426, 1410, 1364, 1248, 1168, 1106; δH (500 MHz, CD3OD, 333 K) 7.73-
7.50 (5H, m, benzoyl-H5), 7.47-7.27 (10H, m, TBDPS Ar-H10), 6.04-5.67 (1H, m, 
4-H1), 5.14 (2H, app. dt, J 10.6 and 1.3, 5-H2), 5.09 (1H, br. s, NH), 4.43-4.24 
(1H, m, 3-H1), 3.96-3.62 (2H, m, ethyl 2-H2), 3.51 (2H, app. br. s, 1-H2), 3.08-
2.79 (2H, m, ethyl 1-H2), 1.87-1.71 (2H, m, 2-H2), 1.40 (9H, s, Boc tBu), 1.04 
(9H, s, TBDPS tBu); δC (125 MHz, CD3OD, 333 K) 174.8 (benzoyl C=O), 158.1 
(Boc C=O), 137.7 (benzoyl C-1), 136.6 (C-4), 134.7 (TBDPS phenyl C2-1), 
130.9 (TBDPS phenyl C2-4), 130.7 (benzoyl C-4), 129.7 (TBDPS phenyl C4-
3,5), 128.9 (benzoyl C2-3,5), 128.8 (TBDPS phenyl C4-2,6), 127.6 (benzoyl C2-
2,6), 118.0 (C-5), 80.2 (Boc tBu C1), 62.8 (ethyl C-2), 62.7 (C-3), 38.6 (C-1), 
33.3 (C-2), 28.8 (Boc tBu C3), 27.4 (TBDPS tBu C3), 19.9 (TBDPS tBu C1), ethyl 
C-1 no observed; HRMS found MH+, 587.3312. C35H46N2O4Si requires MH, 
587.3299; chiral HPLC: OD-H, 5.0:95.0 isopropyl alcohol–hexane over 60 min, 
0.3 mL/min; t1 = 32.49 min (major), t2 = 35.96 min (minor). 
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tert-Butyl N-[(3S)-3-(N-{2-[(tert-butyldiphenylsilyl)oxy]ethyl}-1-phenylforma 
mido)pent-4-en-1-yl]carbamate  
 
BocHN N
OTBDPS
O
129  
 
According to General Procedure E, the silyl derivative 128 (0.11 g, 0.23 mmol) 
gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 80:20 petrol−EtOAc to give the benzoyl derivative 
129116 (0.12 g, 90%) as a colourless oil, [αD25] −18.7 (c 1.00, CHCl3); 
spectroscopically identical to the enantiomer previously prepared; chiral HPLC: 
OD-H, 5.0:95.0 isopropyl alcohol–hexane over 60 min, 0.3 mL/min; t1 = 32.71 
min (minor), t2 = 36.05 min (major). 
 
tert-Butyl N-[(3R)-3-{[(2R)-1-hydroxypropan-2-yl]amino}pent-4-en-1-yl] 
carbamate 
BocHN N
H
OH
89e  
 
According to General Procedure A, the allylic carbonate 88 (2.00 g, 7.70 mmol), 
(S,S,aS)-91 (0.17 g, 0.31 mmol) and (2R)-2-amino-1-propanol (0.78 mL, 10.0 
mmol) gave a crude material. The crude material (terminal:internal alkenes 
>95:<5 and dr 94:6 by 1H-NMR) was purified by flash column chromatography, 
eluting with 90.8:8.2:1.0 DCM−EtOH−NH4OH to give the alkene 89e116 (1.15 g, 
58%, dr >95:<5 by 1H-NMR) as an amorphous white solid, Rf 0.28 (90.8:8.2:1.0 
DCM−EtOH−NH4OH); [αD25] −10.6 (c 1.00, MeOH); νmax/cm-1 3369, 3254, 3074, 
2969, 2934, 2893, 2831, 1682, 1524, 1365, 1250, 1219, 1166, 1039; δH (500 
MHz, CD3OD) 5.62 (1H, ddd, J 17.3, 10.2 and 8.6, 4-H), 5.20-5.10 (2H, m, 5-
H2), 3.47 (1H, dd, J 10.9 and 5.1, hydroxypropyl 1-HA), 3.41 (1H, dd, J 10.9 and 
5.1, hydroxypropyl 1-HB), 3.20 (1H, app. td, J 8.3 and 5.5, 3-H), 3.11 (1H, app. 
dt, J 13.5 and 6.8, 1-HA), 3.02 (1H, app. dt, J 13.9 and 7.2, 1-HB), 2.83-2.76 
(1H, m, hydroxypropyl 2-H), 1.68 (1H, app. td, J 13.1 and 7.1, 2-HA), 1.58-1.47 
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(1H, m, 2-HB), 1.43 (9H, s, tBu), 1.05 (3H, d, J 6.6, hydroxypropyl 3-H3); m/z 
(ES) 259.1 (100%, MH+). 
 
tert-Butyl N-[(3R)-3-(2-oxo-1,3-oxazolidin-3-yl)pent-4-en-1-yl]carbamate 
 
BocHN N
O
O
89f  
 
By modification of an existing procedure,116 CDI (1.70 g, 10.4 mmol) and DBU 
(2.60 mL, 17.4 mmol) were added to a solution of the alkene 89d (1.70 g, 6.95 
mmol) in THF (35.0 mL). The mixture was stirred at 50 °C for 18 h and 
concentrated under reduced pressure. Afterwards, DCM (30 mL) and a 
saturated aqueous solution of NH4Cl (30 mL) were added and the aqueous 
layer was extracted with DCM (3 × 30 mL). The organic layers were combined, 
dried (MgSO4), filtered and concentrated under reduced pressure. The crude 
material was purified by flash column chromatography, eluting with EtOAc to 
give the oxazolidinone derivative 89f (1.77 g, 94%) as a yellow oil, Rf 0.48 
(EtOAc); [αD26] +19.8 (c 1.00, MeOH); νmax/cm-1 3337, 2976, 2930, 1735, 1703, 
1514, 1422, 1365, 1249, 1166; δH (500 MHz, CDCl3) 5.79 (1H, ddd, J 17.0, 10.7 
and 5.8, 4-H), 5.30-5.22 (2H, m, 5-H2), 4.98 (1H, br. s, NH), 4.41 (1H, app. dt, J 
11.0 and 5.6, 3-H), 4.38-4.30 (2H, m, oxazolidinyl 5-H2), 3.50-3.46 (2H, m, 
oxazolidinyl 4-H2), 3.40-3.29 (1H, m, 1-HA), 2.96-2.89 (1H, m, 1-HB), 1.92-1.73 
(2H, m, 2-H2), 1.43 (9H, s, tBu); δC (125 MHz, CD3OD) 160.6 (Boc C=O), 158.3 
(oxazolidinyl C=O), 136.2 (C-4), 117.9 (C-5), 80.0 (tBu C1), 64.0 (oxazolidinyl C-
5), 54.5 (C-3), 41.7 (oxazolidinyl C-3), 38.2 (C-1), 32.2 (C-2), 28.8 (tBu C3); 
HRMS found MH+, 271.1653. C13H22N2O4 requires MH, 271.1652.  
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tert-Butyl N-[(3R)-3-[(3R)-3-methyl-5-oxomorpholin-4-yl]pent-4-en-1-yl] 
carbamate  
BocHN N
O
O
89g  
 
By modification of an existing procedure,116 triethylamine (3.06 mL, 21.9 mmol) 
and trimethylsilyl chloride (1.89 mL, 14.9 mmol) were added to a solution of the 
alkene 89e (1.15 g, 4.45 mmol) in DCM (23.0 mL) at rt. The reaction mixture 
was stirred for 18 h at room temperature. Afterwards, triethylamine (3.06 mL, 
21.9 mmol) was added and the mixture was cooled to 0 °C. Chloroacetyl 
chloride (0.53 mL, 6.68 mmol) was added and the mixture was stirred at 0 °C 
for 15 min. Afterwards, it was allowed to warm to room temperature and stirred 
for 3 h. Acetic acid (2.54 mL, 44.5 mmol) and water (2.54 mL) were added and 
the solution was stirred for 18 h. The solvent was removed under reduced 
pressure. DCM (12 mL) was added and the solution was cooled to 0 °C. 
Subsequently, tetrabutylammonium hydrogensulfate (0.76 g, 2.23 mmol) and an 
aqueous solution of 35% NaOH (12 mL) were added and the solution was 
stirred for 3 h at room temperature. Afterwards, water (24 mL) and DCM (48 
mL) were added and the aqueous layer was extracted with DCM (3 × 35 mL). 
The organic layers were combined, dried (MgSO4), filtered and concentrated 
under reduced pressure. The crude material was purified by flash column 
chromatography, eluting with 60:40 EtOAc−petrol to give the ketomorpholine 
derivative 89g116 (0.65 g, 49%) as a yellow oil, Rf 0.28 (60:40 EtOAc−petrol); 
[αD24] +49.0 (c 1.00, CHCl3); νmax/cm-1 3327, 2974, 2930, 2872, 1705, 1636, 
1518, 1364, 1270, 1248, 1166, 1150; δH (500 MHz, CDCl3) 5.98 (1H, ddd, J 
17.1, 10.5 and 6.5, 4-H), 5.32-5.23 (2H, m, 5-H2), 5.15 (1H, br. s, NH), 4.61-
4.52 (1H, m, 3-H), 4.21 (1H, d, J 16.8, morpholinyl 6-HA), 4.13 (1H, d, J 16.8, 
morpholinyl 6-HB), 3.75 (1H, dd, J 11.6 and 2.7, morpholinyl 2-HA), 3.66 (1H, dd, 
J 11.6 and 2.0, morpholinyl 2-HB), 3.54-3.47 (1H, m, morpholinyl 3-H), 3.33-3.22 
(1H, m, 1-HA), 3.06-2.95 (1H, m, 1-HB), 2.03-1.96 (1H, m, 2-HA), 1.95-1.87 (1H, 
m, 2-HB), 1.43 (9H, s, tBu), 1.31 (3H, d, J 6.5, methylmorpholinyl 1-H3); m/z (ES) 
321.1 (100%, MNa+). 
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5.2.2.3. Cyclisation Reactions 
General Procedure F 
According to an existing procedure,116 a solution of the respective alkene (1.00 
eq) and the respective (het)aryl bromide (1.20 eq) in 1,4-dioxane (concentration 
of alkene 0.17 M) was added to a mixture of Pd(OAc)2 (0.05 eq), the ligand 93 
(0.10 eq) and Cs2CO3 (2.50 eq). The reaction mixture was stirred vigorously for 
18 h at 105 °C. Subsequently, it was filtered through celite and concentrated 
under reduced pressure to give a crude material. 
 
tert‐Butyl (2'S,3'R)‐2'‐[(pyrimidin‐5‐yl)methyl]‐[1,3'‐bipyrrolidine]‐1'‐ 
carboxylate 
BocN
N
N
N
90j  
 
According to General Procedure F, the alkene 89a (1.45 g, 5.70 mmol) and 5-
bromopyrimidine (1.10 g, 6.84 mmol) gave a crude material. The crude material 
(dr >95:<5 by 1H-NMR) was purified by flash column chromatography, eluting 
with 95.4:4.1:0.5 DCM−EtOH−NH4OH to give the pyrrolidine derivative 90j (1.25 
g, 66%, dr >95:<5 by 1H-NMR) as a brown oil, Rf  0.06 (95.4:4.1:0.5 
DCM−EtOH−NH4OH); [αD27] +14.5 (c 1.00, CHCl3); νmax/cm-1 2968, 2796, 1686, 
1559, 1391, 1364, 1166, 1110; δH (500 MHz, CD3OD, 333 K) 9.01 (1H, s, 
pyrimidinyl 2-H), 8.66 (2H, s, pyrimidinyl 4,6-H2), 4.13 (1H, app. t, J 6.8, 2'-H), 
3.58 (1H, m, 5'-HA), 3.27 (1H, app. dt, J 10.9 and 6.4, 5'-HB), 2.89 (2H, app. d, J 
6.8, pyrimidinylmethyl 1-H2), 2.86-2.77 (1H, m, 3'-H), 2.59-2.52 (2H, m, 2-HA 
and 5-HA), 2.51-2.44 (2H, m, 2-HB and 5-HB), 2.12-1.96 (2H, m, 4'-H2), 1.76 
(4H, app. td, J 6.4 and 3.7, 3,4-H4), 1.38 (9H, s, tBu); δC (125 MHz, CD3OD) 
158.9 (pyrimidinyl C2-4,6), 157.5 (pyrimidinyl C-2), 156.1 (pyrimidinyl C-5), 
134.1 (C=O), 81.3 (tBu C1), 69.3 (C-3'), 63.4 (C-2'), 52.8 (C2-2,5), 45.9 (C-5'), 
35.2 (pyrimidinylmethyl C-1), 28.7 (tBu C3), 28.1 (C-4'), 24.2 (C2-3,4); HRMS 
found MH+, 333.2288. C18H28N4O2 requires MH, 333.2285. The absolute 
configuration was determined by comparison with analogues.116 
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tert-Butyl (2R,3S)-3-(morpholin-4-yl)-2-[(pyrimidin-5-yl)methyl]pyrrolidine-
1-carboxylate  
BocN
N
N
N
O
90k  
 
According to General Procedure F, the alkene 89b (1.80 g, 6.66 mmol) and 5-
bromopyrimidine (1.27 g, 8.00 mmol) gave a crude material. The crude material 
(dr >95:<5 by 1H-NMR) was purified by flash column chromatography, eluting 
with 95.4:4.1:0.5 DCM−EtOH−NH4OH to give the pyrrolidine derivative 90k 
(1.42 g, 61%, dr >95:<5 by 1H-NMR) as a yellow-orange oil, Rf 0.06 
(95.4:4.1:0.5 DCM−EtOH−NH4OH); [αD23] −13.0 (c 1.00, CHCl3); νmax/cm-1 2970, 
2856, 2831, 1684, 1390, 1164, 1112; δH (500 MHz, CD3OD, 333 K) 9.01 (1H, s, 
pyrimidinyl 2-H), 8.65 (2H, s, pyrimidinyl 4,6-H2), 4.10 (1H, app. td, J 6.6 and 
2.6, 2-H), 3.66-3.54 (5H, m, 5-HA and morpholinyl 2,6-H4), 3.22 (1H, app. dt, J 
11.0 and 7.1, 5-HB), 2.97-2.85 (3H, m, 3-H and pyrimidinylmethyl 1-H2), 2.47-
2.37 (4H, m, morpholinyl 3,5-H4), 2.07-1.94 (2H, m, 4-H2), 1.38 (9H, s, tBu); δC 
(125 MHz, CD3OD, 333 K) 158.8 (pyrimidinyl C2-4,6), 157.4 (pyrimidinyl C-2), 
155.9 (C=O), 134.1 (pyrimidinyl C-5), 81.3 (tBu C1), 70.7 (C-3), 67.9 
(morpholinyl C2-2,6), 60.9 (C-2), 51.4 (morpholinyl C2-3,5), 46.2 (C-5), 35.4 
(pyrimidinylmethyl C-1), 28.7 (tBu C3), 25.8 (C-4); HRMS found MH+, 349.2241. 
C18H28N4O3 requires MH, 349.2234. The absolute configuration was determined 
by comparison with analogues.116 
 
tert-Butyl (2R, 3S)-3-{8-oxa-3-azabicyclo[3.2.1]octan-3-yl}-2-[(pyridin-3-yl) 
methyl] pyrrolidine-1-carboxylate 
 
BocN
N
N
O
90l  
 
According to General Procedure F, the alkene 89c (0.60 g, 2.02 mmol) and 3-
bromopyridine (0.23 mL, 2.43 mmol) gave a crude material. The crude material 
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(dr >95:<5 by 1H-NMR) was purified by flash column chromatography, eluting 
with EtOAc to give the pyrrolidine derivative 90l (0.29 g, 38%, dr >95:<5 by 1H-
NMR) as a light-brown oil, Rf 0.11 (EtOAc); [αD23] −6.60 (c 1.00, CHCl3); 
νmax/cm-1 2949, 2809, 1685, 1389, 1363, 1162, 1111; δH (500 MHz, CD3OD, 333 
K) 8.40 (2H, d, J 2.4, pyridinyl 2,6-H2), 7.69 (1H, d, J 5.9, pyridinyl 4-H), 7.36 
(1H, dd, J 7.8 and 4.9, pyridinyl 5-H), 4.22-4.15 (2H, m, bicyclooctanyl 1,5-H2), 
4.03 (1H, ddd, J 7.6, 5.4 and 2.3, 2-H), 3.50 (1H, app. td, J 17.4 and 8.0, 5-HA), 
3.23-3.11 (1H, m, 5-HB), 2.99-2.87 (1H, m, 3-H), 2.87-2.78 (2H, m, 
pyridinylmethyl 1-H2), 2.43 (2H, dd, J 17.9 and 10.8, bicyclooctanyl 2-HA and 
bicyclooctanyl 4-HA), 2.29 (2H, app. td, J 11.5 and 2.0, bicyclooctanyl 2-HB and 
bicyclooctanyl 4-HB), 2.00-1.84 (2H, m, 4-H2), 1.80-1.70 (4H, m, bicyclooctanyl 
6,7-H4), 1.42 (9H, s, tBu); δC (125 MHz, CD3OD, 333 K) 156.1 (C=O), 151.0 
(pyridinyl CA-2,6), 148.1 (pyridinyl CB-2,6), 139.2 (pyridinyl C-4), 136.3 (pyridinyl 
C-3), 125.0 (pyridinyl C-5), 81.1 (tBu C1), 76.2 (bicyclooctanyl CA-1,5), 76.1 
(bicyclooctanyl CB-1,5), 69.1 (pyridinylmethyl C-1), 61.6 (C-2), 56.7 
(bicyclooctanyl CA-2,4), 55.5 (bicyclooctanyl CB-2,4), 46.3 (C-5), 37.6 (C-3), 
29.3 (bicyclooctanyl CA-6,7), 29.2 (bicyclooctanyl CB-6,7), 28.8 (tBu C3), 25.8 
(C-4); HRMS found MH+, 374.2445. C21H31N3O3 requires MH, 374.2438. The 
absolute configuration was determined by comparison with analogues.116 
 
tert-Butyl (2S, 3R)-3-(2-oxo-1,3-oxazolidin-3-yl)-2-[(pyridin-3-yl)methyl] 
pyrrolidine-1-carboxylate 
BocN
N
O
N
O
90m  
 
According to General Procedure F, the alkene 89f (1.14 g, 4.22 mmol) and 3-
bromopyridine (0.49 mL, 5.06 mmol) gave a crude material. The crude material 
(dr 83:17 by 1H-NMR) was purified by flash column chromatography, eluting 
with 95.4:4.1:0.5 DCM−EtOH−NH4OH to give the pyrrolidine derivative 90m 
(0.62 g, 42%, dr >95:<5 by 1H-NMR) as a yellow oil, Rf 0.20 (95.4:4.1:0.5 
DCM−EtOH−NH4OH); [αD25] +16.2 (c 1.00, MeOH); νmax/cm-1 2975, 2930, 1742, 
1683, 1479, 1389, 1165, 1115; δH (500 MHz, CD3OD, 333 K) 8.44 (1H, d, J 1.6, 
pyridinyl 2-H), 8.41 (1H, dd, J 4.9 and 1.6, pyridinyl 6-H), 7.74 (1H, d, J 7.7, 
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pyridinyl 4-H), 7.35 (1H, ddd, J 7.7, 4.9 and 0.6, pyridinyl 5-H), 4.31-4.18 (3H, 
m, 3-H and oxazolidinyl 5-H2), 4.11 (1H, app. td, J 6.1 and 4.0, 2-H), 3.65 (1H, 
app. dt, J 11.1 and 7.7, 5-HA), 3.55 (1H, ddd, J 9.1, 8.3 and 7.1, oxazolidinyl 4-
HA), 3.46 (1H, app. td, J 8.7 and 6.6, oxazolidinyl 4-HB), 3.23-3.13 (1H, m, 5-
HB), 3.00 (2H, app. d, J 5.7, pyridinylmethyl 1-H2), 2.14-2.04 (1H, m, 4-HA), 
2.04-1.95 (1H, m, 4-HB), 1.44 (9H, s, tBu); δC (125 MHz, CD3OD, 333 K) 160.0 
(oxazolidinyl C=O), 155.9 (Boc C=O), 151.2 (pyridinyl C-2), 148.3 (pyridinyl C-
6), 139.3 (pyridinyl C-4), 135.3 (pyridinyl C-3), 125.0 (pyridinyl C-5), 81.6 (tBu 
C1), 63.8 (oxazolidinyl C-5), 62.4 (C-2), 58.7 (C-3), 46.0 (C-5), 42.9 (oxazolidinyl 
C-4), 36.6 (pyridinylmethyl C-1), 28.7 (tBu C3), 27.9 (C-4); HRMS found MH+, 
348.1927. C18H25N3O4 requires MH, 348.1917. The absolute configuration was 
determined by comparison with analogues.116 
 
tert-Butyl (2S, 3R)-3-[(3R)-3-methyl-5-oxomorpholin-4-yl]-2-[(pyridin-3-yl) 
methyl] pyrrolidine-1-carboxylate  
 
BocN
N
N
O
O
90n  
 
According to General Procedure F, the alkene 89g (0.65 g, 2.17 mmol) and 3-
bromopyridine (0.25 mL, 2.61 mmol) gave a crude material. The crude material 
(dr 89:11 by 1H-NMR) was purified by flash column chromatography, eluting 
with 96.9:2.8:0.3 DCM−EtOH−NH4OH to give the pyrrolidine derivative 90n116 
(0.50 g, 61%, dr >95:<5 by 1H-NMR) as a yellow oil, Rf 0.15 (96.9:2.8:0.3 
DCM−EtOH−NH4OH); [αD23] +35.4 (c 1.00, CHCl3); νmax/cm-1 2974, 2930, 2872, 
1685, 1645, 1392, 1149, 1119; δH (500 MHz, CD3OD, 333 K) 8.45 (1H, d, J 2.0, 
pyridinyl 2-H), 8.40 (1H, dd, J 4.9 and 1.3, pyridinyl 6-H), 7.76 (1H, d, J 8.0, 
pyridinyl 4-H), 7.35 (1H, dd, J 8.0 and 4.9, pyridinyl 5-H), 4.47 (1H, br. s, under 
signal for residual water, 3-H), 4.18 (1H, app. q, J 5.1, 2-H), 4.11 (1H, d, J 16.9, 
morpholinyl 6-HA), 3.98 (1H, d, J 16.9, morpholinyl 6-HB), 3.80-3.70 (1H, m, 5-
HA), 3.65 (1H, dd, J 11.6 and 1.6, morpholinyl 2-HA), 3.54 (1H, dd, J 11.6 and 
2.4, morpholinyl 2-HB), 3.47-3.41 (1H, m, morpholinyl 3-H), 3.10-3.03 (1H, m, 5-
HB), 3.02 (2H, app. d, J 5.5, pyridinylmethyl 1-H2), 2.07-2.01 (2H, m, 4-H2), 1.44 
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(9H, s, tBu), 1.23 (3H, d, J 6.5, methylmorpholinyl 1-H3); m/z (ES) 376.1 (100%, 
MH+). 
 
 (2'S,3'R)‐2'‐[(Pyrimidin‐5‐yl)methyl]‐1,3'‐bipyrrolidine 
 
HN
N
N
N
95  
 
According to General Procedure B, TFA (4.00 mL, 52.0 mmol) and the 
protected amine 90j (1.20 g, 3.61 mmol) gave the TFA salt of the amine 95 
(1.68 g, >99%) as an amorphous dark brown solid, Rf  0.10 (84.7:13.6:1.7 
DCM−EtOH−NH4OH); [αD24] −18.0 (c 1.00, MeOH); νmax/cm-1 2969, 2487, 1663, 
1560, 1412, 1194, 1170, 1117; δH (500 MHz, CD3OD) 9.16 (1H, s, pyrimidinyl 2-
H), 8.88 (2H, s, pyrimidinyl 4,6-H2), 4.48 (1H, app. p, J 5.2, 2'-H), 4.06 (1H, app. 
dt, J 9.0 and 4.5, 3'-H), 3.62-3.50 (6H, m, 5'-H2 and 2,5-H4), 3.44 (1H, dd, J 15.2 
and 5.8, pyrimidinylmethyl 1-HA), 3.19 (1H, dd, J 15.2 and 9.8, 
pyrimidinylmethyl 1-HB), 2.78-2.64 (1H, m, 4'-HA), 2.57-2.45 (1H, m, 4'-HB), 
2.16-2.08 (4H, m, 3,4-H4); δc (125 MHz, CD3OD) 162.2 (q, J 36.8, TFA C=O), 
159.1 (pyrimidinyl C2-4,6), 158.7 (pyrimidinyl C-2), 117.5 (q, J 289.8, TFA CF3), 
116.0 (q, J 284.4, TFA CF3), 68.1 (C-3'), 62.6 (C-2'), 45.3 (C-5' and C2-2,5), 
32.8 (pyrimidinylmethyl C-1), 28.5 (C-4'), 23.9 (C2-3,4); HRMS found MH+, 
233.1759. C13H21N4 requires MH, 233.1760.  
4‐[(2R,3S)‐2‐[(Pyrimidin‐5‐yl)methyl]pyrrolidin‐3‐yl]morpholine 
HN
N
N
N
O
115  
 
According to General Procedure B, TFA (4.00 mL, 52.0 mmol) and the 
protected amine 90k (1.42 g, 4.07 mmol) gave the TFA salt of the amine 115 
(1.80 g, >99%) as an amorphous orange solid, Rf 0.11 (84.7:13.6:1.7 
DCM−EtOH−NH4OH); [αD25] +15.4 (c 1.00, MeOH); νmax/cm-1 2979, 2482, 1664, 
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1415, 1175, 1124; δH (500 MHz, CD3OD) 9.12 (1H, s, pyrimidinyl 2-H), 8.82 
(2H, s, pyrimidinyl 4,6-H2), 3.98 (1H, app. q, J 7.3, 2-H), 3.67-3.62 (2H, m, 
morpholinyl 2-HA and morpholinyl 6-HA), 3.62-3.56 (2H, m, morpholinyl 2-HB 
and morpholinyl 6-HB), 3.48-3.40 (1H, m, 3-H), 3.40-3.34 (2H, m, 5-H2), 3.25 
(1H, dd, J 14.7 and 7.0, pyrimidinylmethyl 1-HA), 3.17 (1H, dd, J 14.7 and 8.1, 
pyrimidinylmethyl 1-HB), 2.73-2.68 (2H, m, morpholinyl 3-HA and morpholinyl 5-
HA), 2.68-2.63 (2H, m, morpholinyl 3-HB and morpholinyl 5-HB), 2.31-2.18 (2H, 
m, 4-H2); δC (125 MHz, CD3OD) 162.1 (q, J 34.8, TFA C=O), 158.9 (pyrimidinyl 
C2-4,6), 158.4 (pyrimidinyl C-2), 131.4 (pyrimidinyl C-5), 117.6 (q, J 290.1, TFA 
CF3), 115.8 (q, J 289.9, TFA CF3), 70.2 (C-3), 66.4 (morpholinyl C2-2,6), 60.6 
(C-2), 51.6 (C-5), 45.3 (morpholinyl C2-3,5), 33.1 (pyrimidinylmethyl C-1), 24.8 
(C-4); HRMS found MH+, 249.1703. C13H20N4O requires MH, 249.1709. 
 
3‐[(2R,3S)‐2‐[(Pyridin‐3‐yl)methyl]pyrrolidin‐3‐yl]‐8‐oxa‐3‐azabicyclo[3.2.1]
octane 
HN
N
N
O
114  
 
According to General Procedure B, TFA (1.00 mL, 13.1 mmol) and the 
protected amine 90l (0.29 g, 0.77 mmol) gave the TFA salt of the amine 114 
(0.42 g, >99%) as an amorphous red-brown solid, Rf 0.15 (84.7:13.6:1.7 
DCM−EtOH−NH4OH); [αD25] +16.4 (c 1.00, MeOH); νmax/cm-1 2978, 2638, 1662, 
1434, 1172, 1126; δH (500 MHz, CD3OD) 8.88 (1H, d, J 1.2, pyridinyl 2-H), 8.79 
(1H, d, J 5.3, pyridinyl 6-H), 8.52 (1H, app. dt, J 8.2 and 1.8, pyridinyl 4-H), 8.00 
(1H, dd, J 8.0 and 5.3, pyridinyl 5-H), 4.34-4.29 (1H, m, bicyclooctanyl 1,5-HA), 
4.28-4.23 (1H, m, bicyclooctanyl 1,5-HB), 4.03-3.96 (1H, m-under residual 
solvent peak, 2-H), 3.48-3.34 (5H, m, 3-H, 5-H2 and piridinylmethyl 1-H2), 2.75-
2.54 (4H, m, bicyclooctanyl 2,4-H4), 2.26-2.12 (2H, m, 4-H2), 1.85-1.79 (2H, m, 
bicyclooctanyl 6-HA and bicyclooctanyl 7-HA), 1.68 (2H, app. d, J 6.6, 
bicyclooctanyl 6-HB and bicyclooctanyl 7-HB); δC (125 MHz, CD3OD) 161.9 
(app. d, J 35.8, TFA C=O), 159.0 (app. d, J 42.2, TFA C=O), 147.3 (pyridinyl C-
4), 144.3 (pyridinyl C-2), 142.8 (pyridinyl C-6), 138.0 (pyridinyl C-3), 128.3 
(pyridinyl C-5), 117.6 (q, J 289.0, TFA CF3), 116.0 (q, J 284.4, TFA CF3), 75.6 
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(bicyclooctanyl CA-1,5), 75.3 (bicyclooctanyl CB-1,5), 69.7 (C-3), 60.3 (C-2), 
58.6 (bicyclooctanyl CA-2,4), 53.2 (bicyclooctanyl CB-2,4), 45.3 (C-5), 35.2 
(pyridinylmethyl C-1), 28.8 (bicyclooctanyl C2-6,7), 23.7 (C-4); HRMS found 
MH+, 274.1908. C16H23N3O requires MH, 274.1913. 
 
3‐[(2S,3R)‐2‐[(Pyridin‐3‐yl)methyl]pyrrolidin‐3‐yl]‐1,3‐oxazolidin‐2‐one 
 
HN
N
O
N
O
101  
 
According to General Procedure B, TFA (2.00 mL, 26.0 mmol) and the 
protected amine 90m (0.60 g, 1.72 mmol) gave the TFA salt of the amine 101 
(0.78 g, >99%) as an amorphous light brown solid, Rf 0.11 (84.7:13.6:1.7 
DCM−EtOH−NH4OH); [αD23] −11.0 (c 1.00, MeOH); νmax/cm-1 2961, 2687, 2521, 
1725, 1659, 1439, 1170, 1125; δH (500 MHz, CD3OD) 8.70 (1H, d, J 1.7, 
pyridinyl 2-H), 8.63 (1H, d, J 4.8, pyridinyl 6-H), 8.18 (1H, app. dt, J 8.1 and 1.7, 
pyridinyl 4-H), 7.71 (1H, dd, J 7.9 and 4.8, pyridinyl 5-H), 4.37-4.26 (2H, m, 3-H 
and oxazolidinyl 5-HA), 4.18 (1H, app. td, J 8.8 and 7.4, oxazolidinyl 5-HB), 4.08 
(1H, app. q, J 7.7, 2-H), 3.60-3.51 (2H, m, oxazolidinyl 4-H2), 3.52-3.45 (2H, m, 
5-H2), 3.27 (2H, dd, J 7.5 and 2.9, pyridinylmethyl 1-H2), 2.38-2.29 (1H, m, 4-
HA), 2.29-2.21 (1H, m, 4-HB); δC (75 MHz, CD3OD) 162.4 (app d, J 36.1, TFA 
C=O), 159.9 (oxazolidinyl C=O), 147.9 (pyridinyl C-4), 144.0 (pyridinyl C-2), 
142.5 (pyridinyl C-6), 137.7 (pyridinyl C-3), 128.3 (pyridinyl C-5), 117.8 (q, J 
288.2, TFA CF3), 64.12 (oxazolidinyl C-5), 60.5 (C-2), 58.1 (C-3), 44.6 (C-5), 
42.3 (oxazolidinyl C-4), 34.0 (pyridinylmethyl C-1), 26.4 (C-4); HRMS found 
MH+, 248.1387. C13H17N3O2 requires MH, 248.1393. 
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(5R)‐5‐Methyl‐4‐[(2S,3R)‐2‐[(pyridin‐3‐yl)methyl]pyrrolidin‐3‐yl]morpholin‐3
‐one 
HN
N
N
O
O
100  
 
According to General Procedure B, TFA (1.50 mL, 19.6 mmol) and the 
protected amine 90n (0.50 g, 1.33 mmol) gave the TFA salt of the amine 100 
(0.50 g, >99%) as an amorphous light yellow solid, Rf 0.12 (84.7:13.6:1.7 
DCM−EtOH−NH4OH); [αD23] −28.8 (c 1.00, MeOH); νmax/cm-1 2982, 2677, 1663, 
1662, 1172, 1122; δH (500 MHz, CD3OD) 8.72 (1H, s, pyridinyl 2-H), 8.65 (1H, 
d, J 4.8, pyridinyl 6-H), 8.18 (1H, d, J 7.9, pyridinyl 4-H), 7.73 (1H, dd, J 7.9 and 
4.8, pyridinyl 5-H), 4.51 (1H, app. td, J 7.9 and 5.5, 2-H), 4.15 (1H, d, J 16.9, 
morpholinyl 2-HA), 4.03 (1H, d, J 16.9, morpholinyl 2-HB), 3.91 (1H, app. dt, J 
8.9 and 5.7, 3-H), 3.75-3.63 (3H, m, 5-H2 and morpholinyl 6-HA), 3.50-3.42 (2H, 
m, morpholinyl 6-HB and morpholinyl 5-H), 3.21 (2H, app. d, J 7.9, 
pyridinylmethyl 1-H2), 2.65-2.55 (1H, m, 4-HA), 2.39-2.26 (1H, m, 4-HB), 0.97 
(3H, d, J 6.5, methylmorpholinyl 1-H3); δC (125 MHz, CD3OD) 170.7 
(morpholinyl C=O), 162.5 (q, J 36.4, TFA C=O), 146.7 (pyridinyl C-2), 145.1 
(pyridinyl C-4), 144.7 (pyridinyl C-6), 136.4 (pyridinyl C-3), 127.4 (pyridinyl C-5), 
117.9 (q, J 290.1, TFA CF3), 70.8 (morpholinyl C-6), 68.9 (morpholinyl C-2), 
63.1 (C-2), 62.5 (C-3), 54.7 (morpholinyl C-5), 45.5 (C-5), 34.3 (pyridinylmethyl 
C-1), 28.6 (C-4), 18.5 (methylmorpholinyl C-1); HRMS found MH+, 276.1704. 
C15H21N3O2 requires MH, 276.1706. 
 
5.2.3. Experimental for the Lead-Oriented Synthesis Approach Based on a 
Mannich/Alkylation and a Pd-catalysed Connective Reactions 
5.2.3.1. Preparation of Building Blocks 
General Procedure G 
By modification of an existing procedure,143 LiHMDS (2.20 eq of a 1.0 M 
solution in toluene or THF) was added to a solution of the carbonyl derivative 
(1.00 eq) in toluene (0.17 M) at −78 °C. After stirring the mixture for 1.5 h at −78 
°C, a solution of the imidazole derivative 156 (1.20 eq) in toluene (2.50 M) was 
added dropwise and the reaction mixture was stirred at −78 °C for 3 h. 
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Subsequently, the reaction was allowed to warm to rt and a saturated aqueous 
solution of NH4Cl (5 mL per 1.00 mmol of the carbonyl derivative) was added. 
The phases were separated and the aqueous phase was extracted with Et2O or 
EtOAc (3 × (2 mL per 1.00 mmol of the carbonyl derivative)). Finally, the 
organic phases were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure to give a crude material. 
 
General Procedure H 
By modification of an existing procedure,149 LiHMDS (2.20 eq of a 1.0 M 
solution in toluene) was added to a solution of the carbonyl derivative (1.00 eq) 
in the specified amount of toluene at 0 °C. After stirring for 15 min, allyl 
chloroformate (1.20 eq) was added and the reaction mixture was allowed to 
warm to rt and stirred for 1 h. Subsequently, a saturated aqueous solution of 
NH4Cl (3 mL per 1.00 mmol of the carbonyl derivative) was added, the mixture 
was stirred for 15 min, the phases were separated and the aqueous phase was 
extracted with EtOAc (3 × (1 mL per 1.00 mmol of the carbonyl derivative)). The 
organic phases were combined, washed with brine (2 mL per 1.00 mmol of the 
carbonyl derivative), dried (MgSO4), filtered and concentrated under reduced 
pressure to give a crude material.  
 
4-Benzoylmorpholin-3-one 
154a
BzN
O
O
 
 
By modification of an existing procedure,202 triethylamine (19.9 mL, 143 mmol) 
was added to a suspension of 3-oxomorpholine (13.1 g, 130 mmol) in toluene 
(42.0 mL). After warming the reaction mixture to 90 °C, benzoyl chloride (15.0 
mL, 130 mmol) was added dropwise and the reaction mixture was stirred for 18 
h at 90 °C. Subsequently, the solution was allowed to cool to rt, toluene (125 
mL) was added and the solution was cooled to 0 °C. The precipitate was 
removed by filtration and the solvent was concentrated under reduced pressure 
to give a crude material. Afterwards, the crude material was dissolved in Et2O 
(125 mL), cooled to 0 °C and the solvent was removed by filtration. The 
precipitate was washed with cold Et2O (2 × 125 mL) and it was dissolved in 
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DCM (250 mL). Water (250 mL) was added, the phases were separated and 
the aqueous phase was extracted with DCM (3 × 250 mL). The organic layers 
were combined, dried (MgSO4), filtered and concentrated under reduced 
pressure to yield the benzoyl derivative 154a202 (20.7 g, 78%) as white crystals, 
m.p. (Et2O) 61−64 °C; Rf 0.50 (50:50 petrol−EtOAc); νmax/cm-1 2944, 2893, 
2866, 1702, 1672, 1462, 1450, 1375, 1347, 1302, 1278, 1216, 1138; δH (500 
MHz, CDCl3) 7.59-7.56 (2H, m, phenyl 2,6-H2), 7.50 (1H, tt, J 6.9 and 1.2, 
phenyl 4-H), 7.43-7.37 (2H, m, phenyl 3,5-H2), 4.27 (1H, s, 2-H2), 4.02 (2H, dd, 
J 6.0 and 4.4, 6-H2), 3.93 (2H, dd, J 6.0 and 4.4, 5-H2); δC (125 MHz, CDCl3) 
172.8 (C-3), 169.0 (benzoyl C=O), 135.4 (phenyl C-1), 132.0 (phenyl C-4), 
128.2 (phenyl C4-2,3,5,6), 68.8 (C-2), 64.1 (C-6), 44.7 (C-5); HRMS found MH+, 
206.0810. C11H11NO3 requires MH, 206.0811. 
 
Prop-2-en-1-yl 1H-imidazole-1-carboxylate 
 
N N O
O
156  
 
According to an existing procedure,147 a solution of allyl alcohol (4.47 mL, 65.8 
mmol) in DCM (123 mL) was added dropwise to a solution of CDI (16.0 g, 98.7 
mmol) in THF (515 mL) at 0 °C. The reaction mixture was stirred for 2 h at 0 °C. 
Subsequently, the solvent was removed under reduced pressure to give a 
crude product. The crude product was purified by flash column 
chromatography, eluting with 40:60 EtOAc−hexane to yield the imidazole 
derivative 156147 (10.6 g, >99%) as a colourless oil, Rf 0.38 (50:50 
petrol−EtOAc); νmax/cm-1 3131, 2952, 1755, 1471, 1391, 1314, 1278, 1237, 
1171, 1094; δH (500 MHz, CDCl3) 8.13 (1H, s, 2-H), 7.42 (1H, app. t, J 1.5, 5-
H), 7.05 (1H, dd, J 1.5 and 0.9, 4-H), 5.99 (1H, ddt, J 17.3, 10.4 and 6.0, 
propenyl 2-H), 5.44 (1H, dq, J 17.3 and 1.2, propenyl 3-Htrans), 5.36 (1H, dq, J 
10.4 and 1.2, propenyl 3-Hcis), 4.87 (2H, dt, J 6.0 and 1.2, propenyl 1-H2); δC 
(125 MHz, CDCl3) 148.5 (C=O), 137.2 (C-2), 130.7 (propenyl C-2), 130.5 (C-4), 
120.5 (propenyl C-3), 117.2 (C-5), 68.7 (propenyl C-1); HRMS found MH+, 
153.0659. C7H8N2O2 requires MH, 153.0658. 
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Prop-2-en-1-yl-4-benzoyl-3-oxomorpholine-2-carboxylate 
 
146a
BzN
O
O O
O
 
 
According to General Procedure G, the carbonyl derivative 154a (9.32 g, 45.4 
mmol) and LiHMDS (100 mL, 100 mmol of a 1.0 M solution in THF) gave a 
crude material. The crude material (C-acylated:O-acylated >95:<5 by 1H-NMR) 
was extracted with Et2O and purified by flash column chromatography eluting 
with DCM to yield the allyl ester derivative 146a143 (5.00 g, 41%) as a light 
yellow oil, Rf 0.62 (50:50 petrol−EtOAc); νmax/cm-1 2950, 2893, 1745, 1685, 
1449, 1373, 1274, 1227, 1155, 1139; δH (500 MHz, CDCl3) 7.65-7.61 (2H, m, 
phenyl 2,6-H2), 7.51 (1H, tt, J 7.1 and 1.2, phenyl 4-H), 7.42-7.36 (2H, m, 
phenyl 3,5-H2), 5.94 (1H, ddt, J 17.3, 10.5 and 5.9, propenyl 2-H), 5.38 (1H, 
app. dq, J 17.3 and 1.3, propenyl 3-Htrans), 5.30 (1H, app. dq, J 10.5 and 1.3, 
propenyl 3-Hcis), 4.83 (1H, s, 2-H), 4.74 (2H, app. dt, J 5.9 and 1.3, propenyl 1-
H2), 4.35 (1H, ddd, J 12.0, 7.9 and 3.7, 6-HA), 4.07 (1H, ddd, J 12.0, 5.4 and 
3.8, 6-HB), 4.00 (1H, ddd, J 13.3, 7.9 and 3.8, 5-HB), 3.93 (1H, ddd, J 13.3, 5.4 
and 3.7, 5-HA); δC (125 MHz, CDCl3) 172.6 (C-3), 166.5 (benzoyl C=O), 165.6 
(carboxylate C=O), 134.6 (phenyl C-1), 132.4 (phenyl C-4), 131.0 (propenyl C-
2), 128.5 (phenyl C2-2,6), 128.2 (phenyl C2-3,5), 119.7 (propenyl C-3), 77.1 
(under signal for residual solvent, C-2), 66.9 (propenyl C-1), 62.4 (C-6), 44.7 (C-
5); HRMS found MH+, 290.1024. C15H15NO5 requires MH, 290.1022. 
 
Prop-2-en-1-yl 4-oxooxane-3-carboxylate 
 
O
O
146b
O
O
 
 
According to General Procedure G, the carbonyl derivative 154b (3.84 mL, 41.6 
mmol) and LiHMDS (91.6 mL, 91.6 mmol of a 1.0 M solution in toluene) gave a 
crude material. The crude material (C-acylated:O-acylated >95:<5  by 1H-NMR) 
was extracted with EtOAc and purified by flash column chromatography eluting 
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with 5:95 EtOAc−hexane to yield the allyl ester derivative 146b (3.48 g, 45%, 
keto:enol 24:76 by 1H-NMR in CDCl3) as a colourless oil, Rf 0.72 (50:50 
petrol−EtOAc); νmax/cm-1 2968, 2856, 1741, 1718, 1663, 1624, 1395, 1305, 
1216, 1101, 1047; δH (500 MHz, CDCl3) 5.92 (2H, ddt, J 17.3, 10.5 and 5.6, 
propenyl 2-H), 5.34 (1H, app. q, J 1.5, 3-Htransketo), 5.31 (1H, app. dq, J 17.3 and 
1.5, propenyl 3-Htransenol), 5.26 (1H, app. dd, J 10.5 and 1.2, propenyl 3-Hcisketo), 
5.25 (1H, app. dq, J 10.5 and 1.5, propenyl 3-Hcisenol), 4.65 (4H, dt, J 5.6 and 
1.5, propenyl 1-H2), 4.29 (2H, app. t, J 1.7, 2-H2enol), 4.23 (1H, dd, J 11.6 and 
7.1, 2-HAketo), 4.11 (1H, ddd, J 11.6, 5.1 and 0.9, 2-HBketo), 4.05-3.93 (2H, m, 6-
H2keto), 3.84 (2H, t, J 5.7, 6-H2enol), 3.50 (1H, app. ddd, J 6.8, 5.1 and 1.3, 3-
Hketo), 2.67 (1H, ddd, J 14.5, 6.2 and 5.1, 5-HAketo), 2.55 (1H, dddd, J 14.5, 7.1, 
5.5 and 1.3, 5-HBketo), 2.39 (2H, tt, J 5.7 and 1.7, 5-H2enol); δC (75 MHz, CDCl3) 
201.2 (C-4keto), 169.7 (carboxylate C=Oenol), 169.3 (C-4enol), 167.5 (carboxylate 
C=Oketo), 131.9 (propenyl C-2enol), 131.5 (propenyl C-2keto), 118.8 (propenyl C-
3keto), 118.3 (propenyl C-3enol), 97.3 (C-3enol), 69.6 (C-2keto), 68.2 (C-6keto), 66.0 
(propenyl C-1keto), 64.8 (propenyl C-1enol), 63.9 (C-6enol), 63.0 (C-2enol), 57.8 (C-
3keto), 42.0 (C-5keto), 28.8 (C-5enol); HRMS found MNa+, 207.0627. C9H12O4 
requires MNa, 207.0627. Compound 146b existed as a mixture of keto and enol 
tautomers. 
 
1-Benzyl 3-prop-2-en-1-yl 4-hydroxy-1,2,5,6-tetrahydropyridine-1,3-
dicarboxylate 
N
Cbz
O
O
146c
OH
 
 
According to General Procedure H, the carbonyl derivative 154c (10.6 g, 45.45 
mmol) in toluene (68.0 mL) gave a crude material. The crude material (C-
acylated:O-acylated >95:<5 by 1H-NMR) was purified by flash column 
chromatography, eluting with 10:90 EtOAc−hexane to yield the allyl ester 
derivative 146c (5.77 g, 40%, >98% enol by 1H-NMR in CDCl3) as a colourless 
oil, Rf 0.60 (70:30 petrol−EtOAc); νmax/cm-1 3032, 2945, 1697, 1662, 1620, 1422, 
1305, 1227, 1193, 1111, 1056; δH (400 MHz, CDCl3) 7.39-7.31 (5H, m, phenyl), 
5.94 (1H, ddt, J 17.2, 10.5 and 5.6, propenyl 2-H), 5.34 (1H, dd, J 17.2 and 1.4, 
propenyl 3-Htrans), 5.26 (1H, app. dq, J 10.5 and 1.4, propenyl 3-Hcis), 5.17 (2H, 
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s, phenylmethyl 1-H2), 4.69 (2H, app. dt, J 5.6 and 1.4, propenyl 1-H2), 4.18 
(2H, s, 2-H2), 3.65 (2H, t, J 5.9, 6-H2), 2.40 (2H, app. br. s, 5-H2); δC (100 MHz, 
CDCl3) 170.6 (carboxylate C=O), 170.3 (C-4), 155.3 (Cbz C=O), 136.7 (phenyl 
C-1), 131.8 (propenyl C-2), 128.6 (phenyl C2-3,5), 128.2 (phenyl C2-2,6), 128.1 
(phenyl C-4), 118.6 (propenyl C-3), 95.8 (C-3), 67.4 (phenylmethyl C-1), 65.2 
(propenyl C-1), 40.6 (C-2), 40.0 (C-6), 28.8 (C-5); HRMS found MH+, 318.1330. 
C17H19NO5 requires MH, 318.1335. Compound 146c existed as the enol 
tautomer. 
 
Prop-2-en-1-yl 6-methoxy-1-oxo-2,3-dihydro-1H-indene-2-carboxylate 
 
MeO
O
O
O
146d  
 
According to General Procedure H, the carbonyl derivative 154d (7.37 g, 45.4 
mmol) in toluene (100 mL) gave a crude material. The crude material (C-
acylated:O-acylated >95:<5 by 1H-NMR) was purified by flash column 
chromatography, eluting with 10:90 EtOAc−hexane to yield the allyl ester 
derivative 146d146 (5.23 g, 47%) as a brown oil, Rf 0.56 (70:30 petrol−EtOAc); 
νmax/cm-1 2940, 2837, 1736, 1704, 1571, 1491, 1432, 1317, 1296, 1273, 1204, 
1184, 1148, 1024; δH (400 MHz, CDCl3) 7.39 (1H, dd, J 8.3 and 0.8, 4-H), 7.22 
(1H, dd, J 8.3 and 2.5, 5-H), 7.19 (1H, d, J 2.5, 7-H), 5.94 (1H, ddt, J 17.2, 10.5 
and 5.7, propenyl 2-H), 5.37 (1H, app. dq, J 17.2 and 1.4, propenyl 3-Htrans), 
5.26 (1H, app. dq, J 10.5 and 1.4, propenyl 3-Hcis), 4.69 (2H, app. tt, J 5.7 and 
1.4, propenyl 1-H2), 3.83 (3H, s, methoxy), 3.78 (1H, dd, J 8.1 and 3.9, 2-H), 
3.47 (1H, dd, J 16.9 and 3.9, 3-HA), 3.32 (1H, dd, J 16.9 and 8.1, 3-HB); δC (100 
MHz, CDCl3) 199.3 (C-1), 168.9 (carboxylate C=O), 159.8 (C-6), 146.5 (C-3a), 
136.5 (C-7a), 131.7 (propenyl C-2), 127.2 (C-4), 125.0 (C-5), 118.6 (propenyl C-
3), 105.7 (C-7), 66.2 (propenyl C-1), 55.7 (methoxy), 54.0 (C-2), 29.7 (C-3); 
HRMS found MNa+, 269.0782. C14H14O4 requires MNa, 269.0784. 
 
 
 
 
143 
 
Prop-2-en-1-yl 4-oxooxolane-3-carboxylate 
 
O
O
O
O
146e  
 
According to an existing procedure,151 the carbonyl derivative 154g (8.57 mL, 
111 mmol) was added dropwise to a suspension of NaH (4.88 g, 122 mmol of a 
60% dispersion in mineral oil) in Et2O (370 mL). After stirring for 4 h, the solvent 
was removed under reduced pressure and the crude material was dissolved in 
DMSO (222 mL). The solution was cooled to 0 °C and allyl acrylate (16.3 mL, 
122 mmol) was added dropwise. The reaction mixture was allowed to warm to rt 
and stirred overnight. An aqueous solution of 10% HCl (70 mL) and Et2O (200 
mL) were added and the mixture was stirred for 30 min. Water (70 mL) was 
added, the phases were separated and the aqueous phase was extracted with 
Et2O (4 × 100 mL). The organic phases were combined, washed with brine (300 
mL), dried (MgSO4), filtered and concentrated under reduced pressure to give a 
crude material. The crude material was purified by flash column 
chromatography, eluting with 10:90→20:80 EtOAc−hexane to yield the allyl 
ester derivative 146e (5.45 g, 29%) as a pink oil, Rf 0.43 (70:30 petrol−EtOAc); 
νmax/cm-1 2951, 2883, 1770, 1725; δH (400 MHz, CDCl3) 5.90 (1H, ddt, J 17.2, 
10.3 and 5.7, propenyl 2-H), 5.34 (1H, dd, J 17.2 and 1.4, propenyl 3-Htrans), 
5.26 (1H, dd, J 10.3 and 1.4, propenyl 3-Hcis), 4.71-4.60 (2H, m, propenyl 1-H2), 
4.49 (1H, dd, J 9.7 and 8.3, 2-HA), 4.44 (1H, dd, J 9.7 and 8.3, 2-HB), 4.02 (1H, 
d, J 17.1, 5-HA), 3.94 (1H, d, J 17.1, 5-HB), 3.53 (1H, t, J 8.3, 3-H); δC (100 MHz, 
CDCl3) 207.3 (C-4), 166.3 (carboxylate C=O), 131.4 (propenyl C-2), 119.1 
(propenyl C-3), 70.8 (C-5), 69.5 (C-2), 66.5 (propenyl C-1), 53.4 (C-3); HRMS 
found MNa+, 193.0467. C8H10O4 requires MNa, 193.0471. 
 
5.2.3.2. Connective Reactions 
General Procedure I 
According to an existing procedure,142 the sulfone derivative 153 (1.20 eq) was 
added to a solution of the allyl ester derivative (1.00 eq) in DCM (0.10 M) at rt. 
After stirring the mixture for 5 min, Cs2CO3 (2.50 eq) was added and the 
reaction was stirred for the specified time at rt. Subsequently, a saturated 
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aqueous solution of NH4Cl (10 mL per 1.00 mmol of the allyl ester derivative) 
was added and the mixture was stirred for 30 min at rt. The phases were 
separated and the organic phase was extracted with DCM (3 × (5 mL per 1.00 
mmol of the allyl ester derivative)). The organic phases were combined, dried 
(MgSO4), filtered and concentrated under reduced pressure to give a crude 
material.  
 
General Procedure J 
By modification of an existing procedure,157 the specified amount of K2CO3 was 
added to a solution of the allyl ester derivative 146c (1.00 eq) in acetone (0.26 
M). After stirring for 15 min at rt, the specified amount of the arylmethyl bromide 
derivative was added dropwise and the reaction mixture was stirred at 70 °C for 
2 h. Subsequently, the mixture was allowed to cool to rt, a saturated aqueous 
solution of NH4Cl (9 mL per 1.00 mmol of the allyl ester derivative 146c) was 
added and the mixture was stirred for 30 min. Afterwards, EtOAc (6 mL per 1.00 
mmol of the allyl ester derivative 146c) was added, the phases were separated 
and the aqueous phase was extracted with EtOAc (3 × (5 mL per 1.00 mmol of 
the allyl ester derivative 146c)). The organic phases were combined, dried 
(MgSO4), filtered and concentrated under reduced pressure to give a crude 
material. 
 
General Procedure K 
According to an existing procedure,145 PPh3 (0.20 eq) and Pd(OAc)2 (0.05 eq) 
were added to a solution of the quaternary allyl ester derivative (1.00 eq) in THF 
(0.10 M) and the reaction mixture was stirred for 1 h at 70 °C. Subsequently, 
the solution was allowed to cool to rt, filtered through celite and concentrated 
under reduced pressure to give a crude material. 
 
tert-Butyl N-[(benzenesulfonyl)methyl]carbamate 
 
BocHN SO2Ph
153  
 
According to an existing procedure,155 a 37% aqueous solution of formaldehyde 
(43.0 mL, 432 mmol) and formic acid (25.3 mL) were added to a suspension of 
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tert-butyl carbamate (25.3 g, 216 mmol) and benzenesulfinic acid sodium salt 
(70.9 g, 432 mmol) in methanol (253 mL) and water (506 mL). After stirring the 
reaction mixture for 3 days at rt, the solvent was removed by filtration and the 
precipitate was washed with water (100 mL) and Et2O (100 mL). Subsequently, 
the precipitate was dissolved in DCM (500 mL), dried (MgSO4), filtered and 
concentrated under reduced pressure to afford the carbamate derivative 153155 
(37.9 g, 65%) as a crystalline white powder, m.p. (DCM) 155−160 °C; Rf 0.63 
(50:50 petrol−EtOAc); νmax/cm-1 3352, 3011, 2980, 2934, 1699, 1475, 1358, 
1288, 1135, 1087, 1007; δH (400 MHz, CDCl3) 7.92 (2H, d, J 7.5, phenyl 2,6-
H2), 7.65 (1H, t, J 7.5, phenyl 4-H), 7.54 (2H, t, J 7.5, phenyl 3,5-H2), 5.47 (1H, 
t, J 6.9, NH), 4.53 (2H, d, J 6.9, 1-H2), 1.25 (9H, s, tBu); δC (100 MHz, CDCl3) 
153.9 (C=O), 137.0 (phenyl C-1), 134.1 (phenyl C-4), 129.3 (phenyl C2-3,5), 
129.1 (phenyl C2-2,6), 81.1 (tBu C1), 62.2 (C-1), 28.1 (tBu C3); HRMS found 
MH+, 272.0946. C12H17NO4S requires MH, 272.0951. 
 
Prop-2-ene-1-yl-4-benzoyl-2-({[(tert-butoxy)carbonyl]amino}methyl)-3-
oxomorpholine-2-carboxylate 
BzN
O
O
O
O
NHBoc
147a  
 
According to General Procedure I, the allyl ester derivative 146a (5.00 g, 17.3 
mmol) was stirred for 18 h to give a crude material. The crude material was 
purified by flash column chromatography, eluting with 20:80 EtOAc−hexane to 
yield the quaternary allyl ester derivative 147a142 (6.00 g, 83%) as a colourless 
oil, Rf 0.70 (50:50 petrol−EtOAc); νmax/cm-1 3390, 2977, 1687, 1504, 1366, 
1275, 1228, 1143, 1064; δH (500 MHz, CDCl3) 7.69-7.62 (2H, m, phenyl 2,6-
H2), 7.52 (1H, tt, J 7.1 and 1.2, phenyl 4-H), 7.42-7.37 (2H, m, phenyl 3,5-H2), 
5.96 (1H, ddt, J 17.2, 10.4 and 5.8, propenyl 2-H), 5.40 (1H, app. dq, J 17.2 and 
1.3, propenyl 3-Htrans), 5.32 (1H, app. dq, J 10.4 and 1.3, propenyl 3-Hcis), 5.00 
(1H, br. s, NH), 4.74 (2H, app. d, J 5.8, propenyl 1-H2), 4.30-4.23 (1H, m, 6-HA), 
4.19 (1H, dt, J 12.3 and 4.0, 6-HB), 4.00 (1H, ddd, J 13.4, 9.3 and 4.0, 5-HA), 
3.92 (1H, dt, J 13.4 and 3.6, 5-HB), 3.82 (1H, dd, J 14.3 and 7.4, 
methylcarbamate 1-HA), 3.74 (1H, dd, J 14.3 and 5.8, methylcarbamate 1-HB), 
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1.42 (9H, s, tBu); δC (125 MHz, CDCl3) 172.7 (C-3), 167.7 (benzoyl C=O), 167.5 
(carboxylate C=O), 155.7 (Boc C=O), 134.7 (phenyl C-1), 134.4 (phenyl C-4), 
131.0 (propenyl C-3), 128.5 (phenyl C2-2,6), 128.3 (phenyl C2-3,5), 119.9 
(propenyl C-2), 83.0 (C-2), 79.8 (tBu C1), 67.1 (propenyl C-1), 62.1 (C-6), 44.9 
(C-5), 44.7 (methylcarbamate C-1), 28.4 (tBu C3); HRMS found MH+, 419.1814. 
C21H26N2O7 requires MH, 419.1812. 
 
Prop-2-en-1-yl 3-({[(tert-butoxy)carbonyl]amino}methyl)-4-oxooxane-3-
carboxylate 
O
O
O
O
NHBoc
147b  
 
According to General Procedure I, the allyl ester derivative 146b (7.00 g, 38.0 
mmol) was stirred for 18 h to give a crude material. The crude material was 
purified by flash column chromatography, eluting with 20:80 EtOAc−hexane to 
yield the quaternary allyl ester derivative 147b (10.1 g, 85%) as a colourless oil, 
Rf 0.67 (50:50 petrol−EtOAc); νmax/cm-1 3403, 2976, 2934, 2868, 1709, 1501, 
1366, 1249, 1225, 1212, 1163, 1135, 1112; δH (400 MHz, CDCl3) 5.88 (1H, ddt, 
J 17.3, 10.4 and 5.8, propenyl 2-H), 5.31 (1H, app. dq, J 17.3 and 1.4, propenyl 
3-Htrans), 5.24 (1H, app. dq, J 10.4 and 1.4, propenyl 3-Hcis), 5.09 (1H, app. t, J 
5.6, NH), 4.65 (1H, app. t, J 1.4, propenyl 1-HA), 4.64 (1H, app. t, J 1.4, 
propenyl 1-HB), 4.44 (1H, d, J 11.8, 2-HA), 4.14-4.05 (1H, m, 6-HA), 3.87-3.76 
(1H, m, 6-HB), 3.60 (1H, dd, J 14.1 and 6.8, methylcarbamate 1-HA), 3.58 (1H, 
d, J 11.8, 2-HB), 3.50 (1H, dd, J 14.1 and 6.8, methylcarbamate 1-HB), 2.76 (1H, 
ddd, J 15.4, 9.3 and 6.4, 5-HA), 2.59 (1H, app. dt, J 14.9 and 4.4, 5-HB), 1.38 
(9H, s, tBu); δC (100 MHz, CDCl3) 204.1 (C-4), 169.4 (carboxylate C=O), 155.8 
(Boc C=O), 131.3 (propenyl C-2), 119.2 (propenyl C-3), 79.7 (tBu C1), 72.3 (C-
2), 68.4 (C-6), 66.5 (propenyl C-1), 64.0 (C-3), 41.0 (C-5 and methylcarbamate 
C-1), 28.3 (tBu C3); HRMS found MH+, 314.1601. C15H23NO6 requires MH, 
314.1598. 
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1-Benzyl 3-prop-2-en-1-yl 3-({[(tert-butoxy)carbonyl]amino}methyl)-4-
oxopiperidine-1,3-dicarboxylate 
 
N
Cbz
O
O
O
NHBoc
147c  
 
According to General Procedure I, the allyl ester derivative 146c (6.47 g, 20.4 
mmol) was stirred for 18 h to give a crude material. The crude material was 
purified by flash column chromatography, eluting with 20:80 EtOAc−hexane to 
yield the quaternary allyl ester derivative 147c (7.69 g, 84%) as a colourless oil, 
Rf 0.63 (50:50 petrol−EtOAc); νmax/cm-1 3398, 2977, 1697, 1499, 1423, 1365, 
1234, 1138; δH (500 MHz, CD3OD, 333 K) 7.42-7.28 (5H, m, phenyl), 5.86 (1H, 
ddt, J 17.3, 10.5 and 5.8, propenyl 2-H), 5.28 (1H, app. dq, J 17.3 and 1.4, 
propenyl 3-Htrans), 5.19 (1H, app. dq, J 10.5 and 1.4, propenyl 3-Hcis), 5.16 (1H, 
app. s, phenylmethyl 1-HA), 5.15 (1H, app. s, phenylmethyl 1-HB), 4.61 (1H, d, J 
13.9, 2-HA), 4.57-4.52 (2H, m, propenyl 1-H2), 4.18-4.09 (1H, m, 6-HA), 3.61 
(1H, d, J 14.4, methylcarbamate 1-HA), 3.46 (1H, d, J 14.4, methylcarbamate 1-
HB), 3.46-3.39 (1H, m, 6-HB), 3.35 (1H, d, J 13.9, 2-HB), 2.68 (1H, ddd, J 15.2, 
9.9 and 6.5, 5-HA), 2.53 (1H, app. dt, J 15.2 and 4.7, 5-HB), 1.41 (9H, s, tBu); δC 
(125 MHz, CD3OD, 333 K) 205.1 (C-4), 170.3 (carboxylate C=O), 157.9 (Boc 
C=O), 156.8 (Cbz C=O), 137.9 (phenyl C-1), 132.8 (propenyl C-2), 129.5 
(phenyl C2-3,5), 129.2 (phenyl C-4), 129.0 (phenyl C2-2,6), 119.3 (propenyl C-
3), 80.7 (tBu C1), 68.9 (phenylmethyl C-1), 67.6 (propenyl C-1), 63.2 (C-3), 49.5 
(C-2), 44.2 (C-6), 42.9 (methylcarbamate C-1), 40.4 (C-5), 28.7 (tBu C3); HRMS 
found MNa+, 469.1936. C23H30N2O7 requires MNa, 469.1945. 
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Prop-2-en-1-yl 2-({[(tert-butoxy)carbonyl]amino}methyl)-6-methoxy-1-oxo-
2,3-dihydro-1H-indene-2-carboxylate 
 
MeO
O
O
O
NHBoc
147d  
 
According to General Procedure I, the allyl ester derivative 146d (5.12 g, 20.8 
mmol) was stirred for 18 h to give a crude material. The crude material was 
purified by flash column chromatography, eluting with 15:85 EtOAc−hexane to 
yield the quaternary allyl ester derivative 147d (7.80 g, >99%) as an amorphous 
colourless solid, Rf 0.50 (70:30 petrol−EtOAc); νmax/cm-1 3377, 2974, 2940, 
1727, 1697, 1514, 1492, 1280, 1241, 1189, 1161, 1134; δH (300 MHz, CDCl3) 
7.37 (1H, d, J 8.3, 4-H), 7.21 (1H, dd, J 8.3 and 2.6, 5-H), 7.17 (1H, d, J 2.6, 7-
H), 5.81 (1H, ddt, J 17.2, 10.6 and 5.6, propenyl 2-H), 5.20 (1H, dd, J 17.2 and 
1.3, propenyl 3-Htrans), 5.18 (1H, br. s, NH), 5.17 (1H, dd, J 10.6 and 1.3, 
propenyl 3-Hcis), 4.59 (2H, app. dt, J 5.6 and 1.5, propenyl 1-H2), 3.82 (3H, s, 
methoxy), 3.67 (1H, d, J 6.6, methylcarbamate 1-HA), 3.65 (1H, d, J 6.6, 
methylcarbamate 1-HB), 3.45 (1H, d, J 17.2, 3-HA), 3.24 (1H, d, J 17.2, 3-HB), 
1.40 (9H, s, tBu); δC (75 MHz, CDCl3) 201.0 (C-1), 170.8 (carboxylate C=O), 
159.9 (C-6), 156.4 (Boc C=O), 146.4 (C-3a), 136.2 (C-7a), 131.5 (propenyl C-
2), 127.4 (C-4), 125.3 (C-5), 118.6 (propenyl C-3), 105.9 (C-7), 79.7 (tBu C1), 
66.2 (propenyl C-1), 62.4 (C-2), 55.7 (methoxy), 44.0 (methylcarbamate C-1), 
35.0 (C-3), 28.4 (tBu, C3); HRMS found MNa+, 398.1572. C20H25NO6 requires 
MNa, 398.1574. 
 
Prop-2-en-1-yl 3-({[(tert-butoxy)carbonyl]amino}methyl)-4-oxooxolane-3-
carboxylate 
O
O
O
O
NHBoc
147e  
 
According to General Procedure I, the allyl ester derivative 146e (9.60 g, 56.4 
mmol) was stirred for 3 h to give a crude material. The crude material was 
purified by flash column chromatography, eluting with 10:90→15:85 
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EtOAc−petrol to yield the quaternary allyl ester derivative 147e (14.7 g, 87%) as 
a colourless oil, Rf 0.41 (70:30 petrol−EtOAc); νmax/cm-1 3367, 2978, 1770, 
1710, 1504, 1366; δH (400 MHz, CDCl3) 5.86 (1H, ddt, J 17.2, 10.5 and 5.7, 
propenyl 2-H), 5.30 (1H, app. dq, J 17.2 and 1.3, propenyl 3-Htrans), 5.25 (1H, 
app. dq, J 10.5 and 1.3, propenyl 3-Hcis), 5.11 (1H, app. t, J 5.3, NH), 4.65 (1H, 
app. t, J 1.4, propenyl 1-HA), 4.64 (1H, app. t, J 1.4, propenyl 1-HB), 4.49 (1H, d, 
J 9.9, 2-HA), 4.21 (1H, d, J 9.9, 2-HB), 4.11 (1H, d, J 17.2, 5-HA), 4.05 (1H, d, J 
17.2, 5-HB), 3.72-3.55 (2H, m, methylcarbamate 1-H2), 1.40 (9H, s, tBu); δC (100 
MHz, CDCl3) 208.8 (C-4), 168.6 (carboxylate C=O), 156.2 (Boc C=O), 131.1 
(propenyl C-2), 119.2 (propenyl C-3), 80.1 (tBu C1), 73.3 (C-2), 71.2 (C-5), 66.7 
(propenyl C-1), 61.0 (C-3), 41.4 (methylcarbamate C-1), 28.4 (tBu C3); HRMS 
found MNa+, 322.1256. C14H21NO6 requires MNa, 322.1261. 
 
Prop‐2‐en‐1‐yl 2‐({[(tert‐butoxy)carbonyl]amino}methyl)prop‐2‐enoate 
 
BocHN O
O
157  
 
According to General Procedure I, the allyl ester derivative 146e (0.41 g, 2.41 
mmol) was stirred for 18 h to give a crude material. The crude material was 
purified by flash column chromatography, eluting with 10:90 EtOAc−hexane to 
yield the α,β-unsaturated ester 157 (0.39 g, 67%) as a light-yellow oil, Rf 0.54 
(70:30 petrol−EtOAc); νmax/cm-1 3366, 2978, 2933, 1702, 1509, 1365, 1249, 
1154; δH (400 MHz, CDCl3) 6.26 (1H, s, 3-HA), 5.93 (1H, ddt, J 17.1, 10.4 and 
5.6, propenyl 2-H), 5.78 (1H, s, 3-HB), 5.32 (1H, app. dq, J 17.1 and 1.4, 
propenyl 3-Htrans), 5.23 (1H, app. dq, J 10.4 and 1.4, propenyl 3-Hcis), 4.99 (1H, 
br. s, NH), 4.65 (2H, dt, J 5.6 and 1.4, propenyl 1-H2), 3.94 (2H, d, J 6.0, 
methylcarbamate 1-H2), 1.42 (9H, s, tBu); δC (100 MHz, CDCl3) 165.9 (C-1), 
155.7 (Boc C=O), 137.3 (C-2), 132.0 (propenyl C-2), 126.6 (C-3), 118.4 
(propenyl C-3), 79.6 (tBu C1), 65.5 (propenyl C-1), 41.7 (methylcarbamate C-1), 
28.5 (tBu C3); HRMS found MNa+, 264.1205. C12H19NO4 requires MNa, 
264.1206. 
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1-Benzyl 3-prop-2-en-1-yl 3-benzyl-4-oxopiperidine-1,3-dicarboxylate 
 
N
Cbz
O
O
O
147f  
 
According to General Procedure J, the allyl ester derivative 146c (0.75 g. 2.36 
mmol), K2CO3 (1.30 g, 9.44 mmol) and (bromomethyl)benzene (0.56 mL, 4.72 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 20:80 EtOAc−hexane to yield the quaternary allyl 
ester derivative 147f (0.86 g, 89%) as a colourless oil, Rf 0.38 (70:30 
petrol−EtOAc); νmax/cm-1 3063, 3030, 2936, 1698, 1427, 1266, 1239, 1217, 
1178, 1121; δH (500 MHz, CDCl3, 323 K) 7.41-7.15 (10H, phenyl), 5.77 (1H, ddt, 
J 16.9, 10.7 and 5.6, propenyl 2-H), 5.26 (1H, dd, J 16.9 and 1.3, propenyl 3-
Htrans), 5.21 (1H, app. dq, J 10.7 and 1.3, propenyl 3-Hcis), 5.17 (1H, app. s, Cbz 
phenylmethyl 1-HA), 5.16 (1H, app. s, Cbz phenylmethyl 1-HB), 4.72 (1H, dd, J 
13.8 and 2.1, 2-HA), 4.50 (2H, d, J 5.6, propenyl 1-H2), 4.25 (1H, app. br. s, 6-
HA), 3.31 (1H, d, J 13.9, phenylmethyl 1-HA), 3.31-3.25 (1H, m, 6-HB), 3.17 (1H, 
d, J 13.9, phenylmethyl 1-HB), 3.14 (1H, d, J 13.8, 2-HB), 2.75 (1H, ddd, J 14.9, 
10.4 and 6.6, 5-HA), 2.49 (1H, app. dt, J 14.9 and 4.4, 5-HB); δC (125 MHz, 
CDCl3, 323 K) 203.5 (C-4), 169.5 (carboxylate C=O), 155.2 (Cbz C=O), 136.6 
(Cbz phenyl C-1), 135.6 (phenyl C-1), 131.4 (propenyl C-2), 130.6 (phenyl C2-
2,6), 128.6 (Cbz phenyl C2-3,5), 128.5 (phenyl C2-3,5), 128.2 (Cbz phenyl C2-
2,6), 128.0 (Cbz phenyl C-4), 127.2 (phenyl C-4), 119.3 (propenyl C-3), 67.7 
(Cbz phenylmethyl C-1), 66.4 (propenyl C-1), 62.3 (C-3), 50.1 (C-2), 43.5 (C-6), 
40.0 (C-5), 37.6 (phenylmethyl C-1); HRMS found MNa+, 430.1624. C24H25NO5 
requires MNa, 430.1630. 
 
 
 
 
 
 
151 
 
1-Benzyl 3-prop-2-en-1-yl 4-oxo-3-[(pyridin-3-yl)methyl]piperidine-1,3-
dicarboxylate 
N
Cbz
O
O
O
N
147g  
 
According to General Procedure J, the allyl ester derivative 146c (1.00 g. 3.15 
mmol), K2CO3 (2.17 g, 15.7 mmol) and 3-(bromomethyl)pyridine hydrobromide 
(1.03 g, 4.10 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 60:40 EtOAc−hexane to yield the 
quaternary allyl ester derivative 147g (0.63 g, 49%) as a yellow oil, Rf 0.50 
(EtOAc); νmax/cm-1 3031, 2946, 1697, 1423, 1235, 1215, 1177, 1125; δH (500 
MHz, CD3OD, 333 K) 7.23 (2H, d, J 6.3, pyridinyl 2,6-H2), 6.51 (1H, d, J 7.9, 
pyridinyl 4-H), 6.20-6.14 (5H, m, phenyl), 6.14-6.11 (1H, m, pyridinyl 5-H), 4.58 
(1H, ddt, J 16.9, 10.1 and 6.0, propenyl 2-H), 4.05 (1H, dd, J 16.9 and 1.4, 
propenyl 3-Htrans), 4.01 (1H, dd, J 10.1 and 1.4, propenyl 3-Hcis), 3.97 (1H, app. 
s, phenylmethyl 1-HA), 3.96 (1H, app. s, phenylmethyl 1-HB), 3.50 (1H, dd, J 
13.6 and 2.2, 2-HA), 3.30-3.27 (1H, m, propenyl 1-HA), 3.10-3.04 (1H, m, 6-HA), 
2.18 (1H, d, J 14.3, pyridinylmethyl, 1-HA), 2.18-2.15 (2H, m, 6-HB and propenyl 
1-HB), 2.12 (1H, d, J 13.6, 2-HB), 1.82 (1H, d, J 14.3, pyridinylmethyl 1-HB), 
1.63-1.52 (1H, m, 5-HA), 1.35 (1H, app. dt, J 14.9 and 4.1, 5-HB); δC (125 MHz, 
CD3OD, 333 K) 204.6 (C-4), 170.5 (carboxylate C=O), 156.6 (Cbz C=O), 151.9 
(pyridinyl 2-C), 148.7 (pyridinyl C-6), 140.1 (pyridinyl C-4), 137.8 (phenyl C-1), 
133.8 (pyridinyl C-3), 132.5 (propenyl C-2), 129.5 (phenyl C2-3,5), 129.1 (phenyl 
C-4), 128.9 (phenyl C2-2,6), 124.7 (pyridinyl C-5), 119.8 (propenyl C-3), 68.8 
(phenylmethyl C-1), 67.5 (propenyl C-1), 63.3 (C-3), 51.2 (C-2), 44.5 (C-6), 40.6 
(C-5), 35.4 (pyridinylmethyl C-1); HRMS found MH+, 409.1755. C23H24N2O5 
requires MH, 409.1763. 
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tert-Butyl N-{[4-benzoyl-3-oxo-2-(prop-2-en-1-yl)morpholin-2-yl]methyl} 
carbamate 
BzN
O
O NHBoc
148h  
 
According to General Procedure K, the quaternary allyl ester derivative 147a 
(6.00 g, 14.3 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 20:80 EtOAc−hexane to yield the 
lactam derivative 148h142 (4.30 g, 80%) as a brown oil, Rf 0.65 (50:50 
petrol−EtOAc); νmax/cm-1 3379, 2977, 2933, 1682, 1505, 1366, 1277, 1246, 
1221, 1140, 1116, 1087; δH (400 MHz, CDCl3) 7.55 (2H, d, J 7.6, phenyl 2,6-
H2), 7.50 (1H, t, J 7.6, phenyl 4-H), 7.39 (2H, t, J 7.6, phenyl 3,5-H2), 5.88 (1H, 
ddt, J 16.0, 11.1 and 7.3, propenyl 2-H), 5.20 (1H, app. d, J 10.5, propenyl 3-
Hcis), 5.19 (1H, app. d, J 16.8, propenyl 3-Htrans), 4.90 (1H, br. s, NH), 4.10-4.04 
(2H, m, 6-H2), 3.98 (1H, app. dt, J 9.9 and 4.8, 5-HA), 3.90 (1H, app. dt, J 13.1 
and 4.8, 5-HB), 3,62 (1H, dd, J 14.0 and 7.1, methylcarbamate 1-HA), 3.39 (1H, 
dd, J 14.0 and 5.6, methylcarbamate 1-HB), 2.67 (1H, dd, J 14.3 and 7.3, 
propenyl 1-HA), 2.51 (1H, dd, J 14.3 and 7.0, propenyl 1-HB), 1.43 (9H, s, tBu); 
δC (100 MHz, CDCl3) 172.9 (C-3), 172.6 (benzoyl C=O), 155.8 (Boc C=O), 
135.4 (phenyl C-1), 132.0 (phenyl C-4), 131.6 (propenyl C-2), 128.2 (phenyl C2-
3,5), 128.0 (phenyl C2-2,6), 119.8 (propenyl C-3), 82.1 (C-2), 79.7 (tBu C1), 60.4 
(C-6), 45.7 (methylcarbamate C-1), 45.4 (C-5), 39.7 (propenyl C-1), 28.4 (tBu 
C3); HRMS found MH+, 375.1919. C20H26N2O5 requires MH, 375.1914 
 
tert-Butyl N-[(4-benzoyl-3-oxomorpholin-2-yl)methyl]carbamate 
 
BzN
O
O
NHBoc
158
 
 
By modification of an existing procedure,142 toluene (8.00 mL) was added to a 
mixture of PPh3 (20.0 mg, 76.2 µmol) and Pd(OAc)2 (4.26 mg, 18.9 µmol). After 
stirring the mixture for 30 min at rt, a solution of the quaternary allyl ester 
derivative 147a (0.16 g, 0.28 mmol) in toluene (4.00 mL) was added and the 
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reaction mixture was stirred for 16 h at 40 °C. Subsequently, the solution was 
allowed to cool to rt, filtered through celite and concentrated under reduced 
pressure to give a crude product. The crude product was purified by flash 
column chromatography, eluting with 20:80 EtOAc−hexane to yield the lactam 
derivative 158 (50.0 mg, 39%) as a colourless oil, Rf 0.52 (50:50 petrol−EtOAc); 
νmax/cm-1 3369, 2976, 2930, 1682, 1507, 1366, 1275, 1226, 1158, 1136; δH (400 
MHz, CDCl3) 7.57-7.54 (2H, m, phenyl 2,6-H2), 7.51 (1H, tt, J 7.5 and 1.3, 
phenyl 4-H), 7.41 (2H, app. t, J 7.5, phenyl 3,5-H2), 4.94 (1H, br., NH), 4.26-
4.21 (2H, m, 2-H and 6-HA), 4.02-3.95 (1H, m, 5-HA), 3.95-3.88 (2H, m, 6-HB 
and 5-HB), 3.68-3.53 (2H, m, methylcarbamate 1-H2), 1.45 (9H, s, tBu); δC (100 
MHz, CDCl3) 173.0 (C-3 and benzoyl C=O), 155.7 (Boc C=O), 135.3 (phenyl C-
1), 132.2 (phenyl C-4), 128.3 (phenyl C2-3,5), 128.1 (phenyl C2-2,6), 79.8 (tBu 
C1), 77.5 (C-2), 63.4 (C-6), 45.1 (C-5), 41.9 (methylcarbamate C-1), 28.5 (tBu 
C3); HRMS found MNa+, 357.1431. C17H22N2O5 requires MNa, 357.1426.  
 
tert-Butyl N-{[4-oxo-3-(prop-2-en-1-yl)oxan-3-yl]methyl}carbamate 
 
O
O NHBoc
148i  
 
According to General Procedure K, the quaternary allyl ester derivative 147b 
(10.1 g, 32.2 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 10:90 EtOAc−hexane to yield the 
ketone derivative 148i (6.60 g, 76%) as a brown oil, Rf 0.39 (70:30 
petrol−EtOAc); νmax/cm-1 3351, 2975, 2932, 2861, 1702, 1504, 1365, 1246, 
1214, 1163, 1115; δH (400 MHz, CDCl3) 5.66 (1H, app. dq, J 16.8 and 7.5, 
propenyl 2-H), 5.15-5.10 (2H, m, propenyl 3-H2), 4.83 (1H, br. s, NH), 4.14-4.07 
(1H, m, 6-HA), 3.83 (1H, d, J 11.8, 2-HA), 3.80-3.77 (1H, m, 6-HB), 3.59 (1H, d, J 
11.8, 2-HB), 3.35 (1H, dd, J 14.3 and 7.9, methylcarbamate 1-HA), 3.26 (1H, dd, 
J 14.3 and 5.5, methylcarbamate 1-HB), 2.65 (1H, ddd, J 15.1, 9.8 and 6.5, 5-
HA), 2.53 (1H, dd, J 14.3 and 7.5, propenyl 1-HA), 2.47 (1H, app. dt, J 15.1 and 
4.1, 5-HB), 2.34 (1H, dd, J 14.3 and 7.5, propenyl 1-HB), 1.41 (9H, s, tBu); δC 
(100 MHz, CDCl3) 210.1 (C-4), 156.0 (Boc C=O), 131.9 (propenyl C-2), 119.3 
(propenyl C-3), 79.4 (tBu C1), 73.1 (C-2), 68.2 (C-6), 55.1 (C-3), 42.0 
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(methylcarbamate C-1), 40.1 (C-5), 36.9 (propenyl C-1), 28.3 (tBu C3); HRMS 
found MH+, 270.1701. C14H23NO4 requires MH, 270.1699. 
 
Benzyl 3-({[(tert-butoxy)carbonyl]amino}methyl)-4-oxo-3-(prop-2-en-1-yl) 
piperidine-1-carboxylate 
N
Cbz
O NHBoc
148j  
 
According to General Procedure K, the quaternary allyl ester derivative 147c 
(7.56 g, 16.9 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 20:80 EtOAc−hexane to yield the 
ketone derivative 148j (5.93 g, 87%) as a yellow oil, Rf 0.74 (50:50 
petrol−EtOAc); νmax/cm-1 3366, 2976, 2931, 1689, 1429, 1365, 1273, 1157; δH 
(500 MHz, CD3OD, 333 K) 7.42-7.27 (5H, m, phenyl), 5.67 (1H, app. dq, J 16.9 
and 8.0, propenyl 2-H), 5.18 (2H, s, phenylmethyl 1-H2), 5.06 (1H, app. d, J 
10.8, propenyl 3-Hcis), 5.05 (1H, app. d, J 18.8, propenyl 3-Htrans), 3.93-3.83 
(1H, m, 6-HA), 3.75 (1H, d, J 14.0, 2-HA), 3.67 (1H, app. br. s, 6-HB), 3.52 (1H, 
d, J 14.0, 2-HB), 3.37 (1H, d, J 14.7, methylcarbamate 1-HA), 3.15 (1H, d, J 
14.7, methylcarbamate 1-HB), 2.63-2.53 (1H, m, 5-HA), 2.53-2.45 (1H, m, 5-HB), 
2.34 (1H, dd, J 14.2 and 7.0, propenyl 1-HA), 2.24 (1H, dd, J 14.2 and 8.0, 
propenyl 1-HB), 1.41 (9H, s, tBu); δC (125 MHz, CD3OD) 211.1 (4-C), 158.2 (Boc 
C=O), 157.2 (Cbz C=O), 137.9 (phenyl C-1), 133.6 (propenyl C-2), 129.6 
(phenyl C2-3,5), 129.2 (phenyl C2-2,6), 129.0 (phenyl C-4), 119.4 (propenyl C-
3), 80.5 (tBu C1), 68.8 (phenylmethyl C-1), 55.2 (C-3), 50.3 (C-2), 44.2 (C-6 and 
methylcarbamate C-1), 39.6 (C-5), 37.7 (propenyl C-1), 28.7 (tBu C3); HRMS 
found MNa+, 425.2043. C22H30N2O5 requires MNa, 425.2046. 
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tert-Butyl N-{[6-methoxy-1-oxo-2-(prop-2-en-1-yl)-2,3-dihydro-1H-inden-2-
yl]methyl} carbamate 
MeO
O
NHBoc
148k  
 
According to General Procedure K, the quaternary allyl ester derivative 147d 
(7.80 g, 20.8 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 10:90 EtOAc−hexane to yield the 
ketone derivative 148k (5.58 g, 81%) as an amorphous brown solid, Rf 0.57 
(70:30 petrol−EtOAc); νmax/cm-1 3359, 2975, 2928, 1694, 1490, 1274, 1245, 
1161; δH (400 MHz, CDCl3) 7.31 (1H, d, J 8.4, 4-H), 7.18 (1H, dd, J 8.4 and 2.6, 
5-H), 7.13 (1H, d, J 2.6, 7-H), 5.60 (1H, ddt, J 17.0, 10.1 and 7.4, propenyl 2-H), 
5.07 (1H, dd, J 17.0 and 1.9, propenyl 3-Htrans), 5.00 (1H, dd, J 10.1 and 1.9, 
propenyl 3-Hcis), 4.90 (1H, app. t, J 5.4, NH), 3.80 (3H, s, methoxy), 3.46 (1H, 
dd, J 13.7 and 6.6, methylcarbamate 1-HA), 3.29 (1H, dd, J 13.7 and 6.1, 
methylcarbamate 1-HB), 3.00 (1H, d, J 17.2, 3-HA), 2.93 (1H, d, J 17.2, 3-HB), 
2.45-2.27 (2H, m, propenyl 1-H2), 1.38 (9H, s, tBu); δC (100 MHz, CDCl3) 209.9 
(C-1), 159.6 (C-6), 156.4 (Boc C=O), 146.5 (C-3a), 137.4 (C-7a), 132.9 
(propenyl C-2), 127.4 (C-4), 124.8 (C-5), 119.1 (propenyl C-3), 105.2 (C-7), 
79.5 (Boc C1), 55.7 (methoxy), 54.0 (C-2), 45.7 (methylcarbamate C-1), 39.4 
(propenyl C-1), 34.9 (C-3), 28.4 (Boc C3); HRMS found MNa+, 354.1679. 
C19H25NO4 requires MNa, 354.1675. 
 
tert-Butyl N-{[4-oxo-3-(prop-2-en-1-yl)oxolan-3-yl]methyl}carbamate 
 
O
O NHBoc
148l  
 
According to General Procedure K, the quaternary allyl ester derivative 147e 
(14.7 g, 49.1 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 20:80 EtOAc−hexane to yield the 
ketone derivative 148l (11.0 g, 88%) as a light-brown oil, Rf 0.42 (85:15 
petrol−EtOAc); νmax/cm-1 3357, 2977, 2933, 1697, 1515, 1392, 1366, 1248, 
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1158, 1059; δH (400 MHz, CDCl3) 5.70 (1H, ddt, J 16.6, 10.5 and 7.4, propenyl 
2-H), 5.14-5.10 (1H, m, propenyl 3-Htrans), 5.12-5.08 (1H, m, propenyl 3-Hcis), 
4.84 (1H, app. t, J 5.3, NH), 4.10 (1H, d, J 9.9, 2-HA), 3.99 (1H, d, J 9.9, 2-HB), 
3.94 (2H, app. s, 5-H2), 3.31 (1H, app. s, methylcarbamate 1-HA), 3.29 (1H, 
app. s, methylcarbamate 1-HB), 2.27 (1H, app. d, J 1.2, propenyl 1-HA), 2.25 
(1H, app. d, J 1.2, propenyl 1-HB), 1.40 (9H, s, tBu); δC (100 MHz, CDCl3) 217.6 
(C-4), 156.2 (Boc C=O), 131.9 (propenyl C-2), 119.8 (propenyl C-3), 79.9 (tBu 
C1), 73.8 (C-2), 71.5 (C-5), 52.5 (C-3), 42.4 (methylcarbamate C-1), 36.3 
(propenyl C-1), 28.4 (tBu C3); HRMS found MNa+, 278.1363. C13H21NO4 
requires MNa, 278.1362. 
 
Benzyl 3-benzyl-4-oxo-3-(prop-2-en-1-yl)piperidine-1-carboxylate 
 
N
Cbz
O
148m  
 
According to General Procedure K, the quaternary allyl ester derivative 147f 
(0.83 g, 2.03 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 20:80 EtOAc−hexane to yield the 
ketone derivative 148m (0.66 g, 89%) as a brown oil, Rf 0.45 (70:30 
petrol−EtOAc); νmax/cm-1 3063, 3029, 2916, 1694, 1430, 1231; δH (500 MHz, 
CD3OD, 333 K) 7.36-7.04 (10H, m, phenyl), 5.70 (1H, ddt, J 17.6, 10.4 and 7.3, 
propenyl 2-H), 5.13 (2H, s, Cbz phenylmethyl 1-H2), 5.05 (1H, app. d, J 10.4, 
propenyl 3-Hcis), 5.03 (1H, app. d, J 17.6, propenyl 3-Htrans), 3.77 (1H, app. dt, J 
13.0 and 6.5, 6-HA), 3.68 (1H, d, J 13.8, 2-HA), 3.58 (1H, d, J 13.8, 2-HB), 3.56-
3.51 (1H, m, 6-HB), 2.93 (1H, d, J 13.9, phenylmethyl 1-HA), 2.80 (1H, d, J 13.9, 
phenylmethyl 1-HB), 2.55-2.40 (2H, m, 5-H2), 2.31 (1H, dd, J 14.3 and 6.8, 
propenyl 1-HA), 2.16 (1H, dd, J 14.3 and 7.8, propenyl 1-HB); δC (125 MHz, 
CD3OD, 333 K) 212.0 (C-4), 157.2 (Cbz C=O), 137.9 (Cbz phenyl C-1), 137.8 
(phenyl C-1), 134.0 (propenyl C-2), 131.5 (phenyl C2-3,5), 129.5 (Cbz phenyl 
C2-3,5), 129.2 (phenyl C2-2,6 and Cbz phenyl C2-2,6), 129.0 (Cbz phenyl C-4), 
127.7 (phenyl C-4), 119.3 (propenyl C-3), 68.7 (Cbz phenylmethyl C-1), 54.6 
(C-3), 51.0 (C-2), 43.8 (C-6), 40.7 (phenylmethyl C-1), 39.7 (C-5), 39.6 
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(propenyl C-1); HRMS found MNa+, 386.1717. C23H25NO3 requires MNa, 
386.1732. 
 
Benzyl 4-oxo-3-(prop-2-en-1-yl)-3-[(pyridin-3-yl)methyl]piperidine-1-
carboxylate 
N
Cbz
O
N
148n  
 
According to General Procedure K, the quaternary allyl ester derivative 147g 
(0.60 g, 1.47 mmol) gave a crude material. The crude material was purified by 
flash column chromatography, eluting with 60:40 EtOAc−hexane to yield the 
ketone derivative 148n (0.43 g, 80%) as a yellow oil, Rf 0.48 (EtOAc); νmax/cm-1 
3030, 2915, 1693, 1422, 1230; δH (500 MHz, CD3OD, 333 K) 8.37 (1H, dd, J 4.9 
and 1.7, pyridinyl 6-H), 8.32 (1H, d, J 2.3, pyridinyl 2-H), 7.58 (1H, d, J 7.9, 
pyridinyl 4-H), 7.37-7.24 (6H, m, phenyl and pyridinyl 5-H), 5.69 (1H, ddt, J 
17.1, 10.3 and 7.3, propenyl 2-H), 5.15 (2H, s, phenylmethyl 1-H2), 5.09 (1H, 
app. dt, J 10.3 and 1.6, propenyl 3-Hcis), 5.05 (1H, dd, J 17.1 and 1.6, propenyl 
3-Htrans), 3.87-3.81 (1H, m, 6-HA), 3.74 (1H, dd, J 13.8 and 1.2, 2-HA), 3.57 (1H, 
d, J 13.8, 2-HB), 3.56-3.51 (1H, m, 6-HB), 2.98 (1H, d, J 14.2, pyridinylmethyl 1-
HA), 2.84 (1H, d, J 14.2, pyridinylmethyl 1-HB), 2.56 (1H, ddd, J 15.6, 8.3 and 
6.1, 5-HA), 2.48 (1H, app. dt, J 15.6 and 6.1, 5-HB), 2.29 (1H, dd, J 14.6 and 
6.8, propenyl 1-HA), 2.20 (1H, dd, J 14.6 and 7.7, propenyl 1-HB); δC (125 MHz, 
CD3OD, 333 K) 211.3 (C-4), 157.2 (Cbz C=O), 151.8 (pyridinyl C-2), 148.4 
(pyridinyl C-6), 140.0 (pyridinyl C-4), 137.9 (phenyl C-1), 134.5 (pyridinyl C-3), 
133.5 (propenyl C-2), 129.5 (phenyl C2-3,5), 129.2 (phenyl C2-2,6), 129.1 
(phenyl C-4), 124.7 (pyridinyl C-5), 119.7 (propenyl C-3), 68.7 (phenylmethyl C-
1), 54.5 (C-3), 51.0 (C-2), 43.9 (C-6), 39.6 (propenyl C-1), 39.5 (C-5), 37.5 
(pyridinylmethyl C-1); HRMS found MH+, 365.1862. C22H24N2O3 requires MH, 
365.1865. 
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5.2.3.3. Cyclisation Reactions 
General Procedure L 
By modification of an existing procedure,158 2-methyl-2-butene (7.50 eq) was 
added dropwise to BH3•THF (3.50 eq of a 1.0 M solution in THF) at 0 °C. The 
mixture was stirred for 2 h at 0 °C. Subsequently, a solution of the alkene 
derivative (1.00 eq) in THF (0.35 M) at 0 °C was added dropwise. The reaction 
mixture was stirred for 45 min at 0 °C and for 1 h at rt. Afterwards, NaBO3•4H2O 
(7.50 eq) and water (3 mL per 1.00 mmol of the alkene derivative) were added. 
After stirring the mixture vigorously for 18 h at rt, EtOAc (3 mL per 1.00 mmol of 
the alkene derivative) was added, the phases were separated and the aqueous 
phase was extracted with EtOAc (4 × (3 mL per 1.00 mmol of the alkene 
derivative)). Subsequently, the organic phases were combined, dried (MgSO4), 
filtered and concentrated under reduced pressure to give a crude material. 
 
General Procedure M 
TFA (20.0 eq) and Et3SiH (1.50 eq) were added to a solution of the hemiacetal 
derivative (1.00 eq) in DCM (0.10 M) at rt. The reaction mixture was stirred for 
18 h at rt. After removing the solvent and TFA under reduced pressure, the 
crude material was dissolved in DCM (0.10 M), and Et3N (10.0 eq) and Boc2O 
(1.20 eq) were added. After stirring the reaction mixture for 18 h at rt, a 
saturated aqueous solution of NaHCO3 (10 mL per 1.00 mmol of the hemiacetal 
derivative) was added, the phases were separated and the aqueous phase was 
extracted with DCM (3 × (4 mL per 1.00 mmol of the hemiacetal derivative)). 
Subsequnetly, the organic phases were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure to give a crude material. 
 
General Procedure N 
By modification of an existing procedure,161 Et3SiH (16.0 eq) was added 
dropwise to a solution of the hemiacetal derivative (1.00 eq) in DCM (16.0 mM) 
at rt. The mixture was cooled to –78 °C and BF3•Et2O (4.00 eq) was added 
dropwise. After stirring the reaction mixture at –78 °C for 2 h, it was allowed to 
warm to rt and stirred overnight. The solvent was removed under reduced 
pressure and the crude material was dissolved in DCM (0.10 M). Subsequently, 
Et3N (5.00 eq) and Boc2O (1.20 eq) were added and the reaction mixture was 
stirred overnight at rt. A saturated aqueous solution of NH4Cl (10 mL per 1.00 
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mmol of the hemiacetal derivative) was added, the phases were separated and 
the aqueous phase was extracted with DCM (3 × (3 mL per 1.00 mmol of the 
hemiacetal derivative)). The organic phases were combined, dried (MgSO4), 
filtered and concentrated under reduced pressure to give a crude material. 
 
General Procedure O 
TFA (20.0 eq) and Et3SiH (1.50 eq) were added to a solution of the hemiacetal 
derivative (1.00 eq) in DCM (0.10 M) at rt. The reaction mixture was stirred for 
18 h at rt. A saturated aqueous solution of NaHCO3 (10 mL per 1.00 mmol of 
the hemiacetal derivative) was added, the phases were separated and the 
aqueous phase was extracted with DCM (3 × (4 mL per 1.00 mmol of the 
hemiacetal derivative)). Subsequently, the organic phases were combined, 
dried (MgSO4), filtered and concentrated under reduced pressure to give a 
crude material. 
 
General Procedure P 
TsOH•H2O (0.03 eq) was added to a solution of the hemiacetal or hemiaminal 
derivative in MeOH (0.30 M) at rt. The reaction mixture was stirred for 18 h at rt. 
Subsequently, the solvent was removed under reduced pressure to give a 
crude material. 
 
General Procedure Q 
Ozonized oxygen gas was passed through a solution of the alkene derivative 
(1.00 eq) in DCM (0.10 M) at −78 °C until the solution became blue in colour. 
Subsequently, the solution was purged with oxygen gas until the blue colour 
disappeared and dimethyl sulfide (20.0 eq) was added dropwise. After stirring 
the reaction mixture for 30 min at −78 °C, it was allowed to warm to rt. Finally, it 
was stirred at rt for 18 h and the solvent was removed under reduced pressure 
to yield a crude material. 
 
General Procedure R 
According to an existing procedure,142 the specified amount of a solution of 
diisobutylaluminium hydride 1.0 M in DCM was added dropwise to a solution of 
the ketone derivative (1.00 eq) in DCM (0.18 M) at the specified temperature. 
After stirring the reaction mixture for 1 h at the same temperature, the mixture 
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was allowed to warm to rt and a saturated aqueous solution of potassium 
sodium tartrate tetrahydrate (5 mL per 1.00 mmol of the ketone derivative) was 
added dropwise. Subsequently, the mixture was stirred for 18 h at rt, the 
phases were separated and the aqueous phase was extracted with DCM (5 × (3 
mL per 1.00 mmol of the ketone derivative). The organic phases were 
combined, dried (MgSO4), filtered and concentrated under reduced pressure to 
give a crude material. 
 
General Procedure S 
According to an existing procedure,119 NaHCO3 (2.00 eq) and I2 (1.10 eq) were 
added to a solution of the alkene derivative (1.00 eq) in acetonitrile (0.10 M) at 
0 °C. The reaction mixture was stirred at rt for the specified time. Subsequently, 
a saturated aqueous solution of Na2S2O3 (7 mL per 1.00 mmol of the alkene 
derivative) was added, the phases were separated and the aqueous phase was 
extracted with EtOAc (3 × (7 mL per 1.00 mmol of the alkene derivative)). The 
organic phases were combined, washed with brine (3 mL per 1.00 mmol of the 
alkene derivative), dried (MgSO4), filtered and concentrated under reduced 
pressure to give a crude material. 
 
General Procedure T 
tBuOK (3.00 eq) was added to a solution of the alcohol derivative (1.00 eq) in 
THF (75.0 mM) at 0 °C. After stirring the reaction mixture for the specified time 
at rt, a saturated aqueous solution of NH4Cl (10 mL per 1.00 mmol of the 
alcohol derivative) and EtOAc (10 mL per 1.00 mmol of the alcohol derivative) 
were added. The phases were separated and the aqueous phase was extracted 
with EtOAc (4 × (5 mL per 1.00 mmol of the alcohol derivative)). The organic 
phases were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure to yield a crude material. 
 
General Procedure U 
By modification of an existing procedure,142 pyridine (31.0 eq) was added to a 
solution of the alcohol derivative (1.00 eq) in Ac2O (26.4 eq) at rt. Subsequently, 
the reaction mixture was stirred for 18 h at rt and the solvent was removed 
under reduced pressure. The crude material was dissolved in DCM (3 mL per 
1.00 mmol of the alcohol derivative) and an aqueous solution of 10% CuSO4 (3 
161 
 
mL per 1.00 mmol of the alcohol derivative) was added. After stirring the 
mixture for 5 min at rt, the phases were separated and the aqueous phase was 
extracted with DCM (3 × (2 mL per 1.00 mmol of the alcohol derivative)). The 
organic phases were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure to yield the specified acetate derivative. 
 
General Procedure V 
Ozonized oxygen gas was passed through a solution of the alkene derivative 
(1.00 eq) in DCM (0.10 M) at −78 °C until the solution became blue in colour. 
Subsequently, the solution was purged with oxygen gas until the blue colour 
disappeared and dimethyl sulfide (20.0 eq) was added dropwise. After stirring 
the reaction mixture for 30 min at −78 °C, it was allowed to warm to rt. 
Afterwards, it was stirred at rt for 18 h and the solvent was removed under 
reduced pressure. The crude material was dissolved in acetic acid (0.20 M) and 
NaBH(OAc)3 (7.00 eq) was added. The reaction mixture was stirred for 2 h at rt. 
Subsequently, a saturated aqueous solution of NaHCO3 (50 mL per 1.00 mmol 
of the alkene) and DCM (20 mL per 1.00 mmol of the alkene) were added. The 
mixture was stirred for 1 h at rt, the phases were separated and the aqueous 
phase was extracted with DCM (4 × (10 mL per 1.00 mmol of the alkene)). The 
organic phases were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure to give a crude material. 
 
General Procedure W 
Ozonized oxygen gas was passed through a solution of the alkene derivative 
(1.00 eq) in DCM (0.10 M) at −78 °C until the solution became blue in colour. 
Subsequently, the solution was purged with oxygen gas until the blue colour 
disappeared and dimethyl sulfide (20.0 eq) was added dropwise. After stirring 
the reaction mixture for 30 min at −78 °C, it was allowed to warm to rt. 
Afterwards, it was stirred at rt for 18 h and the solvent was removed under 
reduced pressure. The crude material was dissolved in DCM (0.10 M) and 
pyridinium dichromate (2.00 eq) and celite (0.4 g per 1.00 mmol of the alkene 
derivative) were added. The reaction mixture was stirred for 1 week at rt. 
Subsequently, the mixture was filtered through celite and concentrated under 
reduced pressure to give a crude material. 
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General Procedure X 
By modification of an existing procedure,178 triethylamine (2.00 eq) and 
methanesulfonyl chloride (1.20 eq) were added to a solution of the alcohol 
derivative (1.00 eq) in DCM (0.20 M) at 0 °C. The reaction mixture was stirred 
for 2 h at rt. Subsequently, TFA (65.0 eq) was added dropwise and the mixture 
was stirred for a further 5 h at rt. Afterwards, the solvent and TFA were removed 
under reduced pressure. After dissolving the crude product in DCM (0.20 M), 
triethylamine (35.0 eq) was added and the resulting mixture was stirred for 18 h 
at rt. Subsequently, Boc2O (1.20 eq) was added and the reaction was stirred for 
a further 18 h at rt. A saturated aqueous solution of NaHCO3 (5 mL per 1.00 
mmol of the alcohol derivative) was added, the phases were separated and the 
aqueous phase was extracted with DCM (3 × (3 mL per 1.00 mmol of the 
alcohol derivative)). The organic phases were combined, dried (MgSO4), filtered 
and concentrated under reduced pressure to give a crude material. 
 
General Procedure Y 
The respective aldehyde (1.50 eq) and TFA (35.0 eq) were added dropwise to a 
solution of the ketone derivative (1.00 eq) in MeOH (0.18 M). The reaction 
mixture was stirred at 65 °C for 4 days. Subsequently, the mixture was allowed 
to cool to rt and the solvent and TFA were removed under reduced pressure to 
give a crude material. 
 
tert-Butyl N-({8a-hydroxy-octahydropyrano[4,3-b]pyran-4a-yl}methyl) 
carbamate 
O
O
HO
NHBoc
159a  
 
According to General Procedure L, the alkene derivative 148i (0.50 g, 1.85 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 50:50 EtOAc−hexane to yield the hemiacetal 
derivative 159a (0.41 g, 76%, dr >95:<5 by 1H-NMR) as an amorphous 
colourless solid, Rf 0.25 (50:50 petrol−EtOAc); νmax/cm-1 3301, 2960, 2880, 
1692, 1594, 1365, 1283, 1273, 1254, 1170, 1109, 1068; δH (400 MHz, CD3OD) 
6.32 (1H, app.t, J 5.1, NH), 4.06 (1H, ddd, J 12.4, 11.2 and 3.0, 2-HA), 3.85 (1H, 
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d, J 11.6, 5-HA), 3.80 (1H, app. tt, J 5.5 and 1.2, 7-HA), 3.69-3.60 (2H, m, 2-HB 
and 7-HB), 3.44 (1H, d, J 11.6, 5-HB), 3.40-3.32 (3H, m, OH and 
methylcarbamate 1-H2), 2.02 (1H, td, J 13.1 and 5.5, 8-HA), 1.92 (1H, app. td, J 
13.3 and 4.9, 3-HA), 1.79 (1H, app. qt, J 13.3 and 4.6, 3-HB), 1.57 (1H, app. d, J 
13.5, 8-HB), 1.47 (9H, s, tBu), 1.46-1.39 (1H, m, 4-HA), 1.25 (1H, app. d, J 13.7, 
4-HB); δC (100 MHz, CD3OD) 158.7 (Boc C=O), 96.0 (C-8a), 79.8 (tBu C1), 70.5 
(C-5), 66.7 (C-7), 60.8 (C-2), 45.0 (methylcarbamate C-1), 41.9 (C-4a), 36.9 (C-
8), 28.7 (tBu C3), 24.6 (C-4), 22.3 (C-3); HRMS found MNa+, 310.1628. 
C14H25NO5 requires MNa, 310.1624.  
 
Benzyl 4a-({[(tert-butoxy)carbonyl]amino}methyl)-8a-hydroxy-octahydro-
2H-pyrano[3,2-c]pyridine-6-carboxylate 
 
N
Cbz
O
HO
NHBoc
159b  
 
According to General Procedure L, the alkene derivative 148j (0.20 g, 0.49 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 30:70 EtOAc−hexane to yield the hemiacetal 
derivative 159b (0.12 g, 58%, dr >95:<5 by 1H-NMR) as an amorphous 
colourless solid, Rf 0.37 (50:50 petrol−EtOAc); νmax/cm-1 3317, 2957, 2889, 
2472, 1672, 1432, 1363, 1250, 1164, 1142, 1089, 1065; δH (500 MHz, CD3OD, 
333 K) 7.42-7.26 (5H, m, phenyl), 5.14 (1H, d, J 12.4, phenylmethyl 1-HA), 5.11 
(1H, d, J 12.4, phenylmethyl 1-HB), 4.02 (1H, td, J 11.9 and 3.2, 2-HA), 3.95 (1H, 
app. dt, J 13.1 and 2.6, 7-HA), 3.66-3.57 (2H, m, 2-HB and 5-HA), 3.40-3.33 (3H, 
m, 5-HB and methylcarbamate 1-H2), 3.08 (1H, td, J 13.1 and 3.4, 7-HB), 2.93 
(1H, br. s, OH), 1.95 (1H, td, J 13.5 and 5.0, 4-HA), 1.83-1.71 (2H, m, 8-HA and 
3-HA), 1.65-1.51 (1H, m, 8-HB), 1.42 (10H, s, tBu and 3-HB), 1.30 (1H, app. d, J 
13.5, 4-HB); δC (125 MHz, CD3OD, 333 K) 158.4 (Boc C=O), 157.3 (Cbz C=O), 
138.1 (phenyl C-1), 129.6 (phenyl C2-3,5), 129.1 (phenyl C2-2,6), 129.0 (phenyl 
C-4), 96.6 (C-8a), 80.1 (tBu C1), 68.6 (phenylmethyl C-1), 61.0 (C-2), 49.0 (C-5), 
47.3 (C-4a), 44.6 (methylcarbamate C-1), 42.9 (C-7), 35.7 (C-8), 28.8 (tBu C3), 
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25.8 (C-4), 22.1 (C-3); HRMS found MNa+, 443.2147. C22H32N2O6 requires 
MNa, 443.2152. 
 
tert-Butyl N-{[2-(3-hydroxypropyl)-6-methoxy-1-oxo-2,3-dihydro-1H-inden-
2-yl]methyl} carbamate 
MeO
O
NHBoc
OH159c  
 
According to General Procedure L, the alkene derivative 148k (0.50 g, 1.50 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 50:50 EtOAc−hexane to yield the alcohol 
derivative 159c (0.32 g, 61%, >98% as primary alcohol by 1H-NMR in CDCl3) as 
a pale-yellow oil, Rf 0.40 (30:70 petrol−EtOAc); νmax/cm-1 3368, 2931, 2870, 
1687, 1490, 1365, 1274, 1245, 1161, 1054, 1024; δH (400 MHz, CDCl3) 7.32 
(1H, d, J 8.4, 4-H), 7.18 (1H, dd, J 8.4 and 2.6, 5-H), 7.13 (1H, d, J 2.6, 7-H), 
4.95 (1H, app. t, J 5.0, NH), 3.82 (3H, s, methoxy), 3.54 (2H, t, J 6.3, 
hydroxypropyl 3-H2), 3.45 (1H, dd, J 13.5 and 7.0, methylcarbamate 1-HA), 3.25 
(1H, dd, J 13.5 and 5.9, methylcarbamate 1-HB), 2.98 (1H, d, J 17.1, 3-HA), 2.93 
(1H, d, J 17.1, 3-HB), 1.81 (1H, br. s, OH), 1.74-1.64 (2H, m, hydroxypropyl 1-
H2), 1.56-1.44 (1H, m, hydroxypropyl 2-HA), 1.37 (9H, s, tBu), 1.36-1.28 (1H, m, 
hydroxypropyl 2-HB); δC (100 MHz, CDCl3) 210.5 (C-1), 159.6 (C-6), 156.5 (Boc 
C=O), 146.5 (C-3a), 137.5 (C-7a), 127.4 (C-4), 124.9 (C-5), 105.2 (C-7), 79.6 
(Boc C1), 62.8 (hydroxypropyl C-3), 55.7 (methoxy), 54.0 (C-2), 45.8 
(methylcarbamate C-1), 35.6 (C-3), 31.0 (hydroxypropyl C-1), 28.4 (tBu C3), 
27.5 (hydroxypropyl C-2); HRMS found MNa+, 372.1784. C19H27NO5 requires 
MNa, 372.1781. Compound 159c existed as the primary alcohol. 
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tert-Butyl N-({7a-hydroxy-hexahydro-2H-furo[3,4-b]pyran-4a-yl}methyl) 
carbamate 
O
O
NHBoc
HO
159d  
 
According to General Procedure L, the alkene derivative 148l (1.00 g, 3.91 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 40:60 EtOAc−hexane to yield the hemiacetal 
derivative 159d (0.78 g, 73%, hemiacetal:primary alcohol 67:33 by 1H-NMR in 
CDCl3, dr >95:<5 by 1H-NMR) as a colourless oil, Rf 0.19 (50:50 petrol−EtOAc); 
νmax/cm-1 3342, 2936, 2881, 1688, 1510,1365, 1248, 1164, 1049, 1008; δH (400 
MHz, CDCl3) 5.30 (1H, s, NHalcohol), 4.94 (1H, app. t, J 6.6, NHhemiacetal), 4.05 
(1H, d, J 8.7, 5-HAalcohol), 3.89-3.80 (2H, m, 2-HAhemiacetal and hydroxypropyl 3-
HAalcohol), 3.79-3.73 (4H, m, 2-H2alcohol, 5-H2hemiacetal), 3.73-3.66 (2H, m, 2-
HBhemiacetal and hydroxypropyl 3-HBalcohol), 3.63 (1H, d J 8.7, 5-HBalcohol), 3.61-
3.57 (2H, m, 7-H2hemiacetal), 3.37-3.25 (3H, m, methylcarbamate 1-H2alcohol and 
methylcarbamate 1-HAhemiacetal), 3.30 (1H, dd, J 14.4 and 4.5, methylcarbamate 
1-HBhemiacetal), 1.85-1.67 (2H, m, 3-HAhemiacetal and hydroxypropyl 2-HAalcohol), 
1.66-1.57 (2H, m, 4-HAhemiacetal and hydroxypropyl 1-HAalcohol), 1.54-1.45 (2H, m, 
3-HBhemiacetal and hydroxypropyl 2-HBalcohol), 1.46-1.36 (20H, m, 4-HBhemiacetal, 
hydroxypropyl 1-HBalcohol, tBuhemiacetal and tBualcohol); δC (100 MHz, CDCl3) 218.1 
(C-4alcohol), 157.0 (Boc C=Ohemiacetal), 156.4 (Boc C=Oalcohol), 103.4 (C-
7ahemiacetal), 80.0 (tBu C1alcohol), 79.7 (tBu C1hemiacetal), 77.2 (C-5hemiacetal), 74.5 (C-
2alcohol), 73.9 (C-7hemiacetal), 71.5 (C-5alcohol), 62.5 (hydroxypropyl C-3alcohol), 61.2 
(C-2hemiacetal), 52.2 (C-3alcohol), 46.3 (methylcarbamate C-1hemiacetal), 44.9 (C-
4ahemiacetal), 42.3 (methylcarbamate C-1alcohol), 28.5 (tBu C3hemiacetal), 28.4 (tBu 
C3alcohol), 28.1 (hydroxypropyl C-1alcohol), 27.1 (hydroxypropyl C-2alcohol), 22.5 (C-
4hemiacetal), 21.1 (C-3hemiacetal); HRMS found MNa+, 296.1463. C13H23NO5 
requires MNa, 296.1468. Compound 159d existed as a mixture of the 
hemiacetal and primary alcohol. 
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Benzyl 4a-benzyl-8a-hydroxy-octahydro-2H-pyrano[3,2-c]pyridine-6-
carboxylate 
N
Cbz
O
HO
159e  
 
According to General Procedure L, the alkene derivative 148m (0.60 g, 1.65 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 30:70 EtOAc−hexane to yield the hemiacetal 
derivative 159e (0.52 g, 83%, >90% as single hemiacetal by 1H-NMR in 
CD3OD) as colourless oil, Rf 0.39 (50:50 petrol−EtOAc); νmax/cm-1 3399, 2943, 
2877, 2523, 2068, 1672, 1431, 1269, 1248, 1138, 1071; δH (500 MHz, CD3OD, 
333 K) 7.44-7.25 (5H, m, Cbz phenyl), 7.17-7.06 (5H, m, phenyl), 5.16 (2H, s, 
Cbz phenylmethyl 1-H2), 4.12-3.95 (2H, m, 2-HA and 7-HA), 3.64-3.59 (1H, m, 5-
HA), 3.59-3.56 (1H, m, 2-HB), 3.27 (1H, d, J 13.3, 5-HB), 3.14 (1H, t, J 12.9, 7-
HB), 2.79 (2H, s, phenylmethyl 1-H2), 1.97 (1H, td, J 13.1 and 5.2, 8-HA), 1.82 
(1H, td, J 13.5 and 5.0, 4-HA), 1.74-1.66 (1H, m, 3-HA), 1.66-1.60 (1H, m, 8-HB), 
1.37-1.24 (1H, m, 3-HB), 0.77 (1H, app. d, J 13.5, 4-HB); δC (125 MHz, CD3OD, 
333 K) 157.7 (Cbz C=O), 138.9 (Cbz phenyl C-1 and phenyl C-1), 132.2 (phenyl 
C2-3,5), 129.5 (Cbz phenyl C2-3,5), 129.1 (phenyl C2-2,6 and Cbz phenyl C2-
2,6), 128.7 (Cbz phenyl C-4), 126.9 (phenyl C-4), 96.9 (C-8a), 68.5 (Cbz 
phenylmethyl C-1), 60.7 (C-2), 46.9 (C-5), 42.7 (C-7), 41.5 (C-4a), 39.1 
(phenylmethyl C-1), 35.1 (C-8), 27.3 (C-4), 22.2 (C-3); HRMS found MNa+, 
404.1830. C23H27NO4 requires MNa, 404.1837. Compound 159e existed >90% 
as a single hemiacetal. 
 
Benzyl 8a-hydroxy-4a-[(pyridin-3-yl)methyl]-octahydro-2H-pyrano[3,2-c] 
pyridine-6-carboxylate 
N
Cbz
O
HO
159f
N
 
 
According to General Procedure L, the alkene derivative 148n (0.20 g, 0.55 
mmol) gave a crude material. The crude material was purified by flash column 
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chromatography, eluting with 80:20→100:0 EtOAc−hexane to yield the 
hemiacetal derivative 159f (0.15 g, 70%, >90% as single hemiacetal by 1H-
NMR in CD3OD) as a colourless oil, Rf 0.26 (EtOAc); νmax/cm-1 3339, 2943, 
2877, 2519, 2065, 1692, 1426, 1351, 1270, 1247, 1212, 1138, 1072, 1024; δH 
(500 MHz, CD3OD, 333 K) 8.37 (1H, app. s, pyridinyl 6-H), 8.31 (1H, d, J 4.9, 
pyridinyl 2-H), 7.70-7.57 (1H, m, pyridinyl 4-H), 7.51-7.23 (5H, m, phenyl), 7.15 
(1H, br. s, pyridinyl 5-H ), 5.18 (2H, s, phenylmethyl 1-H2), 4.15-3.98 (2H, m, 7-
HA and 2-HA), 3.60 (1H, ddd, J 11.3, 5.4 and 1.6, 2-HB), 3.55 (1H, d, J 13.5, 5-
HA), 3.31 (1H, d, J 13.5, 5-HB), 3.13 (1H, td, J 12.9 and 3.3, 7-HB), 2.85 (1H, d, J 
13.7, pyridinylmethyl 1-HA), 2.80 (1H, d, J 13.7, pyridinylmethyl 1-HB), 1.98 (1H, 
td, J 13.3 and 5.4, 8-HA), 1.85 (1H, td, J 13.4 and 4.9, 4-HA), 1.77-1.67 (1H, m, 
3-HA), 1.64 (1H, app. d, J 14.1, 8-HB), 1.34 (1H, app. d, J 13.7, 3-HB), 0.77 (1H, 
app. d, J 13.4, 4-HB); δC (125 MHz, CD3OD, 333 K) 157.5 (Cbz C=O), 152.3 
(pyridinyl C-2), 147.7 (pyridinyl C-6), 140.6 (pyridinyl C-4), 138.1 (phenyl C-1), 
135.5 (pyridinyl C-3), 129.6 (phenyl C2-3,5), 129.2 (phenyl C2-2,6), 129.0 
(phenyl C-4), 124.4 (pyridinyl C-5), 96.7 (C-8a), 68.6 (phenylmethyl C-1), 60.6 
(C-2), 46.9 (C-5), 42.7 (C-7), 41.6 (C-4a), 36.5 (pyridinylmethyl C-1), 35.3 (C-8), 
27.4 (C-4), 22.1 (C-3); HRMS found MH+, 383.1961. C22H26N2O4 requires MH, 
383.1965. Compound 159f existed >90% as a single hemiacetal. 
 
tert-Butyl N-{[(4aR*,8aR*)-octahydropyrano[4,3-b]pyran-4a-yl]methyl} 
carbamate 
O
O
NHBoc
149a
H
 
 
According to General Procedure M, the hemiacetal derivative 159a (0.16 g, 
0.55 mmol) gave a crude material. The crude material (dr >95:<5 by 1H-NMR) 
was purified by flash column chromatography, eluting with 30:70 
EtOAc−hexane to yield the ether derivative 149a (0.15 g, 99%, dr >95:<5 by 1H-
NMR) as colourless blocks, (CHCl3/Et2O), 98–102 °C; Rf 0.50 (50:50 
petrol−EtOAc); νmax/cm-1 3318, 2959, 2932, 2873, 2858, 2824, 1710, 1546, 
1365, 1249, 1169, 1094, 1073, 1057; δH (400 MHz, CDCl3) 4.73 (1H, br. s, NH), 
3.97 (1H, app. dd, J 11.6 and 4.9, 2-HA), 3.85 (1H, d, J 11.6, 5-HA), 3.72-3.64 
(2H, m, 7-H2), 3.42 (1H, app. t, J 3.8, 8a-H), 3.37 (1H, td, J 11.6 and 2.3, 2-HB), 
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3.30-3.23 (3H, m, 5-HB and methylcarbamate 1-H2), 2.08 (1H, dddd, J 14.4, 
10.6, 7.2 and 3.3, 8-HA), 1.78-1.64 (1H, m, 3-HA), 1.54 (1H, app. dd, J 14.4 and 
2.8, 8-HB), 1.48-1.37 (3H, m, 3-HB and 4-H2), 1.43 (9H, s, tBu); δC (100 MHz, 
CDCl3) 156.4 (Boc C=O), 79.4 (tBu C1), 74.6 (C-8a), 67.9 (C-5), 67.7 (C-2), 63.4 
(C-7), 45.7 (methylcarbamate C-1), 36.8 (C-4a), 28.6 (C-4), 28.5 (tBu C3), 28.3 
(C-8), 22.3 (C-3); HRMS found MH+, 272.1856. C14H25NO4 requires MH, 
272.1856. The relative configuration was determined using X-ray 
crystallography and NOESY (500 MHz, CDCl3), nOe observed between 8a-H 
and 8-HA, 8a-H and 8-HB, 8a-H and NH. 
 
Benzyl (4aR*,8aR*)-4a-({[(tert-butoxy)carbonyl]amino}methyl)-octahydro-
2H-pyrano[ 3,2-c]pyridine-6-carboxylate 
 
N
Cbz
O
H
NHBoc
149b  
 
According to General Procedure M, the hemiacetal derivative 159b (0.10 g, 
0.24 mmol) gave a crude material. The crude material (dr >95:<5 by 1H-NMR) 
was purified by flash column chromatography, eluting with 20:80 
EtOAc−hexane to yield the ether derivative 149b (49.0 mg, 51%, dr >95:<5 by 
1H-NMR) as colourless oil, Rf 0.45 (50:50 petrol−EtOAc); νmax/cm-1 3320, 2925, 
2874, 2851, 1711, 1672, 1534, 1445, 1432, 1360, 1281, 1246, 1220, 1163, 
1149, 1131, 1086; δH (500 MHz, CD3OD, 333 K) 7.40-7.25 (5H, m, phenyl), 5.12 
(2H, s, phenylmethyl 1-H2), 3.94 (1H, app. dt, J 11.1 and 2.4, 2-HA), 3.87 (1H, 
app. dt, J 13.1 and 3.0, 7-HA), 3.51 (1H, d, J 13.5, 5-HA), 3.42-3.33 (3H, m, 2-
HB, 5-HB and 8a-H), 3.16 (1H, d, J 14.3, methylcarbamate 1-HA), 3.12 (1H, app. 
dt, J 13.1 and 3.3, 7-HB), 2.84 (1H, d, J 14.3, methylcarbamate 1-HB), 2.01-1.91 
(1H, m, 8-HA), 1.82-1.69 (1H, m, 3-HA), 1.63-1.52 (2H, m, 8-HB and 4-HA), 1.50-
1.44 (1H, m, 3-HB), 1.43 (10H, s, tBu and 4-HB); δC (125 MHz, CD3OD, 333 K) 
158.5 (Boc C=O), 157.5 (Cbz C=O), 138.2 (phenyl C-1), 129.5 (phenyl C2-3,5), 
129.1 (phenyl C2-2,6), 128.9 (phenyl C-4), 80.3 (tBu C1), 76.2 (C-8a), 68.6 (C-
2), 68.4 (phenylmethyl C-1), 46.1 (C-5), 45.9 (methylcarbamate C-1), 40.5 (C-
7), 38.8 (C-4a), 30.0 (C-4), 28.8 (tBu C3), 28.3 (C-8), 23.1 (C-3); HRMS found 
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MNa+, 427.2202. C22H32N2O5 requires MNa, 427.2203. The relative 
configuration was determined using NOESY (500 MHz, CD3OD, 333 K), nOe 
observed between 8a-H and 8-HA, 8a-H and 8-HB, 8a-H and methylcarbamate 
1-HA, 8a-H and methylcarbamate 1-HB. 
 
tert-Butyl N-{[(4aR*,9bS*)-8-methoxy-2H,3H,4H,4aH,5H,9bH-indeno[1,2-
b]pyran-4a-yl]methyl}carbamate 
 
MeO
OH
NHBoc
149c  
 
According to General Procedure N, the alcohol derivative 159c (0.10 g, 0.28 
mmol) gave a crude material. The crude material (dr >95:<5 by 1H-NMR) was 
purified by flash column chromatography, eluting with 20:80 EtOAc−hexane to 
yield the ether derivative 149c (62.0 mg, 65%, dr >95:<5 by 1H-NMR) as a 
colourless oil, Rf 0.48 (60:40 petrol−EtOAc); νmax/cm-1 3336, 2929, 2856, 1696, 
1513, 1488, 1451, 1364, 1275, 1264, 1244, 1166, 1152, 1079, 1029; δH (400 
MHz, CDCl3) 7.09 (1H, d, J 8.2, 6-H), 6.89 (1H, d, J 2.4, 9-H), 6.77 (1H, dd, J 
8.2 and 2.4, 7-H), 4.76 (1H, app. t, J 6.3, NH), 4.74 (1H, s, 9b-H), 3.78 (3H, s, 
methoxy), 3.60 (2H, app. t, J 4.3, 2-H2), 3.37 (1H, dd, J 14.0 and 6.9, 
methylcarbamate 1-HA), 3.25 (1H, dd, J 14.0 and 6.3, methylcarbamate 1-HB), 
2.60 (2H, app. s, 5-H2), 1.79-1.67 (1H, m, 3-HA), 1.67-1.58 (1H, m, 4-HA), 1.57-
1.47 (1H, m, 4-HB), 1.43 (10H, s, tBu and 3-HB); δC (100 MHz, CDCl3) 159.1 (C-
8), 156.3 (Boc C=O), 143.0 (C-9a), 133.1 (C-5a), 126.4 (C-6), 114.6 (C-7), 
109.5 (C-9), 82.8 (C-9b), 79.3 (tBu C1), 63.1 (C-2), 55.5 (methoxy), 46.2 
(methylcarbamate C-1), 39.0 (C-5), 28.5 (tBu C3), 28.0 (C-4), 22.0 (C-3); HRMS 
found MNa+, 356.1838. C19H27NO4 requires MNa, 356.1832. The relative 
configuration was determined using NOESY (500 MHz, CD3OD), nOe observed 
between 9b-H and methylcarbamate 1-HA, 9b-H and methylcarbamate 1-HB. 
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tert-Butyl N-{[(4aR*,7aS*)-hexahydro-2H-furo[3,4-b]pyran-4a-yl]methyl} 
carbamate 
O
O
NHBoc
H
149d  
 
According to General Procedure N, the hemiacetal derivative 159d (0.74 g, 2.70 
mmol) gave a crude material. The crude material (dr >95:<5 by 1H-NMR) was 
purified by flash column chromatography, eluting with 20:80 EtOAc−hexane to 
yield the ether derivative 149d (0.30 g, 43%, dr >95:<5 by 1H-NMR) as 
colourless oil, Rf 0.35 (50:50 petrol−EtOAc); νmax/cm-1 3318, 2949, 2928, 2875, 
2855, 1677, 1540, 1365, 1276, 1250, 1160, 1135, 1093, 1081, 1059, 1034; δH 
(500 MHz, CDCl3) 4.76 (1H, app. t, J 5.1, NH), 4.11 (1H, dd, J 10.1 and 4.0, 7-
HA), 3.92-3.86 (1H, m, 2-HA), 3.87 (1H, d, J 8.4, 5-HA), 3.79 (1H, app. d, J 10.1, 
7-HB), 3.73 (1H, app. d, J 4.0, 7a-H), 3.51 (1H, d, J 8.4, 5-HB), 3.31 (1H, td, J 
11.4 and 2.3, 2-HB), 3.15 (1H, dd, J 14.1 and 6.8, methylcarbamate 1-HA), 2.98 
(1H, dd, J 14.1 and 6.5, methylcarbamate 1-HB), 1.80-1.69 (1H, m, 3-HA), 1.69-
1.64 (2H, m, 4-H2), 1.53-1.46 (1H, m, 3-HB), 1.43 (9H, s, tBu); δC (100 MHz, 
CDCl3) 156.5 (Boc C=O), 80.3 (C-7a), 79.7 (tBu C1), 74.2 (C-7), 71.2 (C-5), 66.2 
(C-2), 46.5 (methylcarbamate C-1), 45.9 (C-4a), 28.5 (tBu C3), 24.3 (C-4), 21.7 
(C-3); HRMS found MNa+, 280.1517. C13H23NO4 requires MNa, 280.1519. The 
relative configuration was determined using NOESY (500 MHz, CDCl3), nOe 
observed between 7a-H and methylcarbamate 1-HA, 7a-H and 
methylcarbamate 1-HB, 7a-H and NH. 
 
Benzyl (4aR*,8aR*)-4a-benzyl-octahydro-2H-pyrano[3,2-c]pyridine-6-
carboxylate 
N
Cbz
O
H
149e  
 
According to General Procedure O, the hemiacetal derivative 159e (0.45 g, 1.18 
mmol) gave a crude material. The crude material (dr 93:7 by 1H-NMR) was 
purified by flash column chromatography, eluting with 10:90 EtOAc−hexane to 
171 
 
yield the ether derivative 149e (0.27 g, 63%, dr >95:<5 by 1H-NMR) as 
colourless oil, Rf 0.40 (70:30 petrol−EtOAc); νmax/cm-1 3061, 3028, 2932, 2851, 
1692, 1427, 1265, 1243, 1210, 1129, 1086, 1074, 1025; δH (500 MHz, CD3OD, 
333 K) 7.35-7.25 (5H, m, Cbz phenyl), 7.15 (5H, app. br. s, phenyl), 5.19 (1H, d,  
J 12.4, Cbz phenylmethyl 1-HA), 5.15 (1H, d, J 12.4, Cbz phenylmethyl 1-HB), 
3.97 (1H, app. ddt, J 13.0, 5.5 and 2.0, 7-HA), 3.92 (1H, app. ddt, J 11.3, 4.7 
and 1.8, 2-HA), 3.60 (1H, d, J 13.3, 5-HA), 3.38-3.29 (3H, m, 5-HB, 8a-H and 2-
HB), 3.15 (1H, td, J 13.0 and 3.2, 7-HB), 2.75 (1H, d, J 13.4, phenylmethyl 1-HA), 
2.40 (1H, d, J 13.4, phenylmethyl 1-HB), 2.10 (1H, dddd, J 14.4, 13.0, 5.5 and 
3.2, 8-HA), 1.76-1.69 (1H, m, 3-HA), 1.69-1.63 (1H, m, 8-HB), 1.48 (1H, td, J 13.8 
and 4.7, 4-HA), 1.37 (1H, app. ddt, J 13.2, 4.7 and 2.4, 3-HB), 1.10 (1H, app. dt, 
J 13.8 and 3.6, 4-HB); δC (125 MHz, CD3OD, 333 K) 157.7 (Cbz C=O), 138.2 
(phenyl C-1 and Cbz phenyl C-1), 131.9 (phenyl C2-3,5), 129.5 (Cbz phenyl C2-
3,5), 129.1 (phenyl C2-2,6 and Cbz phenyl C2-2,6), 128.9 (Cbz phenyl C-4), 
127.2 (phenyl C-4), 78.7 (C-8a), 68.7 (Cbz phenylmethyl C-1), 68.5 (C-2), 46.4 
(C-5), 42.3 (phenylmethyl C-1), 40.2 (C-7), 37.7 (C-4a), 31.7 (C-4), 28.0 (C-8), 
23.3 (C-3); HRMS found MNa+, 388.1880. C23H27NO3 requires MNa, 388.1888. 
The relative configuration was determined using NOESY (500 MHz, CD3OD, 
333 K), nOe observed between 8a-H and phenylmethyl 1-HA, 8a-H and 
phenylmethyl 1-HB, 8a-H and 8-HA, 8a-H and 8-HB. 
 
Benzyl (4aR*,8aR*)-4a-[(pyridin-3-yl)methyl]-octahydro-2H-pyrano[3,2-c] 
pyridine-6-carboxylate 
N
Cbz
O
H
N
149f  
 
According to General Procedure O, the hemiacetal derivative 159f (0.13 g, 0.34 
mmol) gave a crude material. The crude material (dr 91:9 by 1H-NMR) was 
purified by flash column chromatography, eluting with 70:30 EtOAc−hexane to 
yield the ether derivative 149f (0.11 g, 88%, dr 91:9 by 1H-NMR) as colourless 
oil, Rf 0.32 (EtOAc); νmax/cm-1 3030, 2934, 2851, 1690, 1424, 1266, 1243, 1207, 
1130, 1085, 1025; δH (500 MHz, CD3OD, 333 K) 8.36 (1H, d, J 6.8, pyridinyl 6-
H), 8.35 (1H, s, pyridinyl 2-H), 7.76-7.57 (1H, m, pyridinyl 4-H), 7.39 (2H, d, J 
7.9, phenyl 2,6-H2), 7.34 (2H, t, J 7.9, phenyl 3,5-H2), 7.28 (1H, t, J 7.9, phenyl 
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4-H), 7.20 (1H, app. br. s, pyridinyl 5-H), 5.18 (2H, s, phenylmethyl, 1-H2), 3.99 
(1H, ddd, J 13.0, 3.0 and 1.3, 7-HA), 3.96-3.91 (1H, m, 2-HA), 3.55 (1H, d, J 
13.4, 5-HA), 3.40-3.33 (3H, m, 5-HB, 8a-H and 2-HB), 3.14 (1H, td, J 13.0 and 
3.3, 7-HB), 2.81 (1H, d, J 13.5, pyridinylmethyl 1-HA), 2.40 (1H, d, J 13.5, 
pyridinylmethyl 1-HB), 2.13-2.02 (1H, m, 8-HA), 1.74-1.68 (1H, m, 8-HB), 1.68-
1.63 (1H, m, 3-HA), 1.45 (1H, td, J 13.4 and 3.0, 4-HA), 1.41-1.36 (1H, m, 3-HB), 
1.07 (1H, app. d, J 13.4, 4-HB); δC (125 MHz, CD3OD, 333 K) 157.6 (Cbz C=O), 
152.0 (pyridinyl C-2), 148.0 (pyridinyl C-6), 140.3 (pyridinyl C-4), 138.2 (phenyl 
C-1), 134.7 (pyridinyl C-3), 129.6 (phenyl C2-3,5), 129.1 (phenyl C2-2,6), 129.0 
(phenyl C-4), 124.5 (pyridinyl C-5), 78.7 (C-8a), 68.7 (phenylmethyl C-1), 68.5 
(C-2), 45.8 (C-5), 40.2 (C-7), 39.1 (pyridinylmethyl C-1), 37.6 (C-4a), 31.7 (C-4), 
28.0 (C-8), 23.2 (C-3); HRMS found MH+, 367.2015. C22H26N2O3 requires MH, 
367.2021. The relative configuration was determined using NOESY (500 MHz, 
CD3OD, 333 K), nOe observed between 8a-H and pyridinylmethyl 1-HB, 8a-H 
and 8-HA, 8a-H and 8-HB. 
 
tert-Butyl N-({8a-methoxy-octahydropyrano[4,3-b]pyran-4a-yl}methyl) 
carbamate 
 
O
O
MeO
NHBoc
161  
 
According to General Procedure P, the hemiacetal derivative 159a (0.23 g, 0.80 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 20:80 EtOAc−petrol to yield the acetal derivative 
161 (0.20 g, 83%, dr >95:<5 by 1H-NMR) as an amorphous white solid, Rf 0.59 
(50:50 petrol−EtOAc); νmax/cm-1 3325, 3068, 2971, 2949, 2929, 2876, 1714, 
1546, 1363, 1267, 1248, 1224, 1165, 1140, 1125, 1115, 1098, 1076, 1064, 
1021; δH (400 MHz, CDCl3) 5.03 (1H, br. s, NH), 3,91-3.84 (1H, m, 7-HA), 3.85 
(1H, d, J 11.7, 5-HA), 3.67-3.60 (2H, m, 2-H2), 3.55 (1H, app. td, J 12.9 and 2.8, 
7-HB), 3.37 (1H, d, J 11.7, 5-HB), 3.33-3.27 (2H, m, methylcarbamate 1-H2), 
3.18 (3H, s, methoxy 1-H3), 1.93 (1H, td, J 13.8 and 5.0, 4-HA), 1.83 (1H, app. 
td, J 13.1 and 5.7, 8-HA), 1.77-1.71 (1H, m, 3-HA), 1.67 (1H, app. d, J 13.1, 8-
HB), 1.42 (9H, s, tBu), 1.39-1.32 (1H, m, 3-HB), 1.10 (1H, app. d, J 13.6, 4-HB); 
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δC (100 MHz, CDCl3) 156.4 (C=O), 98.5 (C-8a), 78.9 (tBu C1), 70.9 (C-5), 65.8 
(C-7), 60.3 (C-2), 46.7 (methoxy C-1), 44.9 (methylcarbamate C-1), 40.7 (C-4a), 
31.0 (C-8), 28.5 (tBu C3), 23.3 (C-4), 21.1 (C-3). HRMS found MNa+, 324.1789. 
C15H27NO5 requires MNa, 324.1781. 
 
tert-Butyl 3-hydroxy-10-oxo-7-oxa-2-azaspiro[4.5]decane-2-carboxylate 
 
O
O NBoc
OH
163  
 
According to General Procedure Q, the alkene derivative 148i (0.25 g, 0.93 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 50:50 EtOAc−hexane to yield the hemiaminals 
163 (0.19 g, 75%, dr 66:34 by 1H-NMR) as an amorphous colourless solid, Rf 
0.23 and 0.34 (50:50 petrol−EtOAc); νmax/cm-1 3432, 2956, 2923, 2852, 1697, 
1382, 1365, 1255, 1223, 1169, 1149, 1115, 1097; δH (400 MHz, CDCl3) 5.53 
(1H, app. d, J 6.5, 3-Hmajor), 2.46 (1H, app. d, J 4.9 3-Hminor), 4.11 (4H, app. d, J 
11.6, 8-HA and 6-HA), 3.89 (2H, ddd, J 11.6, 8.8 and 4.5, 8-HB), 3.76 (1H, d, J 
11.6, 6-HBmajor), 3.72-3.60 (4H, m, 6-HBminor, 1-HA and 1HBminor), 3.50 (1H, d, J 
11.2, 1-HBmajor), 2.93 (1H, br. s, OHminor), 2.70-2.43 (6H, m, 9-H2 and 4-HA), 1.75 
(2H, app. d, J 14.1, 4-HB), 1.64 (1H, br. s, OHmajor), 1.48 (18H, s, tBu); δC (100 
MHz, CDCl3) 206.2 (C2-10), 154.8 (Boc 2C=O), 81.7 (C2-3), 80.9 (tBu 2C1), 75.5 
(C2-6), 68.5 (C2-8), 56.6 (C-5major), 55.8 (C-5minor), 51.1 (C-1minor), 50.9 (C-1major), 
40.9 (C2-9), 36.6 (C-4minor), 36.0 (C-4major), 28.5 (tBu 2C3); HRMS found MNa+, 
294.1314. C13H21NO5 requires MNa, 294.1311.  
 
tert-Butyl N-{[(3aR,7aS)-1-benzyl-octahydropyrano[4,3-b]pyrrol-3a-yl] 
methyl}carbamate 
O
BnN
NHBoc
164
H
 
 
Benzylamine (12.9 µL, 117 µmol), acetic acid (12.2 µL, 214 µmol) and 
NaBH(OAc)3 (56.7 mg, 267 µmol) were added to a solution of the hemiaminals 
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163 (29.0 mg, 107 µmol) in DCM (1.00 mL) at rt. The reaction mixture was 
stirred for 18 h at rt. Subsequently, a saturated aqueous solution of NaHCO3 (1 
mL) was added and the solution was stirred for 5 min. The phases were 
separated and the aqueous phase was extracted with DCM (3 × 1 mL). The 
organic phases were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure to give a crude product. The crude product was purified by 
flash column chromatography, eluting with 20:80 EtOAc−hexane to yield the 
amine derivative 164 (11.0 mg, 30%, dr 83:17 by 1H-NMR) as an amorphous 
colourless solid, Rf 0.53 (50:50 petrol−EtOAc); νmax/cm-1 3323, 2965, 2924, 
2792, 1712, 1537, 1452, 1388, 1268, 1247, 1165, 1131, 1085; δH (400 MHz, 
CDCl3) 7.35-7.21 (5H, m, phenyl), 5.22 (1H, br. s, NH), 3.96 (1H, d, J 13.3, 
phenylmethyl 1-HA), 3.80 (1H, td, J 10.9 and 3.1, 6-HA), 3.66-3.61 (1H, m, 6-
HB), 3.59 (1H, d, J 11.8, 4-HA), 3.45 (1H, d, J 11.8, 4-HB), 3.39-3.30 (1H, m, 
methylcarbamate 1-HA), 3.29-3.20 (2H, m, phenylmethyl 1-HB and 
methylcarbamate 1-HB), 2.92 (1H, td, J 9.4 and 4.5, 2-HA), 2.50 (1H, app. s, 7a-
H), 2.39-2.27 (1H, m, 2-HB), 1.91-1.78 (1H, m, 7-HA), 1.70 (1H, app. dq, J 14.6 
and 3.6, 7-HB), 1.63-1.51 (1H, m, 3-HA), 1.45 (9H, s, tBu), 1.39-1.28 (1H, m, 3-
HB); δC (100 MHz, CDCl3) 156.5 (C=O), 139.7 (phenyl C-1), 128.5 (phenyl C2-
3,5), 128.3 (phenyl C2-2,6), 127.0 (phenyl C-4), 79.2 (tBu C1), 71.2 (C-4), 64.0 
(C-6), 63.0 (C-7a), 57.1 (phenylmethyl C-1), 51.2 (C-2), 46.3 (methylcarbamate 
C-1), 44.1 (C-3a), 29.4 (C-3), 28.5 (tBu C3), 24.0 (C-7); HRMS found MH+, 
347.2337. C20H30N2O3 requires MH, 347.2329. The relative configuration was 
determined using NOESY (500 MHz, CDCl3), nOe observed between 7a-H and 
methylcarbamate 1-HA, 7a-H and methylcarbamate 1-HB, 7a-H and 7-HA, 7a-H 
and 7-HB. 
 
tert-Butyl N-{[(3R*, 4R*)-4-hydroxy-3-(prop-2-en-1-yl)oxan-3-yl]methyl} 
carbamate 
O
OH NHBoc
167a  
 
According to General Procedure R, the ketone derivative 148i (0.50 g, 1.85 
mmol) and diisobutylaluminium hydride (4.08 mL, 4.08 mmol of a 1.0 M solution 
in DCM) were stirred at –78 °C to give a crude material. The crude material (dr 
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86:14 by 1H-NMR) was purified by flash column chromatography, eluting with 
50:50 EtOAc−hexane to yield the alcohol derivative 167a (0.47 g, 93%, dr 86:14 
by 1H-NMR) as a yellow oil, Rf 0.31 (70:30 petrol−EtOAc); νmax/cm-1 3340, 2975, 
2932, 2856, 1682, 1512, 1365, 1274, 1248, 1163, 1083; δH (400 MHz, CDCl3) 
5.83 (1H, ddt, J 15.3, 9.5 and 7.7, propenyl 2-H), 5.13 (1H, app. d, J 15.3, 
propenyl 3-Htrans), 5.10 (1H, app. d, J 9.5, propenyl 3-Hcis), 4.80 (1H, app. t, J 
7.0, NH), 3.97 (1H, app. dd, J 11.6 and 4.0, 6-HA), 3.68 (1H, dd, J 11.1 and 4.8, 
4-H), 3.61 (1H, d, J 11.4, 2-HA), 3.39 (1H, td, J 11.6 and 2.9, 6-HB), 3.35-3.33 
(1H, app. d, J 8.0, methylcarbamate 1-HA), 2.98 (1H, d, J 11.4, 2-HB), 2.70 (1H, 
dd, J 14.9 and 5.4, methylcarbamate 1-HB), 2.43 (1H, dd, J 14.0 and 7.2, 
propenyl 1-HA), 2.26 (1H, dd, J 14.0 and 8.1, propenyl 1-HB), 1.85 (1H, app. qd, 
J 11.9 and 4.8, 5-HA), 1.70 (1H, app. dt, J 13.1 and 1.84, 5-HB), 1.45 (9H, s, 
tBu); δC (100 MHz, CDCl3) 157.8 (Boc C=O), 134.0 (propenyl C-2), 118.6 
(propenyl C-3), 80.3 (tBu C1), 70.3 (C-2), 70.1 (C-4), 67.2 (C-6), 43.7 
(methylcarbamate C-1), 42.9 (C-3), 31.6 (propenyl C-1), 29.5 (C-5), 28.4 (tBu 
C3); HRMS found MH+, 272.1855. C14H25NO4 requires MH, 272.1856. The 
relative configuration was determined by comparison with the carbocyclic 
analogue142 and using NOESY (500 MHz, CDCl3), nOe observed between 4-H 
and methylcarbamate 1-HB. 
 
Benzyl (3R*,4R*)-3-({[(tert-butoxy)carbonyl]amino}methyl)-4-hydroxy-3-
(prop-2-en-1-yl)piperidine-1-carboxylate 
 
N
Cbz
OH NHBoc
167b  
 
According to General Procedure R, the ketone derivative 148j (0.50 g, 1.24 
mmol) and diisobutylaluminium hydride (1.36 mL, 1.36 mmol of a 1.0 M solution 
in DCM) were stirred at –100 °C to give a crude material. The crude material (dr 
>95:<5 by 1H-NMR) was purified by flash column chromatography, eluting with 
30:70 EtOAc−hexane to yield the alcohol derivative 167b (0.39 g, 78%, dr 
>95:<5 by 1H-NMR) as a colourless oil, Rf 0.55 (50:50 petrol−EtOAc); νmax/cm-1 
3367, 2975, 2935, 2870, 2492, 1672, 1428, 1364, 1234, 1155, 1079; δH (500 
MHz, CD3OD, 333 K) 7.37-7.27 (5H, m, phenyl), 5.87 (1H, app. dd, J 13.3 and 
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7.0, propenyl 2-H), 5.11 (2H, s, phenylmethyl 1-H2), 5.03 (1H, app. d, J 17.0 
propenyl 3-Htrans), 5.00 (1H, app. d, J 10.2, propenyl 3-Hcis), 3.95 (1H, app. d, J 
13.3, 6-HA), 3.72 (1H, d, J 13.7, 2-HA), 3.63 (1H, dd, J 9.7 and 4.4, 4-H), 3.15 
(1H, d, J 14.3, methylcarbamate 1-HA), 3.06 (1H, app. br. s, 6-HB), 2.95 (1H, d, 
J 14.3, methylcarbamate 1-HB), 2.78 (1H, d, J 13.7, 2-HB), 2.18 (1H, dd, J 14.2 
and 7.9, propenyl 1-HA), 2.09 (1H, dd, J 14.2 and 7.0, propenyl 1-HB), 1.78-1.71 
(1H, m, 5-HA), 1.70-1.60 (1H, m, 5-HB), 1.43 (9H, s, tBu); δC (125 MHz, CD3OD, 
333 K) 158.9 (Boc C=O), 157.3 (Cbz C=O), 138.1 (phenyl C-1), 135.2 (propenyl 
C-2), 129.5 (phenyl C2-3,5), 129.1 (phenyl C2-2,6), 129.0 (phenyl C-4), 118.6 
(propenyl C-3), 80.5 (tBu C1), 71.8 (C-4), 68.5 (phenylmethyl C-1), 48.3 (C-2), 
45.0 (methylcarbamate C-1), 43.6 (C-3), 43.0 (C-6), 33.3 (propenyl C-1), 29.8 
(C-5), 28.8 (tBu C3); HRMS found MNa+, 427.2205. C22H32N2O5 requires MNa, 
427.2203. The relative configuration was determined by analogy with the 
carbocyclic analogue142 and using NOESY (500 MHz, CD3OD), nOe observed 
between 4-H and methylcarbamate 1-HA, 4-H and methylcarbamate 1-HB. 
 
tert-Butyl N-{[(1R*,2S*)-1-hydroxy-6-methoxy-2-(prop-2-en-1-yl)-2,3-
dihydro-1H-inden -2-yl]methyl}carbamate 
 
MeO NHBoc
OH
167c  
 
According to General Procedure R, the ketone derivative 148k (1.00 g, 3.01 
mmol) and diisobutylaluminium hydride (6.63 mL, 6.63 mmol of a 1.0 M solution 
in DCM) were stirred at –78 °C to give a crude material. The crude material (dr 
90:10 by 1H-NMR) was purified by flash column chromatography, eluting with 
20:80 EtOAc−hexane to yield the alcohol derivative 167c (0.63 g, 63%, dr 
>95:<5 by 1H-NMR) as a yellow oil, Rf 0.37 (70:30 petrol−EtOAc); νmax/cm-1 
3368, 2976, 2931, 2835, 1685, 1512, 1490, 1435, 1365, 1272, 1245, 1159, 
1029; δH (400 MHz, CDCl3) 7.03 (1H, d, J 8.2, 4-H), 6.91 (1H, d, J 2.4, 7-H), 
6.75 (1H, dd, J 8.2 and 2.4, 5-H), 5.85-5.68 (1H, m, propenyl 2-H), 5.03 (1H, 
app. d, J 19.7, propenyl 3-Htrans), 5.04 (1H, app. d, J 11.7, propenyl 3-Hcis), 4.94 
(1H, app. t, J 6.3, NH), 3.79 (3H, s, methoxy), 3.29 (1H, dd, J 14.2 and 6.9, 
methylcarbamate 1-HA), 3.20 (1H, dd, J 14.2 and 5.8, methylcarbamate 1-HB), 
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2.73 (1H, d, J 15.4, 3-HA), 2.51 (1H, d, J 15.4, 3-HB), 2.34 (1H, dd, J 14.2 and 
7.4, propenyl 1-HA), 2.05 (1H, dd, J 14.2 and 7.3, propenyl 1-HB), 1.44 (9H, s, 
tBu); δC (100 MHz, CDCl3) 159.2 (C-6), 157.1 (Boc C=O), 145.5 (C-7a), 135.2 
(propenyl C-2), 131.4 (C-3a), 125.6 (C-4), 118.0 (propenyl C-3), 114.5 (C-5), 
108.9 (C-7), 80.7 (C-1), 79.8 (tBu C1), 55.6 (methoxy), 52.7 (C-2), 46.5 
(methylcarbamate C-1), 36.8 (C-3), 34.6 (propenyl C-1), 28.5 (tBu C3); HRMS 
found MNa+, 356.1838. C19H27NO4 requires MNa, 356.1832. The relative 
configuration was determined from compound 150c. 
 
tert-Butyl N-{[(3R*,4S*)-4-hydroxy-3-(prop-2-en-1-yl)oxolan-3-yl]methyl} 
carbamate 
O
OH NHBoc
167d  
 
According to General Procedure R, the ketone derivative 148l (2.00 g, 7.83 
mmol) and diisobutylaluminium hydride (17.2 mL, 17.2 mmol of a 1.0 M solution 
in DCM) were stirred at –78 °C to give a crude material. The crude material (dr 
>95:<5 by 1H-NMR) was purified by flash column chromatography, eluting with 
20:80→40:60 EtOAc−hexane to yield the alcohol derivative 167d (1.85 g, 92%, 
dr >95:<5 by 1H-NMR) as a light-yellow oil, Rf 0.29 (50:50 petrol−EtOAc); 
νmax/cm-1 3341, 2976, 2930, 2872, 1686, 1516, 1365, 1272, 1248, 1162, 1068, 
1046; δH (400 MHz, CDCl3) 5.83 (1H, ddt, J 17.2, 10.1 and 7.5, propenyl 2-H), 
5.17 (1H, dd, J 17.2 and 1.8, propenyl 3-Htrans), 5.12 (1H, dd, J 10.1 and 1.8, 
propenyl 3-Hcis), 4.84 (1H, app. t, J 5.0, NH), 4.24-4.10 (2H, m, 5-HA and 4-H), 
3.71-3.67 (1H, m, 5-HB), 3.66 (1H, d, J 8.9, 2-HA), 3.54 (1H, d, J 8.9, 2-HB), 
3.17-3.02 (2H, m, methylcarbamate, 1-H2), 2.60 (1H, br. s, OH), 2.33 (1H, dd, J 
14.3 and 7.7, propenyl 1-HA), 2.26 (1H, dd, J 14.3 and 7.1, propenyl 1-HB), 1.43 
(9H, s, tBu); δC (100 MHz, CDCl3) 156.9 (Boc C=O), 134.7 (propenyl C-2), 118.5 
(propenyl C-3), 79.9 (tBu C1), 75.6 (C-4), 74.3 (C-5), 73.9 (C-2), 50.2 (C-3), 44.1 
(methylcarbamate C-1), 33.5 (propenyl C-1), 28.5 (tBu C3); HRMS found MNa+, 
280.1514. C13H23NO4 requires MNa, 280.1519. The relative configuration was 
determined from compound 150d. 
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tert-Butyl N-{[(2R*,3aR*,7aR*)-2-(iodomethyl)-hexahydro-2H-furo[3,2-
c]pyran-3a-yl]methyl}carbamate 
 
O
O
I
NHBoc
169
H
 
 
According General Procedure S, the alkene derivative 167a (0.10 g, 0.37 mmol) 
was stirred for 18 h to give a crude material. The crude material (dr 80:20 by 1H-
NMR) was purified by flash column chromatography, eluting with 15:85 
EtOAc−hexane to yield the tetrahydrofuran derivative 169 (57.0 mg, 39%, dr 
>95:<5 by 1H-NMR) as an amorphous colourless solid, Rf 0.50 (50:50 
petrol−EtOAc); νmax/cm-1 3323, 2975, 2950, 2923, 2895, 2868, 2848, 1703, 
1547, 1349, 1273, 1252, 1235, 1164, 1139, 1069; δH (500 MHz, CDCl3, 323 K) 
4.85 (1H, br. s, NH), 4.06 (1H, app. dtd, J 8.5, 6.9 and 5.3, 2-H), 3.78 (1H, app. 
t, J 3.8, 7a-H), 3.71 (1H, ddd, J 11.4, 5.7 and 2.7, 6-HA), 3.63 (1H, td, J 11.4 
and 3.1, 6-HB), 3.56 (1H, d, J 11.9, 4-HA), 3.48 (1H, d, J 11,9, 4-HB), 3.35-3.29 
(3H, m, methylcarbamate 1-H2 and iodomethyl 1-HA), 3.24 (1H, dd, J 10.0 and 
6.9, iodomethyl 1-HB), 1.98 (1H, dd, J 13.4 and 8.5, 3-HA), 1.95-1.91 (1H, m, 7-
HA), 1.82 (1H, app. dq, J 14.9 and 3.0, 7-HB), 1.45 (9H, s, tBu), 1.29 (1H, dd, J 
13.4 and 6.9, 3-HB); δC (125 MHz, CDCl3) 156.3 (C=O), 79.5 (tBu C1), 77.9 (C-
7a), 77.0 (C-2), 71.0 (C-4), 64.0 (C-6), 44.8 (methylcarbamate C-1), 44.6 (C-
3a), 38.9 (C-3), 28.5 (tBu C3), 26.9 (C-7), 9.43 (iodomethyl C-1); HRMS found 
MH+, 398.0823. C14H24INO4 requires MH, 398.0822. The relative configuration 
was determined by NOESY (500 MHz, CDCl3) nOe observed between 
methylcarbamate 1-HA and 2-H, methylcarbamate 1-HB and 2-H, 2-H and 7a-H. 
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(4aR*, 8aR*)-4a-(Prop-2-en-1-yl)-octahydropyrano[3,4-e][1,3]oxazin-2-one 
 
O
NHO
O
150a
H
 
 
According to General Procedure T, the alcohol derivative 167a (20.0 mg, 73.7 
µmol) was stirred for 1 h to yield the crude carbamate derivative 150a (14.0 mg, 
96%) as an amorphous colourless solid, Rf 0.20 (EtOAc); νmax/cm-1 3277, 2964, 
2922, 2852, 1707, 1660, 1471, 1442, 1366, 1312, 1256, 1179, 1101, 1081, 
1059; δH (400 MHz, CDCl3) 5.91 (1H, br. s, NH), 5.87-5.72 (1H, m, propenyl 2-
H), 5.22 (1H, app. d, J 2.5, propenyl 3-HA), 5.18 (1H, app. s, propenyl 3-HB), 
4.25 (1H, dd, J 12.0 and 4.9, 8a-H), 4.11 (1H, app. dd, J 12.1 and 5.3, 7-HA), 
3.88 (1H, dd, J 11.6 and 1.2, 5-HA), 3.46 (1H, td, J 12.1 and 2.7, 7-HB), 3.14 
(1H, dd, J 11.3 and 4.4, 4-HA), 2.94 (1H, dd, J 11.6 and 1.7, 5-HB), 2.81 (1H, dd, 
J 11.3 and 1.4, 4-HB), 2.61 (1H, dd, J 13.9 and 6.7, propenyl 1-HA), 2.18 (1H, 
dd, J 13.9 and 8.2, propenyl 1-HB), 2.03 (1H, app. qd, J 12.6 and 5.3, 8-HA), 
1.87-1.77 (1H, m, 8-HB); δC (100 MHz, CDCl3) 154.0 (C-2), 132.1 (propenyl C-
2), 120.3 (propenyl C-3), 78.9 (C-8a), 70.4 (C-5), 66.7 (C-7), 45.2 (C-4), 35.5 
(C-4a), 28.6 (propenyl C-1), 26.8 (C-8); HRMS found MH+, 198.1124. 
C10H15NO3 requires MH, 198.1124. 
 
Benzyl (4aR*,8aR*)-2-oxo-4a-(prop-2-en-1-yl)-octahydro-2H-pyrido[3,4-e] 
[1,3]oxazine-6-carboxylate 
N
Cbz
NHO
H
O
150b  
 
According to General Procedure T, the alcohol derivative 167b (0.12 g, 0.30 
mmol) was stirred for 1 h to yield a crude material. The crude material was 
purified by flash column chromatography, eluting with 80:20 EtOAc−hexane to 
yield the carbamate derivative 150b (62.0 mg, 63%) as a colourless oil, Rf 0.42 
(10:90 MeOH−EtOAc); νmax/cm-1 3480, 3376, 3215, 3133, 2938, 2874, 1671, 
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1437, 1311, 1267, 1236, 1215, 1157, 1112, 1086, 1054; δH (500 MHz, CD3OD, 
333 K) 7.38-7.25 (5H, m, phenyl), 5.81 (1H, app. br. s, propenyl 2-H), 5.13 (2H, 
s, phenylmethyl 1-H2), 5.12-5.04 (2H, m, propenyl 3-H2), 4.34 (1H, app. dt, J 
13.0 and 2.1, 7-HA), 4.28 (1H, dd, J 10.0 and 6.8, 8a-H), 4.20 (1H, d, J 13.7, 5-
HA), 3.15 (1H, d, J 11.7, 4-HA), 2.96-2.90 (1H, m, 7-HB), 2.87 (1H, d, J 11.7, 4-
HB), 2.51 (1H, d, J 13.7, 5-HB), 2.20 (1H, dd, J 14.3 and 6.4, propenyl 1-HA), 
2.03 (1H, dd, J 14.3 and 8.6, propenyl 1-HB), 1.86-1.75 (2H, m, 8-H2); δC (125 
MHz, CD3OD, 333 K) 157.0 (C-2), 156.3 (Cbz C=O), 137.9 (phenyl C-1), 133.6 
(propenyl C-2), 129.5 (phenyl C2-3,5), 129.2 (phenyl C2-2,6), 129.1 (phenyl C-
4), 120.2 (propenyl C-3), 81.0 (C-8a), 68.7 (phenylmethyl C-1), 48.6 (C-5), 46.6 
(C-4), 43.2 (C-7), 36.1 (C-4a), 29.8 (propenyl C-1), 26.6 (C-8); HRMS found 
MNa+, 353.1473. C18H22N2O4 requires MNa, 353.1477. 
 
(4aR*,9bS*)-8-Methoxy-4a-(prop-2-en-1-yl)-2H,3H,4H,4aH,5H,9bH-indeno 
[2,1-e][1,3] oxazin-2-one 
MeO NH
O
O
H
150c  
 
According to General Procedure T, the alcohol derivative 167c (20.0 mg, 60.0 
µmol) was stirred for 18 h to yield a crude material. The crude material was 
purified by flash column chromatography, eluting with 70:30 EtOAc−hexane to 
yield the carbamate derivative 150c (9.00 mg, 58%) as colourless blocks, m.p. 
(CHCl3/pentane), 180–185 °C; Rf 0.46 (EtOAc); νmax/cm-1 3231, 3122, 2935, 
2354, 1691, 1481, 1434, 1295, 1242, 1081; δH (400 MHz, CDCl3) 7.13 (1H, d, J 
8.2, 6-H), 7.00 (1H, d, J 2.5, 9-H), 6.79 (1H, dd, J 8.2 and 2.5, 7-H), 5.84 (1H, 
br. s, NH), 5.72 (1H, ddt, J 17.0, 10.1 and 7.5, propenyl 2-H), 5.39 (1H, s, 9b-H), 
5.12 (1H, ddt, J 10.1, 1.7 and 0.9, propenyl 3-Hcis), 5.03 (1H, app. dq, J 17.0 
and 1.7, propenyl 3-Htrans), 3.80 (3H, s, methoxy), 3.54-3.41 (2H, m, 4-H2), 2.95 
(1H, d, J 14.7, 5-HA), 2.45 (1H, d, J 14.7, 5-HB), 2.20 (1H, dd, J 14.5 and 7.5, 
propenyl 1-HA), 1.84 (1H, dd, J 14.5 and 7.0, propenyl 1-HB); δC (100 MHz, 
CDCl3) 159.4 (C-8), 155.1 (C-2), 139.6 (C-9a), 133.1 (propenyl C-2), 131.3 (C-
5b), 126.5 (C-6), 119.6 (propenyl C-3), 114.5 (C-7), 108.2 (C-9), 85.8 (C-9b), 
55.6 (methoxy), 49.0 (C-4), 45.3 (C-4a), 35.6 (C-5), 31.2 (propenyl C-1); HRMS 
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found MH+, 260.1275. C15H17NO3 requires MH, 260.1281. The relative 
configuration was determined using X-ray crystallography. 
 
(4aR*,7aS*)-4a-(Prop-2-en-1-yl)-hexahydro-2H-furo[3,4-e][1,3]oxazin-2-one 
 
O
NHOH
O
150d  
 
According to General Procedure T, the alcohol derivative 167d (0.56 g, 2.17 
mmol) was stirred for 18 h to yield a crude material. The crude material was 
purified by flash column chromatography, eluting with EtOAc to yield the 
carbamate derivative 150d (0.26 g, 65%) as colourless blocks, m.p. (DCM), 
138–142 °C; Rf 0.20 (EtOAc); νmax/cm-1 3254, 3132, 2979, 2950, 2929, 2895, 
1700, 1384, 1301, 1257, 1132, 1104, 1076, 1014; δH (400 MHz, CDCl3) 6.57 
(1H, br. s, NH), 5.78 (1H, ddt, J 17.1, 9.8 and 7.4, propenyl 2-H), 5.27-5.12 (2H, 
m, propenyl 3-H2), 4.58 (1H, dd, J 10.1 and 8.0, 7a-H), 4.05 (1H, dd, J 10.1 and 
8.0, 7-HA), 4.01 (1H, d, J 8.6, 5-HA), 3.70 (1H, dd, J 10.1 and 8.0, 7-HB), 3.46 
(1H, d, J 8.6, 5-HB), 3.38 (1H, dd, J 11.1 and 4.3, 4-HA), 3.18 (1H, d, J 11.1, 4-
HB), 2.34-2.17 (2H, m, propenyl 1-H2); δC (100 MHz, CDCl3) 154.9 (C-2), 132.0 
(propenyl C-2), 120.4 (propenyl C-3), 80.5 (C-7a), 71.7 (C-5), 64.9 (C-7), 46.7 
(C-4), 40.5 (C-4a), 29.9 (propenyl C-1); HRMS found MH+, 184.0964. C9H13NO3 
requires MH, 184.0968. The relative configuration was determined using X-ray 
crystallography. 
 
(3R*, 4R*)-3-({[(tert-Butoxy)carbonyl]amino}methyl)-3-(prop-2-en-1-yl)oxan 
-4-yl acetate 
O
OAc NHBoc
171a  
 
According to General Procedure U, the alcohol derivative 167a (0.36 g, 1.35 
mmol) gave the acetyl derivative 171a (0.40 g, 95%) as a yellow oil, Rf 0.71 
(50:50 petrol−EtOAc); νmax/cm-1 3355, 2973, 2933, 2859, 1739, 1714, 1508, 
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1365, 1236, 1164, 1089; δH (400 MHz, CDCl3) 5.88-5.73 (1H, m, propenyl 2-H), 
5.11 (1H, app. s, propenyl 3-Htrans), 5.08 (1H, app. d, J 2.5, propenyl 3-Hcis), 
5.00 (1H, app. t, J 6.9, 4-H), 4.95 (1H, br. s, NH), 3.86 (1H, app. dt, J 11.6 and 
4.6, 6-HA), 3.68 (1H, d, J 12.0, 2-HA), 3.55-3.46 (1H, m, 6-HB), 3.28 (1H, dd, J 
14.6 and 8.2, methylcarbamate 1-HA), 3.18 (1H, d, J 12.0, 2-HB), 2.87 (1H, dd, J 
14.6 and 5.5, methylcarbamate 1-HB), 2.35 (1H, dd, J 14.1 and 7.5, propenyl 1-
HA), 2.13-2.04 (1H, m, propenyl 1-HB), 2.08 (3H, s, acetyl), 1.87-1.79 (2H, m, 5-
H2), 1.41 (9H, s, tBu); δC (100 MHz, CDCl3) 170.9 (acetyl C=O), 156.2 (Boc 
C=O), 133.1 (propenyl C-2), 118.8 (propenyl C-3), 79.4 (tBu C1), 71.5 (C-4), 
70.4 (C-2), 65.8 (C-6), 42.3 (methylcarbamate C-1), 42.0 (C-3), 33.5 (propenyl 
C-1), 28.4 (tBu C3), 27.6 (C-5), 21.2 (acetyl CH3). HRMS found MNa+, 
336.1791. C16H27NO5 requires MNa, 336.1786. 
 
Benzyl (3R*,4R*)-4-(acetyloxy)-3-({[(tert-butoxy)carbonyl]amino}methyl)-3-
(prop-2-en-1-yl)piperidine-1-carboxylate 
 
N
Cbz
OAc NHBoc
171b  
 
According to General Procedure U, the alcohol derivative 167b (0.34 g, 0.84 
mmol) gave the acetyl derivative 171b (0.36 g, 95%) as a colourless oil, Rf 0.70 
(50:50 petrol−EtOAc); νmax/cm-1 3367, 2976, 2936, 1738, 1697, 1510, 1434, 
1365, 1232, 1160, 1036; δH (500 MHz, CD3OD, 333 K) 7.38-7.26 (5H, m, 
phenyl), 5.93-5.78 (1H, m, propenyl 2-H), 5.12 (2H, s, phenylmethyl 1-H2), 5.05 
(1H, app. d, J 10.2, propenyl 3-Hcis), 5.04 (1H, app. d, J 17.2, propenyl 3-Htrans), 
4.85 (1H, dd, J 8.3 and 4.0, 4-H), 3.71 (1H, app. br. s, 6-HA), 3.57 (1H, d, J 
13.9, 2-HA), 3.35 (1H, app. br. s, 6-HB), 3.16 (1H, d, J 13.9, 2-HB), 3.13 (1H, d, J 
15.1, methylcarbamate 1-HA), 3.03 (1H, d, J 15.1, methylcarbamate 1-HB), 2.22-
2.08 (2H, m, propenyl 1-H2), 2.05 (3H, s, acetyl), 1.96-1.86 (1H, m, 5-HA), 1.75-
1.66 (1H, m, 5-HB), 1.42 (9H, s, tBu); δC (125 MHz, CD3OD, 333 K) 172.1 (acetyl 
C=O), 158.2 (Boc C=O), 157.2 (Cbz C=O), 138.0 (phenyl C-1), 134.5 (propenyl 
C-2), 129.5 (phenyl C2-3,5), 129.1 (phenyl C2-2,6), 129.0 (phenyl C-4), 118.8 
(propenyl C-3), 80.3 (tBu C1), 73.2 (C-4), 68.6 (phenylmethyl C-1), 48.6 (C-2), 
43.6 (C-6), 42.9 (C-3), 42.2 (methylcarbamate C-1), 35.3 (propenyl C-1), 28.8 
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(tBu C3), 27.1 (C-5), 21.0 (acetyl CH3); HRMS found MNa+, 469.2304. 
C24H34N2O6 requires MNa, 469.2309. 
 
(1R*,2S*)-2-({[(tert-Butoxy)carbonyl]amino}methyl)-6-methoxy-2-(prop-2-en 
-1-yl)-2,3-dihydro-1H-inden-1-yl acetate 
 
MeO NHBoc
OAc
171c  
 
According to General Procedure U, the alcohol derivative 167c (0.63 g, 1.89 
mmol) gave the acetyl derivative 171c (0.70 g, 99%) as a pale-yellow oil, Rf 
0.50 (70:30 petrol−EtOAc); νmax/cm-1 3376, 2976, 2930, 1712, 1493, 1366, 
1233, 1163, 1029; δH (400 MHz, CDCl3) 7.08 (1H, d, J 8.9, 4-H), 6.81 (2H, app. 
d, J 6.3, 5-H and 7-H), 6.04 (1H, s, 1-H), 5.86 (1H, ddt, J 16.6, 10.4 and 7.4, 
propenyl 2-H), 5.06 (1H, d, J 16.6, propenyl 3-Htrans), 5.05 (1H, d, J 10.4, 
propenyl 3-Hcis), 4.96 (1H, app. t, J 7.5, NH), 3.78 (3H, s, methoxy), 3.27 (1H, 
dd, J 14.2 and 6.9, methylcarbamate 1-HA), 3.11 (1H, dd, J 14.2 and 6.2, 
methylcarbamate 1-HB), 2.86 (1H, d, J 15.9, 3-HA), 2.67 (1H, d, J 15.9, 3-HB), 
2.21 (2H, app. d, J 7.4, propenyl 1-H2), 2.13 (3H, s, acetyl), 1.42 (9H, s, tBu); δC 
(100 MHz, CDCl3) 171.4 (acetyl C=O), 159.1 (C-6), 156.3 (Boc C=O), 141.5 (C-
7a), 134.4 (propenyl C-2), 133.5 (C-3a), 125.7 (C-4), 118.2 (propenyl C-3), 
115.5 (C-5), 110.1 (C-7), 80.5 (C-1), 79.4 (tBu C1), 55.6 (methoxy), 51.8 (C-2), 
45.5 (methylcarbamate C-1), 38.2 (C-3), 36.5 (propenyl C-1), 28.5 (tBu C3), 21.2 
(acetyl CH3); HRMS found MNa+, 398.1934. C21H29NO5 requires MNa, 
398.1937. 
 
(3R*,4S*)-4-({[(tert-Butoxy)carbonyl]amino}methyl)-4-(prop-2-en-1-yl) 
oxolan-3-yl acetate 
O
OAc NHBoc
171d  
 
According to General Procedure U, the alcohol derivative 167d (1.76 g, 6.83 
mmol) gave the acetyl derivative 171d (1.95 g, 95%) as a yellow oil, Rf 0.52 
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(50:50 petrol−EtOAc); νmax/cm-1 3254, 3139, 2974, 2938, 2874, 1737, 1704, 
1449, 1395, 1366, 1352, 1249, 1233, 1223, 1162, 1131, 1082, 1020; δH (400 
MHz, CDCl3) 5.72 (1H, ddt, J 17.3, 10.0 and 7.4, propenyl 2-H), 5.18-5.04 (3H, 
m, 3-H and propenyl 3-H2), 4.91 (1H, app. t, J 5.0, NH), 4.25 (1H, dd, J 10.6 
and 5.6, 2-HA), 3.71 (1H, dd, J 10.6 and 2.9, 2-HB), 3.68 (1H, d, J 9.0, 5-HA), 
3.61 (1H, d, J 9.0, 5-HB), 3.21 (1H, dd, J 14.2 and 6.4, methylcarbamate 1-HA), 
3.13 (1H, dd, J 14.2 and 6.4, methylcarbamate 1-HB), 2.30-2.14 (2H, m, 
propenyl 1-H2), 2.08 (3H, s, acetyl), 1.43 (9H, s, tBu); δC (100 MHz, CDCl3) 
170.7 (acetyl C=O), 156.4 (Boc C=O), 133.9 (propenyl C-2), 118.7 (propenyl C-
3), 79.7 (tBu C1), 77.2 (C-3), 74.7 (C-5), 73.4 (C-2), 50.1 (C-4), 43.9 
(methylcarbamate C-1), 34.0 (propenyl C-1), 28.5 (tBu C3), 21.0 (acetyl CH3); 
HRMS found MNa+, 322.1621. C15H25NO5 requires MNa, 322.1624. 
 
tert-Butyl (5R*,10R*)-10-(acetyloxy)-3-hydroxy-7-oxa-2-azaspiro[4.5]decane 
-2-carboxylate 
172a
O
OAc NBoc
OH
 
 
According to General Procedure Q, the alkene derivative 171a (69.0 mg, 0.22 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 30:70→50:50 EtOAc−hexane to yield 
hemiaminals 172a (51.0 mg, 74%, dr 58:42 by 1H-NMR) as an amorphous 
colourless solid, Rf  0.53 and 0.33 (50:50 EtOAc−petrol); νmax/cm-1 3451, 2973, 
2861, 1739, 1694, 1389, 1365, 1233, 1160; δH (500 MHz, CD3OD, 333 K) 5.08-
4.99 (1H, m, 3-Hmajor), 4.95-4.86 (1H, m, 3-Hminor) 4.79-4.68 (2H, m, 10-H), 3.81-
3.63 (2H, m, 8-HA), 3.54-3.36 (6H, m, 8-HB, 6-HA and 1-HA), 3.30-3.09 (4H, m, 
6-HB and 1-HB), 2.02-1.91 (8H, m, acetyl and 4-HA), 1.83-1.68 (4H, m, 4-HB and 
9-HA), 1.64-1.54 (2H, m, 9-HB), 1.38 (18H, s, tBu); δC (125 MHz, CD3OD, 333 K) 
171.9 (acetyl 2C=O), 156.0 (Boc C=Omajor), 155.7 (Boc C=Ominor), 90.5 (C-
3major), 89.8 (C-3minor), 81.8 (tBu C1major), 81.7 (tBu C1minor), 74.5 (C-10major), 73.4 
(C-8major), 72.9 (C-10minor), 72.4 (C-8minor) 65.4 (C-6major), 64.7 (C-6minor) 52.3 (C-
1major), 50.6 (C-1minor), 46.1 (C2-5), 39.0 (C-4minor), 37.4 (C-4major), 30.1 (C-9major), 
29.5 (C-9minor), 28.6 (tBu 2C3), 20.8 (acetyl 2CH3); HRMS found MNa+, 
338.1575. C15H25NO6 requires MNa, 338.1579.  
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tert-Butyl (5R*, 10R*)-10-(acetyloxy)-7-oxa-2-azaspiro[4.5]decane-2-
carboxylate 
O
NBocOAc
173a  
 
By modification of an existing procedure,175 NaBH(OAc)3 (93.0 mg, 441 µmol) 
was added to a solution of the hemiaminals 172a (20.0 mg, 63.4 µmol) in AcOH 
(0.30 mL) at rt. The reaction mixture was stirred for 3 h at rt. Subsequently, a 
saturated aqueous solution of NaHCO3 (1 mL) and DCM (1 mL) were added. 
The phases were separated and the aqueous phase was extracted with DCM (4 
× 1 mL). The organic phases were combined, dried (MgSO4), filtered and 
concentrated under reduced pressure to give a crude product. The crude 
product was purified by flash column chromatography, eluting with 25:75 
EtOAc−hexane to yield the pyrrolidine derivative 173a (15.0 mg, 79%) as a 
colourless oil, Rf 0.47 (50:50 petrol−EtOAc); νmax/cm-1 2971, 2863, 1738, 1691, 
1398, 1364, 1234, 1172, 1145, 1103, 1090, 1071; δH (500 MHz, CDCl3, 323 K) 
4.91 (1H, dd, J 7.5 and 3.8, 10-H), 3.81 (1H, ddd, J 11.2, 7.0 and 3.9, 8-HA), 
3.65 (1H, d, J 11.5, 6-HA), 3.61 (1H, ddd, J 11.2, 7.4 and 3.7, 8-HB), 3.48-3.45 
(1H, m, 3-HA), 3.37-3.26 (1H, m, 3-HB), 3.34 (1H, d, J 11.5, 6-HB), 3.29 (1H, d, J 
11.3, 1-HA), 3.16 (1H, m, 1-HB), 2.08 (3H, s, acetyl), 1.94-1.86 (2H, m, 9-HA and 
4-HA), 1.84-1.78 (1H, m, 4-HB), 1.75-1.67 (1H, m, 9-HB), 1.46 (9H, s, tBu); δC 
(125 MHz, CDCl3, 323 K) 170.3 (acetyl C=O), 154.6 (Boc C=O), 79.6 (tBu C1), 
72.2 (C-10), 71.4 (C-6), 65.0 (C-8), 51.3 (C-1), 44.4 (C2-3,5), 29.2 (C-9), 28.7 
(C-4 and tBu C3), 21.1 (acetyl CH3); HRMS found MH+, 300.1805. C15H25NO5 
requires MH, 300.1805. 
 
7-Benzyl 2-tert-butyl (5R*,10S*)-10-(acetyloxy)-2,7-diazaspiro[4.5]decane-
2,7-dicarboxylate 
N
Cbz
OAc NBoc
173b  
According to General Procedure V, the alkene derivative 171b (0.10 g, 0.23 
mmol) gave a crude material. The crude material was purified by flash column 
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chromatography, eluting with 30:70 EtOAc−hexane to yield the pyrrolidine 
derivative 173b (61.0 mg, 61%) as a colourless oil, Rf 0.41 (50:50 
petrol−EtOAc); νmax/cm-1 2974, 2876, 1737, 1688, 1430, 1398, 1364, 1233, 
1211, 1145, 1101, 1059, 1041; δH (500 MHz, CD3OD, 333 K) 7.38-7.26 (5H, m, 
phenyl), 5.16 (1H, d, J 12.4, phenylmethyl 1-HA), 5.09 (1H, d, J 12.4, 
phenylmethyl 1-HB), 4.90 (1H, dd, J 7.1 and 3.7, 10-H), 3.61 (1H, ddd, J 12.5, 
7.7 and 4.2, 8-HA), 3.53 (1H, d, J 13.4, 6-HA), 3.52-3.47 (1H, m, 8-HB), 3.45-
3.40 (1H, m, 3-HA), 3.38 (1H, d, J 13.4, 6-HB), 3.35-3.27 (1H, m, 3-HB), 3.22 
(1H, d, J 11.2, 1-HA), 3.12 (1H, d, J 11.2, 1-HB), 2.06 (3H, s, acetyl), 1.93-1.84 
(1H, m, 4-HA), 1.82-1.74 (1H, m, 9-HA), 1.73-1.63 (2H, m, 4-HB and 9-HB), 1.43 
(9H, s, tBu); δC (125 MHz, CD3OD, 333 K) 171.9 (acetyl C=O), 157.1 (Boc 
C=O), 156.3 (Cbz C=O), 138.0 (phenyl C-1), 129.6 (phenyl C2-3,5), 129.1 
(phenyl C-4), 128.9 (phenyl C2-2,6), 81.1 (tBu C1), 73.9 (C-10), 68.6 
(phenylmethyl C-1), 52.6 (C-1), 49.2 (C-6), 47.5 (C-5), 45.4 (C-3), 41.6 (C-8), 
30.2 (C-4), 28.9 (C-9), 28.8 (tBu C3), 20.8 (acetyl CH3); HRMS found MNa+, 
455.2147. C23H32N2O6 requires MNa, 455.2152. 
 
tert-Butyl (2R*,3R*)-3-(acetyloxy)-5-methoxy-1,3-dihydrospiro[indene-2,3'-
pyrrolidine]-1'-carboxylate 
MeO
OAc
NBoc
173c  
 
According to General Procedure V, the alkene derivative 171c (0.10 g, 0.26 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 20:80 EtOAc−hexane to yield the pyrrolidine 
derivative 173c (49.0 mg, 51%) as a colourless oil, Rf 0.38 (70:30 
petrol−EtOAc); νmax/cm-1 2974, 2933, 1733, 1689, 1492, 1395, 1365, 1227, 
1163, 1144, 1118, 1100, 1020; δH (500 MHz, CD3OD, 333 K) 7.14 (1H, d, J 8.3, 
7-H), 6.92 (1H, d, J 2.5, 4-H), 6.86 (1H, dd, J 8.3 and 2.5, 6-H), 5.92 (1H, s, 3-
H), 3.76 (3H, s, methoxy), 3.50-3.37 (2H, m, 5'-H2), 3.33 (1H, d, J 11.0, 2'-HA), 
3.16 (1H, d, J 11.0, 2'-HB), 3.01 (1H, d, J 15.3, 1-HA), 2.77 (1H, d, J 15.3, 1-HB), 
2.15 (1H, app. dt, J 13.0 and 7.4, 4'-HA), 2.06 (3H, s, acetyl), 1.89 (1H, app. dt, 
J 13.0 and 6.8, 4'-HB), 1.44 (9H, s, tBu); δC (100 MHz, CD3OD, 333 K) 172.5 
(acetyl C=O), 160.7 (C-5), 156.5 (Boc C=O), 142.9 (C-3a), 136.1 (C-7a), 126.6 
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(C-7), 116.9 (C-6), 112.2 (C-4), 82.1 (C-3), 81.0 (tBu C1), 57.2 (C-2'), 56.0 
(methoxy), 55.0 (C-2), 46.3 (C-5'), 41.5 (C-1), 32.1 (C-4'), 28.8 (tBu C3), 20.8 
(acetyl CH3); HRMS found MNa+, 384.1779. C20H27NO5 requires MNa, 
384.1781. 
 
tert-Butyl (4R*,5S*)-4-(acetyloxy)-2-oxa-7-azaspiro[4.4]nonane-7-
carboxylate 
O
OAc
NBoc
173d  
 
According to General Procedure V, the alkene derivative 171d (0.25 g, 0.83 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 30:70 EtOAc−hexane to yield the pyrrolidine 
derivative 173d (0.18 g, 76%) as a colourless oil, Rf 0.42 (50:50 petrol−EtOAc); 
νmax/cm-1 2975, 2934, 2873, 1738, 1693, 1400, 1366, 1236, 1161, 1122; δH (500 
MHz, CD3OD, 333 K) 5.04 (1H, dd, J 4.9 and 2.1, 4-H), 4.09 (1H, dd, J 10.7 and 
4.9, 3-HA), 3.71 (1H, dd, J 10.7 and 2.1, 3-HB), 3.70 (1H, d, J 8.6, 1-HA), 3.67 
(1H, d, J 8.6, 1-HB), 3.40-3.34 (1H, m, 8-HA), 3.34-3.28 (1H, m, 8-HB), 3.28-3.22 
(2H, m, 6-H2), 2.04 (3H, s, acetyl), 2.03-2.01 (1H, m, 9-HA), 1.81 (1H, ddd, J 
13.6, 8.0 and 6.1, 9-HB), 1.42 (9H, s, tBu); δC (125 MHz, CD3OD, 333 K) 172.1 
(acetyl C=O), 156.3 (Boc C=O), 81.1 (tBu C1), 78.9 (C-4), 75.9 (C-1), 74.2 (C-3), 
55.5 (C-6), 54.0 (C-5), 46.1 (C-8), 28.8 (C-9 and tBu C3), 20.6 (acetyl CH3); 
HRMS found MNa+, 308.1465. C14H23NO5 requires MNa, 308.1468. 
 
tert-Butyl 9-benzoyl-10-oxo-6-oxa-2,9-diazaspiro[4.5]decane-2-carboxylate 
 
BzN
O
NBocO
173e  
 
According to General Procedure V, the alkene derivative 148h (0.20 g, 0.53 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 20:80 EtOAc−hexane to yield the pyrrolidine 
derivative 173e (94.0 mg, 49%) as a colourless oil, Rf 0.63 (50:50 
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petrol−EtOAc); νmax/cm-1 2974, 2888, 1682, 1394, 1366, 1313, 1279, 1234, 
1172, 1132, 1100, 1082; δH (500 MHz, CD3OD, 333 K) 7.57-7.53 (2H, m, phenyl 
2,6-H2), 7.50 (1H, tt, J 7.2 and 1.6, phenyl 4-H), 7.41 (2H, td, J 7.2 and 1.6, 
phenyl 3,5-H2), 4.13-4.01 (2H, m, 7-H2), 3.99-3.86 (2H, m, 8-H2), 3.69 (2H, app. 
s, 1-H2), 3.54 (1H, ddd, J 10.5, 8.5 and 3.5, 3-HA), 3.47 (1H, ddd, J 10.5, 8.9 
and 7.5, 3-HB), 2.43-2.35 (1H, m, 4-HA), 2.35-2.26 (1H, m, 4-HB), 1.46 (9H, s, 
tBu); δC (125 MHz, CD3OD, 333 K) 174.6 (C-10), 173.3 (benzoyl C=O), 156.2 
(Boc C=O), 136.9 (phenyl C-1), 132.9 (phenyl C-4), 129.3 (phenyl C2-3,5), 
129.0 (phenyl C2-2,6), 81.3 (C-5), 81.1 (tBu C1), 61.4 (C-7), 56.6 (C-1), 46.8 (C-
8), 45.9 (C-3), 36.6 (C-4), 28.8 (tBu C3); HRMS found MNa+, 383.1575. 
C19H24N2O5 requires MNa, 383.1577. 
 
tert-Butyl (5R*, 10R*)-10-(acetyloxy)-3-oxo-7-oxa-2-azaspiro[4.5]decane-2-
carboxylate 
O
NBocOAc
174a
O
 
 
Pyridinium dichromate (47.4 mg, 0.126 mmol) and celite (20 mg) were added to 
a solution of the hemiaminals 172a (20.0 mg, 63.4 µmol) in DCM (1.00 mL) at 
rt. The reaction mixture was stirred for 1 week at rt. Subsequently, the mixture 
was filtered through celite and concentrated under reduced pressure to give a 
crude product. The crude product was purified by flash column 
chromatography, eluting with 40:60 EtOAc−hexane to yield the pyrrolidine 
derivative 174a (13.0 mg, 65%) as a colourless oil, Rf 0.30 (50:50 
petrol−EtOAc); νmax/cm-1 2975, 2933, 2857, 1785, 1738, 1711, 1367, 1310, 
1230, 1147, 1093, 1044, 1025; δH (500 MHz, CDCl3) 4.90 (1H, dd, J 8.8 and 
4.2, 10-H), 3.88 (1H, app. dt, J 12.0 and 4.7, 8-HA), 3.70 (1H, d, J 11.6, 6-HA), 
3.57 (1H, ddd, J 12.0, 9.0 and 3.3, 8-HB), 3.49 (2H, app. s, 1-H2), 3.36 (1H, d, J 
11.6, 6-HB), 2.68 (1H, d, J 17.9, 4-HA), 2.49 (1H, d, J 17.9, 4-HB), 2.09 (3H, s, 
acetyl), 1.90 (1H, app. dq, J 13.0 and 4.0, 9-HA), 1.68 (1H, app dtd, J 13.9, 9.3 
and 4.5, 9-HB), 1.52 (9H, s, tBu); δC (125 MHz, CDCl3) 171.9 (C-3), 170.3 
(acetyl C=O), 149.9 (Boc C=O), 83.5 (tBu C1), 72.3 (C2-6,10), 65.3 (C-8), 51.0 
(C-1), 38.6 (C-5), 37.9 (C-4), 28.7 (C-9), 28.1 (tBu C3), 21.1 (acetyl CH3); HRMS 
found MH+, 314.1598. C15H23NO6 requires MH, 314.1598. 
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7-Benzyl 2-tert-butyl (5R*,10S*)-10-(acetyloxy)-3-oxo-2,7-diazaspiro[4.5] 
decane-2,7-dicarboxylate 
N
Cbz
OAc NBoc
O
174b  
 
According to General Procedure W, the alkene derivative 171b (0.20 g, 0.45 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 35:65 EtOAc−hexane to yield the pyrrolidine 
derivative 174b (0.12 g, 60%) as a colourless oil, Rf 0.42 (50:50 petrol−EtOAc); 
νmax/cm-1 2978, 1785, 1738, 1696, 1432, 1367, 1315, 1229, 1148, 1104, 1041; 
δH (500 MHz, CD3OD, 333 K) 7.37-7.27 (5H, m, phenyl), 5.15 (1H, d, J 12.3, 
phenylmethyl 1-HA), 5.12 (1H, d, J 12.3, phenylmethyl 1-HB), 4.97 (1H, dd, J 8.4 
and 3.9, 10-H), 3.80-3.75 (1H, m, 8-HA), 3.73 (1H, dd, J 13.6 and 1.5, 6-HA), 
3.58 (1H, d, J 11.2, 1-HA), 3.53 (1H, d, J 11.2, 1-HB), 3.39-3.34 (1H, m, 8-HB), 
3.32 (1H, d, J 13.6, 6-HB), 2.63 (1H, d, J 17.7, 4-HA), 2.33 (1H, d, J 17.7, 4-HB), 
2.04 (3H, s, acetyl), 1.83 (1H, app. ddt, J 14.0, 6.4 and 3.9, 9-HA), 1.67 (1H, dtd, 
J 14.0, 8.4 and 4.4, 9-HB), 1.49 (9H, s, tBu); δC (125 MHz, CD3OD, 333 K) 174.1 
(C-3), 171.7 (acetyl C=O), 157.1 (Boc C=O), 151.3 (Cbz C=O), 137.9 (phenyl 
C-1), 129.6 (phenyl C2-3,5), 129.2 (phenyl C-4), 128.9 (phenyl C2-2,6), 84.5 (tBu 
C1), 74.7 (C-10), 68.7 (phenylmethyl C-1), 53.3 (C-1), 50.2 (C-6), 41.9 (C-8), 
40.3 (C-5), 39.4 (C-4), 28.3 (C-9), 28.2 (tBu C3) 20.7 (acetyl CH3); HRMS found 
MNa+, 469.1942. C23H30N2O7 requires MNa, 469.1945. 
 
tert-Butyl (2R*,3R*)-3-(acetyloxy)-5-methoxy-5'-oxo-1,3-dihydrospiro 
[indene-2,3'-pyrrolidine]-1'-carboxylate 
 
MeO
OAc
NBoc
O
174c  
 
According to General Procedure W, the alkene derivative 171c (0.10 g, 0.26 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 25:75 EtOAc−hexane to yield the pyrrolidine 
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derivative 174c (37.0 mg, 37%) as a colourless oil, Rf 0.48 (50:50 
petrol−EtOAc); νmax/cm-1 2978, 2934, 1784, 1737, 1715, 1492, 1367, 1310, 
1224, 1150, 1022; δH (400 MHz, CDCl3, 323 K) 7.13 (1H, d, J 8.3, 7-H), 6.91 
(1H, d, J 2.6, 4-H), 6.85 (1H, dd, J 8.3 and 2.6, 6-H), 6.00 (1H, s, 3-H), 3.78 
(3H, s, methoxy), 3.76 (1H, d, J 11.0, 2'-HA), 3.57 (1H, d, J 11.0, 2'-HB), 3.06 
(1H, d, J 15.3, 1-HA), 2.90 (1H, d, J 15.3, 1-HB), 2.83 (1H, d, J 17.4, 4'-HA), 2.44 
(1H, d, J 17.4, 4'-HB), 2.08 (3H, s, acetyl), 1.51 (9H, s, tBu); δC (100 MHz, 
CDCl3, 323 K) 172.1 (C-5'), 170.7 (acetyl C=O), 159.7 (C-5), 150.0 (Boc C=O), 
141.1 (C-3a), 133.1 (C-7a), 125.9 (C-7), 116.2 (C-6), 111.1 (C-4), 83.2 (tBu C1), 
81.1 (C-3), 56.2 (C-2'), 55.7 (methoxy), 47.5 (C-2), 41.8 (C-1), 40.4 (C-4'), 28.2 
(tBu C3), 20.9 (acetyl CH3); HRMS found MNa+, 398.1583. C20H25NO6 requires 
MNa, 398.1574. 
 
tert-Butyl (4R*,5S*)-4-(acetyloxy)-8-oxo-2-oxa-7-azaspiro[4.4]nonane-7-
carboxylate 
O
OAc
NBoc
O
174d  
 
According to General Procedure W, the alkene derivative 171d (0.25 g, 0.83 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 40:60→60:40 EtOAc−hexane to yield the 
pyrrolidine derivative 174d (0.19 g, 76%) as a yellow oil, Rf 0.34 (40:60 
petrol−EtOAc); νmax/cm-1 2977, 2933, 2873, 1786, 1737, 1699, 1389, 1366, 
1311, 1230, 1151, 1104, 1062, 1047, 1023; δH (500 MHz, CD3OD, 333 K) 5.15 
(1H, dd, J 5.3 and 2.7, 4-H), 4.20 (1H, dd, J 10.8 and 5.3, 3-HA), 3.86 (1H, d, J 
8.7, 1-HA), 3.75 (1H, dd, J 10.8 and 2.7, 3-HB), 3.73 (1H, d, J 11.0, 6-HA), 3.72 
(1H, d, J 8.7, 1-HB), 3.68 (1H, d, J 11.0, 6-HB), 2.78 (1H, d, J 17.8, 9-HA), 2.48 
(1H, d, J 17.8, 9-HB), 2.08 (3H, s, acetyl), 1.52 (9H, s, tBu); δC (125 MHz, 
CD3OD, 333 K) 174.1 (C-8), 172.0 (acetyl C=O), 151.3 (Boc C=O), 84.5 (tBu 
C1), 79.4 (C-4), 76.2 (C-1), 73.7 (C-3), 55.7 (C-6), 46.7 (C-5), 37.2 (C-9), 28.3 
(tBu C3), 20.6 (acetyl CH3); HRMS found MNa+, 322.1257. C14H21NO6 requires 
MNa, 322.1261. 
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tert-Butyl (5R*,10R*)-10-(acetyloxy)-3-methoxy-7-oxa-2-azaspiro[4.5] 
decane-2-carboxylate 
O
NBocOAc
OMe
175  
 
According to General Procedure P, the hemiaminals 172a (0.15 g, 0.48 mmol) 
gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 20:80 EtOAc−hexane to yield the aminals 175 
(0.12 g, 77%, dr 77:23 by 1H-NMR) as a colourless oil, Rf 0.33 (50:50 
petrol−EtOAc); νmax/cm-1 2973, 2934, 2859, 1740, 1697, 1390, 1366, 1234, 
1164, 1068; δH (500 MHz, CD3OD, 333 K) 5.16 (1H, app. d, J 6.3, 3-Hminor), 
5.13 (1H, app. d, J 5.7, 3-Hmajor), 4.99 (1H, dd, J 5.5 and 3.5, 10-Hminor), 4.85 
(1H, dd, J 7.6 and 3.8, 10-Hmajor), 3.94 (1H, d, J 11.5, 6-HAminor) 3.83 (1H, d, J 
11.5, 6-HAmajor), 3.79 (2H, ddd, J 11.2, 7.0 and 3.9, 8-HA), 3.62-3.59 (2H, m, 8-
HB), 3.57 (1H, d, J 11.5, 6-HBmajor), 3.54 (2H, d, J 11.6, 1-HA), 3.47 (1H, d, J 
11.5, 6-HBminor), 3.33-3.27 (8H, m, 1-HB and methoxy 1-H3), 2.08 (3H, s, acetyl 
1-H3minor), 2.05 (3H, s, acetyl 1-H3major), 2.00 (2H, dd, J 13.8 and 5.7, 4-HA), 1.91 
(2H, app. d, J 13.8, 4-HB), 1.86-1.80 (2H, m, 9-HA), 1.73-1.64 (2H, m, 9-HB), 
1.49 (9H, s, tBuminor), 1.48 (9H, s, tBumajor); δC (125 MHz, CD3OD, 333 K) 172.0 
(acetyl C=Omajor), 171.9 (acetyl C=Ominor) 156.0 (Boc 2C=O), 90.7 (C-3major), 
89.9 (C-3minor), 81.8 (tBu 2C1), 74.5 (C-10major), 73.4 (C-6major), 72.9 (C-10minor), 
72.4 (C-6minor), 65.4 (C-8major), 64.6 (C-8minor), 56.0 (methoxy C-1major), 55.7 
(methoxy C-1minor), 52.4 (C2-1), 46.3 (C2-5), 37.3 (C2-4), 30.1 (C-9major), 29.5 (C-
9minor), 28.6 (tBu 2C3), 20.8 (acetyl 2CH3); HRMS found MNa+, 352.1740. 
C16H27NO6 requires MNa, 352.1730. 
 
tert-Butyl (5R*,10R*)-10-(acetyloxy)-3-phenyl-7-oxa-2-azaspiro[4.5]decane-
2-carboxylate 
O
NHOAc
176  
 
According to an existing procedure,166 PhMgBr (0.75 mL, 0.75 mmol of a 1.0 M 
solution in THF) was added dropwise to a suspension of CuBr•Me2S (0.15 g, 
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0.75 mmol) in Et2O (1.50 mL) at –40 °C. The suspension was stirred at –40 °C 
for 1 h and Subsequently it was cooled to –78 °C. Subsequently, Et2O•BF3 
(92.6 µL, 0.75 mmol) and a solution of the aminals 175 (0.10 g, 0,30 mmol) in 
Et2O (0.50 mL) were added and the reaction mixture was warmed to 0 °C. The 
reaction was stirred at 0 °C for 18 h. Subsequently, it was warmed to rt, a 
saturated aqueous solution of NH4Cl (2 mL) and EtOAc (2 mL) were added, the 
phases were separated and the aqueous phase was extracted with EtOAc (4 × 
2 mL). The organic phases were combined, washed with brine (4 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure to give a crude 
product. The crude product (dr 50:50 by 1H-NMR) was purified by flash column 
chromatography, eluting with 20:80 EtOAc−hexane to yield the phenyl 
derivative 176 (0.10 g, 88%, dr 57:43 by 1H-NMR) as a colourless oil, Rf 0.56 
(50:50 petrol−EtOAc); νmax/cm-1 3504, 2972, 2930, 2859, 1738, 1688, 1392, 
1363, 1234, 1159, 1090, 1070; δH (500 MHz, CD3OD, 333 K) 7.24-7.16 (5H, m, 
phenylminor), 7.14-7.05 (5H, m phenylmajor), 4.91 (1H, dd, J 7.4 and 3.9, 10-
Hminor), 4.87-4.78 (1H, m, 10-Hmajor), 4.80-4.73 (1H, m, 3-Hminor) 4.66 (1H, app. t, 
J 8.4, 3-Hmajor), 3.70 (2H, ddd, J 11.3, 7.5 and 3.7, 8-HA), 3.60 (2H, d, J 11.5, 6-
HA), 3.56 (2H, ddd, J 11.3, 6.7 and 4.1, 8-HB), 3.45 (2H, d, J 12.0, 1-HA), 3.35 
(2H, d, J 12.0, 1-HB), 3.29 (2H, J 11.5, 6-HB), 2.46 (1H, app. dd, J 13.5 and 8.5, 
4-HAminor), 2.28 (1H, ddd, J 13.5, 8.0 and 1.3, 4-HAmajor), 2.00 (3H, s, acetylminor), 
1.91 (3H, s, acetylmajor), 1.86-1.79 (1H, m, 9-HAminor), 1.79-1.71 (2H, m, 4-HBmajor 
and 9-HAmajor), 1.70-1.62 (2H, m, 4-HBminor and 9-HBminor), 1.58 (1H, app. dtd, J 
13.8, 6.7 and 3.7, 9-HBmajor); δC (125 MHz, CD3OD, 333 K) 172.0 (C=Ominor), 
171.8 (C=Omajor), 156.3 (phenyl C-1major), 156.1 (phenyl C-1minor), 129.4 (phenyl 
C2-4), 127.8 (phenyl C2-3,5major), 127.7 (phenyl C2-3,5minor), 126.6 (phenyl C2-
2,6minor), 126.5 (phenyl C2-2,6major), 73.5 (C-6minor), 73.1 (C2-10), 71.4 (C-6major), 
65.7 (C-8minor), 65.5 (C-8major), 62.4 (C-3major), 61.6 (C-3minor), 55.3 (C-1major), 
53.1 (C-10minor), 46.9 (C-5major), 46.6 (C-5minor), 41.4 (C-4major), 41.2 (C-4minor), 
30.2 (C-9major), 29.7 (C-9minor), 20.9 (acetyl CH3minor) 20.7 (acetyl CH3major); 
HRMS found MH+, 276.1594. C16H21NO3 requires MH, 276.1594. 
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(3R*,4R*)-3-({[(tert-Butoxy)carbonyl]amino}methyl)-3-(3-hydroxypropyl) 
oxan-4-yl acetate 
O
OAc NHBoc
177a
OH
 
 
According to General Procedure L, the alkene derivative 171a (0.22 g, 0.69 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 60:40 EtOAc−hexane to yield the alcohol 
derivative 177a (0.17 g, 73%) as a light-yellow oil, Rf 0.13 (50:50 petrol−EtOAc); 
νmax/cm-1 3364, 2960, 2865, 1712, 1514, 1365, 1237, 1165, 1083, 1048, 1027; 
δH (400 MHz, CDCl3) 5.05 (1H, app. t, J 6.9, NH), 4.95 (1H, app. t, J 6.4, 4-H), 
3.81 (1H, app. dt, J 10.7 and 5.0, 6-HA), 3.67-3.58 (3H, m, 2-HA and 
hydroxypropyl 3-H2), 3.54 (1H, app. dt, J 12.0 and 6.3, 6-HB), 3.28 (1H, dd, J 
14.4 and 7.9, methylcarbamate 1-HA), 3.21 (1H, d, J 12.0, 2-HB), 2.94 (1H, dd, J 
14.4 and 5.6, methylcarbamate 1-HB), 2.07 (3H, s, acetyl), 1.98 (1H, br. s, OH), 
1.82 (2H, app. q, J 5.9, 5-H2), 1.65-1.32 (4H, m, hydroxypropyl 1,2-H4), 1.41 
(9H, s, tBu); δC (100 MHz, CDCl3) 170.9 (acetyl C=O), 156.5 (Boc C=O), 79.5 
(tBu C1), 71.5 (C-4), 70.1 (C-2), 65.4 (C-6), 62.9 (hydroxypropyl C-3), 41.7 
(methylcarbamate C-1), 41.3 (C-3), 28.4 (tBu C3), 27.4 (C-5), 25.7 
(hydroxypropyl C-2), 24.6 (hydroxypropyl C-1), 21.2 (acetyl CH3); HRMS found 
MH+, 332.2072. C16H29NO6 requires MH, 332.2067. 
 
Benzyl (3R*,4R*)-4-(acetyloxy)-3-({[(tert-butoxy)carbonyl]amino}methyl)-3-
(3-hydroxypropyl)piperidine-1-carboxylate 
 
N
Cbz
OAc
OH
NHBoc
177b  
 
According to General Procedure L, the alkene derivative 171b (0.25 g, 0.55 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 60:40 EtOAc−hexane to yield the alcohol 
derivative 177b (0.22 g, 86%) as a colourless oil, Rf 0.38 (20:80 petrol−EtOAc); 
νmax/cm-1 3400, 2937, 2872, 2508, 1681, 1433, 1365, 1235, 1157, 1035; δH (500 
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MHz, CD3OD, 333 K) 7.38-7.28 (5H, m, phenyl), 5.12 (2H, s, phenylmethyl 1-
H2), 4.87 (1H, dd, J 8.1 and 3.8, 4-H), 3.68 (1H, app. br. s, 6-HA), 3.53 (1H, app. 
br. s, 2-HA), 3.53-3.40 (2H, m, hydroxypropyl 3-H2), 3.38 (1H, app. br. s, 6-HB), 
3.18 (2H, d, J 14.7, 2-HB and methylcarbamate 1-HA), 3.03 (1H, d, J 14.7, 
methylcarbamate 1-HB), 2.05 (3H, s, acetyl), 1.95-1.86 (1H, m, 5-HA), 1.76-1.63 
(1H, m, 5-HB), 1.61-1.53 (1H, m, hydroxypropyl 2-HA), 1.53-1.44 (2H, m, 
hydroxypropyl 2-HB and hydroxypropyl 1-HA), 1.42 (9H, s, tBu), 1.40-1.32 (1H, 
m, hydroxypropyl 1-HB); δC (125 MHz, CD3OD, 333 K) 172.2 (acetyl C=O), 
158.3 (Boc C=O), 157.2 (Cbz C=O), 138.1 (phenyl C-1), 129.5 (phenyl C2-3,5), 
129.1 (phenyl C2-2,6), 129.0 (phenyl C-4), 80.3 (tBu C1), 73.5 (C-4), 68.5 
(phenylmethyl C-1), 63.6 (hydroxypropyl C-3), 48.7 (C-2), 43.1 
(methylcarbamate C-1), 42.5 (C-6), 42.2 (C-3), 28.8 (tBu C3), 27.2 
(hydroxypropyl C-1), 27.0 (hydroxypropyl C-2), 21.0 (acetyl CH3); HRMS found 
MNa+, 487.2411. C24H36N2O7 requires MNa, 487.2420. 
 
(1R*,2S*)-2-({[(tert-Butoxy)carbonyl]amino}methyl)-2-(3-hydroxypropyl)-6-
methoxy-2,3-dihydro-1H-inden-1-yl acetate 
 
MeO NHBoc
OAc
OH177c  
 
According to General Procedure L, the alkene derivative 171c (0.20 g, 0.53 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 50:50 EtOAc−hexane to yield the alcohol 
derivative 177c (0.17 g, 83%) as a colourless oil, Rf 0.36 (30:70 petrol−EtOAc); 
νmax/cm-1 3376, 3270, 3145, 2937, 2873, 1705, 1493, 1394, 1368, 1234, 1167, 
1144, 1121, 1008; δH (400 MHz, CDCl3) 7.08 (1H, d, J 8.1, 4-H), 6.81 (2H, app. 
d, J 7.6, 5-H and 7-H), 5.97 (1H, s, 1-H), 5.06 (1H, app. t, J 7.0, NH), 3.77 (3H, 
s, methoxy), 3.67-3.51 (2H, m, hydroxypropyl 3-H2), 3.24-3.04 (2H, m, 
methylcarbamate 1-H2), 2.83 (1H, d, J 15.8, 3-HA), 2.65 (1H, d, J 15.8, 3-HB), 
2.11 (3H, s, acetyl), 1.87 (1H, br. s, OH), 1.63-1.49 (4H, m, hydroxypropyl 1,2-
H4), 1.41 (9H, s, tBu); δC (100 MHz, CDCl3) 171.5 (acetyl C=O), 159.1 (C-6), 
156.7 (Boc C=O), 141.6 (C-7a), 133.7 (C-3a), 125.7 (C-4), 115.6 (C-5), 110.3 
(C-7), 80.6 (C-1), 79.6 (tBu C1), 63.2 (hydroxypropyl C-3), 55.6 (methoxy), 51.7 
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(C-2), 45.0 (methylcarbamate C-1), 38.7 (C-3), 28.5 (tBu C3), 27.6 
(hydroxypropyl C-1), 27.3 (hydroxypropyl C-2), 21.3 (acetyl CH3); HRMS found 
MNa+, 416.2049. C21H31NO6 requires MNa, 416.2043. 
 
(3R*,4S*)-4-({[(tert-Butoxy)carbonyl]amino}methyl)-4-(3-hydroxypropyl) 
oxolan-3-yl acetate 
O
OAc NHBoc
OH
177d  
 
According to General Procedure L, the alkene derivative 171d (0.25 g, 0.83 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 60:40 EtOAc−hexane to yield the alcohol 
derivative 177d (0.11 g, 41%) as a colourless oil, Rf 0.52 (EtOAc); νmax/cm-1 
3365, 2972, 2932, 2873, 1712, 1689, 1526, 1365, 1242, 1164, 1035, 1004; δH 
(400 MHz, CDCl3) 4.86 (1H, br. s, NH), 4.15 (1H, dd, J 9.5 and 5.7, 2-HA), 4.12-
4.02 (3H, m, 2-HB and hydroxypropyl 3-H2), 3.65 (1H, dd, J 9.5 and 3.6, 3-H), 
3.61 (1H, d, J 8.9, 5-HA), 3.56 (1H, d, J 8.9, 5-HB), 3.10 (2H, app. d, J 6.5, 
methylcarbamate 1-H2), 2.56 (1H, br. s, OH), 2.04 (3H, s, acetyl), 1.77-1.47 
(4H, m, hydroxypropyl 1-H2 and hydroxypropyl 2-H2), 1.42 (9H, s, tBu); δC (100 
MHz, CDCl3) 171.3 (acetyl C=O), 156.7 (Boc C=O), 79.9 (tBu C1), 75.5 (C-3), 
74.7 (C-2), 74.1 (C-5), 65.0 (hydroxypropyl C-3), 50.1 (C-4), 43.5 
(methylcarbamate C-1), 28.5 (tBu C3), 24.5 (hydroxypropyl C-2), 23.9 
(hydroxypropyl C-1), 21.1 (acetyl CH3); HRMS found MNa+, 340.1727. 
C15H27NO6 requires MNa, 340.1730. 
 
tert-Butyl N-{[2-(3-hydroxypropyl)-3-oxomorpholin-2-yl]methyl}carbamate 
 
HN
O
O
OH
NHBoc
177e  
 
According to General Procedure L, the alkene derivative 148h (0.20 g, 0.53 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with EtOAc to yield the alcohol derivative 177e (0.11 g, 
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71%) as a pale oil, Rf 0.20 (10:90 MeOH−EtOAc); νmax/cm-1 3307, 2974, 2932, 
2876, 1696, 1660, 1509, 1484, 1365, 1340, 1269, 1248, 1163, 1124, 1063; δH 
(400 MHz, CDCl3) 7.20 (1H, br. s, 4-H), 5.12 (1H, app. t, J 5.0, 
methylcarbamate NH), 3.96-3.78 (2H, m, 6-H2), 3.65-3.49 (3H, m, 
hydroxypropyl 3-H2 and methylcarbamate 1-HA), 3.49-3.40 (1H, m, 5-HA), 3.40-
3.28 (2H, m, 5-HB and methylcarbamate 1-HB), 2.54 (1H, br. s, OH), 2.00-1.85 
(1H, m, hydroxypropyl 1-HA), 1.79-1.64 (2H, m, hydroxypropyl 1-HB and 
hydroxypropyl 2-HA), 1.63-1.51 (1H, m, hydroxypropyl 2-HB), 1.42 (9H, s, tBu); 
δC (100 MHz, CDCl3) 172.8 (C-3), 156.2 (Boc C=O), 80.9 (tBu C1), 79.5 (C-2), 
62.5 (hydroxypropyl C-3), 59.5 (C-6), 44.9 (C-5), 42.2 (methylcarbamate C-1), 
31.3 (hydroxypropyl C-2), 28.5 (tBu C3), 26.6 (hydroxypropyl C-1); HRMS found 
MNa+, 311.1574. C13H24N2O5 requires MNa, 311.1577. 
 
tert-Butyl (5R*, 6R*)-5-(acetyloxy)-2-oxa-8-azaspiro[5.5]undecane-8-
carboxylate 
O
OAc
179a
Boc
N
 
 
According to General Procedure X, the alcohol derivative 177a (0.10 g, 0.30 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 20:80 EtOAc−hexane to yield the piperidine 
derivative 179a (54.0 mg, 57%) as a colourless oil, Rf 0.59 (50:50 
petrol−EtOAc); νmax/cm-1 2936, 2857, 1737, 1687, 1423, 1365, 1274, 1234, 
1160, 1141, 1090, 1040; δH (500 MHz, CDCl3, 323 K) 4.89 (1H, dd, J 6.2 and 
3.7, 5-H), 3.71 (1H, ddd, J 12.1, 8.7 and 3.6, 3-HA), 3.65 (1H, app. t, J 5.1, 3-
HB), 3.62 (1H, d, J 12.0, 1-HA), 3.50 (1H, d, J 13.7, 7-HA), 3.42-3.34 (1H, m, 9-
HA), 3.32-3.28 (1H, m, 9-HB), 3.25 (1H, d, J 12.0, 1-HB), 3.24 (1H, d, J 13.7, 7-
HB), 2.05 (3H, s, acetyl), 2.03-1.98 (1H, m, 4-HA), 1.69-1.60 (1H, m, 4-HB), 1.53-
1.48 (3H, m, 10-H2 and 11-HA), 1.43 (9H, s, tBu), 1.42-1.38 (1H, m, 11-HB); δC 
(125 MHz, CDCl3, 323 K) 170.1 (acetyl C=O), 154.9 (Boc C=O), 79.7 (tBu C1), 
71.1 (C-5), 70.8 (C-1), 64.7 (C-3), 49.4 (C-7), 44.5 (C-9), 37.5 (C-6), 28.5 (tBu 
C3), 27.4 (C-4), 26.6 (C-10), 21.0 (acetyl CH3), 20.5 (C-11); HRMS found MNa+, 
336.1789. C16H27NO5 requires MNa, 336.1786. 
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2-Benzyl 8-tert-butyl (5R*,6S*)-5-(acetyloxy)-2,8-diazaspiro[5.5]undecane-
2,8-dicarboxylate 
N
Cbz
OAc
Boc
N
179b  
 
According to General Procedure X, the alcohol derivative 177b (50.0 mg, 0.12 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 30:70 EtOAc−hexane to yield the piperidine 
derivative 179b (19.0 mg, 40%) as a colourless oil, Rf 0.60 (50:50 
petrol−EtOAc); νmax/cm-1 2936, 2866, 1737, 1686, 1425, 1364, 1273, 1232, 
1205, 1154, 1108, 1038; δH (500 MHz, CD3OD, 333 K) 7.37-7.27 (5H, m, 
phenyl), 5.14 (1H, d, J 12.4, phenylmethyl 1-HA), 5.11 (1H, d, J 12.4, 
phenylmethyl 1-HB), 4.89 (1H, dd, J 6.8 and 3.6, 5-H), 3.63-3.44 (3H, m, 3-H2 
and 1-HA), 3.44-3.33 (4H, m, 9-H2, 1-HB and 7-HA), 3.19 (1H, d, J 12.9, 7-HB), 
2.06 (3H, s, acetyl), 1.99-1.90 (1H, m, 4-HA), 1.74-1.65 (1H, m, 4-HB), 1.64-1.58 
(1H, m, 11-HA), 1.57-1.47 (2H, m, 10-H2), 1.43 (9H, s, tBu), 1.41-1.36 (1H, m, 
11-HB); δC (125 MHz, CD3OD, 333 K) 171.9 (acetyl C=O), 157.1 (Boc C=O), 
156.5 (Cbz C=O), 138.1 (phenyl C-1), 129.5 (phenyl C2-3,5), 129.1 (phenyl C2-
2,6), 129.0 (phenyl C-4), 81.3 (tBu C1), 72.7 (C-5), 68.5 (phenylmethyl C-1), 
50.2 (C-7), 49.0 (C-1), 45.5 (C-9), 41.7 (C-3), 39.3 (C-6), 28.7 (tBu C3), 28.0 (C-
10), 27.2 (C-4), 21.7 (C-11), 20.8 (acetyl CH3); HRMS found MNa+, 469.2306. 
C24H34N2O6 requires MNa, 469.2314. 
 
tert-Butyl (2R*,3S*)-3-(acetyloxy)-5-methoxy-1,3-dihydrospiro[indene-2,3'-
piperidine]-1'-carboxylate 
MeO
OAc
NBoc
179c  
 
According to General Procedure X, the alcohol derivative 177c (50.0 mg, 0.13 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 10:90 EtOAc−hexane to yield the piperidine 
derivative 179c (6.00 mg, 13%) as a colourless oil, Rf 0.50 (70:30 
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petrol−EtOAc); νmax/cm-1 2928, 2851, 1732, 1689, 1493, 1426, 1365, 1285, 
1234, 1152, 1018; δH (500 MHz, CDCl3, 323 K) 7.10 (1H, d, J 8.3, 7-H), 6.98 
(1H, d, J 2.5, 4-H), 6.84 (1H, dd, J 8.3 and 2.5, 6-H), 5.83 (1H, s, 3-H), 3.78 
(3H, s, methoxy), 3.60-3.48 (1H, m, 6'-HA), 3.32 (1H, ddd, J 12.8, 7.0 and 5.1, 
6'-HB), 3.25 (1H, d, J 13.2, 2'-HA), 3.15 (1H, d, J 13.2, 2'-HB), 2.81 (1H, d, J 
15.6, 1-HA), 2.66 (1H, d, J 15.6, 1-HB), 2.04 (3H, s, acetyl), 1.87-1.78 (1H, m, 4'-
HA), 1.69 (1H, app. dt, J 13.0 and 5.6, 4'-HB), 1.61-1.54 (2H, m, 5'-H2), 1.40 (9H, 
s, tBu); δC (100 MHz, CDCl3, 323 K) 170.8 (acetyl C=O), 159.3 (C-5), 155.0 
(Boc C=O), 141.7 (C-3a), 135.2 (C-7a), 125.9 (C-7), 116.3 (C-6), 111.7 (C-4), 
80.6 (C-3), 79.7 (tBu C1), 55.7 (methoxy), 51.8 (C-2'), 47.4 (C-2), 44.3 (C-6'), 
39.8 (C-1), 30.4 (C-4'), 28.6 (tBu C3), 22.9 (C-5'), 21.2 (acetyl CH3); HRMS 
found MNa+, 398.1935. C21H29NO5 requires MNa, 398.1937. 
 
tert-Butyl 5-oxo-1-oxa-4,8-diazaspiro[5.5]undecane-8-carboxylate 
 
HN
O
Boc
NO
179e  
 
According to General Procedure X, the alcohol derivative 177e (78.0 mg, 0.27 
mmol) gave a crude material. The crude material was purified by flash column 
chromatography, eluting with 60:40 EtOAc−hexane to yield the piperidine 
derivative 179e (42.0 mg, 57%) as a colourless oil, Rf 0.44 (EtOAc); νmax/cm-1 
3192, 3071, 2954, 2925, 1687, 1667, 1421, 1364, 1335, 1276, 1243, 1175, 
1150, 1107, 1086; δH (500 MHz, CD3OD, 333 K) 4.37 (1H, br. s, 4-H), 4.16 (1H, 
d, J 13.9, 7-HA), 3.95 (1H, app. d, J 12.3, 9-HA), 3.79 (1H, ddd, J 12.1, 8.5 and 
3.5, 2-HA), 3.72 (1H, app. br. s, 2-HB), 3.32 (1H, ddd, J 12.5, 8.5 and 4.2, 3-HA), 
3.26-3.15 (1H, m, 3-HB), 3.00 (1H, app. br. s, 7-HB), 2.69 (1H, app. br. s, 9-HB), 
1.93 (1H, app. td, J 13.5 and 4.5, 10-HA), 1.86-1.76 (1H, m, 10-HB), 1.75-1.62 
(1H, m, 11-HA), 1.36 (10H, s, 11-HB and tBu); δC (125 MHz, CD3OD, 333 K) 
173.9 (C-5), 157.1 (Boc C=O), 81.1 (tBu C1), 77.6 (C-6), 60.1 (C-2), 45.0 (C-7), 
43.1 (C-9), 43.0 (C-3), 32.8 (C-10), 28.7 (tBu C3), 20.6 (C-11); HRMS found 
MNa+, 293.1466. C13H22N2O4 requires MNa, 293.1471. 
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tert-Butyl N-{[(3R*,4R*)-4-(benzyloxy)-3-(prop-2-en-1-yl)oxan-3-yl]methyl} 
carbamate 
O
OBn NHBoc
182  
 
By modification of an existing procedure,179 NaH (37.0 mg, 0.92 mmol of a 60% 
dispersion in mineral oil) was added to a mixture of the alcohol derivative 167a 
(0.23 g, 0.84 mmol), benzyl bromide (0.12 mL, 1.00 mmol) and 
tetrabutylammonium iodide (62.0 mg, 0.17 mmol) in THF (5.00 mL) at 0 °C. The 
reaction mixture was stirred for 18 h at rt. Subsequently, a saturated aqueous 
solution of NaHCO3 (5 mL) was added, the phases were separated and the 
aqueous phase was extracted with EtOAc (4 × 5 mL). The organic phases were 
combined, dried (MgSO4), filtered and concentrated under reduced pressure to 
give a crude product. The crude product was purified by flash column 
chromatography, eluting with 10:90 EtOAc−hexane to yield the benzyl 
derivative 182 (0.26 g, 86%) as a colourless oil, Rf 0.75 (50:50 petrol−EtOAc); 
νmax/cm-1 3426, 3344, 2973, 2930, 2859, 1712, 1504, 1453, 1365, 1243, 1165, 
1088; δH (400 MHz, CDCl3) 7.40-7.27 (5H, m, phenyl), 5.81 (1H, ddt, J 15.2, 
10.1 and 7.5, propenyl 2-H), 5.17-5.01 (2H, m, propenyl 3-H2), 4.87 (1H, app. t, 
J 4.8, NH), 4.66 (1H, d, J 11.6, phenylmethyl 1-HA), 4.39 (1H, d, J 11.6, 
phenylmethyl 1-HB), 4.05-3.90 (1H, m, 6-HA), 3.67 (1H, d, J 11.8, 2-HA), 3.48 
(1H, app. td, J 7.9 and 3.8, 4-H), 3.45-3.38 (1H, m, 6-HB), 3.18-3.09 (1H, m, 
methylcarbamate 1-HA), 3.01 (1H, d, J 11.8, 2-HB), 3.00 (1H, d, J 13.5, 
methylcarbamate 1-HB), 2.33 (2H, app. d, J 7.6, propenyl 1-H2), 2.00-1.90 (1H, 
m, 5-HA), 1.78 (1H, app. dtd, J 13.7, 9.5 and 4.5, 5-HB), 1.41 (9H, s, tBu); δC 
(100 MHz, CDCl3) 156.1 (C=O), 138.4 (phenyl C-1), 133.8 (propenyl C-2), 
128.6 (phenyl C2-3,5), 127.8 (phenyl C2-2,6), 126.2 (phenyl C-4), 118.6 
(propenyl C-3), 81.3 (tBu C1), 78.9 (C-4), 70.6 (C-2), 70.3 (phenylmethyl C-1), 
66.0 (C-6), 44.3 (methylcarbamate C-1), 42.1 (C-3), 32.1 (propenyl C-1), 28.5 
(tBu C3), 26.3 (C-5); HRMS found MH+, 362.2328. C21H31NO4 requires MH, 
362.2325. 
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tert-Butyl 10-oxo-3-(pyridin-3-ylmethyl)-7-oxa-2-azaspiro[4.5]decane-2-
carboxylate 
O
NBoc
N
183
O
 
 
According to General Procedure F, the alkene derivative 148i (0.18 g, 0.67 
mmol) and 3-bromopyridine (77.1 µL, 0.80 mmol) were combined to give a 
crude product. The crude product (dr 65:35 by 1H-NMR) was purified by flash 
column chromatography, eluting with 97.0:2.7:0.3 DCM−EtOH−NH4OH to yield 
the pyrrolidine derivative 183 (80.0 mg, 34%, dr 69:31 by 1H-NMR) as a yellow 
oil, Rf 0.40 (EtOAc); νmax/cm-1 2971, 2930, 2861, 1709, 1685, 1391, 1364, 1222, 
1147, 1111, 1094, 1027; δH (500 MHz, CD3OD, 333 K) 8.41-8.40 (2H, m, 
pyridine 2,6-H2minor), 8.39 (2H, app. d, J 3.4, pyridine 2,6-H2major), 7.70-7.65 (2H, 
m, pyridine 4-H), 7.35 (2H, app. dtd, J 8.0, 5.0 and 0.8, pyridine 5-H), 4.17-4.09 
(2H, m, 3-H), 4.06 (1H, d, J 11.9, 1-HAmajor), 4.03-3.97 (2H, m, 8-HA), 3.94-3.80 
(2H, m, 8-HB), 3.72 (2H, d, J 11.5, 6-HA), 3.65 (2H, d, J 11.5, 6-HB), 3.54 (1H, d, 
J 11.5, 1-HAminor), 3.33 (1H, d, J 11.5, 1-HBminor), 3.11 (1H, dd, J 13.5 and 4.6, 
pyridinylmethyl 1-HAmajor), 3.04 (1H, dd, J 13.5 and 4.0, pyridinylmethyl 1-
HAminor), 2.97 (1H, d, J 11.9, 1-HBmajor), 2.82 (1H, dd, J 13.5 and 8.0, 
pyridinylmethyl 1-HBmajor), 2.78 (1H, dd, J 13.5 and 8.4, pyridinylmethyl 1-HBminor) 
2.67-2.59 (2H, m, 9-HA), 2.54-2.44 (2H, m, 9-HB), 2.37 (1H, ddd, J 13.4, 8.0 and 
1.2, 4-HAmajor), 2.17 (1H, app. dd, J 13.4 and 5.4, 4-HAminor), 1.85 (1H, app. dd, J 
13.4 and 8.1, 4-HBminor), 1.54-1.38 (19H, m, tBu and 4-HBmajor); δC (125 MHz, 
CD3OD, 333 K) 208.9 (C-10minor), 208.8 (C-10major), 156.2 (Boc C=Omajor), 156.0 
(Boc C=Ominor), 151.1 (pyridine CA-2,6minor), 151.0 (pyridine CA-2,6major), 148.3 
(pyridine CB-2,6major), 148.2 (pyridine CB-2,6minor) 139.1 (pyridine C2-4), 135.9 
(pyridine C2-3), 125.0 (pyridine C2-5), 81.6 (tBu C1minor), 81.5 (tBu C1major), 76.1 
(C-6major), 75.8 (C-6minor), 69.4 (C-8minor), 69.3 (C-8major), 59.2 (C-3major), 58.7 (C-
3minor), 57.8 (C-5minor), 57.6 (C-5major), 53.7 (C-1major), 53.6 (C-1minor), 41.7 
(pyridinylmethyl C2-1), 40.0 (C2-9), 36.8 (C2-4), 28.7 (tBu 2C3); HRMS found 
MH+, 347.1975. C19H26N2O4 requires MH, 347.1970.   
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tert-Butyl (3R*,5S*,10S*)-10-(benzyloxy)-3-[(pyridin-3-yl)methyl]-7-oxa-2-
azaspiro[4.5] decane-2-carboxylate 
 
O
OBn NBoc
N
185  
 
According to General Procedure F, the alkene 182 (0.10 g, 0.28 mmol) and 3-
bromopyridine (31.8 µL, 0.33 mmol) gave a crude material. The crude material 
(dr 67:33 by 1H-NMR) was purified by flash column chromatography, eluting 
with 70:30→50:50 hexane−EtOAc to yield the pyrrolidine derivative 185 (38.0 
mg, 31%, dr >95:<5 by 1H-NMR) as a grey oil, Rf 0.56 (EtOAc); νmax/cm-1 2928, 
2858, 1685, 1393, 1364, 1155, 1085; δH (500 MHz, CDCl3, 323 K) 8.44 (1H, d, J 
1.7, pyridinyl 2-H), 8.40 (1H, app. s, pyridinyl 6-H), 7.43 (1H, d, J 4.5, pyridinyl 
4-H), 7.38-7.25 (5H, m, phenyl), 7.13 (1H, dd, J 7.7 and 4.5, pyridinyl 5-H), 4.61 
(1H, d, J 11.7, phenylmethyl 1-HA), 4.36 (1H, d, J 11.7, phenylmethyl 1-HB), 
4.04 (1H, app. br. s, 3-H), 3.83 (1H, m, 8-HA), 3.54 (1H, d, J 11.4, 6-HA), 3.50-
3.43 (2H, m, 1-HA and 8-HB), 3.26 (1H, app. br. s, 10-H), 3.15 (1H, d, J 11.4, 6-
HB), 3.13-2.87 (2H, m, 1-HB and pyridinylmethyl 1-HA), 2.72 (1H, app. br. s, 
pyridinylmethyl 1-HB), 1.99 (1H, dd, J 13.6 and 8.0, 4-HA), 1.78-1.71 (2H, m, 4-
HB and 9-HA), 1.66-1.56 (1H, m, 9-HB), 1.48 (9H, s, tBu); δC (125 MHz, CDCl3, 
323 K) 154.7 (C=O), 151.0 (pyridinyl C-2), 147.8 (pyridinyl C-6), 138.5 (pyridinyl 
C-3), 137.0 (pyridinyl C-4), 134.0 (phenyl C-1), 128.5 (phenyl C2-3,5), 127.8 
(phenyl C-4), 127.7 (phenyl C2-2,6), 123.2 (pyridinyl C-5), 79.7 (tBu C1), 76.7 
(C-10), 71.7 (C-6), 70.7 (phenylmethyl C-1), 64.9 (C-8), 57.1 (C-3), 51.1 (C-1), 
46.5 (C-5), 37.7 (C-4), 34.1 (pyridinylmethyl C-1), 28.6 (C-9 and tBu C3); HRMS 
found MH+, 439.2604. C26H34N2O4 requires MH, 439.2596. The relative 
stereochemistry was determined using NOESY (500 MHz, CDCl3, 323 K) nOe 
observed between 3-H and 6-HA. 
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tert-Butyl (5R*,10R*)-10-(benzyloxy)-3-(iodomethyl)-7-oxa-2-azaspiro[4.5] 
decane-2-carboxylate (186) 
(5R*,6R*,11S*)-5-(Benzyloxy)-11-(iodomethyl)-2,10-dioxa-8-azaspiro[5.6] 
dodecan-9-one (187) 
          
O
NBocOBn
I
186           
O
O
H
NOBn
O
I
187  
 
According General Procedure S, the alkene derivative 182 (0.10 g, 0.28 mmol) 
was stirred for 3 days to give a crude material. The crude material was purified 
by flash column chromatography, eluting with 15:85 EtOAc−hexane to yield the 
pyrrolidine derivative 186 (41.0 mg, 30%, dr 77:23 by 1H-NMR) as a yellow oil, 
Rf 0.63 (50:50 petrol−EtOAc); νmax/cm-1 2928, 2857, 1687, 1391, 1364, 1157, 
1087; δH (500 MHz, CDCl3, 323 K) 7.37-7.26 (10H, m, phenyl), 4.67 (1H, d, J 
11.8, phenylmethyl 1-HAmajor), 4.64 (1H, d, J 11.9, phenylmethyl 1-HAminor), 4.45 
(1H, d, J 11.8, phenylmethyl 1-HBmajor), 4.42 (1H, d, J 11.9, phenylmethyl 1-
HBminor), 3.92-3.82 (2H, m, 8-HA), 3.79-3.75 (2H, m, 3-H) 3.73 (2H, d, J 11.1, 6-
HA), 3.61 (2H, d, J 11,3, 1-HA), 3.58-3.49 (4H, m, 8-HB and iodomethyl 1-HA), 
3.44-3.40 (4H, m, 10-H and iodomethyl 1-HB), 3.33 (2H, d, J 11.1, 6-HB), 3.21 
(2H, d, J 11.3, 1-HB), 2.20-2.08 (2H, m, 9-HA), 1.93-1.65 (6H, m, 9-HB and 4-
H2), 1.47 (9H, s, tBumajor), 1.45 (9H, s, tBuminor); δC (125 MHz, CDCl3, 323 K) 
154.3 (2C=O), 138.5 (phenyl C-1major), 138.4 (phenyl C-1minor), 128.6 (phenyl 
C2-3,5minor), 128.5 (phenyl C2-3,5major), 127.8 (phenyl C-4minor), 127.7 (phenyl C-
4major), 127.6 (phenyl C4-2,6), 80.1 (tBu C1minor), 80.0 (tBu C1major), 78.0 (C-
10minor), 77.1 (C-10major), 73.0 (C2-6), 71.1 (phenylmethyl C-1minor), 70.9 
(phenylmethyl C-1major), 64.9 (C-8major), 63.2 (C-8minor), 56.3 (C-3major), 55.2 (C-
3minor), 52.3 (C-1minor), 51.6 (C-1major), 46.3 (C-5major), 45.8 (C-5minor), 36.6 (C2-4), 
28.6 (tBu 2C3), 27.4 (C-9major), 26.3 (C-9minor), 13.7 (iodomethyl C-1major), 12.9 
(iodomethyl C-1minor); HRMS found MH+, 488.1295. C21H30INO4 requires MH, 
488.1292. 
 
Also obtained was the carbamate derivative 187 (10.0 mg, 8%, dr >95:<5 by 1H-
NMR) as an amorphous colourless solid, Rf 0.73 (50:50 petrol−EtOAc); νmax/cm 
-1 2979, 2955, 2928, 2854, 1683, 1604, 1477, 1453, 1402, 1361, 1249, 1165, 
1137, 1091, 1066, 1020; δH (500 MHz, CDCl3, 323 K) 7.35-7.29 (2H, m, phenyl 
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3,5-H2), 7.28-7.24 (1H, m, phenyl 4-H), 7.19 (2H, d, J 7.5 phenyl 2,6-H2), 4.60 
(1H, d, J 15.8, phenylmethyl 1-HA), 4.45 (1H, d, J 15.8, phenylmethyl 1-HB), 
4.08 (1H, app. dtd, J 8.6, 6.9 and 5.6, 11-H), 3.80 (1H, app. t, J 3.7, 5-H), 3.71-
3.64 (2H, m, 3-H2), 3.59 (1H, d, J 11.9, 1-HA), 3.45 (1H, d, J 11.9, 1-HB), 3.37-
3.30 (2H, m, 7-H2 and iodomethyl 1-HA), 3.24 (1H, dd, J 9.9 and 6.9, iodomethyl 
1-HB), 2.26 (1H, app. t, J 11.0, 12-HA), 1.97-1.86 (1H, m, 4-HA), 1.80 (1H, app. 
dq, J 14.8 and 3.2, 4-HB), 1.31 (1H, dd, J 13.6 and 6.9, 12-HB); δC (125 MHz, 
CDCl3) 156.7 (C-9), 138.5 (phenyl C-1), 128.6 (phenyl C2-3,5), 127.3 (phenyl C-
4), 126.9 (phenyl C2-2,6), 77.8 (C-5), 77.3 (C-11), 70.7 (C-1), 64.1 (C-3), 53.2 
(phenylmethyl C-1), 50.4 (C-7), 46.4 (C-6), 39.0 (C-12), 26.7 (C-4), 9.6 
(iodomethyl C-1); HRMS found MH+, 432.0671. C17H22INO4 requires MH, 
432.0671. The relative configuration was determined using NOESY (500 MHz, 
CDCl3, 323 K) nOe observed between 5-H and 11-H. 
 
(1R*, 5S*)-1-(Prop-2-en-1-yl)-3-oxa-7-azabicyclo[3.3.1]nonan-9-one 
 
O
H
N
O
152  
 
According to General Procedure Y, paraformaldehyde (16.8 mg, 0.56 mmol) 
and the ketone derivative 148i (0.10 g, 0.37 mmol) gave a crude material. The 
crude material was purified by flash column chromatography, eluting with 
95.4:4.1:0.5 DCM−EtOH−NH4OH to yield the bridged bicyclic derivative 152 
(20.0 mg, 30%) as a yellow oil, Rf 0.40 (92.4:6.8:0.8 DCM−EtOH−NH4OH); 
νmax/cm-1 3362, 3074, 2922, 2848, 1709, 1674, 1638, 1455, 1435, 1375, 1234, 
1211, 1082; δH (400 MHz, CD3OD) 5.86 (1H, ddt, J 15.4, 11.0 and 7.5, propenyl 
2-H), 5.09 (1H, dd, J 10.5 and 1.5, propenyl 3-Hcis), 5.08 (1H, dd, J 16.7 and 
1.5, propenyl 3-Htrans), 4.43 (1H, app. dt, J 11.3 and 1.6, 4-HA), 4.26 (1H, dd, J 
11.3 and 1.6, 2-HA), 3.97 (1H, app. dt, J 11.3 and 2.5, 4-HB), 3.73 (1H, dd, J 
11.3 and 3.1, 2-HB), 3.63 (1H, app. dt, J 13.8 and 2.2, 6-HA), 3.49 (1H, dd, J 
13.7 and 2.4, 8-HA), 3.13 (1H, app. dt, J 13.8 and 2.9, 6-HB), 2.89 (1H, dd, J 
13.7 and 3.1, 8-HB), 2.37 (1H, app. s, 5-H), 2.15 (2H, app. d, J 7.5, propenyl 1-
H2); δC (100 MHz, CD3OD) 213.7 (C-9), 134.0 (propenyl C-2), 118.7 (propenyl 
C-3), 79.3 (C-2), 75.9 (C-4), 60.3 (C-8), 55.8 (C-6), 53.9 (C-1), 52.7 (C-5), 35.3 
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(propenyl C-1). HRMS found MH+, 182.1179. C10H15NO2 requires MH, 
182.1175. 
 
(1R*,5S*,6R*)-6-phenyl-1-(prop-2-en-1-yl)-3-oxa-7-azabicyclo[3.3.1]nonan-
9-one 
O
H
N
O
188  
 
According to General Procedure Y, benzaldehyde (57.6 µL, 0.56 mmol) and the 
ketone derivative 148i (0.10 g, 0.37 mmol) gave a crude material. The crude 
material (dr >95:<5 by 1H-NMR) was purified by flash column chromatography, 
eluting with 97:2.7:0.3 DCM−EtOH−NH4OH to yield the bridged bicyclic 
derivative 188 (32.0 mg, 33%, dr >95:<5 by 1H-NMR) as an amorphous yellow 
solid, Rf 0.40 (50:50 petrol−EtOAc); νmax/cm-1 3337, 3059, 3030, 2921, 2851, 
1708, 1470, 1372, 1225, 1210, 1088; δH (500 MHz, CDCl3) 7.34-7.18 (5H, m, 
phenyl), 5.75 (1H, ddt, J 17.3, 10.0 and 7.5, propenyl 2-H), 5.03 (1H, dd, J 10.0 
and 1.9, propenyl 3-Hcis), 5.00 (1H, dd, J 17.3 and 1.9, propenyl 3-Htrans), 4.27 
(1H, app. s, 6-H), 4.16 (1H, dd, J 11.4 and 1.6, 2-HA), 4.06 (1H, app. d, J 11.7, 
4-HA), 3.69 (1H, dd, J 11.4 and 3.1, 2-HB), 3.61 (1H, app. dt, J 11.7 and 2.1, 4-
HB), 3.54 (1H, d, J 13.8, 8-HA), 2.97 (1H, dd, J 13.8 and 3.2, 8-HB), 2.82 (1H, br. 
s, NH), 2.51 (1H, app. s, 5-H), 2.18 (1H, dd, J 14.4 and 7.3, propenyl 1-HA), 
2.11 (1H, dd, J 14.4 and 7.7, propenyl 1-HB); δC (125 MHz, CDCl3) 212.0 (C-9), 
139.1 (phenyl C-1), 132.4 (propenyl C-2), 128.8 (phenyl C2-3,5), 127.6 (phenyl 
C-4), 126.2 (phenyl C2-2,6), 118.7 (propenyl C-3), 78.4 (C-2), 70.1 (C-4), 66.9 
(C-6), 58.8 (C-8), 56.6 (C-5), 52.2 (C-1), 34.3 (propenyl C-1); HRMS found MH+, 
258.1491. C16H19NO2 requires MH, 258.1488. The relative configuration was 
determined using NOESY (500 MHz, CDCl3), nOe observed between phenyl 
and 4-HA, 6-H and 8-HB, 5-H and 6-H. 
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5.2.4. Experimental for the Decoration of the Scaffolds 
5.2.4.1. Preparation of the BACE1 Capping Group 
2-(tert-Butylamino)quinoline-3-carbaldehyde 
 
N
O
H
NHtBu
229  
 
By modification of an existing procedure,192 tert-butylamine (27.4 mL, 261 
mmol) was added to a solution of the chloroquinoline derivative 228 (5.00 g, 
26.1 mmol) in N-methyl-2-pyrrolidone (141 mL) at rt. After stirring for 3 days at 
130 °C, the mixture was allowed to cool to rt and an aqueous solution of 1.0 M 
HCl (210 mL) was added. The mixture was stirred for 1.5 h and the resulting 
precipitate was removed by filtration. Subsequently, toluene (150 mL) and water 
(150 mL) were added. The phases were separated and the aqueous phase was 
extracted with toluene (10 × 100 mL). The organic phases were combined, 
dried (MgSO4), filtered and concentrated under reduced pressure to yield a 
crude material. The crude material was purified by flash column 
chromatography eluting with 5:95 EtOAc−hexane to yield the amine derivative 
229 (3.10 g, 52%) as a bright yellow amorphous solid, Rf 0.57 (80:20 
petrol−EtOAc); νmax/cm-1 3335, 2961, 2839, 2725, 1670, 1620, 1573, 1535, 
1400, 1356, 1219; δH (400 MHz, CDCl3) 9.93 (1H, s, CHO), 8.16 (1H, s, 4-H), 
8.04 (1H, br. s, NH), 7.69-7.52 (3H, m, 5,7,8-H3), 7.21-7.15 (1H, m, 6-H), 1.60 
(9H, s, tBu); δC (100 MHz, CDCl3) 193.4 (CHO), 154.2 (C-2), 150.9 (C-8a), 
148.7 (C-4), 133.3 (C-7), 129.2 (C-5), 126.9 (C-8), 122.2 (C-6), 121.5 (C-3), 
117.8 (C-4a), 51.7 (tBu C1), 29.1 (tBu C3); HRMS found MH+, 229.1336. 
C14H16N2O requires MH, 229.1340. 
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Ethyl (2E)-3-[2-(tert-butylamino)quinolin-3-yl]prop-2-enoate 
 
N NHtBu
230
OEt
O
 
 
By modification of an existing procedure,192 LiCl (0.81 g, 19.3 mmol) was added 
to acetonitrile (82.0 mL) and the resulting suspension was stirred overnight at rt. 
Subsequently, the aldehyde derivative 229 (2.00 g, 8.76 mmol), triethyl 
phosphonoacetate (2.43 mL, 12.3 mmol) and DBU (1.60 mL, 10.7 mmol) were 
added. After stirring the reaction mixture for 4 h at rt, a saturated aqueous 
solution of NaHCO3 (80 mL) and EtOAc (40 mL) were added. The phases were 
separated and the aqueous phase was extracted with EtOAc (3 × 20 mL). The 
organic phases were combined, dried (MgSO4), filtered and concentrated under 
reduced pressure to yield a crude material. The crude material was purified by 
flash column chromatography eluting with 4:96 EtOAc−hexane to yield the 
alkene derivative 230 (2.58 g, 99%) as a yellow oil, Rf 0.27 (96:4 petrol−EtOAc); 
νmax/cm-1 3402, 3054, 2960, 1706, 1613, 1600, 1511, 1410, 1301, 1173, 1162; 
δH (400 MHz, CDCl3) 7.88 (1H, s, 4-H), 7.72 (1H, d, J 15.9, propenoate 3-H), 
7.68 (1H, d, J 8.3. 8-H), 7.56 (1H, dd, J 8.0 and 1.5, 5-H), 7.53 (1H, ddd, J 8.3, 
6.9 and 1.5. 7-H), 7.19 (1H, ddd, J 8.0, 6.9 and 1.2, 6-H), 6.46 (1H, d, J 15.9, 
propenoate 2-H), 4.60 (1H, br.s, NH), 4.31 (2H, q, J 7.1, ethyl 1-H2), 1.60 (9H, 
s, tBu), 1.37 (3H, t, J 7.1. ethyl 2-H3); δC (100 MHz, CDCl3) 166.6 (propenoate 
C-1), 153.5 (C-2), 148.6 (C-8a), 139.7 (propenoate C-3), 135.6 (C-4), 130.2 (C-
7), 127.8 (C-5), 126.7 (C-8), 122.6 (C-3), 122.4 (C-6), 121.9 (propenoate C-2), 
119.2 (C-4a), 60.8 (ethyl C-1), 52.3 (tBu C1), 29.3 (tBu C3), 14.4 (ethyl C-2); 
HRMS found MH+, 299.1751. C18H22N2O2 requires MH, 299.1759. 
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Ethyl 3-[2-(tert-butylamino)quinolin-3-yl]propanoate 
 
N NHtBu
227
OEt
O
 
 
Hydrogen gas was passed through a mixture of the alkene derivative 230 (2.58 
g, 8.64 mmol) and Pd (0.46 g, 0.43 mmol of a 10% Pd/C) in EtOH (173 mL) for 
30 min. Subsequently, the suspension was filtered through a pad of celite and 
the filtrate was concentrated under reduced pressure to yield a crude material. 
The crude material was purified by flash column chromatography eluting with 
4:96 EtOAc−hexane to yield the ester derivative 227 (2.53 g, 97%) as a light 
yellow amorphous solid, Rf 0.39 (90:10 petrol−EtOAc); νmax/cm-1 3468, 2962, 
2911, 2868, 1720, 1626, 1521, 1421, 1359, 1261, 1228, 1212, 1038; δH (300 
MHz, CDCl3) 7.71 (1H, d, J 8.3, 8-H), 7.55 (1H, s, 4-H), 7.53 (1H, dd, J 8.1 and 
1.3, 5-H), 7.48 (1H, ddd, J 8.3, 7.3 and 1.3, 7-H), 7.18 (1H, ddd, J 8.1, 7.3 and 
1.2, 6-H), 4.71 (1H, br. s, NH), 4.19 (1H, q, J 7.1, ethyl 1-H2), 2.89-2.80 (2H, m, 
propanoate 3-H2), 2.74-2.66 (2H, m, propanoate 2-H2), 1.61 (9H, s, tBu), 1.28 
(3H, t, J 7.1, ethyl 2-H3); δC (75 MHz, CDCl3) 173.1 (propanoate C-1), 154.6 (C-
2), 146.9 (C-8a), 134.2 (C-4), 128.5 (C-7), 126.8 (C-5), 126.5 (C-8), 123.1 (C-3), 
122.6 (C-4a), 121.8 (C-6), 60.9 (ethyl C-1), 51.9 (tBu C1), 33.0 (propanoate C-
2), 29.4 (tBu C3), 26.2 (propanoate C-3), 14.3 (ethyl C-2); HRMS found MH+, 
301.1907. C18H24N2O2 requires MH, 301.1916. 
 
5.2.4.2. Decoration of the Scaffolds 
General Procedure Z 
By modification of an existing procedure,194,203 NaOMe (0.10 eq of a 0.5 M 
solution in MeOH) was added to a solution of the respective acetate derivative 
(1.00 eq) in MeOH (10.0 mL for each 1.00 mmol of the acetate derivative). After 
stirring for 45 min at rt, the solvent was removed under reduced pressure. 
Subsequently, DCM (10.0 mL for each 1.00 mmol of the acetate derivative) and 
TFA (18.0 eq) were added, the mixture was stirred at rt for 1 h and it was 
concentrated under reduced pressure. Afterwards, toluene (6.00 mL for each 
1.00 mmol of the acetate derivative) and the ester derivative 227 (1.05 eq) were 
added. Subsequently, the specified amount of Et3N and the specified amount of 
208 
 
TBD were added and the reaction mixture was stirred for the indicated time at 
75 °C. Finally, the solvent was removed under reduced pressure to yield a 
crude material. 
 
General Procedure AA 
By modification of an existing procedure,194 TFA (17.0 eq) was added to a 
solution of the respective carbamate derivative (1.00 eq) in DCM (9.00 mL for 
each 1.00 mmol of the carbamate derivative). The mixture was stirred at rt for 1 
h and it was concentrated under reduced pressure. Afterwards, toluene (5.00 
mL for each 1.00 mmol of the carbamate derivative), the specified amount of 
Et3N, the specified amount of TBD and the ester derivative 227 (1.05 eq) were 
added and the reaction mixture was stirred for 4 days at 75 °C. Finally, the 
solvent was removed under reduced pressure to yield a crude material. 
 
General Procedure AB 
By modification of an existing procedure,194 hydrogen gas was passed through 
a mixture of the respective carbamate derivative (1.00 eq) and Pd (0.03 eq of a 
10% Pd/C) in MeOH (7.30 mL for each 1.00 mmol of the carbamate derivative) 
for 1 h at rt. Subsequently, the suspension was filtered through a pad of celite 
and the solvent was removed under reduced pressure. Toluene (7.30 mL for 
each 1.00 mmol of the carbamate derivative), the ester derivative 227 (1.05 eq) 
and the specified amount of TBD were added and the reaction mixture was 
stirred for 2 days at 75 °C. Finally, the solvent was removed under reduced 
pressure to yield a crude material. 
 
General Procedure AC 
By modification of an existing procedure,194 the respective amine (1.00 eq) and 
the specified amount of TBD were added to a solution of the ester derivative 
227 (1.05 eq) in the specified amount of toluene. If an amine hydrochloride salt 
was used, Et3N (17.0 eq) was also added. The reaction mixture was stirred for 
the specified time at 75 °C. Subsequently, the solvent was removed under 
reduced pressure to yield a crude material. 
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General Procedure AD 
The specified amount of TFA was added to the respective amide derivative 
(1.00 eq) and the reaction was stirred for the specified time at 75 °C under air 
atmosphere. Subsequently, the mixture was concentrated under reduced 
pressure and it was loaded into a SCX pad, which was eluted with MeOH and 
with a solution of saturated NH3 in MeOH. The fraction containing the saturated 
solution of NH3 in MeOH was collected and concentrated under reduced 
pressure to yield a crude material or the respective amine derivative. 
 
3‐[2‐(tert‐Butylamino)quinolin‐3‐yl]‐1‐[(5R*,6R*)‐5‐hydroxy‐2‐oxa‐8‐ 
azaspiro[5.5] undecan‐8‐yl]propan‐1‐one 
 
N
N
O
NHtBu
231a
O
HO
 
 
According to General Procedure Z, the acetate derivative 179a (50.0 mg, 0.16 
mmol), TBD (62.3 mg, 0.45 mmol) and Et3N (0.75 mL, 5.40 mmol) were stirred 
for 5 days to yield a crude material. The crude material was purified by flash 
column chromatography eluting with 60:40→100:0 EtOAc−hexane to yield the 
amide derivative 231a (14.0 mg, 21%, rotamers 78:22 by 1H-NMR) as a 
colourless oil, Rf 0.48 (EtOAc); νmax/cm-1 3385, 2954, 2927, 2857, 1621, 1517, 
1470, 1446, 1415, 1355, 1260, 1213, 1085; δH (400 MHz, CDCl3) 7.68 (2H, dd, 
J 8.5 and 2.6, quinolinyl 8-H), 7.54 (2H, s, quinolinyl 4-H), 7.50 (2H, dd, J 7.9 
and 1.6, quinolinyl 5-H), 7.46 (2H, ddd, J 8.5, 7.0 and 1.6, quinolinyl 7-H), 7.15 
(2H, app. td, J 7.4 and 3.3, quinolinyl 6-H), 5.07 (2H, br. s, NH), 4.29-4.19 (1H, 
m, 9-HAminor), 3.87-3.72 (2H, m, 3-HA), 3.63-3.51 (6H, m, 1-HA, 3-HB and 7-HA), 
3.49 (2H, dd, J 7.6 and 3.9, 5-H), 3.42-3.29 (1H, m, 9-HAmajor), 3.28-3.22 (1H, m, 
9-HBmajor), 3.15 (2H, d, J 13.6, 1-HB), 3.10 (2H, d, J 11.9, 7-HB), 2.99-2.81 (5H, 
m, propanone 3-H2 and 9-HBminor), 2.79-2.56 (4H, m, propanone 2-H2), 2.00-
1.89 (2H, m, 4-HA), 1.82 (2H, app. ddt, J 13.5, 8.6 and 4.0, 10-HA), 1.71-1.61 
(2H, m, 4-HB), 1.58 (18H, s, tBu), 1.55-1.38 (6H, m, 10-HB and 11-H2); δC (100 
MHz, CDCl3) 171.3 (propanone C-1minor), 171.1 (propanone C-1major), 155.0 
(quinolinyl C2-2), 147.0 (quinolinyl C2-8a), 134.7 (quinolinyl C-4major), 134.6 
(quinolinyl C-4minor), 128.5 (quinolinyl C-7major), 128.4 (quinolinyl C-7minor), 126.7 
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(quinolinyl C2-5), 126.5 (quinolinyl C2-8), 123.6 (quinolinyl C2-3), 123.1 
(quinolinyl C2-4a), 121.7 (quinolinyl C-6major), 121.6 (quinolinyl C-6minor), 70.7 (C-
1major), 69.9 (C2-5), 68.6 (C-1minor), 65.2 (C-3major), 64.3 (C-3minor), 51.9 (tBu C2), 
50.3 (C-7minor), 47.5 (C-7major), 46.6 (C-9major), 42.9 (C-9minor), 38.9 (C2-6), 32.0 
(propanone C-2minor), 31.7 (propanone C-2major), 30.7 (C2-4), 29.4 (tBu C6), 26.9 
(propanone C-3major), 26.8 (propanone C-3minor), 21.3 (C2-10), 20.4 (C2-11); 
HRMS found MH+, 426.2748. C25H35N3O3 requires MH, 426.2756. 
 
3‐[2‐(tert‐Butylamino)quinolin‐3‐yl]‐1‐[(5R*,10R*)‐10‐hydroxy‐7‐oxa‐2‐azasp
iro[4.5] decan‐2‐yl]propan‐1‐one 
 
N
N
O
NHtBu
231b
O
HO
 
 
According to General Procedure Z, the acetate derivative 173a (41.3 mg, 0.14 
mmol), TBD (73.0 mg, 0.52 mmol) and Et3N (0.75 mL, 5.40 mmol) were stirred 
for 4 days to yield a crude material. The crude material was purified by flash 
column chromatography eluting with 90:10→100:0 EtOAc−hexane to yield the 
amide derivative 231b (34.0 mg, 60%, rotamers >95:<5 by 1H-NMR) as a 
colourless oil, Rf 0.31 (EtOAc); νmax/cm-1 3360, 2954, 2862, 1621, 1518, 1447, 
1416, 1355, 1213, 1082; δH (400 MHz, CDCl3) 7.67 (2H, d, J 8.3, quinolinyl 8-
H), 7.52 (2H, app. d, J 5.9, quinolinyl 4-H), 7.49 (2H, dd, J 7.9 and 1.6, 
quinolinyl 5-H), 7.45 (2H, ddd, J 8.3, 6.9 and 1.6, quinolinyl 7-H), 7.14 (2H, app. 
t, J 7.4, quinolinyl 6-H), 5.10 (2H, br. s, NH), 3.91-3.78 (2H, m, 8-HA), 3.72-3.52 
(4H, m, 6-HA and 10-H), 3.53-3.32 (6H, m, 1-HA, 3-HA and 8-HB), 3.31-3.18 (4H, 
m, 1-HB and 3-HB), 3.11 (2H, d, J 11.5, 6-HB), 2.87 (4H, t, J 7.4, propanone 3-
H2), 2.63-2.53 (4H, m, propanone 2-H2), 2.12-2.00 (2H, m, 4-HA), 1.93-1.82 (2H, 
m, 4-HB), 1.82-1.72 (2H, m, 9-HA), 1.70-1.58 (2H, m, 9-HB), 1.57 (18H, s, tBu); 
δC (100 MHz, CDCl3) 171.1 (propanone C2-1), 154.8 (quinolinyl C2-2), 146.9 
(quinolinyl C2-8a), 134.5 (quinolinyl C-4minor), 134.4 (quinolinyl C-4major), 128.5 
(quinolinyl C2-7), 126.7 (quinolinyl C2-5), 126.4 (quinolinyl C2-8), 123.7 
(quinolinyl C2-3), 123.0 (quinolinyl C2-4a), 121.7 (quinolinyl C2-6), 71.3 (C-
6major), 70.4 (C-6minor), 69.7 (C-10major), 69.5 (C-10minor), 65.6 (C-8major), 64.8 (C-
8minor), 51.8 (C-3minor), 50.9 (C-3major), 48.2 (tBu C2), 46.5 (C2-5), 45.5 (C-1major), 
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44.5 (C-1minor), 33.7 (propanone C2-2), 33.3 (C2-9), 32.3 (C-4major), 32.1 (C-
4minor), 29.4 (tBu C6), 26.4 (propanone C-3minor), 26.3 (propanone C-3major); 
HRMS found MH+, 412.2598. C24H33N3O3 requires MH, 412.2600. 
 
3‐[2‐(tert‐Butylamino)quinolin‐3‐yl]‐1‐[(4R*,5S*)‐4‐hydroxy‐2‐oxa‐7‐azaspir
o[4.4]nonan‐7‐yl]propan‐1‐one 
 
N
N
O
NHtBu
231c
O
HO
 
 
According to General Procedure Z, the acetate derivative 173d (0.10 g, 0.35 
mmol), TBD (0.12 mg, 0.87 mmol) and Et3N (0.50 mL, 3.60 mmol) were stirred 
for 2 days to yield a crude material. The crude material was purified by flash 
column chromatography eluting with 80:20→100:0 EtOAc−hexane to yield the 
amide derivative 231c (0.10 g, 72%, rotamers 53:47 by 1H-NMR) as a 
colourless amorphous solid, Rf 0.34 (EtOAc); νmax/cm-1 3278, 2950, 2914, 2866, 
1625, 1517, 1453, 1418, 1353, 1216, 1054; δH (400 MHz, DMSO-d6) 7.66 (2H, 
s, quinolinyl 4-H), 7.56 (2H, dd, J 8.0 and 1.5, quinolinyl 5-H), 7.50 (2H, d, J 8.4, 
quinolinyl 8-H), 7.42 (2H, ddd, J 8.4, 6.8 and 1.5, quinolinyl 7-H), 7.13 (2H, ddd, 
J 8.0, 6.8 and 1.3, quinolinyl 6-H), 5.88 (1H, br. s, NHminor), 5.82 (1H, br. s, 
NHmajor), 5.18 (2H, app. t, J 4.1, OH), 3.95-3.81 (2H, m, 4-H), 3.59-3.35 (12H, 
m, 1,3,8-H6), 3.24 (2H, app. s, 6-HA), 3.19 (2H, app. s, 6-HB), 2.84 (4H, td, J 6.9 
and 4.0, propanone 3-H2), 2.59 (4H, app. q, J 6.4, propanone 2-H2), 2.15 (1H, 
ddd, J 12.7, 7.9 and 6.3, 9-HAminor), 2.05 (1H, ddd, J 13.0, 7.7 and 5.9, 9-
HAmajor), 1.75-1.65 (1H, m, 9-HBminor), 1.59 (1H, app. dt, J 13.0 and 7.7, 9-
HBmajor), 1.53 (18H, s, tBu); δC (100 MHz, DMSO-d6) 170.2 (propanone C-1minor), 
170.1 (propanone C-1major), 155.0 (quinolinyl C2-2), 146.1 (quinolinyl C2-8a), 
134.2 (quinolinyl C2-4), 128.1 (quinolinyl C2-7), 126.7 (quinolinyl C2-5), 125.5 
(quinolinyl C2-8), 125.0 (quinolinyl C2-3), 124.8 (quinolinyl C2-4a), 121.2 
(quinolinyl C2-6), 74.5 (C-3minor), 74.4 (C-3major), 73.8 (C-4major), 73.7 (C-1major), 
73.6 (C-4minor), 73.5 (C-1minor), 54.2 (C-6minor), 54.1 (C-5majoror), 53.6 (C-6major), 
52.2 (C-5minor), 51.1 (tBu C2), 45.1 (C-8minor), 44.6 (C-8major), 32.9 (propanone C-
2major), 32.6 (propanone C-2minor), 28.9 (tBu C6), 27.5 (C-9minor), 25.7 (C-9major), 
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25.3 (propanone C-3minor), 25.1 (propanone C-3major); HRMS found MH+, 
398.2435. C23H31N3O3 requires MH, 398.2443. 
 
3‐[2‐(tert‐Butylamino)quinolin‐3‐yl]‐1‐[(2R*,3R*)‐3‐hydroxy‐5‐methoxy‐1,3‐ 
dihydrospiro[indene‐2,3'‐pyrrolidin]‐1'‐yl]propan‐1‐one 
 
N
N
O
NHtBu
231d
HO
OMe
 
 
According to General Procedure Z, the acetate derivative 173c (50.0 mg, 0.14 
mmol), TBD (73.0 mg, 0.52 mmol) and Et3N (0.75 mL, 5.40 mmol) were stirred 
for 4 days to yield a crude material. The crude material was purified by flash 
column chromatography eluting with 70:30→100:0 EtOAc−hexane to yield the 
amide derivative 231d (49.0 mg, 75%, rotamers 53:47 by 1H-NMR) as a 
colourless oil, Rf 0.56 (EtOAc); νmax/cm-1 3338, 2956, 1619, 1517, 1487, 1445, 
1414, 1387, 1354, 1270, 1248, 1213, 1147, 1028; δH (400 MHz, CDCl3) 7.69 
(2H, app. t, J 9.3, quinolinyl 8-H), 7.57-7.41 (6H, m, quinolinyl 4,5,7-H3), 7.21-
7.09 (2H, m, quinolinyl 6-H), 7.04-6.97 (2H, m, 7-H), 6.92-6.83 (2H, m, 4-H), 
6.78 (2H, app. dt, J 8.3 and 2.4, 6-H), 5.14 (2H, br. s, NH), 4.61 (1H, s, 3-Hminor), 
4.58 (1H, d, J 2.5, 3-Hmajor), 3.77 (3H, s, methoxymajor), 3.76 (3H, s, 
methoxyminor), 3.71-3.59 (2H, m, 5’-HA), 3.56-3.43 (2H, m, 5’-HB), 3.35-3.23 (2H, 
m, 2’-HA), 3.14 (2H, app. t, J 9.7, 2’-HB), 2.96-2.84 (4H, m, propanone 3-H2), 
2.83-2.74 (2H, m, 1-HA), 2.65-2.55 (4H, m, propanone 2-H2), 2.54-2.46 (2H, m, 
1-HB), 2.29 (1H, app. dt, J 12.4 and 7.4, 4’-HAmajor), 2.18 (1H, app. dt, J 12.6 and 
7.7, 4’-HAminor), 1.97-1.80 (1H, m, 4’-HBmajor), 1.79-1.61 (1H, m, 4’-HBminor), 1.58 
(9H, s, tBumajor), 1.57 (9H, s, tBuminor); δC (100 MHz, CDCl3) 171.2 (propanone C-
1major), 171.1 (propanone C-1minor), 159.3 (C-5major), 159.2 (C-5minor), 155.0 
(quinolinyl C-2major), 154.9 (quinolinyl C-2minor), 147.0 (quinolinyl C-8amajor), 
146.9 (quinolinyl C-8aminor), 145.0 (C-3amajor), 144.9 (C-3aminor), 134.7 (quinolinyl 
C-4major), 134.5 (quinolinyl C-4minor), 133.0 (C-7aminor), 132.8 (C-7amajor), 128.5 
(quinolinyl C-7major), 128.4 (quinolinyl C-7minor), 126.7 (quinolinyl C2-5), 126.4 
(quinolinyl C2-8), 125.9 (C-7major), 125.7 (C-7minor), 123.7 (quinolinyl C-3major), 
123.6 (quinolinyl C-3minor), 123.0 (quinolinyl C-4amajor), 122.9 (quinolinyl C-
4aminor), 121.7 (quinolinyl C-6major), 121.6 (quinolinyl C-6minor), 115.1 (C-6minor), 
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115.0 (C-6major), 110.0 (C-4minor), 109.7 (C-4major), 79.3 (C-3minor), 79.1 (C-3major), 
56.7 (C-2’major), 55.6 (methoxy), 55.4 (C-2’minor), 54.0 (C2-2), 53.9 (tBu C2), 46.1 
(C-5’minor), 45.3 (C-5’major), 40.3 (C-1major), 40.0 (C-1minor), 35.7 (C2-4’), 34.3 
(propanone C-2major), 33.6 (propanone C-2minor), 29.4 (tBu C6), 26.6 (propanone 
C-3major), 26.4 (propanone C-3minor); HRMS found MH+, 474.2757. C29H35N3O3 
requires MH, 474.2756. 
 
N‐{[(4aR*,8aR*)‐Octahydropyrano[4,3‐b]pyran‐4a‐yl]methyl}‐3‐[2‐(tert‐butyl
amino) quinolin‐3‐yl]propanamide 
 
N
N
H
O
NHtBu
231e
O
HO
 
 
According to General Procedure AA, the carbamate derivative 149a (50.0 mg, 
0.18 mmol), TBD (76.5 mg, 0.55 mmol) and Et3N (0.55 mL, 3.94 mmol) gave a 
crude material. The crude material was purified by flash column 
chromatography eluting with 60:40→100:0 EtOAc−hexane to yield the amide 
derivative 231e (22.0 mg, 28%) as a colourless oil, Rf 0.50 (EtOAc); νmax/cm-1 
3314, 2952, 2926, 2859, 1648, 1623, 1516, 1486, 1447, 1415, 1355, 1274, 
1259, 1214, 1098, 1080, 1024; δH (400 MHz, CDCl3) 7.66 (1H, dd, J 8.3 and 
1.2, quinolinyl 8-H), 7.53 (1H, s, quinolinyl 4-H), 7.48 (1H, dd, J 8.0 and 1.5, 
quinolinyl 5-H), 7.44 (1H, ddd, J 8.3, 6.9 and 1.5, quinolinyl 7-H), 7.14 (1H, ddd, 
J 8.0, 6.9 and 1.2, quinolinyl 6-H), 5.92 (1H, t, J 6.4, amide NH), 4.96 (1H, br. s, 
tBu NH), 3.93-3.86 (1H, m, 2-HA), 3.82 (1H, d, J 11.7, 5-HA), 3.64 (2H, app. dd, 
J 9.3 and 2.2, 7-H2), 3.40 (1H, dd, J 13.9 and 6.4, methylpropanamide 1-HA), 
3.30 (1H, app. s, 8a-H), 3.28-3.24 (1H, m, 2-HB), 3.24-3.19 (1H, m, 
methylpropanamide 1-HB), 3.22 (1H, dd, J 11.7 and 1.7, 5-HB), 2.89 (2H, t, J 
7.1, propanamide 3-H2), 2.54 (2H, td, J 7.1 and 1.8, propanamide 2-H2), 1.95 
(1H, app. dtd, J 14.8, 9.1 and 3.2, 8-HA), 1.59-1.50 (1H, m, 3-HA), 1.58 (9H, s, 
tBu), 1.48-1.38 (1H, m, 8-HB), 1.31-1.15 (3H, m, 3-HB and 4-H2); δC (100 MHz, 
CDCl3) 172.3 (propanamide C-1), 154.7 (quinolinyl C-2), 147.0 (quinolinyl C-
8a), 134.7 (quinolinyl C-4), 128.5 (quinolinyl C-7), 126.7 (quinolinyl C-5), 126.5 
(quinolinyl C-8), 123.1 (quinolinyl C-3), 123.0 (quinolinyl C-4a), 121.7 (quinolinyl 
C-6), 74.8 (C-8a), 68.0 (C-5), 67.6 (C-2), 63.4 (C-7), 51.9 (tBu C1), 45.2 
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(methylpropanamide C-1), 36.2 (C-4a), 35.7 (propanamide C-2), 29.4 (tBu C3), 
28.8 (C-4), 28.7 (C-8), 26.8 (propanamide C-3), 22.1 (C-3); HRMS found MH+, 
426.2753. C25H35N3O3 requires MH, 426.2756. 
 
N-{[(4aR*,7aS*)-Hexahydro-2H-furo[3,4-b]pyran-4a-yl]methyl}-3-[2-(tert-
butylamino)quinolin-3-yl]propanamide 
 
N
N
H
O
NHtBu
231f
O
O
H
 
 
According to General Procedure AA, the carbamate derivative 149d (0.10 g, 
0.39 mmol), TBD (0.13 g, 0.93 mmol) and Et3N (0.50 mL, 3.58 mmol) gave a 
crude material. The crude material was purified by flash column 
chromatography eluting with 70:30→100:0 EtOAc−hexane to yield the amide 
derivative 231f (50.0 mg, 31%) as a colourless amorphous solid, Rf 0.53 
(EtOAc); νmax/cm-1 3410, 3336, 2959, 2943, 2908, 2875, 1653, 1621, 1549, 
1520, 1488, 1450, 1417, 1355, 1277, 1263, 1214, 1189; δH (400 MHz, CDCl3) 
7.67 (1H, app. d, J 8.3, quinolinyl 8-H), 7.54 (1H, s, quinolinyl 4-H), 7.49 (1H, 
dd, J 8.0 and 1.4, quinolinyl 5-H), 7.47-7.42 (1H, m, quinolinyl 7-H), 7.15 (1H, 
ddd, J 8.0, 6.9 and 1.2, quinolinyl 6-H), 5.66 (1H, t, J 6.3, amide NH), 4.94 (1H, 
br. s, tBu NH), 4.02 (1H, dd, J 10.1 and 4.1, 7-HA), 3.84-3.77 (1H, m, 2-HA), 3.81 
(1H, d, J 8.6, 5-HA), 3.74 (1H, d, J 10.1, 7-HB), 3.61 (1H, d, J 4.1, 7a-H), 3.46 
(1H, d, J 8.6, 5-HB), 3.27 (1H, dd, J 14.0 and 6.3, methylpropanamide 1-HA), 
3.15 (1H, app. td, J 11.5 and 2.4, 2-HB), 3.11 (1H, dd, J 14.0 and 6.3, 
methylpropanamide 1-HB), 2.90 (2H, t, J 7.0, propanamide 3-H2), 2.56 (2H, t, J 
7.0, propanamide 2-H2), 1.58 (9H, s, tBu), 1.49 (1H, app. dd, J 11.2 and 4.3, 
3,4-HA), 1.48-1.46 (1H, m, 3,4-HB), 1.39-1.30 (1H, m, 3,4-HC), 1.28-1.21 (1H, m, 
3,4-HD); δC (100 MHz, CDCl3) 172.5 (propanamide C-1), 154.7 (quinolinyl C-2), 
147.0 (quinolinyl C-8a), 134.7 (quinolinyl C-4), 128.6 (quinolinyl C-7), 126.7 
(quinolinyl C-5), 126.5 (quinolinyl C-8), 123.0 (quinolinyl C-3), 121.8 (quinolinyl 
C2-4a,6), 80.3 (C-7a), 74.2 (C-7), 71.1 (C-5), 66.0 (C-2), 51.9 (tBu C1), 45.5 (C-
4a), 45.4 (methylpropanamide C-1), 35.6 (propanamide C-2), 29.4 (tBu C3), 
26.8 (propanamide C-3), 24.4 (C-4), 21.5 (C-3); HRMS found MH+, 412.2594. 
C24H33N3O3 requires MH, 412.2600. 
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1‐[(4aR*,8aR*)‐4a‐Benzyl‐octahydro‐2H‐pyrano[3,2‐c]pyridin‐6‐yl]‐3‐[2‐(tert‐ 
butylamino)quinolin‐3‐yl]propan‐1‐one 
N
N
O
NHtBu
231g
O
H
 
 
According to General Procedure AB, the carbamate derivative 149e (50.0 mg, 
0.14 mmol) and TBD (29.5 mg, 0.21 mmol) gave a crude material. The crude 
material was purified by flash column chromatography eluting with 30:70 
EtOAc−hexane to yield the amide derivative 231g (15.0 mg, 23%, rotamers 
65:35 by 1H-NMR) as a colourless oil, Rf 0.44 (50:50 EtOAc−petrol); νmax/cm-1 
3305, 2951, 2925, 2868, 1634, 1622, 1582, 1543, 1447, 1419, 1352, 1272, 
1227, 1212, 1116, 1090; δH (400 MHz, CDCl3) 7.68 (2H, d, J 8.6, quinolinyl 8-
H), 7.58 (2H, s, quinolinyl 4-H), 7.47-7.40 (4H, m, quinolinyl 5,7-H2), 7.31-7.15 
(8H, m, phenyl 2,6-H2major and phenyl 3,4,5-H3), 7.12 (2H, app. q, J 6.9, 
quinolinyl 6-H), 7.07-7.00 (2H, m, phenyl 2,6-H2minor), 5.14 (2H, br. s, NH), 4.42 
(1H, app. d, J 13.1, 7-HAminor), 4.18 (1H, d, J 13.2, 5-HAmajor), 3.95-3.81 (2H, m, 
2-HA), 3.70-3.61 (1H, m, 7-HAmajor), 3.46 (1H, d, J 13.2, 5-HAminor), 3.40-3.20 (5H, 
m, 2-HB, 7-HBmajor and 8a-H), 3.14 (1H, d, J 13.2, 5-HBmajor), 3.07 (1H, d, J 13.2, 
5-HBminor), 3.00-2.89 (5H, m, 7-HBminor and propanone 3-H2), 2.86-2.71 (5H, m, 
phenylmethyl 1-HAminor and propanone 2-H2), 2.63 (1H, d, J 13.4, phenylmethyl 
1-HAmajor), 2.47 (1H, d, J 13.4, phenylmethyl 1-HBminor), 2.25 (1H, d, J 13.4, 
phenylmethyl 1-HBmajor), 2.17-2.07 (1H, m, 8-HAminor), 1.94-1.81 (1H, m, 8-
HAmajor), 1.78-1.61 (4H, m, 3-HA and 8-HB), 1.60 (9H, s, tBumajor), 1.56 (9H, s, 
tBuminor), 1.59-1.52 (2H, m, 3-HB), 1.45-1.31 (2H, m, 4-HA), 1.17-1.05 (2H, m, 4-
HB); δC (100 MHz, CDCl3) 171.8 (propanone C-1minor). 171.2 (propanone C-
1major), 154.9 (quinolinyl C2-2), 147.0 (quinolinyl C2-8a), 136.8 (phenyl C2-1), 
134.6 (quinolinyl C-4major), 134.5 (quinolinyl C-4minor), 131.0 (phenyl C2-2,6major), 
130.7 (phenyl C2-2,6minor), 128.4 (quinolinyl C-7major), 128.3 (quinolinyl C-7minor), 
128.1 (phenyl C4-3,5), 126.7 (quinolinyl C2-5), 126.5 (quinolinyl C2-8), 126.4 
(phenyl C2-4), 123.6 (quinolinyl C2-3), 123.1 (quinolinyl C2-4a), 121.7 (quinolinyl 
C2-6), 77.1 (C-8amajor), 75.4 (C-8aminor), 67.8 (C-2major), 67.2 (C-2minor), 51.9 (tBu 
C1major), 51.8 (tBu C1minor), 48.7 (C-5minor), 43.6 (C-5major), 41.4 (phenylmethyl C2-
1), 41.0 (C-7major), 37.4 (C-4aminor), 37.3 (C-4amajor), 36.5 (C-7minor), 32.1 
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(propanone C2-2), 30.6 (C2-4), 29.4 (tBu C3major), 29.3 (tBu C3minor), 28.0 (C2-8), 
27.0 (propanone C2-3), 22.3 (C-3major), 22.2 (C-3minor); HRMS found MH+, 
486.3116. C31H39N3O2 requires MH, 486.3120. 
 
1‐[(4aR*,8aR*)‐4a‐[(Pyridin‐3‐yl)methyl]‐octahydro‐2H‐pyrano[3,2‐c]pyridin‐
6‐yl]‐3‐[2‐(tert‐butylamino)quinolin‐3‐yl]propan‐1‐one 
 
N
N
O
NHtBu
231h
O
N
H
 
 
According to General Procedure AB, the carbamate derivative 149f (50.0 mg, 
0.14 mmol) and TBD (43.4 mg, 0.31 mmol) gave a crude material. The crude 
material was purified by flash column chromatography eluting with 
90:10→100:0 EtOAc−hexane to yield the amide derivative 231h (13.0 mg, 20%, 
rotamers 80:20 by 1H-NMR) as a colourless oil, Rf 0.17 (EtOAc); νmax/cm-1 
3312, 2926, 2852, 1622, 1518, 1474, 1447, 1415, 1354, 1272, 1213, 1118, 
1091; δH (400 MHz, CDCl3) 8.46 (2H, br. s, pyridinyl 6-H), 8.33 (1H, br. s, 
pyridinyl 2-Hmajor), 8.26 (1H, br. s, pyridinyl 2-Hminor), 7.71-7.61 (4H, m, pyridinyl 
4-H and quinolinyl 8-H), 7.56 (2H, s, quinolinyl 4-H), 7.42 (2H, ddd, J 8.4, 6.9 
and 1.5, quinolinyl 7-H), 7.38 (2H, dd, J 8.1 and 1.5, quinolinyl 5-H), 7.25-7.19 
(2H, m, pyridinyl 5-H), 7.07 (2H, ddd, J 8.1, 6.9 and 1.2, quinolinyl 6-H), 5.16 
(1H, br. s, NHminor), 5.05 (1H, br. s, NHmajor), 4.43 (1H, app. d, J 13.0, 7-HAminor), 
4.13 (1H, d, J 13.3, 5-HAmajor), 3.91 (2H, dd, J 11.4 and 4.5, 2-HA), 3.72-3.61 
(1H, m, 7-HAmajor), 3.48 (1H, d, J 13.3, 5-HAminor), 3.37-3.27 (3H, m, 2-HB and 7-
HBmajor), 3.25 (2H, s, 8a-H), 3.10 (2H, d, J 13.3, 5-HB), 3.04-2.82 (5H, m, 7-
HBminor and propanone 3-H2), 2.78-2.68 (4H, m, propanone 2-H2), 2.64 (1H, d, J 
13.8 pyridinylmethyl 1-HAminor), 2.52 (1H, d, J 13.6, pyridinylmethyl 1-HAmajor), 
2.27 (1H, d, J 13.8 pyridinylmethyl 1-HBminor), 2.09 (1H, d, J 13.6, pyridinylmethyl 
1-HBmajor), 2.05-1.97 (1H, m, 8-HAminor), 1.80-1.70 (1H, m, 8-HAmajor), 1.69-1.60 
(2H, m, 8-HB), 1.59 (9H, s, tBumajor), 1.54 (9H, s, tBuminor), 1.55-1.50 (2H, m, 3-
HA), 1.39-1.32 (2H, m, 3-HB), 1.30-1.23 (2H, m, 4-HA), 1.10-1.00 (2H, m, 4-HB); 
δC (100 MHz, CDCl3) 171.2 (propanone C2-1), 154.8 (quinolinyl C2-2), 151.6 
(pyridinyl C2-2), 147.7 (quinolinyl C2-8a), 147.0 (pyridinyl C2-6), 138.3 (pyridinyl 
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C2-4), 134.9 (quinolinyl C2-4), 132.4 (pyridinyl C2-3), 128.5 (quinolinyl C2-7), 
126.7 (quinolinyl C2-5), 126.5 (quinolinyl C2-8), 123.4 (quinolinyl C2-3), 123.0 
(quinolinyl C2-4a), 121.8 (quinolinyl C2-6), 121.7 (pyridinyl C2-5), 77.2 (C-
8amajor), 74.8 (C-8aminor), 67.9 (C2-2), 51.9 (tBu C2), 43.1 (C2-5), 41.0 (C2-7), 38.2 
(pyridinylmethyl C2-1), 36.4 (C2-4a), 31.8 (propanone C2-2), 30.8 (C2-4), 29.4 
(tBu C3major), 29.3 (tBu C3minor), 28.1 (C2-8), 27.1 (propanone C2-3), 22.1 (C2-3); 
HRMS found MH+, 487.3071. C30H38N4O2 requires MH, 487.3073. 
 
3-[2-(tert-Butylamino)quinolin-3-yl]-N-(cyclohexylmethyl)propanamide 
 
N
N
H
O
NHtBu
231i  
 
According to General Procedure AC, the amine derivative 232 (0.11 mL, 0.88 
mmol), TBD (61.2 mg, 0.44 mmol) and toluene (1.00 mL) were stirred overnight 
to give a crude material. The crude material was purified by flash column 
chromatography eluting with 20:80 EtOAc−hexane to yield the amide derivative 
231i192 (0.30 g, 98%) as a colourless amorphous solid, Rf 0.47 (60:40 
petrol−EtOAc); νmax/cm-1 3423, 3252, 3083, 2948, 2923, 2850, 1621, 1524, 
1449, 1413, 1352, 1271, 1222; δH (400 MHz, CDCl3) 7.68 (1H, d, J 8.2, 
quinolinyl 8-H), 7.50 (1H, s, quinolinyl 4-H), 7.49-7.40 (2H, m, quinolinyl 5,7-H2), 
7.15 (1H, ddd, J 7.9, 6.9 and 1.1, quinolinyl 6-H), 5.50 (1H, t, J 5.9, amide NH), 
5.03 (1H, br. s, tBu NH), 3.07 (2H, t, J 6.4, methylpropanamide 1-H2), 2.87 (2H, 
t, J 7.1, propanamide 3-H2), 2.48 (2H, t, J 7.1, propanamide 2-H2), 1.81-1.61 
(4H, m, 2-HA, 6-HA and 3,4,5-H2), 1.58 (9H, s, tBu), 1.36 (1H, app. dtp, J 14.1, 
6.6 and 3.5, 1-H), 1.22-1.02 (4H, m, 3,4,5-H4), 0.92-0.79 (2H, m, 2-HB and 6-
HB); δC (100 MHz, CDCl3) 172.0 (propanamide C-1), 154.8 (quinolinyl C-2), 
147.0 (quinolinyl C-8a), 134.5 (quinolinyl C-4), 128.4 (quinolinyl C-7), 126.7 
(quinolinyl C-5), 126.4 (quinolinyl C-8), 123.4 (quinolinyl C-3), 123.0 (quinolinyl 
C-4a), 121.6 (quinolinyl C-6), 51.8 (tBu C1), 46.0 (methylpropanamide C-1), 37.9 
(C-1), 35.7 (propanamide C-2), 30.9 (C2-2,6), 29.3 (tBu C3), 26.8 (propanamide 
C-3), 26.4 (C-4), 25.8 (C2-3,5); HRMS found MH+, 368.2695. C23H33N3O 
requires MH, 368.2701. 
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3-[2-(tert-Butylamino)quinolin-3-yl]-N-[(oxolan-3-yl)methyl]propanamide 
 
N
N
H
O
NHtBu
231j
O
 
 
According to General Procedure AC, the amine derivative 233 (0.10 g, 0.98 
mmol), TBD (68.2 mg, 0.49 mmol) and toluene (1.00 mL) were stirred overnight 
to give a crude material. The crude material was purified by flash column 
chromatography eluting with 50:50→100:0 EtOAc−hexane to yield the amide 
derivative 231j (0.32 g, 90%) as a yellow oil, Rf 0.45 (EtOAc); νmax/cm-1 3307, 
2959, 2928, 2866, 1644, 1623, 1516, 1485, 1448, 1414, 1355, 1273, 1212; δH 
(400 MHz, CDCl3) 7.69 (1H, d, J 8.3, quinolinyl 8-H), 7.51 (1H, s, quinolinyl 4-
H), 7.49-7.42 (2H, m, quinolinyl 5,7-H2), 7.16 (1H, t, J 7.4, quinolinyl 6-H), 5.71 
(1H, t, J 6.1, amide NH), 5.01 (1H, br. s, tBu NH), 3.79 (1H, app. td, J 8.3 and 
5.3, 5-HA), 3.74-3.60 (2H, m, 2-HA and 5-HB), 3.45 (1H, dd, J 8.8 and 5.1, 2-HB), 
3.23 (2H, t, J 6.4, methylpropanamide 1-H2), 2.87 (2H, t, J 7.1, propanamide 3-
H2), 2.49 (2H, t, J 7.1, propanamide 2-H2), 2.37 (1H, app. hept, J 6.6, 3-H), 
1.98-1.84 (1H, m, 4-HA), 1.59 (9H, s, tBu), 1.54-1.41 (1H, m, 4-HB); δC (100 
MHz, CDCl3) 172.3 (propanamide C-1), 154.7 (quinolinyl C-2), 147.0 (quinolinyl 
C-8a), 134.5 (quinolinyl C-4), 128.5 (quinolinyl C-7), 126.7 (quinolinyl C-5), 
126.4 (quinolinyl C-8), 123.2 (quinolinyl C-3), 123.0 (quinolinyl C-4a), 121.7 
(quinolinyl C-6), 71.3 (C-2), 67.7 (C-5), 51.9 (tBu C1), 42.6 (methylpropanamide 
C-1), 39.0 (C-3), 35.6 (propanamide C-2), 29.8 (C-4), 29.3 (tBu C3), 26.7 
(propanamide C-3); HRMS found MH+, 356.2334. C21H29N3O2 requires MH, 
356.2338. 
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3‐[2‐(tert‐Butylamino)quinolin‐3‐yl]‐1‐(morpholin‐4‐yl)propan‐1‐one 
 
N
N
O
NHtBu
O
231k  
 
According to General Procedure AC, the amine derivative 234 (71.6 µL, 0.83 
mmol), TBD (57.7 mg, 0.41 mmol) and toluene (1.00 mL) were stirred for 4 days 
to give a crude material. The crude material was purified by flash column 
chromatography eluting with 50:50 EtOAc−hexane to yield the amide derivative 
231k (0.16 g, 56%) as a pale yellow oil, Rf 0.36 (40:60 petrol−EtOAc); νmax/cm-1 
3452, 3391, 2954, 2915, 2860, 2242, 1639, 1624, 1515, 1419, 1354, 1272, 
1216, 1116; δH (400 MHz, CDCl3) 7.68 (1H, d, J 8.3, quinolinyl 8-H), 7.52 (1H, s, 
quinolinyl 4-H), 7.50 (1H, dd, J 8.0 and 1.5, quinolinyl 5-H), 7.46 (1H, ddd, J 8.3, 
7.0 and 1.5, quinolinyl 7-H), 7.16 (1H, ddd, J 8.0, 7.0 and 1.2, quinolinyl 6-H), 
5.09 (1H, br. s, NH), 3.63 (4H, app. s, 2-HA, 3-HA, 5-HA and 6-HA), 3.55-3.49 
(2H, m, 2-HB and 6-HB), 3.42-3.36 (2H, m, 3-HB and 5-HB), 2.92 (2H, t, J 7.1, 
propanone 3-H2), 2.65 (2H, t, J 7.1, propanone 2-H2), 1.58 (9H, s, tBu); δC (100 
MHz, CDCl3) 170.8 (propanone C-1), 154.8 (quinolinyl C-2), 147.0 (quinolinyl C-
8a), 134.6 (quinolinyl C-4), 128.5 (quinolinyl C-7), 126.6 (quinolinyl C-5), 126.5 
(quinolinyl C-8), 123.5 (quinolinyl C-3), 123.0 (quinolinyl C-4a), 121.7 (quinolinyl 
C-6), 66.9 (CA-2,6), 66.5 (CB-2,6), 51.8 (tBu C1), 46.0 (CA-3,5), 42.2 (CB-3,5), 
31.8 (propanone C-2), 29.3 (tBu C3), 26.6 (propanone C-3); HRMS found MH+, 
342.2179. C20H27N3O2 requires MH, 342.2181. 
 
1‐(3‐Benzylpiperidin‐1‐yl)‐3‐[2‐(tert‐butylamino)quinolin‐3‐yl]propan‐1‐one 
 
N
N
O
NHtBu
231l  
 
According to General Procedure AC, the amine hydrochloride derivative 235 
(67.1 mg, 0.32 mmol), TBD (0.10 g, 0.72 mmol) and toluene (2.00 mL) were 
stirred for 2 days to give a crude material. The crude material was purified by 
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flash column chromatography eluting with 20:80 EtOAc−hexane to yield the 
amide derivative 231l (50.0 mg, 37%, rotamers 51:49 by 1H-NMR) as a 
colourless oil, Rf 0.37 (70:30 petrol−EtOAc); νmax/cm-1 3455, 2942, 2923, 2869, 
2848, 1645, 1623, 1517, 1489, 1449, 1437, 1420, 1353, 1278, 1215, 1194, 
1175; δH (400 MHz, CDCl3) 7.71 (2H, dd, J 8.3 and 3.7, quinolinyl 8-H), 7.57-
7.38 (6H, m, quinolinyl 4,5,7-H3), 7.33-7.06 (12H, phenyl and quinolinyl 6-H), 
5.19 (1H, br. s, NHminor), 5.17 (1H, br. s, NHmajor), 4.55 (1H, ddt, J 12.9, 3.8 and 
1.7, phenylmethyl 1-HAminor), 4.44 (1H, app. dt, J 12.9 and 3.8, phenylmethyl 1-
HAmajor), 3.74 (1H, app. dt, J 12.4 and 4.2, phenylmethyl 1-HBminor), 3.66-3.59 
(1H, m, phenylmethyl 1-HBmajor), 2.97 (2H, app. dd, J 12.0 and 2.8, 6-H2major), 
2.93 (2H, t, J 7.2, propanone 3-H2minor), 2.84 (2H, t, J 7.2, propanone 3-H2major), 
2.78-2.70 (2H, m, 6-H2minor), 2.69-2.62 (4H, m, 2-H2major and propanone 2-
H2minor), 2.55-2.48 (2H, m, propanone 2-H2major), 2.47-2.38 (2H, m, 2-H2minor), 
1.86-1.62 (6H, m, 3-H, 4-HA and 5-HA), 1.60 (18H, s, tBu), 1.49-1.07 (4H, m, 4-
HB and 5-HB); δC (100 MHz, CDCl3) 170.5 (propanone C-1minor), 170.4 
(propanone C-1major), 154.9 (quinolinyl C2-2), 147.0 (quinolinyl C2-8a), 139.5 
(phenyl C-1minor), 139.3 (phenyl C-1major), 134.5 (quinolinyl C-4major), 134.3 
(quinolinyl C-4minor), 129.1 (phenyl C2-2,6minor), 128.8 (phenyl C2-2,6major), 128.6 
(quinolinyl C2-7), 128.4 (phenyl C2-3,5major), 128.3 (phenyl C2-3,5minor), 126.6 
(quinolinyl C2-5), 126.4 (quinolinyl C2-8), 126.1 (phenyl C2-4), 124.0 (quinolinyl 
C-3major), 123.8 (quinolinyl C-3minor), 123.1 (quinolinyl C2-4a), 121.6 (quinolinyl 
C2-6), 51.8 (tBu C2), 51.3 (C-2major), 48.0 (C-2minor), 46.4 (phenylmethyl C-1minor), 
42.9 (phenylmethyl C-1major), 40.3 (C-6minor), 40.0 (C-6major), 38.8 (phenylmethyl 
C-3major), 37.8 (phenylmethyl C-3minor), 32.2 (propanone C-2minor), 31.9 
(propanone C-2major), 30.9 (C-4major), 30.8 (C-4minor), 29.4 (tBu C6), 26.7 
(propanone C-3minor), 26.5 (propanone C-3major), 25.8 (C-5minor), 24.7 (C-5major); 
HRMS found MH+, 430.2858. C28H35N3O requires MH, 430.2858. 
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3-[2-(tert-Butylamino)quinolin-3-yl]-N-[(oxan-3-yl)methyl]propanamide 
 
N
N
H
O
NHtBu
231m
O
 
 
According to General Procedure AC, the amine hydrochloride derivative 236 
(48.1 mg, 0.32 mmol), TBD (0.10 g, 0.72 mmol) and toluene (2.00 mL) were 
stirred for 2 days to give a crude material. The crude material was purified by 
flash column chromatography eluting with 60:40 EtOAc−hexane to yield the 
amide derivative 231m (50.0 mg, 43%) as a colourless oil, Rf 0.45 (30:70 
petrol−EtOAc); νmax/cm-1 3429, 3294, 3089, 2953, 2920, 2843, 1641, 1622, 
1557, 1518, 1448, 1413, 1354, 1212, 1089; δH (400 MHz, CDCl3) 7.67 (1H, dd, 
J 8.4 and 1.2, quinolinyl 8-H), 7.49 (1H, s, quinolinyl 4-H), 7.48-7.42 (2H, m, 
quinolinyl 5,7-H2), 7.14 (1H, ddd, J 8.0, 7.0 and 1.2, quinolinyl 6-H), 5.61 (1H, t, 
J 6.2, amide NH), 5.00 (1H, br. s, tBu NH), 3.81-3.72 (2H, m, 2-HA and 6-HA), 
3.35 (1H, ddd, J 11.2, 9.7 and 3.3, 6-HB), 3.14-3.11 (1H, m, 2-HB), 3.10 (2H, t, J 
6.2, methylpropanamide 1-H2), 2.85 (2H, t, J 7.1, propanamide 3-H2), 2.47 (2H, 
t, J 7.1, propanamide 2-H2), 1.76-1.63 (2H, m, 3-H and 4-HA), 1.58 (9H, s, tBu), 
1.55-1.45 (2H, m, 5-H2), 1.16 (1H, app. dtd, J 13.7, 10.5 and 4.6, 4-HB); δC (100 
MHz, CDCl3) 172.2 (propanamide C-1), 154.7 (quinolinyl C-2), 147.0 (quinolinyl 
C-8a), 134.5 (quinolinyl C-4), 128.5 (quinolinyl C-7), 126.7 (quinolinyl C-5), 
126.4 (quinolinyl C-8), 123.3 (quinolinyl C-3), 123.0 (quinolinyl C-4a), 121.7 
(quinolinyl C-6), 71.1 (C-2), 68.5 (C-6), 51.9 (tBu C1), 41.7 (methylpropanamide 
C-1), 36.3 (C-3), 35.5 (propanamide C-2), 29.3 (tBu C3), 27.3 (C-4), 26.7 
(propanamide C-3), 25.0 (C-5); HRMS found MH+, 370.2488. C22H31N3O2 
requires MH, 370.2494. 
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3‐(2‐Aminoquinolin‐3‐yl)‐1‐[(5R*,6R*)‐5‐hydroxy‐2‐oxa‐8‐azaspiro[5.5]unde
can‐8‐yl]propan‐1‐one 
N
N
O
NH2
215
O
HO
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231a (11.3 mg, 26.5 µmol) were stirred for 3 h to give a crude material. The 
crude material was purified by flash column chromatography eluting with 
93.9:5.42:0.68 DCM−EtOH−NH4OH to yield the amine derivative 215 (9.80 mg, 
>99%, rotamers 78:22 by 1H-NMR) as a pale yellow oil, Rf 0.68 (84.7:13.6:1.70 
DCM−EtOH−NH4OH); νmax/cm-1 3337, 3200, 2929, 2854, 1617, 1498, 1468, 
1432, 1260, 1233, 1132, 1083, 1002; δH (400 MHz, CDCl3) 7.70 (2H, app. d, J 
10.1, quinolinyl 4-H), 7.63 (2H, d, J 8.4, quinolinyl 8-H), 7.57 (2H, dd, J 8.0 and 
1.6, quinolinyl 5-H), 7.50 (2H, ddd, J 8.4, 6.9 and 1.6, quinolinyl 7-H), 7.23 (2H, 
app. tt, J 8.0 and 1.3, quinolinyl 6-H), 5.39 (2H, br. s, NH2minor), 5.37 (2H, br. s, 
NH2major), 4.27 (1H, app. d, J 13.1, 9-HAminor), 3.85-3.75 (2H, m, 3-HA), 3.74-3.62 
(2H, m, 3-HB), 3.60 (2H, d, J 11.9, 1-HA), 3.56-3.50 (4H, m, 5-H and 7-HA), 3.46-
3.36 (1H, m, 9-HAmajor), 3.35-3.25 (1H, m, 9-HBmajor), 3.10 (2H, d, J 12.6, 7-HB), 
3.05-2.75 (7H, m, 1-HB, 9-HBminor and propanone 3-H2), 2.74-2.55 (4H, m, 
propanone 2-H2), 2.12-1.81 (2H, m, 4-HA), 1.75-1.65 (2H, m, 10-HA), 1.64-1.44 
(8H, m, 4-HB, 10-HB and 11-H2); δC (100 MHz, CDCl3) 171.3 (propanone C-
1minor), 171.1 (propanone C-1major), 156.7 (quinolinyl C2-2), 146.7 (quinolinyl C2-
8a), 136.7 (quinolinyl C2-4), 129.2 (quinolinyl C2-7), 127.0 (quinolinyl C2-5), 
125.5 (quinolinyl C2-8), 124.3 (quinolinyl C2-3), 123.5 (quinolinyl C2-4a), 122.7 
(quinolinyl C-6major), 122.6 (quinolinyl C-6minor), 70.6 (C-1major), 69.8 (C-5major), 
69.7 (C-5minor), 68.4 (C-1minor), 65.3 (C-3minor), 64.2 (C-3major), 50.3 (C-7minor), 
47.6 (C-7major), 46.6 (C-9major), 42.9 (C-9minor), 39.0 (C-6major), 38.9 (C-6minor), 
32.4 (propanone C-2major), 32.3 (propanone C-2minor), 30.7 (C2-4), 26.9 
(propanone C-3minor), 26.6 (propanone C-3major), 21.3 (C2-10), 20.5 (C2-11); 
HRMS found MH+, 370.2123. C21H27N3O3 requires MH, 370.2130. 
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3‐(2‐Aminoquinolin‐3‐yl)‐1‐[(5R*,10R*)‐10‐hydroxy‐7‐oxa‐2‐azaspiro[4.5]de
can‐2‐yl]propan‐1‐one 
N
N
O
NH2
216
O
HO
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231b (10.0 mg, 24.3 µmol) were stirred for 3 h to give the amine derivative 216 
(8.00 mg, 93%, rotamers >95:<5 by 1H-NMR) as a colourless oil, Rf 0.63 
(84.7:13.6:1.70 DCM−EtOH−NH4OH); νmax/cm-1 3410, 3324, 3149, 2941, 2878, 
2850, 1655, 1624, 1473, 1438, 1340, 1328, 1134, 1108, 1086, 1068; δH (400 
MHz, CDCl3) 7.67 (2H, d, J 5.3, quinolinyl 4-H), 7.62 (2H, d, J 8.4, quinolinyl 8-
H), 7.55 (2H, d, J 8.0, quinolinyl 5-H), 7.50 (2H, ddd, J 8.4, 6.8 and 1.5, 
quinolinyl 7-H), 7.22 (2H, app. t, J 7.4, quinolinyl 6-H), 5.76 (2H, br. s, NHmajor), 
5.70 (2H, br. s, NHminor), 3.93-3.81 (2H, m, 8-HA), 3.74-3.65 (2H, m, 10-H), 3.63 
(2H, d, J 12.5, 6-HA), 3.56-3.45 (4H, m, 3-HA and 8-HB), 3.44-3.33 (4H, m, 1-HA 
and 3-HB), 3.32-3.24 (2H, m, 1-HB), 3.19-3.10 (2H, app. dd, J 11.6 and 2.4, 6-
HB), 2.98 (4H, t, J 6.8, propanone 3-H2), 2.62 (4H, t, J 6.8, propanone 2-H2), 
2.08 (2H, app. dt, J 12.9 and 9.1, 4-HA), 1.98-1.86 (2H, m, 4-HB), 1.85-1.75 (2H, 
m, 9-HA), 1.69-1.55 (2H, m, 9-HB); δC (100 MHz, CDCl3) 171.2 (propanone C-
1major), 171.1 (propanone C-1minor), 156.7 (quinolinyl C2-2), 146.0 (quinolinyl C-
8aminor), 145.8 (quinolinyl C-8amajor), 137.0 (quinolinyl C2-4), 129.4 (quinolinyl C2-
7), 127.0 (quinolinyl C2-5), 124.9 (quinolinyl C-8minor), 124.8 (quinolinyl C-8major), 
124.1 (quinolinyl C-3minor), 124.0 (quinolinyl C-3major), 123.8 (quinolinyl C-
4amajor), 123.7 (quinolinyl C-4aminor), 122.8 (quinolinyl C2-6), 71.4 (C-6major), 70.6 
(C-6minor), 69.8 (C-10major), 69.5 (C-10minor), 65.7 (C-8major), 65.0 (C-8minor), 51.8 
(C-3minor), 51.1 (C-3major), 48.5 (C-5minor), 46.5 (C-5major), 45.6 (C-1major), 44.7 (C-
1minor), 34.1 (propanone C2-2), 33.9 (C2-9), 32.4 (C-4major), 32.3 (C-4minor), 26.1 
(propanone C-3minor), 26.0 (propanone C-3major); HRMS found MH+, 356.1971. 
C20H25N3O3 requires MH, 356.1974. 
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3‐(2‐Aminoquinolin‐3‐yl)‐1‐[(4R*,5S*)‐4‐hydroxy‐2‐oxa‐7‐azaspiro[4.4]nona
n‐7‐yl]propan‐1‐one 
N
N
O
NH2
217
O
HO
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231c (20.0 mg, 50.3 µmol) were stirred for 3 h to give the amine derivative 217 
(17.1 mg, >99%, rotamers 53:47 by 1H-NMR) as a colourless oil, Rf 0.51 
(84.7:13.6:1.70 DCM−EtOH−NH4OH); νmax/cm-1 3326, 3148, 2919, 2872, 1625, 
1567, 1471, 1431, 1362, 1327, 1216, 1124, 1054; δH (400 MHz, CDCl3) 7.66 
(2H, s, quinolinyl 4-H), 7.59 (2H, dd, J 8.4 and 5.2, quinolinyl 8-H), 7.55 (2H, d, 
J 8.0, quinolinyl 5-H), 7.49 (2H, app. ddt, J 8.4, 6.8 and 1.6, quinolinyl 7-H), 
7.21 (2H, ddd, J 8.0, 6.8 and 1.2, quinolinyl 6-H), 5.61 (4H, br. s, NH2), 4.01-
3.87 (2H, m, 4-H), 3.81-3.69 (6H, m, 1-H2 and 3-HA), 3.68-3.55 (2H, m, 3-HB), 
3.54-3.44 (2H, m, 8-HA), 3.43-3.38 (2H, m, 8-HB), 3.21 (2H, d, J 10.3, 6-HA), 
3.08 (2H, d, J 10.3, 6-HB), 3.05-2.86 (4H, m, propanone 3-H2), 2.66-2.50 (4H, 
m, propanone 2-H2), 2.31 (1H, ddd, J 13.2, 7.8 and 5.7, 9-HAmajor), 2.22 (1H, 
ddd, J 13.2, 7.6 and 5.8, 9-HAminor), 1.80 (1H, app. dt, J 12.9 and 7.6, 9-HBmajor), 
1.71 (1H, app. dt, J 13.0 and 7.8, 9-HBminor); δC (100 MHz, CDCl3) 171.2 
(propanone C2-1), 156.7 (quinolinyl C2-2), 146.2 (quinolinyl C2-8a), 137.1 
(quinolinyl C-4minor), 137.0 (quinolinyl C-4major), 129.5 (quinolinyl C-7minor), 129.4 
(quinolinyl C-7major), 127.1 (quinolinyl C2-5), 125.0 (quinolinyl C-8major), 124.9 
(quinolinyl C-8minor), 124.1 (quinolinyl C-3major), 124.0 (quinolinyl C-3minor), 123.5 
(quinolinyl C2-4a), 122.9 (quinolinyl C-6minor), 122.8 (quinolinyl C-6major), 75.3 
(C2-1), 74.9 (C2-4), 74.4 (C2-3), 55.5 (C-6minor), 54.7 (C-5minor), 54.4 (C-6major), 
52.7 (C-5major), 46.1 (C-8major), 45.3 (C-8minor), 34.3 (propanone C-2minor), 33.7 
(propanone C-2major), 28.3 (C2-9), 26.3 (propanone C-3major), 26.2 (propanone 
C-3minor); HRMS found MH+, 342.1807. C19H23N3O3 requires MH, 342.1817. 
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3‐(2‐Aminoquinolin‐3‐yl)‐1‐[(2R*,3R*)‐3‐hydroxy‐5‐methoxy‐1,3‐dihydros 
piro[indene‐2,3'‐pyrrolidin]‐1'‐yl]propan‐1‐one 
 
N
N
O
NH2
218
HO
OMe
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231d (18.0 mg, 38.0 µmol) were stirred for 3 h to give a crude material. The 
crude material was purified by flash column chromatography eluting with 
95.4:4.08:0.52 DCM−EtOH−NH4OH to yield the amine derivative 218 (5.00 mg, 
32%, rotamers 53:47 by 1H-NMR) as a colourless oil, Rf 0.27 (92.4:6.76:0.84 
DCM−EtOH−NH4OH); νmax/cm-1 3341, 3214, 3057, 2960, 2921, 1613, 1490, 
1432, 1259, 1095, 1019; δH (400 MHz, CDCl3) 7.75-7.45 (8H, m, quinolinyl 
4,5,7,8-H4), 7.23-7.15 (2H, m, quinolinyl 6-H), 7.07-7.00 (2H, m, 7-H), 6.88 (2H, 
app. ddd, J 9.4, 7.2 and 2.5, 4-H), 6.79 (2H, dd, J 8.3 and 2.6, 6-H), 5.51 (2H, 
br. s, NHminor), 5.47 (2H, br. s, NHmajor), 4.64 (1H, s, 3-Hmajor), 4.50 (1H, s, 3-
Hminor), 3.78 (3H, methoxyminor), 3.77 (3H, methoxymajor), 3.75-3.63 (2H, m, 5’-
HA), 3.61-3.49 (2H, m, 5’-HB), 3.42-3.23 (2H, m, 2’-HA), 3.22-3.11 (2H, m, 2’-
HB), 3.10-2.95 (4H, m, propanone 3-H2), 2.94-2.81 (2H, m, 1-HA), 2.73-2.61 
(4H, m, propanone 2-H2), 2.60-2.49 (2H, m, 1-HB), 2.37-2.28 (1H, m, 4’-HAminor), 
2.27-2.18 (1H, m, 4’-HAmajor), 1.96-1.84 (1H, m, 4’-HBminor), 1.83-1.65 (1H, m, 4’-
HBmajor); δC (100 MHz, CDCl3) 171.3 (propanone C-1major), 171.2 (propanone C-
1minor), 159.4 (C-5major), 159.3 (C-5minor), 156.8 (quinolinyl C2-2), 146.7 (quinolinyl 
C-8aminor), 146.6 (quinolinyl C-8amajor), 145.0 (C-3amajor), 144.9 (C-3aminor), 136.8 
(quinolinyl C-4major), 136.7 (quinolinyl C-4minor), 133.1 (C-7aminor), 132.9 (C-
7amajor), 129.3 (quinolinyl C-7major), 129.2 (quinolinyl C-7minor), 127.0 (quinolinyl 
C2-5), 126.0 (C-7minor), 125.8 (C-7major), 125.5 (quinolinyl C-8major), 125.3 
(quinolinyl C-8minor), 124.3 (quinolinyl C2-3), 123.6 (quinolinyl C2-4a), 122.7 
(quinolinyl C-6minor), 122.6 (quinolinyl C-6major), 115.2 (C-6minor), 115.1 (C-6major), 
109.8 (C-4major), 109.7 (C-4minor), 80.0 (C-3major), 79.4 (C-3minor), 56.7 (C2-2’), 
55.6 (methoxy), 54.1 (C-2major), 53.9 (C-2minor), 46.3 (C-5’major), 45.3 (C-5’minor), 
40.3 (C-1minor), 40.0 (C-1major), 36.0 (C2-4’), 34.4 (propanone C-2major), 33.9 
(propanone C-2minor), 26.4 (propanone C-3minor), 26.2 (propanone C-3major); 
HRMS found MH+, 418.2125. C25H27N3O3 requires MH, 418.2130. 
226 
 
N‐{[(4aR*,8aR*)‐Octahydropyrano[4,3‐b]pyran‐4a‐yl]methyl}‐3‐(2‐aminoqui
nolin‐3‐yl)propanamide 
N
N
H
O
NH2
219
O
HO
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231e (11.7 mg, 27.5 µmol) were stirred for 3 h to give the amine derivative 219 
(10.0 mg, 98%) as a colourless oil, Rf 0.43 (92.4:6.76:0.84 
DCM−EtOH−NH4OH); νmax/cm-1 3316, 3209, 3058, 2930, 2859, 1632, 1555, 
1498, 1433, 1258, 1235, 1097, 1078, 1024; δH (400 MHz, CDCl3) 7.67 (1H, s, 
quinolinyl 4-H), 7.62 (1H, dd, J 8.3 and 1.2, quinolinyl 8-H), 7.55 (1H, dd, J 8.1 
and 1.5, quinolinyl 5-H), 7.50 (1H, ddd, J 8.3, 6.9 and 1.5, quinolinyl 7-H), 7.22 
(1H, ddd, J 8.1, 6.9 and 1.2, quinolinyl 6-H), 6.03 (1H, t, J 6.3, amide NH), 5.29 
(2H, br. s, NH2), 3.92-3.84 (1H, m, 2-HA), 3.80 (1H, d, J 11.7, 5-HA), 3.66-3.59 
(2H, m, 7-H2), 3.37 (1H, dd, J 13.9 and 6.7, methylpropanamide 1-HA), 3.32-
3.24 (2H, m, 8a-H and methylpropanamide 1-HB), 3.23-3.15 (1H, m, 2-HB), 3.21 
(1H, d, J 11.7, 5-HB), 2.99 (2H, t, J 7.1, propanamide 3-H2), 2.58 (2H, t, J 7.1, 
propanamide 2-H2), 2.03-1.88 (1H, m, 8-HA), 1.62-1.49 (1H, m, 3-HA), 1.48-1.40 
(1H, m, 8-HB), 1.31-1.12 (3H, m, 3-HB and 4-H2); δC (100 MHz, CDCl3) 172.5 
(propanamide C-1), 156.4 (quinolinyl C-2), 146.6 (quinolinyl C-8a), 136.8 
(quinolinyl C-4), 129.3 (quinolinyl C-7), 127.0 (quinolinyl C-5), 125.5 (quinolinyl 
C-8), 124.3 (quinolinyl C-3), 122.8 (quinolinyl C-6), 122.7 (quinolinyl C-4a), 74.7 
(C-8a), 67.8 (C-5), 67.6 (C-2), 63.4 (C-7), 45.1 (methylpropanamide C-1), 36.3 
(C-4a), 36.0 (propanamide C-2), 28.7 (C-4), 28.6 (C-8), 26.9 (propanamide C-
3), 22.1 (C-3); HRMS found MH+, 370.2120. C21H27N3O3 requires MH, 
370.2130. 
 
 
 
 
 
 
 
227 
 
N-{[(4aR*,7aS*)-Hexahydro-2H-furo[3,4-b]pyran-4a-yl]methyl}-3-(2-
aminoquinolin-3-yl)propanamide 
 
N
N
H
O
NH2
220
O
O
H
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231f (11.0 mg, 26.7 µmol) were stirred for 3 h to give the amine derivative 220 
(10.0 mg, >99%) as a pale yellow oil, Rf 0.65 (84.7:13.6:1.70 
DCM−EtOH−NH4OH); νmax/cm-1 3322, 3206, 3055, 2927, 2876, 1632, 1550, 
1498, 1472, 1433, 1262, 1097, 1082, 1055; δH (400 MHz, CDCl3) 7.69 (1H, s, 
quinolinyl 4-H), 7.62 (1H, d, J 8.4, quinolinyl 8-H), 7.55 (1H, dd, J 8.0 and 1.5, 
quinolinyl 5-H), 7.50 (1H, ddd, J 8.4, 6.9 and 1.5, quinolinyl 7-H), 7.23 (1H, ddd, 
J 8.0, 6.9 and 0.9, quinolinyl 6-H), 6.12 (1H, t, J 5.3, amide NH), 5.51 (2H, br. s, 
NH2), 4.00 (1H, dd, J 10.1 and 4.1, 7-HA), 3.78 (1H, d, J 8.5, 5-HA), 3.82-3.75 
(1H, m, 2-HA), 3.71 (1H, d, J 10.1, 7-HB), 3.60 (1H, d, J 4.0, 7a-H), 3.46 (1H, d, 
J 8.5, 5-HB), 3.24 (1H, dd, J 13.9 and 6.2, methylpropanamide 1-HA), 3.17-3.05 
(2H, m, 2-HB and methylpropanamide 1-HB), 3.00 (2H, t, J 7.0, propanamide 3-
H2), 2.59 (2H, t, J 7.0, propanamide 2-H2), 1.65-1.52 (1H, m, 3-HA), 1.51-1.44 
(2H, m, 4-H2), 1.36-1.27 (1H, m, 3-HB); δC (100 MHz, CDCl3) 172.7 
(propanamide C-1), 156.2 (quinolinyl C-2), 145.9 (quinolinyl C-8a), 137.2 
(quinolinyl C-4), 129.6 (quinolinyl C-7), 127.1 (quinolinyl C-5), 125.0 (quinolinyl 
C-8), 124.1 (quinolinyl C-3), 123.0 (quinolinyl C-6), 122.7 (quinolinyl C-4a), 80.3 
(C-7a), 74.2 (C-7), 71.1 (C-5), 66.1 (C-2), 53.5 (C-4a), 45.5 
(methylpropanamide C-1), 35.8 (propanamide C-2), 24.9 (propanamide C-3), 
24.5 (C-4), 21.5 (C-3); HRMS found MH+, 356.1968. C20H25N3O3 requires MH, 
356.1974. 
 
 
 
 
 
 
 
228 
 
1‐[(4aR*,8aR*)‐4a‐benzyl‐octahydro‐2H‐pyrano[3,2‐c]pyridin‐6‐yl]‐3‐(2‐amin
oquinolin‐3‐yl)propan‐1‐one 
N
N
O
NH2
221
O
H
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231g (10.5 mg, 21.6 µmol) were stirred for 3 h to give the amine derivative 221 
(9.20 mg, >99%, rotamers 69:31 by 1H-NMR) as a pale yellow oil, Rf 0.27 
(EtOAc); νmax/cm-1 3329, 3177, 3052, 3026, 2932, 2852, 1620, 1497, 1470, 
1431, 1264, 1118, 1091, 1075; δH (400 MHz, CDCl3) 7.73 (2H, s, quinolinyl 4-
H), 7.63 (2H, d, J 8.4, quinolinyl 8-H), 7.54 (2H, dd, J 8.2 and 1.4, quinolinyl 5-
H), 7.49 (2H, ddd, J 8.4, 6.9 and 1.4, quinolinyl 7-H), 7.31-7.19 (8H, m, phenyl 
3,4,5-H3 and quinolinyl 6-H), 7.18-7.13 (2H, m, phenyl 2,6-H2major), 7.07-7.01 
(2H, m, phenyl 2,6-H2minor), 5.43 (4H, br. s, NH2), 4.17 (1H, d, J 13.2, 5-HAmajor), 
4.39 (1H, app. d, J 13.3, 7-HAminor), 3.96-3.82 (2H, m, 2-HA), 3.71-3.60 (1H, m, 
7-HAmajor), 3.54 (1H, d, J 13.2, 5-HAminor), 3.40-3.21 (5H, m, 2-HB, 7-HBmajor and 
8a-H), 3.13 (2H, d, J 13.2, 5-HB), 3.10-2.97 (5H, m, 7-HBminor and propanone 3-
H2), 2.94-2.71 (5H, m, phenylmethyl 1-HAminor and propanone 2-H2), 2.64 (1H, d, 
J 13.4, phenylmethyl 1-HAmajor), 2.48 (1H, d, J 13.4, phenylmethyl 1-HBminor), 
2.26 (1H, d, J 13.4, phenylmethyl 1-HBmajor), 2.15-2.06 (1H, m, 8-HAminor), 2.00-
1.85 (1H, m, 8-HAmajor), 1.80-1.53 (4H, m, 3-HA and 8-HB), 1.49-1.31 (4H, m, 3-
HB and 4-HA), 1.18-1.05 (2H, m, 4-HB); δC (100 MHz, CDCl3) 171.2 (propanone 
C2-1), 156.6 (quinolinyl C2-2), 146.6 (quinolinyl C2-8a), 136.7 (phenyl C2-1), 
136.6 (quinolinyl C2-4), 130.9 (phenyl C2-2,6major), 130.7 (phenyl C2-2,6minor) 
129.2 (quinolinyl C2-7), 128.3 (phenyl C2-3,5minor), 128.1 (phenyl C2-3,5major), 
127.0 (quinolinyl C2-5), 126.4 (quinolinyl C2-8), 125.5 (phenyl C2-4), 124.3 
(quinolinyl C2-3), 123.6 (quinolinyl C-4aminor), 123.5 (quinolinyl C-4amajor), 122.7 
(quinolinyl C2-6), 77.2 (C-8amajor), 75.4 (C-8aminor), 67.9 (C2-2), 48.7 (C-5minor), 
43.6 (C-5major), 41.4 (phenylmethyl C2-1), 40.9 (C-7major), 37.3 (C-7minor), 36.6 
(C2-4a), 32.7 (propanone C2-2), 30.7 (C2-4), 28.0 (C2-8), 26.7 (propanone C2-3), 
22.3 (C2-3); HRMS found MH+, 430.2488. C27H31N3O2 requires MH, 430.2494. 
 
229 
 
1‐[(4aR*,8aR*)‐4a‐[(Pyridin‐3‐yl)methyl]‐octahydro‐2H‐pyrano[3,2‐c]pyridin‐
6‐yl]‐3‐(2‐aminoquinolin‐3‐yl)propan‐1‐one 
 
N
N
O
NH2
222
O
H
N
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231h (10.3 mg, 21.2 µmol) were stirred for 3 h to give the amine derivative 222 
(9.00 mg, 99%, rotamers 80:20 by 1H-NMR) as a colourless amorphous solid, 
Rf 0.43 (92.4:6.76:0.84 DCM−EtOH−NH4OH); νmax/cm-1 3332, 3173, 3048, 
2929, 2852, 1619, 1471, 1432, 1272, 1259, 1118, 1089; δH (400 MHz, CDCl3) 
8.46 (2H, dd, J 4.8 and 1.7, pyridinyl 6-H), 8.33 (1H, d, J 2.3, pyridinyl 2-Hmajor), 
8.30 (1H, d, J 2.3, pyridinyl 2-Hminor), 7.72 (1H, s, quinolinyl 4-Hmajor), 7.70 (1H, 
s, quinolinyl 4-Hminor), 7.64-7.57 (4H, m, pyridinyl 4-H and quinolinyl 8-H), 7.53-
7.40 (4H, m, quinolinyl 5,7-H2), 7.25-7.11 (4H, m, quinolinyl 6-H and pyridinyl 5-
H), 5.46 (4H, br. s, NH2), 4.39 (1H, app. d, J 13.2, 7-HAminor), 4.13 (1H, d, J 13.2, 
5-HAmajor), 2.93 (2H, app. dd, J 11.3 and 4.7, 2-HA), 3.67 (1H, ddd, J 11.0, 5.0 
and 2.6, 7-HAmajor), 3.56 (1H, d, J 13.3, 5-HAminor), 3.37-3.29 (3H, m, 2-HB and 7-
HBmajor), 3.28 (2H, s, 8a-H), 3.10 (2H, d, J 13.2, 5-HB), 3.07-2.98 (5H, m, 7-
HBminor and propanone 3-H2), 2.96-2.71 (4H, m, propanone 2-H2), 2.70 (1H, d, J 
13.6, pyridinylmethyl 1-HAminor), 2.55 (1H, d, J 13.6, pyridinylmethyl 1-HAmajor), 
2.37 (1H, d, J 13.6, pyridinylmethyl 1-HBminor), 2.13 (1H, d, J 13.6, 
pyridinylmethyl 1-HBmajor), 2.10-2.00 (1H, m, 8-HAminor), 1.85 (1H, app. tdd, J 
13.2, 5.0 and 2.9, 8-HAmajor), 1.74-1.59 (4H, m, 3-HA and 8-HB), 1.43-1.27 (4H, 
m, 3-HB and 4-HA), 1.10-1.00 (2H, m, 4-HB); δC (100 MHz, CDCl3) 171.2 
(propanone C2-1), 156.5 (quinolinyl C2-2), 151.6 (pyridinyl C2-2), 147.9 
(pyridinyl C2-6 and quinolinyl C2-8a), 138.2 (pyridinyl C2-4), 136.8 (quinolinyl C2-
4), 132.3 (pyridinyl C2-3), 129.3 (quinolinyl C2-7), 126.9 (quinolinyl C2-5), 125.4 
(quinolinyl C2-8), 124.2 (quinolinyl C2-3), 123.4 (quinolinyl C2-4a), 123.3 
(pyridinyl C2-5), 122.7 (quinolinyl C2-6), 77.3 (C-8amajor), 74.9 (C-8aminor), 68.0 
(C2-2), 43.1 (C2-5), 41.0 (C2-7), 38.3 (pyridinylmethyl C2-1), 36.5 (C2-4a), 32.5 
(propanone C2-2), 30.8 (C2-4), 28.1 (C2-8), 26.7 (propanone C2-3), 22.2 (C2-3); 
HRMS found MH+, 431.2438. C26H30N4O2 requires MH, 431.2447. 
230 
 
3-(2-Aminoquinolin-3-yl)-N-(cyclohexylmethyl)propanamide 
 
N
N
H
O
NH2
214  
 
According to General Procedure AD, TFA (2.00 mL) and the amide derivative 
231i (0.10 g, 0.27 mmol) were stirred for 1.5 h to give the amine derivative 
214192 (70.0 mg, 83%) as a colourless amorphous solid, Rf 0.37 (92.4:6.76:0.84 
DCM−EtOH−NH4OH); νmax/cm-1 3461, 3314, 3059, 2915, 2843, 1640, 1539, 
1500, 1437; δH (400 MHz, DMSO-d6) 7.86 (1H, t, J 5.9, NH), 7.69 (1H, s, 
quinolinyl 4-H), 7.56 (1H, d, J 8.0, quinolinyl 5-H), 7.50-7.36 (2H, m, quinolinyl 
7,8-H2), 7.14 (1H, ddd, J 8.0, 6.4 and 1.6, quinolinyl 6-H), 6.40 (2H, br. s, NH2), 
2.88 (2H, app. t, J 6.3, methylpropanamide 1-H2), 2.81 (2H, t, J 7.2, 
propanamide 3-H2), 2.46 (2H, t, J 7.2, propanamide 2-H2), 1.65-1.45 (4H, m, 2-
HA, 6-HA and 3,4,5-H2), 1.35-1.20 (1H, m, 1-H), 1.14-0.95 (4H, m, 3,4,5-H4), 
0.86-0.66 (2H, m, 2-HB and 6-HB); δC (100 MHz, DMSO-d6) 171.2 (propanamide 
C-1), 156.9 (quinolinyl C-2), 146.1 (quinolinyl C-8a), 134.7 (quinolinyl C-4), 
128.3 (quinolinyl C-7), 126.8 (quinolinyl C-8), 124.3 (quinolinyl C-5), 123.3 
(quinolinyl C-4a), 123.2 (quinolinyl C-3), 121.2 (quinolinyl C-6), 44.8 
(methylpropanamide C-1), 37.4 (C-1), 33.9 (propanamide C-2), 30.3 (C2-2,6), 
26.3 (propanamide C-3), 26.0 (C-4), 25.3 (C2-3,5); HRMS found MH+, 
312.2068. C19H25N3O requires MH, 312.2075. 
 
3-(2-Aminoquinolin-3-yl)-N-[(oxolan-3-yl)methyl]propanamide 
 
N
N
H
O
NH2
223
O
 
 
According to General Procedure AD, TFA (2.00 mL) and the amide derivative 
231j (0.10 g, 0.28 mmol) were stirred for 1.5 h to give a crude material. The 
crude material was purified by flash column chromatography eluting with 
92.4:6.76:0.84→84.7:13.6:1.70 DCM−EtOH−NH4OH to yield the amine 
derivative 223 (40.0 mg, 47%) as a colourless amorphous solid, Rf 0.61 
231 
 
(84.7:13.6:1.70 DCM−EtOH−NH4OH); νmax/cm-1 3476, 3329, 3083, 2965, 2924, 
2840, 1637, 1618, 1529, 1501, 1477, 1438, 1260, 1069; δH (400 MHz, CDCl3) 
7.57 (1H, app. d, J 7.9, quinolinyl 8-H), 7.56 (1H, s, quinolinyl 4-H), 7.50 (1H, 
dd, J 8.1 and 1.5, quinolinyl 5-H), 7.45 (1H, ddd, J 8.4, 6.9 and 1.5, quinolinyl 7-
H), 7.18 (1H, ddd, J 8.1, 6.9 and 1.2, quinolinyl 6-H), 6.32 (1H, t, J 6.0, amide 
NH), 5.36 (2H, br. s, NH2), 3.71 (1H, app. td, J 8.3 and 5.3, 5-HA), 3.64-3.50 
(2H, m, 2-HA and 5-HB), 3.38 (1H, dd, J 8.8 and 5.1, 2-HB), 3.25-3.08 (2H, m, 
methylpropanamide 1-H2), 2.89 (2H, t, J 7.1, propanamide 3-H2), 2.47 (2H, t, J 
7.1, propanamide 2-H2), 2.31 (1H, app. ddt, J 8.3, 6.9 and 5.3, 3-H), 1.83 (1H, 
app. dtd, J 13.2, 8.1 and 5.3, 4-HA), 1.42 (1H, dddd, J 12.6, 8.0, 7.1 and 5.7, 4-
HB); δC (100 MHz, CDCl3) 172.5 (propanamide C-1), 156.5 (quinolinyl C-2), 
146.6 (quinolinyl C-8a), 136.4 (quinolinyl C-4), 129.2 (quinolinyl C-7), 127.0 
(quinolinyl C-5), 125.3 (quinolinyl C-8), 124.2 (quinolinyl C-3), 122.7 (quinolinyl 
C-4a), 122.6 (quinolinyl C-6), 71.1 (C-2), 67.7 (C-5), 42.5 (methylpropanamide 
C-1), 39.0 (C-3), 35.5 (propanamide C-2), 29.8 (C-4), 26.8 (propanamide C-3); 
HRMS found MH+, 300.1703. C17H21N3O2 requires MH, 300.1712. 
 
3‐(2‐Aminoquinolin‐3‐yl)‐1‐(morpholin‐4‐yl)propan‐1‐one 
 
N
N
O
NH2
O
224  
 
According to General Procedure AD, TFA (8.00 mL) and the amide derivative 
231k (0.12 g, 0.35 mmol) were stirred for 2 h to give a crude material. The 
crude material was purified by flash column chromatography eluting with 
95.4:4.08:0.52 DCM−EtOH−NH4OH to yield the amine derivative 224 (93.0 mg, 
93%) as colourless crystals, m.p. (DCM), 183–193 °C; Rf 0.31 (92.4:6.76:0.84 
DCM−EtOH−NH4OH); νmax/cm-1 3315, 3133, 2965, 2899, 2853, 1628, 1614, 
1461, 1428, 1408, 1240, 1228, 1108; δH (400 MHz, DMSO-d6) 7.71 (1H, s, 
quinolinyl 4-H), 7.58 (1H, d, J 7.9, quinolinyl 8-H), 7.48-7.35 (2H, m, quinolinyl 
5,7-H2), 7.12 (1H, t, J 7.2, quinolinyl 6-H), 6.29 (2H, br. s, NH2), 3.51-3.45 (4H, 
m, 2,6-H4), 3.45-3.39 (4H, m, 3,5-H4), 2.82 (2H, t, J 7.4, propanone 3-H2), 2.67 
(2H, t, J 7.4, propanone 2-H2); δC (75 MHz, DMSO-d6) 170.2 (propanone C-1), 
157.1 (quinolinyl C-2), 146.6 (quinolinyl C-8a), 134.8 (quinolinyl C-4), 128.2 
232 
 
(quinolinyl C-7), 126.8 (quinolinyl C-8), 124.7 (quinolinyl C-5), 123.4 (quinolinyl 
C-3), 123.3 (quinolinyl C-4a), 121.2 (quinolinyl C-6), 45.3 (C2-2,6), 41.5 (C2-
3,5), 30.7 (propanone C-2), 25.9 (propanone C-3); HRMS found MH+, 
286.1550. C16H19N3O2 requires MH, 286.1555. 
 
3‐(2‐Aminoquinolin‐3‐yl)‐1‐(3‐benzylpiperidin‐1‐yl)propan‐1‐one 
 
N
N
O
NH2
225  
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231l (13.0 mg, 30.3 µmol) were stirred for 3 h to give the amine derivative 225 
(11.3 mg, >99%, rotamers 51:49 by 1H-NMR) as a colourless amorphous solid, 
Rf 0.45 (92.4:6.76:0.84 DCM−EtOH−NH4OH); νmax/cm-1 3369, 3338, 3128, 
2942, 2917, 2865, 2847, 1665, 1619, 1499, 1476, 1452, 1434, 1330, 1279, 
1218, 1143, 1111; δH (400 MHz, CDCl3) 7.69 (1H, s, quinolinyl 4-Hminor), 7.65 
(2H, dd, J 8.4 and 2.6, quinolinyl 8-H), 7.59 (2H, dd, J 8.0 and 1.6, quinolinyl 5-
H), 7.57 (1H, s, quinolinyl 4-Hmajor), 7.53-7.46 (2H, m, quinolinyl 7-H), 7.33-7.23 
(6H, m, phenyl 3,4,5-H3), 7.24-7.17 (2H, m, quinolinyl 6-H), 7.13 (2H, d, J 7.1, 
phenyl 2,6-HA), 7.07 (2H, d, J 7.1, phenyl 2,6-HB), 5.41 (2H, br. s, NHminor), 5.35 
(2H, br. s, NHmajor), 4.50 (1H, ddt, J 12.9, 3.8 and 1.7, phenylmethyl 1-HAminor), 
4.42 (1H, app. dt, J 13.3 and 4.2, phenylmethyl 1-HAmajor), 3.72 (1H, app. dt, J 
13.5 and 4.1, phenylmethyl 1-HBminor), 3.63 (1H, ddt, J 13.3, 3.7 and 1.6, 
phenylmethyl 1-HBmajor), 3.02 (4H, t, J 7.0, 6-H2major and propanone 3-H2major), 
2.93 (2H, t, J 7.0, propanone 3-H2minor), 2.72 (2H, t, J 7.0, propanone 2-H2major), 
2.70-2.63 (4H, m, 2-H2minor and 6-H2minor), 2.55 (2H, t, J 7.0, propanone 2-
H2minor), 2.48-2.34 (2H, m, 2-H2major), 1.85-1.73 (2H, m, 4-HA), 1.75-1.59 (4H, m, 
3-H and 5-HA), 1.48-1.33 (2H, m, 5-HB), 1.29-1.04 (2H, m, 4-HB); δC (100 MHz, 
CDCl3) 170.6 (propanone C-1major), 170.5 (propanone C-1minor), 156.6 (quinolinyl 
C2-2), 146.7 (quinolinyl C2-8a), 139.5 (phenyl C-1minor), 139.3 (phenyl C-1major), 
136.5 (quinolinyl C-4minor), 136.4 (quinolinyl C-4major), 129.2 (phenyl C2-2,6major), 
129.1 (phenyl C2-2,6minor), 128.9 (quinolinyl C2-7), 128.6 (phenyl C2-3,5major), 
128.4 (phenyl C2-3,5minor), 127.0 (quinolinyl C2-5), 126.4 (quinolinyl C2-8), 125.6 
(phenyl C-4major), 125.5 (phenyl C-4minor), 124.3 (quinolinyl C2-3), 123.6 
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(quinolinyl C-4aminor), 123.5 (quinolinyl C-4amajor), 122.6 (quinolinyl C2-6), 51.4 
(C-2major), 48.1 (C-2minor), 46.4 (phenylmethyl C-1minor), 43.0 (phenylmethyl C-
1major), 40.4 (quinolinyl C-6minor), 40.1 (quinolinyl C-6major), 38.8 (quinolinyl C-
3major), 37.7 (quinolinyl C-3minor), 32.7 (propanone C-2minor), 32.4 (propanone C-
2major), 31.0 (C-4major), 30.4 (C-4minor), 26.6 (propanone C2-3), 25.7 (C-5minor), 
24.7 (C-5major); HRMS found MH+, 374.2233. C24H27N3O requires MH, 
374.2232. 
 
3-(2-Aminoquinolin-3-yl)-N-[(oxan-3-yl)methyl]propanamide 
 
N
N
H
O
NH2
226
O
 
 
According to General Procedure AD, TFA (0.50 mL) and the amide derivative 
231m (11.0 mg, 29.7 µmol) were stirred for 3 h to give the amine derivative 226 
(9.30 mg, >99%) as a colourless oil, Rf 0.28 (92.4:6.76:0.84 
DCM−EtOH−NH4OH); νmax/cm-1 3397, 3277, 3148, 3083, 2948, 2930, 2916, 
2850, 1654, 1627, 1565, 1501, 1477, 1154; δH (400 MHz, CDCl3) 7.66 (1H, s, 
quinolinyl 4-H), 7.63 (1H, dd, J 8.5 and 1.2, quinolinyl 8-H), 7.53 (1H, dd, J 8.1 
and 1.5, quinolinyl 5-H), 7.50 (1H, ddd, J 8.5, 6.9 and 1.5, quinolinyl 7-H), 7.23 
(1H, ddd, J 8.1, 6.9 and 1.2, quinolinyl 6-H), 5.81 (1H, t, J 5.2, amide NH), 5.35 
(2H, s, NH2), 3.83-3.61 (2H, m, 2-HA and 6-HA), 3.35 (1H, ddd, J 11.2, 9.6 and 
3.3, 6-HB), 3.14-3.06 (1H, m, 2-HA), 3.11 (2H, t, J 6.5, methylpropanamide 1-
H2), 2.97 (2H, t, J 7.0, propanamide 3-H2), 2.54 (2H, t, J 7.0, propanamide 2-
H2), 1.78-1.62 (2H, m, 3-H and 4-HA), 1.60-1.40 (2H, m, 5-H2), 1.15 (1H, app. 
dtd, J 12.7, 10.1, 9.6 and 4.6, 4-HB); δC (100 MHz, CDCl3) 172.4 (propanamide 
C-1), 156.4 (quinolinyl C-2), 146.4 (quinolinyl C-8a), 136.8 (quinolinyl C-4), 
129.3 (quinolinyl C-7), 127.0 (quinolinyl C-5), 125.3 (quinolinyl C-8), 124.2 
(quinolinyl C-3), 122.9 (quinolinyl C-4a), 122.8 (quinolinyl C-6), 71.0 (C-2), 68.5 
(C-6), 41.7 (methylpropanamide C-1), 36.2 (C-3), 35.8 (propanamide C-2), 27.3 
(C-4), 26.9 (propanamide C-3), 24.9 (C-5); HRMS found MH+, 314.1867. 
C18H23N3O2 requires MH, 314.1868. 
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5.3. Experimental for the Determination of the Biological Activity 
The derived compounds were assessed using a BACE1 red-shifted 
fluorescence-quenching assay kit supplied from ThermoFisher Scientific 
(PanVera®, Part Number P2985).204 The kit was composed of a “Swedish” 
mutant APP peptide tagged with a rhodamine derivative (fluorescence donor) 
and a propietary quenching acceptor (rhodamine-EVNLDAEFK-quencher) in a 
75 µM aqueous solution of 50 mM ammonium bicarbonate (PanVera®, Part 
Number P2986); purified baculovirus-expressed BACE1 in a 50 mM aqueous 
solution of tris(hydroxymethyl) aminomethane (pH 7.5) with 10% glycerol 
(PanVera®, Part Number P2947); and an assay buffer of 50 mM aqueous 
solution of sodium acetate (pH 4.5) (PanVera®, Part Number P2948). The assay 
was performed using black 384 round-bottom well plates (Corning®, Part 
number 4514). 
 
The assay procedure was adapted from an existing protocol.204 The BACE1 
solution and the substrate solution provided were diluted in assay buffer to 
obtain 1 protein unit/mL and a 750 nM solution, respectively, as working 
solutions. The corresponding derived molecules were dissolved in DMSO 
(supplied by Sigma–Aldrich) to obtain a 200 mM or 100 mM solution. Lower 
concentrations of the derived compounds were achieved by serial dilution in 
DMSO in 10–12 steps to obtain different concentrations until 0.30 mM. Finally, 
each concentration in DMSO was diluted 100-fold with assay buffer to obtain 
the working solutions. For determination of inhibition activity, 5 µL of each of the 
working solutions (compound, BACE1 and substrate) was added to each well to 
obtain a total volume of 15 µL/well. For the positive control, a 1% DMSO 
solution in assay buffer was used instead of the working solution of the 
compounds. For the negative control, 1% DMSO solution in assay buffer and 
assay buffer were used instead of the working solutions of the compounds and 
BACE1. The compounds were added to the wells first, followed by the protein 
and 20 min later by the substrate. Each well was repeated in triplicate (Figure 
50). The enzyme inhibition was measured at 25 °C by quantifying the 
fluorescence released using an EnvisionTM 2013 multilabel plate reader 
(PerkinElmer), with BODIPY TMR mirror, λexcitation = 531 nm and λemission = 595 
nm. The measurements were taken every minute over 2 h. 
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A 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 24 
A The 13 derived compounds in 
concentrations of 100 µM in triplicate 
(each compound in a different column) 
     
B      
C      
D 
+ – 
                
E                 
F                 
G                   
P                   
 
B 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 24 
A Derived compound 214, 218, 219 or 221  
in concentrations from up to 0.67 mM to 1 µM in triplicate 
(each concentration in a different column) 
     
B      
C      
D 
+ – 
                
E                 
F                 
G                   
P                   
 
Figure 50: Well plate layout to assess BACE1 inhibition. The + and – means positive and 
negative control, respectively. Positive control does not contain compounds and negative 
control does not contain protein nor compounds. Panel A: First fluorescence-quenching assay 
to identify if some of the 13 derived compounds were inhibitors at 100 µM. Panel B: Successive 
fluorescence-quenching assays to determine the IC50 of the inhibitors 214, 218, 219 and 221 
identified in the previous assay in panel A. 
 
All the data was processed using Graphpad Prism V.6 (Graphpad Software Inc. 
CA). To process the data the average value of fluorescence unit for each 
compound at the specific concentration, for the negative control and for the 
positive control was plotted against the time. A linear fit was applied, the slopes 
were obtained and the % of inhibition was determined (Equation 1). 
 
 
 
Equation 1: Calculation of the % of inhibition from the slopes. 
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The % of inhibition was reported as mean of the triplicate ± SEM. The dose-
response data, expressed as % of inhibition vs log[compound] was represented 
with a sigmoidal dose-response model. This sigmoidal dose-response model 
allowed the determination of the IC50 (Table 29). The values were calculated 
from three independent experiments. 
 
Derived compound LogIC50 ± SEM IC50 Hill slope 
214 -4.508 ± 0.06 31.0 µM -1.55 
218 -4.257 ± 0.01 55.3 µM -3.27 
219 -4.542 ± 0.02 28.7 µM -2.54 
221 -4.074 ± 0.02 84.2 µM -3.80 
Table 29: IC50 values for compounds 214, 218, 219 and 221 obtained from the sigmoidal dose-
response models. Normalised to negative and positive controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
237 
 
Appendix 
 
Library of Virtual Medicinal Chemistry Capping Groups 
The next reagents were used to decorate the scaffolds with the computational 
tool: 
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Type Number Mean MW Range MW Mean clogP Range clogP 
Carboxylic acids 20 118.6 60.0 – 156.6 0.71 -0.49 – 2.12 
Sulfonyl chlorides 15 173.2 114.5 – 211.1 1.24 0.00 – 2.40 
Halides 30 163.3 94.9 – 205.5 1.88 0.68 – 3.24 
Ketones 3 76.7 58.1 – 100.1 -0.32 -0.68 – -0.10 
Aldehydes 15 102.4 44.0 – 140.6 0.93 -0.44 – 2.25 
Isocyanates 15 119.9 71.1 – 167.6 1.01 -0.05 – 2.36 
Amines 20 96.6 31.1 – 141.6 0.25 -0.92 – 1.64 
Boronic acids 15 121.6 59.8 – 157.3 0.90 -0.49 – 2.16 
Properties of the previous medicinal chemistry capping groups used for the derivatisation of the 
virtual scaffolds. These properties are based on the capping group itself. 
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X-Ray Structure Data 
ORTEP diagram of 149a (CCDC 1566497) 
 
 
 
 
Crystal data and structure refinement for 149a 
Empirical formula C14H25NO4 
Formula weight 271.35 
Temperature/K 120.01(19) 
Crystal system monoclinic 
Space group P21/c 
a/Å 11.04739(18) 
b/Å 12.2038(2) 
c/Å 10.96322(18) 
α/° 90.00 
β/° 91.7913(16) 
γ/° 90.00 
Volume/Å3 1477.35(4) 
Z 4 
ρcalcg/cm3 1.220 
µ/mm-1 0.721 
F(000) 592.0 
Crystal size/mm3 0.21 × 0.12 × 0.09 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8 to 147.5 
Index ranges -9 ≤ h ≤ 13, -14 ≤ k ≤ 14, -13 ≤ l ≤ 13 
Reflections collected 6401 
Independent reflections 2882 [Rint = 0.0214, Rsigma = 0.0256] 
Data/restraints/parameters 2882/0/175 
Goodness-of-fit on F2 1.052 
Final R indexes [I>=2σ (I)] R1 = 0.0374, wR2 = 0.0880 
Final R indexes [all data] R1 = 0.0435, wR2 = 0.0918 
Largest diff. peak/hole / e Å-3 0.29/-0.19 
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ORTEP diagram of 150c (CCDC 1566499) 
 
 
 
 
Crystal data and structure refinement for 150c 
Empirical formula C15H17NO3 
Formula weight 259.29 
Temperature/K 119.97(16) 
Crystal system triclinic 
Space group P-1 
a/Å 6.7483(5) 
b/Å 9.9314(7) 
c/Å 11.0967(8) 
α/° 63.764(7) 
β/° 79.148(6) 
γ/° 74.800(6) 
Volume/Å3 641.49(9) 
Z 2 
ρcalcg/cm3 1.342 
µ/mm-1 0.762 
F(000) 276.0 
Crystal size/mm3 0.15 × 0.08 × 0.06 
Radiation CuKα (λ = 1.54184) 
2Θ range for data collection/° 8.916 to 147.94 
Index ranges -8 ≤ h ≤ 7, -12 ≤ k ≤ 10, -13 ≤ l ≤ 12 
Reflections collected 4223 
Independent reflections 2397 [Rint = 0.0277, Rsigma = 0.0391] 
Data/restraints/parameters 2397/0/173 
Goodness-of-fit on F2 1.028 
Final R indexes [I>=2σ (I)] R1 = 0.0379, wR2 = 0.0941 
Final R indexes [all data] R1 = 0.0450, wR2 = 0.0996 
Largest diff. peak/hole / e Å-3 0.35/-0.22 
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ORTEP diagram of 150d (CCDC 1566498) 
 
 
 
 
 
Crystal data and structure refinement for 150d 
Empirical formula C9H13NO3 
Formula weight 183.20 
Temperature/K 120.01(10) 
Crystal system monoclinic 
Space group P21/c 
a/Å 7.65800(10) 
b/Å 9.53160(10) 
c/Å 12.1849(2) 
α/° 90 
β/° 94.8050(10) 
γ/° 90 
Volume/Å3 886.29(2) 
Z 4 
ρcalcg/cm3 1.373 
µ/mm-1 0.859 
F(000) 444.0 
Crystal size/mm3 0.48 × 0.28 × 0.26 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 11.596 to 147.354 
Index ranges -8 ≤ h ≤ 9, -8 ≤ k ≤ 11, -14 ≤ l ≤ 15 
Reflections collected 4943 
Independent reflections 1726 [Rint = 0.0130, Rsigma = 0.0130] 
Data/restraints/parameters 1726/0/118 
Goodness-of-fit on F2 1.072 
Final R indexes [I>=2σ (I)] R1 = 0.0315, wR2 = 0.0799 
Final R indexes [all data] R1 = 0.0339, wR2 = 0.0817 
Largest diff. peak/hole / e Å-3 0.31/-0.19 
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NOESY Spectra  
NOESY Spectra with the nOe enhancements: 
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